0001493152-22-007662.txt : 20220324 0001493152-22-007662.hdr.sgml : 20220324 20220324160829 ACCESSION NUMBER: 0001493152-22-007662 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 89 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220324 DATE AS OF CHANGE: 20220324 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Co-Diagnostics, Inc. CENTRAL INDEX KEY: 0001692415 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 462609396 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38148 FILM NUMBER: 22766564 BUSINESS ADDRESS: STREET 1: 4049 SOUTH HIGHLAND DRIVE CITY: SALT LAKE CITY STATE: UT ZIP: 84124 BUSINESS PHONE: 8012789769 MAIL ADDRESS: STREET 1: 4049 SOUTH HIGHLAND DRIVE CITY: SALT LAKE CITY STATE: UT ZIP: 84124 10-K 1 form10-k.htm
0001692415 false FY P3Y 2024-02-29 0001692415 2021-01-01 2021-12-31 0001692415 2021-06-30 0001692415 2022-03-23 0001692415 2021-12-31 0001692415 2020-12-31 0001692415 2020-01-01 2020-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001692415 us-gaap:CommonStockMember 2019-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001692415 us-gaap:RetainedEarningsMember 2019-12-31 0001692415 2019-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001692415 us-gaap:CommonStockMember 2020-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001692415 us-gaap:RetainedEarningsMember 2020-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001692415 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001692415 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001692415 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001692415 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001692415 us-gaap:CommonStockMember 2021-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001692415 us-gaap:RetainedEarningsMember 2021-12-31 0001692415 us-gaap:IPOMember 2020-01-01 2020-12-31 0001692415 srt:MinimumMember 2021-01-01 2021-12-31 0001692415 srt:MaximumMember 2021-01-01 2021-12-31 0001692415 CODX:TwoCustomersTogetherMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-12-31 0001692415 CODX:TwoCustomersTogetherMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-12-31 0001692415 CODX:TwoCustomersTogetherMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0001692415 CODX:TwoCustomersTogetherMember us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2020-01-01 2020-12-31 0001692415 CODX:AdvancedConceptionsIncAndIdahoMolecularIncMember 2021-12-30 2021-12-31 0001692415 CODX:AdvancedConceptionsIncAndIdahoMolecularIncMember 2021-12-31 0001692415 CODX:AdvancedConceptionsIncMember 2021-01-01 2021-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001692415 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001692415 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001692415 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001692415 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001692415 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001692415 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001692415 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001692415 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001692415 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001692415 us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001692415 CODX:MeasurementInputStrikePriceMember 2021-12-31 0001692415 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001692415 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001692415 us-gaap:MeasurementInputExpectedTermMember 2021-01-01 2021-12-31 0001692415 CODX:MeasurementInputCostOfCapitalMember 2021-12-31 0001692415 us-gaap:MeasurementInputDiscountRateMember 2021-12-31 0001692415 CODX:MeasurementInputEquityVolatilityMember 2021-12-31 0001692415 CODX:MeasurementInputAssetVolatilityMember 2021-12-31 0001692415 CODX:MeasurementInputRevenueVolatilityMember 2021-12-31 0001692415 us-gaap:EquipmentMember srt:MinimumMember 2021-01-01 2021-12-31 0001692415 us-gaap:EquipmentMember srt:MaximumMember 2021-01-01 2021-12-31 0001692415 us-gaap:EquipmentMember 2021-12-31 0001692415 us-gaap:EquipmentMember 2020-12-31 0001692415 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2021-01-01 2021-12-31 0001692415 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001692415 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001692415 us-gaap:OfficeEquipmentMember srt:MinimumMember 2021-01-01 2021-12-31 0001692415 us-gaap:OfficeEquipmentMember srt:MaximumMember 2021-01-01 2021-12-31 0001692415 us-gaap:OfficeEquipmentMember 2021-12-31 0001692415 us-gaap:OfficeEquipmentMember 2020-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2021-01-01 2021-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2021-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2020-12-31 0001692415 us-gaap:NoncompeteAgreementsMember srt:MinimumMember 2021-01-01 2021-12-31 0001692415 us-gaap:NoncompeteAgreementsMember srt:MaximumMember 2021-01-01 2021-12-31 0001692415 us-gaap:NoncompeteAgreementsMember 2021-12-31 0001692415 us-gaap:NoncompeteAgreementsMember 2020-12-31 0001692415 srt:AmericasMember 2021-01-01 2021-12-31 0001692415 srt:AmericasMember 2020-01-01 2020-12-31 0001692415 CODX:RestOfWorldMember 2021-01-01 2021-12-31 0001692415 CODX:RestOfWorldMember 2020-01-01 2020-12-31 0001692415 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0001692415 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-12-31 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-12-31 0001692415 CODX:OptionsMember 2021-01-01 2021-12-31 0001692415 CODX:ThirdPartiesMember 2021-01-01 2021-12-31 0001692415 CODX:AdvancedConceptionsIncAndIdahoMolecularIncMember 2021-01-01 2021-12-31 0001692415 CODX:CommonStockThreeMember 2020-01-01 2020-12-31 0001692415 CODX:CommonStockThreeMember 2020-12-31 0001692415 CODX:CommonStockOneMember 2020-01-01 2020-12-31 0001692415 CODX:CommonStockOneMember 2020-12-31 0001692415 CODX:CommonStockTwoMember 2020-01-01 2020-12-31 0001692415 CODX:CommonStockTwoMember 2020-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001692415 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001692415 CODX:OptionsMember 2020-01-01 2020-12-31 0001692415 CODX:InvestmentRelationsServicesMember 2020-01-01 2020-12-31 0001692415 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001692415 CODX:TwoThousandFifteenLongTermIncentivePlanMember 2021-12-31 0001692415 CODX:StockOptionsMember 2021-01-01 2021-12-31 0001692415 CODX:StockOptionsMember 2020-01-01 2020-12-31 0001692415 CODX:StockOptionsMember 2021-12-31 0001692415 CODX:StockOptionsMember 2020-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001692415 us-gaap:WarrantMember 2021-12-31 0001692415 CODX:ThirdPartiesMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001692415 CODX:ThirdPartiesMember us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001692415 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001692415 us-gaap:MeasurementInputExpectedTermMember 2020-12-31 0001692415 us-gaap:MeasurementInputOptionVolatilityMember 2020-12-31 0001692415 us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0001692415 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001692415 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001692415 us-gaap:StockCompensationPlanMember 2021-01-01 2021-12-31 0001692415 us-gaap:StockCompensationPlanMember 2020-01-01 2020-12-31 0001692415 CODX:ExclusiveLicenseAgreementMember CODX:DrBrentSatterfieldMember 2017-01-01 0001692415 CODX:ExclusiveLicenseAgreementMember CODX:DrBrentSatterfieldMember 2017-01-01 2017-01-30 0001692415 CODX:ExclusiveLicenseAgreementMember CODX:DrBrentSatterfieldMember 2021-12-31 0001692415 2020-02-29 0001692415 us-gaap:SubsequentEventMember us-gaap:CommonStockMember srt:MaximumMember 2022-03-01 2022-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:acre

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549.

 

Form 10-K

 

(Mark One)

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2021

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from_______to_______

 

Commission File Number 001-38148

 

CO-DIAGNOSTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Utah   3841   46-2609396

(State or other jurisdiction of

incorporation or organization)

  

(Primary Standard Industrial

Classification Code Number)

  

(I.R.S. Employer

Identification Number)

 

2401 S. Foothill Drive, Salt Lake City, Utah 84109

(Address of principal executive offices and zip code)

 

(801) 438-1036

(Registrant’s telephone number including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   CODX   The Nasdaq Capital Market

 

Securities registered pursuant to Section 12(g) of the Act: None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer ☐ Accelerated filer ☐
  Non-accelerated filer ☐ Smaller reporting company ☒
      Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common stock was last sold as of the last business day of the registrant’s most recently completed second fiscal quarter was approximately $229,000,000.

 

As of March 23, 2022, there were 33,965,318 shares of common stock, par value $0.001 per share, outstanding.

 

 

 

 

 

 

Table of Contents

 

    Page
     
PART I  
     
Item 1. Business. 4
     
Item 1A. Risk Factors. 13
     
Item 1B. Unresolved Staff Comments. 16
     
Item 2. Properties. 16
     
Item 3. Legal Proceedings. 16
     
Item 4. Mine Safety Disclosures. 17
     
PART II  
     
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. 17
     
Item 6. [Reserved.] 18
     
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 18
     
Item 7A. Quantitative and Qualitative Disclosures About Market Risk. 22
     
Item 8. Financial Statements and Supplementary Data. 23
     
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. 44
     
Item 9A. Controls and Procedures. 44
     
Item 9B. Other Information. 45
     
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 45
     
PART III  
     
Item 10. Directors, Executive Officers and Corporate Governance. 45
     
Item 11. Executive Compensation. 50
     
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 54
     
Item 13. Certain Relationships and Related Transactions, and Director Independence. 55
     
Item 14. Principal Accountant Fees and Services. 56
     
PART IV  
     
Item 15. Exhibits and Financial Statement Schedules. 56

 

2

 

 

PART I

 

Forward-Looking Statements

 

This Annual Report on Form 10-K contains “forward-looking statements” that involve risks and uncertainties. All statements other than statements of historical fact contained in this Annual Report and the documents incorporated by reference herein, including statements regarding future events, our future financial performance, business strategy, and plans and objectives of management for future operations, are forward-looking statements. We have attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology. Although we do not make forward looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve known and unknown risks, uncertainties and other factors and the documents incorporated by reference herein, which may affect our or our industry’s actual results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Moreover, we operate in a highly regulated, very competitive, and rapidly changing environment. New risks emerge from time to time and it is not possible for us to predict all risk factors, nor can we address the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ materially from those contained in any forward-looking statements.

 

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short term and long-term business operations, and financial needs. These forward-looking statements are subject to certain risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this Annual Report, and in particular, the risks discussed below and under the heading “Risk Factors” in other documents we file with the SEC. The following discussion should be read in conjunction with the consolidated financial statements for the fiscal years ended December 31, 2021 and 2020 and notes incorporated by reference therein. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Annual Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statement.

 

You should not place undue reliance on any forward-looking statement, each of which applies only as of the date of this Annual Report. Except as required by law, we undertake no obligation to update or revise publicly any of the forward-looking statements after the date of this Annual Report to conform our statements to actual results or changed expectations.

 

You are advised, however, to consult any further disclosures we make on related subjects in our reports on Forms 10-Q, 8-K and 10-K filed with the SEC. You should understand that it is not possible to predict or identify all risk factors. Consequently, you should not consider this list to be a complete set of all potential risks or uncertainties.

 

Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation:

 

● the results of clinical trials and the regulatory approval process;
   
● market acceptance of any products that may be approved for commercialization;
   
● our ability to protect our intellectual property rights;
   
● the impact of any infringement actions or other litigation brought against us;
   
● competition from other providers and products;
   
● our ability to develop and commercialize new and improved products and services;
   
● changes in government regulation;
   
● and other factors (including the risks contained in the section entitled “Risk Factors” in other documents we file with the SEC) relating to our industry, our operations and results of operations.

 

3

 

 

Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

 

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

 

As used in this Annual Report, the terms “we”, “us”, “our”, “Company” and “Co-Diagnostics” means Co-Diagnostics, Inc., a Utah corporation and its consolidated subsidiaries (the “Company”), unless otherwise indicated.

 

ITEM 1: BUSINESS

 

Overview

 

Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CODX”), develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems (which we refer to as the “MDx Device”). We have also developed a unique, groundbreaking portable PCR device (the “CODX YourTest PCR™ Device”) that has been designed to bring affordable, reliable gold-standard polymerase chain reaction (“PCR”) to patients in point-of-care and even at-home settings.

 

Our diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. CODX’s technical advance involves a novel, patented approach to PCR test design of primer and probe structure (“CoPrimers™”) that eliminates one of the key vexing issues of PCR amplification, the exponential growth of primer-dimer pairs (false positives and false negatives) which adversely interferes with identification of the target DNA/RNA.

 

We believe our proprietary molecular diagnostics technology is paving the way for innovation in disease detection and life sciences research through our enhanced detection of genetic material. For various reasons, including owning our own our platform, we believe we will be able to accomplish this faster and more economically, allowing for significant margins while still positioning the Company to be a low-cost provider of molecular diagnostics and screening services.

 

In addition, continued development has demonstrated the unique properties of our CoPrimer technology that we believe makes it ideally suited for a variety of applications where specificity is key to optimal results, including multiplexing several targets, enhanced Single Nucleotide Polymorphism (“SNP”) detection and enrichment for next generation sequencing.

 

Our scientists use the complex mathematics of DNA/RNA test design to engineer and optimize DNA/RNA tests and to automate algorithms that rapidly screen millions of possible options to pinpoint the optimum design. Dr. Brent Satterfield, our founder, developed the Company’s intellectual property consisting of the predictive mathematical algorithms and patented molecular structure used in the testing process, which together represent a major advance in PCR testing systems. CODX technologies are now protected by more than 20 granted or pending US and foreign patents, as well as certain trade secrets and copyrights. Ownership of our proprietary platform permits us the advantage of avoiding payment of patent royalties required by other PCR test systems, which may allow the sale of diagnostic PCR tests at a lower price than competitors, while enabling us to maintain profit margins.

 

We may either sell or lease the MDx Device to labs and diagnostic centers, through sale or lease agreements, and sell the reagents that comprise our proprietary tests to those laboratories and testing facilities.

 

Our proprietary test design process involves identifying the optimal locations on the target genes for amplification and pair the locations with the optimized primer and probe structure to achieve outputs that meet the design input requirements identified from market research. This is done by following planned and documented processes, procedures and testing. In other words, we use the data resulting from our tests to verify whether we succeeded in designing what we intended at the outset. Verification is a series of testing that concludes that the product is ready to proceed to validation in an evaluation either in our laboratory or in an independent laboratory setting using initial production tests to confirm that the product as designed meets the user needs.

 

4

 

 

Using our proprietary test design system and proprietary reagents, we have designed and obtained regulatory approval in the European Community and/or in India to sell PCR diagnostic tests for the detection of COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In the United States, CODX has obtained Emergency Use Authorization (“EUA”) for its Logix Smart™ COVID-19 detection test from the Food and Drug Administration, or FDA, and sells that test to qualified labs. In addition, our COVID-19 detection test and certain of our other suite of COVID-19 products have been approved for sale in countries such as the United Kingdom, Australia and Mexico by the regulatory bodies in those countries and have been registered for sale in many more countries.

 

In addition to testing for infectious disease, the technology lends itself to identifying any section of a DNA or RNA strand that describe any type of genetic trait, which creates a number of significant applications. We, in conjunction with our customers, are active in designing and licensing tests that identify genetic traits in plant and animal genomes. We also have three multiplexed tests developed to test mosquitos for the identification of diseases carried by the mosquitos to enable municipalities to concentrate their efforts in managing mosquito populations on the specific areas known to be breeding the mosquitos that carry deadly viruses.

 

On January 23, 2020, we announced the completion of the principal design work for a PCR test for the new coronavirus, later named COVID-19, intended to address the potential need for detection of the virus. This test features the Company’s patented CoPrimer technology, and was designed using our proprietary software system, following the guidelines published by the World Health Organization (WHO) and Centers for Disease Control (CDC).

 

On February 24, 2020, we announced that this test had obtained regulatory clearance to be sold as an IVD for the diagnosis of COVID-19 in markets that accept CE-marking as valid regulatory approval, and became available for purchase from the Company’s Utah-based ISO-13485:2016 certified facility—the first US-based company to obtain such a marking for a COVID-19 test.

 

We commenced sales of the COVID-19 tests in February and March of 2020 to international customers and to date have since sold over 30,000,000 of this and other COVID tests in numerous countries around the world through an expanding distributor network.

 

On April 6, 2020, we announced that we had received an Emergency Use Authorization from the FDA allowing us to commence sales of our Logix Smart™ COVID-19 test to laboratories certified by the Center for Medicare and Medicaid Services under the Clinical Laboratories Improvements Act (“CLIA”) to accept human samples for diagnostics testing throughout the United States and have sold our Logix Smart™ COVID-19 test to such CLIA labs since that time.

 

Because we believe that testing for COVID-19 is going to be a consideration for public health worldwide even after the current pandemic has subsided, we have initiated the Eikon platform to facilitate frequent testing in homes, schools, businesses, and the hospitality industry. We believe this may be accomplished through the development of a low-cost testing device, easy to use by non-professionals, that can provide PCR test results in around 30 minutes. The initial project built on this platform, an at-home and point-of-care COVID-19 PCR test, was ultimately facilitated by our development of a saliva or nasal swab-based PCR test that does not require the RNA/DNA extraction. While the final result is believed to be approximately equivalent to those processed by a high-complexity clinical laboratory, it has the advantages of increased speed and ease of handling thanks to lyophilization (or freeze-drying) of our testing reagents to allow for stability at room temperatures.

 

On February 15, 2021, we engaged the services of a group of professionals at Idaho Molecular, Inc and Advanced Conceptions, Inc (the “Entities,”) with the expertise to develop the hardware for such a device using our CoPrimers™ as the reagent chemistry. On December 22, 2021, we announced that we would be acquiring the Entities along with all existing and future assets and intellectual property related to the platform and device. It is expected that the device and test will be available to homes, schools, offices, and the travel industry among other locations at a cost that will allow screening frequently to prevent spread of the COVID-19 virus in the future. The device would also be available to test for other pathogens detectable through saliva or other samples as we develop those tests and offer them to the marketplace. All such tests will be subject to regulatory approval.

 

5

 

 

Infectious Disease Product Offering

 

Using our proprietary test design system and proprietary reagents, we and CoSara Diagnostics Pvt Ltd (“CoSara”), our joint venture for manufacturing in India, design and sell PCR diagnostic tests for detection of diseases and pathogens such as COVID-19, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus, all of which tests have been designed and verified in our laboratories. Our tuberculosis test and Zika test received a CE Mark in 2018, and a triplex test for Zika, dengue and chikungunya received a CE Mark in 2019, qualifying the tests to be sold throughout the European community and in most countries in central and South America. In December, 2019, CoSara received a license to manufacture and sell tuberculosis, hepatitis B, hepatitis C, human papillomavirus 16/18 and malaria tests in India from the Central Drugs Standard Control Organization (“CDSCO”). In February 2020, we received a CE Mark for our Logix Smart™ COVID-19 test followed by an Emergency Use Authorization by the FDA a few weeks later, and in April 2020, our COVID-19 test was approved for manufacture and sale in India by the CDSCO and in Mexico by the INDRE, Mexico’s equivalent to the United States Center for Disease Control. In August 2020, we received approval from the Australian Department of Health Therapeutic Goods Division to sell our COVID-19 test in Australia. Other regulatory approvals and registrations followed those listed here.

 

As explained above, our Logix Smart™ COVID-19 test was designed, developed, submitted for regulatory approval and ready to be used as an IVD in countries that accept a CE Mark as approval for use of the test in a period of just over 30 days. This is a real-world example of how the CODX technology can be used in an evolving epidemic to get diagnostic tools in the hands of medical professionals without delay. It can be similarly used to design a test for mutated strains of the virus should they not be detectable using currently available tests.

 

Caribbean and Central and South America

 

Our initial sales were to entities located in South and Central America. In some of those countries, there are limited regulatory hurdles so we started offering our tests immediately. We have applied for and received registrations for our tests in many of those countries that require registration, and our distributors in those countries have provided us with in country assistance in completing such registrations.

 

We first offered our Zika test in this region because of the demand for such a test, followed by tests for tuberculosis, our triplex test for Zika, chikungunya, and dengue. Sales of those tests have not been material, but with the granting of a CE mark for our Logix Smart™ COVID-19, we began significant sales in this region. Products are manufactured for sale upon receipt of purchase orders from distributors, labs and hospitals.

 

India

 

In January 2017, the Company entered into an agreement to manufacture diagnostics tests for seven infectious diseases with a pharmaceutical manufacturing company in India and formed an Indian joint venture organized as CoSara Diagnostics, Pvt Ltd (“CoSara”). The agreement provided for the construction of a manufacturing plant and the manufacture of the tests named above and the joint sales and marketing of those tests in India. We have received a license for the plant in Ranoli, India to manufacture approved tests and is being used for testing and manufacturing of our products for the Indian market.

 

As mentioned above, the CDSCO has given us the approval for manufacture and sale of the nine tests referred above and the Company has begun manufacture and sale of those tests. The Company has commenced a reagent rental program in India with thermocyclers purchased from third-party vendors and which we refer to as our MDx Device. Each of the reagent rental placements requires the purchase of a minimum number of tests per month. The placement of thermocyclers in India has facilitated the sale of the SaraGene COVID-19 tests in India. The World Health Organization (“WHO”) 2019 Global Tuberculosis Report indicates that India is the country with the highest number of cases of tuberculosis in the world. WHO tuberculosis statistics for India for 2018 give an estimated incidence figure of 2.69 million cases of tuberculosis for India out of a global incidence of approximately 10.0 million.

 

6

 

 

On March 19, 2020, we announced that CoSara received authorization to begin manufacture and sale of COVID-19 tests in India. Those tests in India are branded as SaraGene COVID-19 tests and are sold exclusively by CoSara. The Indian government places restrictions on the price that could be charged for COVID-19 tests which has limited the revenue in India more than we have experienced in other parts of the world. At the time of this report, CoSara has received CDSCO clearance for RT-PCR tests for Mycobacterium tuberculosis, malaria, hepatitis B, hepatitis C, human papillomavirus (HPV), two COVID-19 assays, chikungunya, dengue, a dengue/chikungunya duplex test, and an influenza A/influenza B/COVID-19 (“ABC”) multiplex test.

 

Europe

 

Molecular diagnostics, such as our tests, are governed in Europe by the framework for in vitro diagnostics (IVDs), which encompasses diagnostic products such as reagents, instruments and systems intended for use in diagnosis of disease. The regulatory system for some IVDs allows for a self-certification procedure, placing heavy responsibility on manufacturers. Non self-certified products are subject to the same standards as self-certified products but are also subject to audit and review by a notified body prior to receiving approval to be CE-marked. A CE-marking is a manufacturer’s declaration that a product meets the requirements of the applicable European Commission directive. Examples of current obligations include having in place a qualitative manufacturing process, user instructions that are clear and fit for purpose, and ensuring that the ‘physical’ features of devices and diagnostics do not pose any danger. If a product fulfils these and other related control requirements, it may be CE-marked as an indication that the product is compliant with EU legislation and sold in the European Union. We have received CE Marks for six of our tests including for COVID-19, COVID-19 (2 gene test), ABC (a triplex test for Flu A, Flu B and COVID-19), a DS (Direct Saliva, extraction-free) COVID-19 test, tuberculosis, Zika, and our Zika, dengue, chikungunya triplex tests.

 

We are ISO 13485:2016 certified, relating to the design and manufacture of our medical device products. The ISO certification indicates that we meet the standards required to self-certify certain of our products and affix a CE-marking for sales of our products in countries accepting the CE marking (not in the United States) with only minimal further governmental approvals and registrations in most countries.

 

United States

 

The U.S. Food and Drug Administration (FDA) has granted permission for us to export all of our IVD products. The FDA’s permission to export was granted under Section 801(e) of the Federal Food, Drug, and Cosmetic Act, as amended (the “FDC Act”). Section 801(e) of the FDA Act covers certain medical devices that have not yet received an approved Premarket Approval in the United States by the FDA, such as our products. We have not commenced any Premarket Approval steps with the FDA. Section 801(e) of the FDA Act applies to medical devices that are acceptable to the importing country and that are manufactured under the FDA’s Good Manufacturing Practices. We have received EUA for our COVID-19 test, which allows sales to qualified labs in the United States.

 

Under our EUA, we are actively selling our Logix Smart™ COVID-19 test to CLIA certified laboratories in the United States and the CLIA labs are able to use our test as it is or further validate our COVID-19 or other tests as Laboratory Developed Tests (LDTs), which refers to a diagnostic test that has been validated for use in the CLIA lab. LDTs may be used by the lab only in that laboratory. CLIA laboratories develop the performance characteristics, perform the analytical validation for their LDTs and obtain licenses to offer them as diagnostic services. The FDA has publicly announced its intention to regulate certain LDTs in a phased-in approach, but draft guidance that was published a couple of years ago was withdrawn at the end of the Obama administration and replaced by an informal non-enforceable discussion paper reflecting some of the feedback that it received on LDT regulation. We are currently marketing our Logix Smart™ COVID-19 test to CLIA laboratories throughout the US.

 

Market Opportunity

 

The market opportunity for our tests changed radically with the emergence of the COVID-19 pandemic. Because we were able to respond rapidly and produce a quality product, we have been able to build a distribution network that extends to more than 80 countries with over 50 active distributors, most of which have been the sales network that has allowed us to export products throughout the world. We believe that after the pandemic is brought under control, the network of distributors that we have built in these extra-ordinary times will serve us well in sales of other diagnostic tests.

 

7

 

 

The molecular diagnostics market is a fast-growing portion of the in vitro (test tube-based, controlled environment) diagnostics market. There are several advantages of PCR tests, such as the ones we market and sell, over other forms of diagnostic testing. These advantages include higher specificity and sensitivity, the ability to perform multiplex tests and the ability to test for drug resistance or for individual genes.

 

Mosquito Vector Control Services

 

In response to market demand, we introduced our first diagnostics tests to be used exclusively to test for mosquito borne pathogens in June 2019. Municipalities in the US and many other countries in the world are concerned about the diseases carried by mosquitos and which infect the human population. To prevent outbreaks of potentially harmful viruses, such as Zika or West Nile, from infecting the public the municipalities conduct mitigation operations to eliminate the mosquito populations carrying the diseases. Because it is too expensive and potentially harmful to the environment to spray all mosquito breeding areas, the solution is to identify which particular area has mosquitos that are carrying the harmful viruses. To know where the host mosquitos with the harmful viruses are located, traps are set, mosquitos collected and then tested to find the areas that most needed spraying. There are over 3,000 mosquito abatement districts throughout the United States and almost all of them conduct testing to help make the spraying more effective.

 

Our first vector related test was a triplex test that tests for West Nile, western equine and St. Louis encephalitis. We began shipping the tests in June 2019. We added a second test that tests mosquitos for Zika, chikungunya and dengue in a triplex test. Finally, in November 2019, we completed a test for West Nile, eastern equine and St. Louis encephalitis, specifically for use in the eastern United States. As a result, mosquito abatement districts can test for three target viruses in one test as compared to performing three different tests using other market available tests, which saves our customers money. Additionally, the districts are more effective because they can get test results in a matter of hours using our product instead of weeks when they might otherwise have to wait for a central lab to process the mosquito tests.

 

We have sold our Vector Smart test products and/or related lab equipment to testing districts in different sections of the country and are marketing our products through trade shows, electronic and regular mail solicitations.

 

Competitive Advantages of Co-Diagnostics

 

We believe that we have the following competitive advantages:

 

  ● Affordability: Lower-cost test kits and low-cost MDx-device.
     
  ● Flexibility: CODX’s tests have been designed to run on many vendors’ DNA/RNA diagnostic testing machines. These tests are particularly well suited to the new generation of “lab-on-a-chip” and “point-of-care” (“LOC and POC”), highly portable analysis machinery for field, clinical and office applications.
     
  ● Speed: We believe our rapid assay design system software provides shorter time to product release. This has been demonstrated with the conception, design, product manufacture, clinical verification and submission for a CE Mark for our Logix Smart™ coronavirus disease (COVID-19) test being approximately 30 days.
     
  ● Accuracy: We believe our technology allows us to build tests that are highly sensitive and specific, the two benchmarks for accuracy in PCR testing.
     
  ● Personalized Medicine: We project that rising health care costs in developed and developing nations will increasingly require that health care systems be patient-specific to eliminate waste, misdiagnoses, and ineffectiveness. A critical component will be accurate, more affordable DNA-based diagnostics, especially in at-home and POC settings, which we plan to offer.
     
  ● Low-cost Provider: Our platform technology obviates the need to pay patent royalties typically required of our competitors, which use patented test platforms to design their tests.

 

8

 

 

  ● Worldwide Footprint: With a dynamic technology that encompasses markets worldwide, we anticipate that we can identify the best target markets, not only in high burden developing countries but also in developed nations.
     
  ● Growth Industry Category: We believe that DNA/RNA testing is the fastest-growing segment of in-vitro diagnostic testing.
     
  ● Combination Product Offering: Our sensitive tests can be a well-designed match for a new generation of handheld and other small POC devices now entering the market, including our own MDx and YourTest PCR™ devices. Used together, these affordable tests and devices may revolutionize the molecular diagnostics industry in cost, speed of test results and simplification.
     
  ● Multiplexing: Our existing multiplexed tests demonstrate that our CoPrimer-designed tests are able to test for multiple targets in the same sample without the distortion caused by false negatives and false positives that often occur in multiplexed tests.

 

Liquid Biopsy for Cancer Screening

 

The enhanced specificity of our technology opens up some unique applications for liquid biopsy, demonstrating its ability to detect small quantities of mutations associated with cancer within an environment of large amounts of normal DNA, as we position the Company to take part in this historic and challenging development in human health care.

 

Agricultural Applications

 

SNP detection is also used in the agricultural industry to identify variations in crop genomes to achieve improved seed viability and other desired characteristics, including drought resistance, disease resistance, pest resistance and higher yield.

 

In mid-2017, the Company was first approached by a large agribusiness to evaluate our ability to multiplex certain target genomes. The results of the development project have successfully demonstrated our ability to not only multiplex the target genomes, but targeted SNP’s as well. The project was undertaken in conjunction with the manufacturer of our CoPrimer tests. The results of the project encouraged the parent of our manufacturer to seek a world-wide licensing arrangement for our CoPrimers™ in the agricultural industry, which was completed in October 2018. Pursuant to the exclusive license for the agronomics industry, the licensee pays us a royalty for all CoPrimers™ sold to the licensee’s customers. In January 2019, the licensee formally introduced the product at a large agricultural conference and has branded the product under the name “BHQ CoPrimers™”.

 

9

 

 

Additional Licensing and Assay Development

 

In addition, the unique properties of our CoPrimer technology make them ideally suited to a variety of applications where sensitivity is key to optimal results, including multiplexing several targets, enhanced SNP detection and enrichment for next generation sequencing. Our licensee for our agricultural testing requested an expansion of our license agreement to include test design services for their customers and potential customers, both in the infectious disease arena as well as for agricultural customers. The license was amended in July 2019 and we expect to derive a license fee from our licensee for its design services. If any of its customers desire to commercialize the tests designed, they will need to seek a commercial license directly from us. Because of these unique characteristics of CoPrimers™, research companies and institutions have requested that we design diagnostics to locate and identify uncommon gene sequences and SNPs and create tests for the target sequences in a multiplexed reaction. This application of our technology is in its beginning stages, but we believe that the results from our initial research indicate a significant step forward in defining the capabilities of our technology, which we believe can be translated to revenue producing licensing arrangements.

 

Intellectual Property

 

Because much of our future success and value depends on our proprietary technology, our patent and intellectual property strategy is of critical importance. Five of our initial U.S. patents related to our technology have been granted by the U.S. Patent and Trademark Office (PTO), including the patent for our CoPrimer technology, which we consider our most important patent. One of our patents has been issued in Great Britain but still pending in the United States, and another has been granted in South Korea. As of March 2022, we have an issued patent in Great Britain and India on “Rapid Oligo Probes.” We also have an issued patent in the U.S. on “Primers for Nucleic Acid Extension or Amplification Reactions.” We have another issued patent in the U.S. on “Detection of Primers for Nucleic Acid Extension or Amplification Reactions.” We have 3 patents issued in the US, as well as patents issued in Australia, Korea, and Mexico on “Cooperative Primers, Probes, and Applications Thereof.” We have applications pending in Australia, Canada, Europe, and the U.S. for “Methods and Compositions for Next Generation Sequencing (NGS) Library Preparation.” We have applications pending in the U.S. and internationally as a PCT application for “Allele-Specific Design of Cooperative Primers for Improved Nucleic Acid Variant Genotyping.” Lastly, we have a provisional application on file in the U.S. for “Methods and Compositions Related to Cooperative Primers and Reverse Transcription.

 

We have identified additional applications of the technology, which represent potential patents that further define specific applications of the processes that are covered by the original patents. We intend to continue building our intellectual property portfolio as development continues and resources are available.

 

We have copyrighted our development software that is used by us to develop diagnostic tests based on our technology.

 

Major Customers

 

We had certain customers which were each responsible for generating 10% or more of our total revenue for the year ended December 31, 2021. Two customers together accounted for approximately 48% of total revenue for the year ended December 31, 2021. These customers may not account for the same percentage of sales in future periods. If we were to sell nothing to those customers in the future, it would have a material adverse effect on our financial condition unless we were able to replace those customers with others.

 

Competition

 

The molecular diagnostics industry is extremely competitive. There are many firms that provide some or all of the products we provide and provide many diagnostic tests that we have yet to develop. Many of these competitors are larger than us and have significantly greater financial resources. Because are more recently established, many of our competitors have a competitive advantage in the diagnostic testing industry because they also have other lines of business in the pharmaceutical industry from which they derive revenues and for which they are well known and respected in the medical profession. We will need to overcome the disadvantage of being perceived as a start up with no significant respect from the medical and testing professionals, although this is changing as we continue to market our Logix Smart™ COVID-19 tests and other tests in the United States to well-known and successful laboratories. In the diagnostic testing industry, we compete with such companies as BioMerieux, Siemens, Qiagen, Cue Health, Lumira Dx and Cepheid and with such pharmaceutical companies as Abbott Laboratories, Becton Dickinson and Johnson and Johnson.

 

10

 

 

Many of these competitors already have an established customer base with industry standard technology, which we must overcome to be successful.

 

Competition is, and will likely continue to be, particularly intense in the market for COVID-19 diagnostic tests. Numerous companies in the United States and internationally have announced their intention to offer new products, services and technologies that could be used in substitution for our Logix Smart™ COVID-19 tests. Many of those competitors are significantly larger, and have substantially greater financial, engineering and other resources, than our company. Existing and potential competitors in the market for COVID-19 diagnostic tests include developers of serological, antigen and molecular tests. We also compete with companies from Asia in certain markets who are willing to sell their tests for much less than we sell our tests, which creates competitive price pressure on us.

 

We expect competition to continue to increase as other established and emerging companies enter the market, as customer requirements evolve, and as new products, services and technologies are introduced. The entrance of new competitors is being encouraged by governmental authorities, who are offering funding to support development of testing solutions for COVID-19. Some of our existing or new competitors may have strong relationships with current and potential customers, including governmental authorities, and, as a result, may be able to respond more quickly to new or changing regulatory requirements, new or emerging technologies, and changes in customer requirements.

 

Government Regulation

 

In the United States, we are regulated by the FDA and our products must be approved, cleared, or authorized by the FDA before we are allowed to sell our tests in the United States as in vitro diagnostics. The FDA granted us an EUA to manufacture and sell our Logix Smart™ COVID-19 test to CLIA labs in the United States. Being ISO certified greatly facilitates our applications for CE-Marking, which allows us to sell any CE Marked test in most countries in Europe, South America and Asia, depending on the country and following that country’s registration process. We currently have CE Markings issued for our Logix Smart™ COVID-19 test, tuberculosis test, our Zika virus test, a triplex test that tests for Zika, dengue, and chikungunya simultaneously, a triplex “ABC” test that identifies and distinguishes between Flu A, Flu B and Covid-19, our SARS-CoV-2 2-gene multiplex test, and our DS (Direct Saliva, extraction-free) COVID-19 test. In addition, our Logix Smart™ COVID-19 has received the license to manufacture and sell in India from India’s CDSCO and the National Epidemiology Institute in Mexico evaluated our Logix Smart™ COVID-19 and ABC tests and approved them for sale in Mexico. We have also received approval to sell in Australia. We are in the process of registering for sale our Logix Smart™ COVID-19 and other tests in a number of major countries around the world.

 

Employees

 

As of December 31, 2021, we had 101 full-time and part-time employees at our executive offices and lab facilities in Salt Lake City, Utah. We have engaged independent contractors in India to promote the use of our products and develop outlets for products and employ the services of independent sales representatives on an “as needed” basis.

 

Organizational History and Corporate Information

 

We were incorporated as Co-Diagnostics, Inc., in Utah on April 18, 2013. Our principal executive office is located 2401 S. Foothill Drive, Salt Lake City, Utah 84109. Our telephone number is (801) 438-1036. Our web address is www.codiagnostics.com. The contents of our website are not incorporated by reference in this Annual Report.

 

11

 

 

Implications of Being an Emerging Growth Company

 

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012. We will remain an emerging growth company until the earlier of (i) the last day of the fiscal year following the fifth anniversary of July 12, 2017, the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Securities Act”); (ii) the last day of the fiscal year in which we have total annual gross revenues of $1 billion or more; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under applicable SEC rules. We expect that we will remain an emerging growth company for the foreseeable future, but cannot retain our emerging growth company status indefinitely. We refer to the Jumpstart Our Business Startups Act of 2012 herein as the “JOBS Act”. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from specified disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:

 

  ● being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure;
     
  ● not being required to comply with the requirement of auditor attestation of our internal controls over financial reporting;
     
  ● not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements;
     
  ● reduced disclosure obligations regarding executive compensation; and
     
  ● not being required to hold a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

 

For as long as we continue to be an emerging growth company, we expect that we will take advantage of the reduced disclosure obligations available to us as a result of that classification. Accordingly, the information contained herein may be different than the information received from other public companies.

 

An emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected to avail ourselves of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the dates on which adoption of such standards is required for other public reporting companies.

 

We are also a “smaller reporting company” as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and have elected to take advantage of certain of the scaled disclosure available for smaller reporting companies.

 

12

 

 

ITEM 1A. RISK FACTORS

 

Risks Related to Our Business and Industry

 

We have a limited commercial history upon which to base our prospects and are not certain that we will sustain profitability in the future.

 

We began operations in April 2013, and we have a limited operating history. We were profitable for the years ended December 31, 2021 and 2020, respectively. Our accumulated retained earnings were $54.2 million and $17.5 million as of December 31, 2021 and 2020, respectively. We realized net income for the first time for the three months ended June 30, 2020. We were able to achieve net income during the prior two fiscal years because we were able to develop, market and profitably sell our LogixSmart COVID-19 and other COVID-19 tests, but we do not have any way to predict how long our market for that test will continue. Potential investors should be aware of the difficulties normally encountered by a new enterprise, many of which are beyond our control, including substantial risks and expenses in the course of developing new diagnostic tests, establishing or entering new markets, organizing operations and marketing procedures. The likelihood of our success must be considered in light of these risks, expenses, complications and delays, and the competitive environment in which we operate. There is, therefore, nothing at this time upon which to base an assumption that our business plan will continue to prove successful, and we may not be able to generate significant revenue, raise additional capital or operate profitably. We will continue to encounter risks and difficulties frequently experienced by early commercial stage companies, including scaling up our infrastructure and headcount, and may encounter unforeseen expenses, difficulties or delays in connection with our growth. In addition, as a result of the start-up nature of our business, we can be expected to continue to sustain substantial operating expenses and may not be able to continue generating sufficient revenues to cover expenditures. Any investment in our company is therefore highly speculative and could result in the loss of any investment.

 

Our near-term success has been dependent on the market for our COVID-19 tests and future success is dependent on continued demand for COVID-19 diagnostics and upon our ability to develop and market other commercially accepted diagnostic tests.

 

Our future success will depend, in part, on the continued market for COVID-19 tests, our ability to develop and sell sufficient quantities of other diagnostics tests, and our ability to successfully receive regulatory approval for and profitably market our “YourTest PCR™ Device.” Attracting new customers and distribution networks requires substantial time and expense. Any failure to continue sales of our tests in sufficient quantities to maintain profitability would adversely affect our operating results. Many factors could affect the market acceptance and commercial success of any of our diagnostic tests and devices, including:

 

  ● Our ability to develop additional infectious disease diagnostic tests for which there is a commercial market.
  ● our ability to convince our potential customers of the advantages and economic value of our tests over competing technologies and diagnostic tests;
  ● the breadth of our test menu relative to competitors;
  ● changes to policies, procedures or currently accepted best practices in clinical diagnostic testing;
  ● the extent and success of our marketing and sales efforts; and
  ● our ability to manufacture in quantity our commercial diagnostic tests and meet demand in a timely fashion.

 

General Risk Factors

 

The price of our common stock may fluctuate substantially.

 

The market price of our common stock may be subject to wide fluctuation in response to various factors, some of which are beyond our control. Some factors that may cause the market price of our common stock to fluctuate, in addition to the other risks mentioned in this “Risk Factors” section and elsewhere in this report, are:

 

  ● sales of our common stock by our shareholders, executives, and directors;
  ● our ability to enter new markets;
  ● actual or un-anticipated fluctuations in our annual and quarterly financial results;
  ● our ability to obtain financings to continue and expand our commercial activities, expand our manufacturing operations, conduct research and development activities including, but not limited to, human clinical trials, and other business activities;

 

13

 

 

  ● our ability to secure resources and the necessary personnel to continue and expand our commercial activities, develop additional diagnostic tests, conduct clinical trials and gain approval for our diagnostic tests on our desired schedule;
  ● commencement, enrollment or results of our clinical trials of our diagnostic tests or any future clinical trials we may conduct;
  ● changes in the development status of our diagnostic tests;
  ● any delays or adverse developments or perceived adverse developments with respect to review by the FDA or other similar foreign regulatory authorities of our planned clinical trials;
  ● any delay in our submission for studies or test approvals or adverse regulatory decisions, including failure to receive regulatory approval for our diagnostic tests;
  ● our announcements or our competitors’ announcements regarding new tests, enhancements, significant contracts, acquisitions or strategic investments;
  ● failures to meet external expectations or management guidance;
  ● changes in our capital structure or dividend policy, including as a result of future issuances of securities and sales of large blocks of common stock by our shareholders;
  ● announcements and events surrounding financing efforts, including debt and equity securities;
  ● competition from existing technologies and diagnostic tests or new technologies and diagnostic tests that may emerge;
  ● announcements of acquisitions, partnerships, collaborations, joint ventures, new diagnostic tests, capital commitments, or other events by us or our competitors;
  ● changes in general economic, political and market conditions in any of the regions in which we conduct our business;
  ● changes in industry conditions or perceptions;
  ● changes in valuations of similar companies or groups of companies;
  ● analyst research reports, recommendations and changes in recommendations, price targets and withdrawals of coverage;
  ● departures and additions of key personnel;
  ● disputes and litigations related to intellectual properties, proprietary rights, and contractual obligations;
  ● changes in applicable laws, rules, regulations, or accounting practices and other dynamics;
  ● actions taken by our principal shareholders and release or expiry of lockup or other transfer restrictions; and
  ● other events or factors, many of which may be out of our control.

 

In addition, if the market for stocks in our industry or industries related to our industry, or the stock market in general, experiences a loss of investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, financial condition and results of operations. If any of the foregoing occurs, it could cause our stock price to fall and may expose us to lawsuits that, even if unsuccessful, could be costly to defend and a distraction to management.

 

Future sales of our common stock in the public market may cause our stock price to decline and impair our ability to raise future capital through the sale of our equity securities.

 

There are a substantial number of shares of our common stock held by shareholders who owned shares of our capital stock prior to our initial public offering that may be able to sell in the public market. Sales by such shareholders of a substantial number of shares could significantly reduce the market price of our common stock.

 

Shares issued by us upon exercise of options granted under our equity plan will be eligible for sale in the public market. If any of these holders cause a large number of securities to be sold in the public market, the sales could reduce the trading price of our common stock. These sales also could impede our ability to raise capital in the future.

 

Anti-takeover provisions in our charter documents and Utah law could discourage delay or prevent a change of control of our Company and may affect the trading price of our common stock.

 

We are a Utah corporation and the anti-takeover provisions of the Utah Control Shares Acquisition Act may discourage, delay or prevent a change of control by limiting the voting rights of control shares acquired in a control share acquisition. In addition, our Articles of Incorporation and Bylaws may discourage, delay or prevent a change in our management or control over us that shareholders may consider favorable. Among other things, our Amended and Restated Articles of Incorporation and Bylaws:

 

  ● authorize the issuance of “blank check” preferred stock that could be issued by our board of directors in response to a takeover attempt;
     
  ● provide that vacancies on our board of directors, including newly created directorships, may be filled only by a majority vote of directors then in office, except a vacancy occurring by reason of the removal of a director without cause shall be filled by vote of the shareholders; and
     
  ● limit who may call special meetings of shareholders.

 

14

 

 

These provisions could have the effect of delaying or preventing a change of control, whether or not it is desired by, or beneficial to, our shareholders.

 

NASDAQ may delist our common stock from its exchange, which could limit investors’ ability to make transactions in our common stock and subject us to additional trading restrictions.

 

Should we fail to satisfy the continued listing requirements of the NASDAQ Capital Market, such as the corporate governance requirements or the minimum closing bid price requirement, NASDAQ may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we would take actions to restore our compliance with the NASDAQ Capital Market’s listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the NASDAQ Capital Market’s minimum bid price requirement or prevent future non-compliance with the NASDAQ Capital Market’s listing requirements.

 

If the NASDAQ Capital Market does not maintain the listing of our securities for trading on its exchange, we could face significant material adverse consequences, including:

 

  ● a limited availability of market quotations for our securities;
     
  ● reduced liquidity with respect to our securities;
     
  ● a determination that our shares of common stock are “penny stock” which will require brokers trading in our shares of common stock to adhere to more stringent rules, possibly resulting in a reduced level of trading activity in the secondary trading market for our shares of common stock;
     
  ● a limited amount of news and analyst coverage for our company; and
     
  ● decreased ability to issue additional securities or obtain additional financing in the future.

 

Therefore, it may be difficult for our shareholders to sell any shares if they desire or need to sell them.

 

We do not currently intend to pay dividends on our common stock.

 

We do not expect to pay cash dividends on our common stock. Any future dividend payments are within the absolute discretion of our board of directors and will depend on, among other things, our results of operations, working capital requirements, capital expenditure requirements, financial condition, contractual restrictions, business opportunities, anticipated cash needs, provisions of applicable law and other factors that our board of directors may deem relevant. We may not generate sufficient cash from operations in the future to pay dividends on our common stock.

 

We are an “emerging growth company” and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies, which could make our common stock less attractive to investors.

 

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Investors may find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an “emerging growth company.” We will remain an “emerging growth company” until the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.0 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering; (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission.

 

15

 

 

We have elected to use the extended transition periods for complying with new or revised accounting standards.

 

We have elected to use the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transaction period provided in Section 7(a)(2)(B). As a result, our financial statements may not be comparable to those of companies that comply with public company effective dates.

 

Our management is required to devote substantial time to compliance initiatives.

 

As a public company, we incur significant legal, accounting and other expenses that we did not incur as a newly formed entity. The Sarbanes-Oxley Act, as well as rules subsequently implemented by the Securities and Exchange Commission, and NASDAQ, have imposed various new requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Our management and other personnel devote a substantial amount of time to these new compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time consuming and costly. We expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

None.

 

ITEM 2. PROPERTIES

 

Our headquarters are located at 2401 S. Foothill Drive, Salt Lake City, Utah. Our current facility has approximately 14,000 square feet of laboratory and office space under a lease that expires in February 2024. Our recently acquired subsidiaries also lease additional laboratory and office space under month-to-month leases. We believe the facility we lease is sufficient to meet our needs for the immediate future.

 

ITEM 3. LEGAL PROCEEDINGS

 

In July 2020, we were served in an action filed in the United States District Court for the District of Utah claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The Plaintiff, Gelt Trading, Ltd., a Cayman Islands limited company, demands compensatory damages sustained as a result of our alleged wrongdoing in an amount to be proven at trial. We will vigorously defend this action as we do not believe it has any merit.

 

In July 2020, we were served in an action filed in the United States District Court for the District of Utah claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The Plaintiff, Fernando Hernandez demands compensatory damages sustained as a result of our alleged wrongdoing in an amount to be proven at trial. We will vigorously defend this action as we do not believe it has any merit.

 

In September 2020, we were served in an action filed in the United States District Court for the District of Utah claiming that the officers and the directors harmed the Company by promulgating false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The Plaintiff, Luis Aguliera, on behalf of Co-Diagnostics, Inc. seeks damages from the individual defendants and attorneys’ fees. We will vigorously defend this as we do not believe it has any merit.

 

16

 

 

In December 2020, we were served in an action filed in the United States District Court for the District of Utah claiming that the officers and the directors harmed the Company by promulgating false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The Plaintiff, Melvyn Klein, on behalf of Co-Diagnostics, Inc. seeks damages from the individual defendants and attorneys’ fees. We will vigorously defend this as we do not believe it has any merit.

 

In December 2020, we were served in an action filed in the United States District Court for the District of Utah claiming that the officers and the directors harmed the Company by promulgating false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The Plaintiff, Mathew Wallace, on behalf of Co-Diagnostics, Inc. seeks damages from the individual defendants and attorneys’ fees. We will vigorously defend this as we do not believe it has any merit.

 

From time to time, we may become involved in litigation relating to claims arising out of our operations in the normal course of business. Although we have received inquiries from FINRA, NASDAQ and the SEC, to which we have responded, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of our properties or businesses are subject, which would reasonably be likely to have a material adverse effect on the Company.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER EQUITY SECURITIES

 

Market Information

 

Our common stock has been quoted on the NASDAQ market under the symbol “CODX” since July 12, 2017. The following table sets forth the high and low prices for our common stock for the periods indicated, as reported by NASDAQ.

 

Calendar Quarter Ended:   High  Low 
March 31, 2021   $20.69  $7.86 
June 30, 2021   $9.91  $7.01 
September 30, 2021   $11.82  $7.35 
December 31, 2021   $10.90  $7.90 

 

Calendar Quarter Ended:   High  Low 
March 31, 2020   $21.75  $0.88 
June 30, 2020   $29.72  $6.81 
September 30, 2020   $30.99  $8.07 
December 31, 2020   $16.96  $9.01 

 

Holders

 

As of March 22, 2022, the last reported sales price reported on NASDAQ for our common stock was $6.47 per share. As of March 22, 2022, we had approximately 154 record holders of our common stock. The number of record holders was determined from the records of our transfer agent and does not include beneficial owners of common stock whose shares are held in the names of various security brokers, dealers, and registered clearing agencies. The transfer agent for our common stock is VStock Transfer LLC located at 18 Lafayette Pl, Woodmere, New York 11598.

 

17

 

 

Dividends

 

We have never declared or paid any cash dividends on our capital stock. The payment of dividends on our common stock in the future will depend on our earnings, capital requirements, operating and financial condition and such other factors as our Board of Directors may consider appropriate. We do not anticipate paying dividends on our common stock in the foreseeable future.

 

Recent Sales of Unregistered Securities

 

We issued the unregistered securities below. For the issuances of unregistered securities, we relied on the exemption from registration requirements of the Securities Act of 1933, as amended, available under Section 4(a)(2) promulgated thereunder due to the fact that such issuances did not involve a public offering of securities.

 

  ● During the year ended December 31, 2021, we issued an aggregate of 5,548 shares of our common stock for services rendered pursuant to consulting agreements.

 

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

 

None.

 

ITEM 6. RESERVED

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT OF OPERATIONS

 

The following management’s discussion and analysis of financial condition and results of operations describes the principal factors affecting the results of our operations, financial condition, and changes in financial condition. This discussion should be read in conjunction with the accompanying audited financial statements, and notes thereto, included elsewhere in this report. In addition to historical information, this Annual Report contains forward-looking statements that involve risks, uncertainties, and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including but not limited to those set forth under the caption “Item 1A. Risk Factors” in this Annual Report on Form 10-K.

 

Business Overview

 

Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CODX”), develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. In connection with the sale of our tests we may sell diagnostic equipment from other manufacturers as self-contained lab systems (which we refer to as the “MDx Device”). We have also developed a unique, groundbreaking portable PCR device (the “YourTest PCR™ Device”) that has been designed to bring affordable, reliable gold-standard polymerase chain reaction to patients in point-of-care and even at-home settings.

 

Our diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. CODX’s technical advance involves a novel, patented approach to PCR test design of primer and probe structure (“CoPrimers™”) that eliminates one of the key vexing issues of PCR amplification, the exponential growth of primer-dimer pairs (false positives and false negatives) which adversely interferes with identification of the target DNA/RNA.

 

We believe our proprietary molecular diagnostics technology is paving the way for innovation in disease detection and life sciences research through our enhanced detection of genetic material. For various reasons, including owning our own our platform, we believe we will be able to accomplish this faster and more economically, allowing for significant margins while still positioning the Company to be a low-cost provider of molecular diagnostics and screening services.

 

18

 

 

In addition, continued development has demonstrated the unique properties of our CoPrimer technology that we believe makes it ideally suited for a variety of applications where specificity is key to optimal results, including multiplexing several targets, enhanced Single Nucleotide Polymorphism (“SNP”) detection and enrichment for next generation sequencing.

 

Our scientists use the complex mathematics of DNA/RNA test design to engineer and optimize DNA/RNA tests and to automate algorithms that rapidly screen millions of possible options to pinpoint the optimum design. Dr. Brent Satterfield, our founder, developed the Company’s intellectual property consisting of the predictive mathematical algorithms and patented molecular structure used in the testing process, which together represent a major advance in PCR testing systems. CODX technologies are now protected by more than 20 granted or pending US and foreign patents, as well as certain trade secrets and copyrights. Ownership of our proprietary platform permits us the advantage of avoiding payment of patent royalties required by other PCR test systems, which may allow the sale of diagnostic PCR tests at a lower price than competitors, while enabling us to maintain profit margins.

 

We may either sell or lease the MDx Device to labs and diagnostic centers, through sale or lease agreements, and sell the reagents that comprise our proprietary tests to those laboratories and testing facilities.

 

Our proprietary test design process involves identifying the optimal locations on the target genes for amplification and pair the locations with the optimized primer and probe structure to achieve outputs that meet the design input requirements identified from market research. This is done by following planned and documented processes, procedures and testing. In other words, we use the data resulting from our tests to verify whether we succeeded in designing what we intended at the outset. Verification is a series of testing that concludes that the product is ready to proceed to validation in an evaluation either in our laboratory or in an independent laboratory setting using initial production tests to confirm that the product as designed meets the user needs.

 

Using our proprietary test design system and proprietary reagents, we have designed and obtained regulatory approval in the European Community and/or in India to sell PCR diagnostic tests for the detection of COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In the United States, CODX has obtained Emergency Use Authorization (“EUA”) for its Logix Smart™ COVID-19 detection test from the Food and Drug Administration, or FDA, and sells that test to qualified labs. In addition, our COVID-19 detection test and certain of our other suite of COVID-19 products have been approved for sale in countries such as the United Kingdom, Australia and Mexico by the regulatory bodies in those countries and have been registered for sale in many more countries.

 

In addition to testing for infectious disease, the technology lends itself to identifying any section of a DNA or RNA strand that describe any type of genetic trait, which creates a number of significant applications. We, in conjunction with our customers, are active in designing and licensing tests that identify genetic traits in plant and animal genomes. We also have three multiplexed tests developed to test mosquitos for the identification of diseases carried by the mosquitos to enable municipalities to concentrate their efforts in managing mosquito populations on the specific areas known to be breeding the mosquitos that carry deadly viruses.

 

19

 

 

RESULTS OF OPERATIONS

 

Results of Operations for the Years Ended December 31, 2021 and 2020

 

The table below provides a comparison of our operating results for the year ended December 31, 2021 as compared to the year ended December 31, 2020.

 

   Years Ended December 31,   Year Change 
   2021   2020   Change   % 
Revenue  $97,885,603   $74,552,758   $23,332,845    31%
Cost of revenue   11,574,944    16,591,346    (5,016,402)   -30%
Gross profit   86,310,659    57,961,412    28,349,247    49%
Operating expenses                    
Sales and marketing   13,397,813    4,665,113    8,732,700    187%
General and administrative   11,550,615    8,278,734    3,271,881    40%
Research and development   14,961,916    3,185,290    11,776,626    370%
Depreciation and amortization   335,363    138,635    196,728    142%
Total operating expenses   40,245,707    16,267,772    23,977,935    147%
Income from operations   46,064,952    41,693,640    4,371,312    10%
Other income (expense)                    
Interest income   45,631    97,215    (51,584)   -53%
Loss on disposition of assets   (44,355)   (175)   (44,180)   25246%
Gain (loss) on equity method investment in joint venture   (430,433)   778,385    (1,208,818)   -155%
Total other income (expense)   (429,157)   875,425    (1,304,582)   -149%
Income before income taxes   45,635,795    42,569,065    3,066,730    7%
Income tax provision   8,977,231    90,536    8,886,695    9816%
Net income  $36,658,564   $42,478,529   $(5,819,965)   -14%

 

Revenues

 

For the year ended December 31, 2021, we generated $97.9 million of revenue compared to revenue of $74.5 million in the year ended December 31, 2020. The increase in revenue of $23.3 million was primarily due to sales of our LogixSmart COVID-19 test throughout the world, which was developed in response to the current COVID-19 pandemic. Of the total revenue in 2021 and 2020, respectively, $0.5 million and $3.7 million was from the sale of third party manufactured equipment and supplies that we sourced and sold to customers to facilitate usage of our test.

 

Cost of Revenues and Gross Profit

 

Cost of revenues decreased by $5.0 million from $16.6 million for the year ended December 31, 2020 to $11.6 million for the year ended December 31, 2021. The decrease in cost of revenues was due to a reduction of production costs and the reduction in sales of third-party equipment, which have a higher cost of sales than tests, and the commission structure of certain sales of tests sold during the year. Our gross margin was 88.2% for the year ended December 31, 2021 compared to 77.7% for the year ended December 31, 2020. The increase in gross margin was due to the reduction of production costs, as well as the mix of products we sold, with the majority of our 2021 revenue came from sales of our test reagents, which has a higher profit margin than sales of equipment.

 

Operating Expenses

 

We incurred total operating expenses of $40.2 million for the year ended December 31, 2021 compared to total operating expenses of $16.3 million for the year ended December 31, 2020. The increase in operating expenses was primarily due to the increase in business activities experienced as a result of our increase in revenue, increased third party sales commissions, reflected in sales and marketing, and increased investment in research and development.

 

Sales and marketing expenses for the year ended December 31, 2021 were $13.4 million compared to $4.7 million for the year ended December 31, 2020. The increase of $8.7 million was primarily a result of increased expenses related to stock-based compensation, and personnel related expenses, including commissions paid to our sales team and distributors, due to the growth in revenue noted above.

 

20

 

 

General and administrative expenses increased $3.3 million from $8.3 million for the year ended December 31, 2020 to $11.6 million for the year ended December 31, 2021. The increase in general and administrative expenses was primarily due to increased activity to support the growth of our business. The primary drivers of the increased expenses related to increases in stock-based compensation, employee related expenses and increased expenses for professional services.

 

Our research and development expenses increased by $11.8 million from $3.2 million for the year ended December 31, 2020, to $15.0 million for the year ended December 31, 2021. The primary increase in expenses related to expenditures of over $9.2 million for our point-of-care device, as well as increases in salaries and related benefits, including stock-based compensation, as we have added additional employees to our research and development team to increase our product development activities. Additionally, there has been an increase in professional and lab services utilized to further help us in our research and product development activities.

 

Other Income (Expense)

 

Other expense was $0.4 million for the year ended December 31, 2021, compared to other income of $0.9 million for the year ended December 31, 2020. The decrease in other income of $1.3 million was primarily related to recording a loss of $0.4 million in 2021 from our India joint venture. For the year ended December 31, 2020 we recorded a gain of $0.8 million from our India joint venture.

 

Net Income

 

We realized net income for the year ended December 31, 2021 of $36.7 million compared to net income of $42.5 million for the year ended December 31, 2020. The decrease in net income of $5.8 million was primarily the result of sales of our LogixSmart COVID-19 test and resulting margins from those sales offset by increased operating expenses as discussed above. Additionally, we recorded income tax expense of $9.0 million during the year ended December 31, 2021, compared to $0.1 million for the year ended December 31, 2020. During 2020, we released our deferred tax asset valuation allowance and recorded a deferred tax asset since we utilized our net operating losses from prior years during the year ended December 31, 2020.

 

LIQUIDITY AND CAPITAL RESOURCES

 

At December 31, 2021, we had cash and cash equivalents of $88.6 million and marketable investment securities of $1.3 million that could readily be converted into cash if needed. Additionally, our total current assets at December 31, 2021, were $115.1 million compared to total current liabilities of $12.6 million.

 

Net cash provided by operating activities during the year ended December 31, 2021 was $41.1 million, compared to $28.2 million for the year ended December 31, 2020. The increase in cash from operating activities was primarily due to our increased revenue and decrease in inventory, offset by increases in accounts receivable.

 

We received $4.1 million of cash from investing activities during the year ended December 31, 2021 as compared to $5.8 million of cash used in investing activities during the year ended December 31, 2020. The increase in cash provided by investing activities is primarily due to net cash acquired from business acquisitions and proceeds received from maturities of marketable investment securities.

 

Net cash provided by financing activities was $0.5 million for the year ended December 31, 2021, compared to $19.7 million for the year ended December 31, 2020. The decrease is primarily due to net proceeds of $18.0 million received from a series of three registered direct offerings in 2020 pursuant to our shelf registration in addition to receiving $1.7 million from the exercise of warrants and options for the year ended December 31, 2020.

 

Since commencing sales of our Logix Smart™ COVID-19 test in March 2020, we have used our cash generated from those sales to fund the purchase of inventories and the development of our point-of-care device, and to pay our operating expenses. We have increased our work force most significantly in research and development in order to continue development of a new device and additional tests that will enable continued use of our distributor network to sell additional products throughout the world.

 

21

 

 

We believe that our existing capital resources and the cash generated from future sales will be sufficient to meet our projected operating requirements for the next 12 months. However, our available capital resources may be consumed more rapidly than currently expected and we may need or want to raise additional financing for strategic opportunities. If needed, we expect additional investment capital to come from (i) additional issuances of our common stock with existing and new investors or (ii) the private placement of other securities with investors similar to those that have provided funding in the past. We may not be able to secure such financing in a timely manner or on favorable terms, if at all.

 

On October 30, 2020, we filed a Registration Statement on Form S-3 (File No: 333-249651) with the Securities and Exchange Commission (the “SEC”). The SEC declared the Form S-3 effective on November 5, 2020. Pursuant to a prospectus supplement to the Form S-3, we may offer and sell up to $100 million of the following securities separately or together, in one or more series or classes and in amounts, at prices and on terms described in one or more offerings: common stock; preferred stock; warrants to purchase our securities, each of which may be convertible into equity securities; or units comprised of, or other combinations of, the foregoing securities through underwriting syndicates managed or co-managed by one or more underwriters or dealers, through agents or directly to purchasers. Each time our securities are offered, we will provide a prospectus supplement to the Form S-3 containing more specific information about the particular offering. To date, we have not filed a prospectus supplement to, or sold any securities under, this Form S-3.

 

Below is a summary of the direct offerings done in 2020:

 

  ● In January 2020, we sold an aggregate of 3,448,278 shares of common stock to institutional investors for $1.45 per share for gross proceeds of approximately $5.0 million pursuant to a shelf-registration statement on Form S-3 (File No: 333-226835) declared effective by the SEC on September 7, 2018 (the “Shelf Registration Statement”).
     
  ● On February 10, 2020, the Company entered into securities purchase agreements with certain institutional investors pursuant to which such investors purchased an aggregate of 3,324,676 shares of common stock at a purchase price of $ 3.08 per share in a registered direct offering pursuant to the Shelf Registration Statement. The aggregate gross proceeds for the sale of the shares were approximately $10.2 million. The closing of the offering occurred on or about February 13, 2020.
     
  ● On February 28, 2020, the Company entered into securities purchase agreements with certain institutional investors pursuant to which such investors purchased an aggregate of 470,000 shares of common stock at a purchase price of $9.00 per share in a registered direct offering pursuant to the Shelf Registration Statement. The aggregate gross proceeds for the sale of the shares were approximately $4.0 million. The closing of the offering occurred on or about February 28, 2020.

 

The foregoing estimates, expectations and forward-looking statements are subject to change as we make strategic operating decisions from time to time and as our revenue and expenses fluctuate from period to period.

 

Off-Balance Sheet Arrangements

 

As of December 31, 2021 and 2020, we had no off-balance sheet arrangements.

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not required.

 

22

 

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

 

CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2021 AND 2020

 

Table of Contents

 

Report of Independent Registered Public Accounting Firm (PCAOB ID No. 457)   23
Balance Sheets   24
Statements of Operations   25
Statement of Changes in Stockholders’ Equity   26
Statements of Cash Flows   27
Notes to Financial Statements   28

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Stockholders of Co-Diagnostics, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying balance sheets of Co-Diagnostics, Inc. (the Company) as of December 31, 2021 and 2020, and the related statements of operations, changes in stockholders’ equity, and cash flows for each of the years in the two-year period ended December 31, 2021, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020 and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2021, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Haynie & Company

Salt Lake City, Utah

March 24, 2022

 

We have served as the Company’s auditor since 2016.

 

23

 

 

CO-DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

 

   December 31, 2021   December 31, 2020 
Assets          
Current assets          
Cash and cash equivalents  $88,607,234   $42,976,713 
Marketable investment securities   1,255,266    4,335,446 
Accounts receivable, net   20,839,182    12,136,833 
Inventory   2,004,169    7,995,189 
Prepaid expenses   2,338,444    369,028 
Note receivable   75,000    - 
Total current assets   115,119,295    67,813,209 
Property and equipment, net   1,933,216    949,639 
Goodwill   14,706,818    - 
Intangible assets, net   27,195,000    - 
Investment in joint venture   1,004,953    1,927,125 
Deferred tax asset   -    547,224 
Note receivable   75,000    - 
Total assets  $160,034,282   $71,237,197 
Liabilities and stockholders’ equity          
Current liabilities          
Accounts payable  $607,506   $598,318 
Accrued expenses, current   3,859,652    2,849,503 
Accrued expenses (related party), current   -    120,000 
Contingent consideration liabilities, current   

5,767,304

    - 
Income taxes payable   2,213,088    189,729 
Deferred revenue   150,000    305,307 
Total current liabilities   12,597,550    4,062,857 
Long-term liabilities          
Income taxes payable   1,067,853    

447,831

 
Deferred tax liability   7,228,444    - 
Contingent consideration liabilities   4,665,337    - 
Accrued expenses (related party), noncurrent   -    30,000 
Total long-term liabilities   

12,961,634

    477,831 
Total liabilities   25,559,184    4,540,688 
Commitments and contingencies (Note 14)   -    - 
Stockholders’ equity          
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2021 and December 31, 2020   -    - 
Common stock, $0.001 par value; 100,000,000 shares authorized; 33,819,862 and 28,558,033 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively   33,820    28,558 
Additional paid-in capital   80,271,999    49,157,236 
Accumulated earnings   54,169,279    17,510,715 
Total stockholders’ equity   134,475,098    66,696,509 
Total liabilities and stockholders’ equity  $160,034,282   $71,237,197 

 

See accompanying notes to consolidated financial statements.

 

24

 

 

CO-DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

 

   2021   2020 
   Years Ended December 31, 
   2021   2020 
Revenue  $97,885,603   $74,552,758 
Cost of revenue   11,574,944    16,591,346 
Gross profit   86,310,659    57,961,412 
Operating expenses          
Sales and marketing   13,397,813    4,665,113 
General and administrative   11,550,615    8,278,734 
Research and development   14,961,916    3,185,290 
Depreciation and amortization   335,363    138,635 
Total operating expenses   40,245,707    16,267,772 
Income from operations   46,064,952    41,693,640 
Other income (expense)          
Interest income   45,631    97,215 
Loss on disposition of assets   (44,355)   (175)
Gain (loss) on equity method investment in joint venture   (430,433)   778,385 
Total other income (expense)   (429,157)   875,425 
Income before income taxes   45,635,795    42,569,065 
Income tax provision   8,977,231    90,536 
Net income  $36,658,564   $42,478,529 
Earnings per common share:          
Basic  $1.27   $1.59 
Diluted  $1.23   $1.52 
Weighted average shares outstanding:          
Basic   28,874,555    26,720,133 
Diluted   29,903,686    28,000,341 

 

See accompanying notes to consolidated financial statements.

 

25

 

 

CO-DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

 

                                    
    Convertible Preferred Stock     Common Stock     Additional Paid-in     Accumulated Earnings     

Total Stockholders’

 
    Shares     Amount     Shares     Amount     Capital     (Deficit)     Equity 
Balance as of December 31, 2019   25,600   $26    17,342,922   $17,343   $26,687,701   $(24,967,814)  $1,737,256 
Public offering, net of offering costs of $1,457,922   -    -    7,242,954    7,243    18,004,840    -    18,012,083 
Common stock issued for warrant exercises   -    -    856,660    857    269,143    -    270,000 
Common stock issued for option exercises   -    -    871,229    871    1,459,729    -    1,460,600 
Stock-based compensation expense   -    -    110,935    111    2,737,930    -    2,738,041 
Conversion of preferred stock to common   (25,600)   (26)   2,133,333    2,133    (2,107)   -    - 
Net income   -    -    -    -    -    42,478,529    42,478,529 
Balance as of December 31, 2020   -   $-    28,558,033   $28,558   $49,157,236   $17,510,715   $66,696,509 
Common stock issued for option exercises   -    -    189,225    189    450,209    -    450,398 
Stock-based compensation expense   -    -    444,050    444    5,508,960    -    5,509,404 
Common stock issued for acquisitions   -    -    4,628,554    4,629    25,155,594    -    25,160,223 
Net income   -    -    -    -    -    36,658,564    36,658,564 
Balance as of December 31, 2021   -   $-    33,819,862   $33,820   $80,271,999   $54,169,279   $134,475,098 

 

See accompanying notes to consolidated financial statements.

 

26

 

 

CO-DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   2021   2020 
   Years Ended December 31, 
   2021   2020 
Cash flows from operating activities          
Net income  $36,658,564   $42,478,529 
Adjustments to reconcile net income to cash used in operating activities:          
Depreciation and amortization   335,363    138,635 
Stock-based compensation expense   5,509,404    2,738,041 
Loss (gain) from equity method investment   430,433    (778,385)
Loss on disposition of assets   44,355    175 
Deferred income taxes   930,081    (547,224)
Bad debt expense   69,672    954,804 
Changes in assets and liabilities:          
Accounts receivable   (8,740,851)   (12,960,255)
Prepaid expenses   (2,049,095)   (6,462)
Inventory   5,705,361    (7,915,241)
Deferred revenue   (155,307)   303,984 
Income taxes payable   2,643,381    - 
Accounts payable and accrued expenses   (299,937)   3,758,634 
Net cash provided by operating activities   41,081,424    28,165,235 
Cash flows from investing activities          
Purchases of property and equipment   (669,463)   (774,397)
Purchases of marketable investment securities   -    (9,310,000)
Proceeds from maturities of marketable investment securities   3,080,180    4,974,554 
Investment in joint venture   491,739    (714,500)
Business combinations, net of cash acquired   1,196,243    - 
Net cash provided by (used in) investing activities   4,098,699    (5,824,343)
Cash flows from financing activities          
Proceeds from sale of common stock   -    19,470,005 
Proceeds from exercise of options and warrants   450,398    1,730,599 
Payment of offering costs   -    (1,457,921)
Net cash provided by financing activities   450,398    19,742,683 
Net increase in cash and cash equivalents   45,630,521    42,083,575 
Cash and cash equivalents at beginning of period   42,976,713    893,138 
Cash and cash equivalents at end of period  $88,607,234   $42,976,713 
Supplemental disclosure of cash flow information          
Interest paid  $-   $- 
Income taxes paid  $5,403,769   $- 
Supplemental disclosure of non-cash investing and financing transactions          
Inventory moved to property, plant and equipment  $285,659   $117,220 
Fair value of common stock issued as consideration for business acquisitions  $25,160,223   $- 
Fair value of contingent common stock and warrants issued as consideration for business acquisitions  $10,432,641   $- 

 

See accompanying notes to consolidated financial statements.

 

27

 

 

CO-DIAGNOSTICS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED DECEMBER 31, 2021 AND 2020

 

Note 1 – Overview and Basis of Presentation

 

Description of Business

 

Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CODX”), is developing robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The Company develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA). In connection with the sale of these tests, the Company may sell diagnostic equipment and supplies from other manufacturers.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include receivables and other long-lived assets, legal and regulatory contingencies, income taxes, share based arrangements, and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates.

 

Basis of Presentation

 

The accompanying audited consolidated financial statements of Co-Diagnostics, Inc. and its wholly owned subsidiaries have been prepared to reflect the financial position, results of operations and cash flows of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated.

 

Note 2 – Summary of Significant Accounting Policies

 

Reclassifications

 

Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.

 

Cash and Cash Equivalents

 

Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of December 31, 2021 and December 31, 2020. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.

 

Marketable Investment Securities

 

The Company’s marketable investment securities are comprised of investments in certificates of deposit. The Company determines the appropriate classification of its marketable investment securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable investment securities as available-for-sale securities as the Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. As a result, the Company classifies its marketable investment securities, including securities with stated maturities beyond twelve months, within current assets in the consolidated balance sheets. Any unrealized gains or losses are immaterial.

 

Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At December 31, 2021 total accounts receivable was $21,508,779 with an allowance for uncollectable accounts of $669,597 resulting in a net amount of $20,839,182. At December 31, 2020 total accounts receivable was $12,928,633 with an allowance for uncollectable accounts of $791,800 resulting in a net amount of $12,136,833.

 

28

 

 

Equity-Method Investments

 

Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.

 

Inventory

 

Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At December 31, 2021, the Company had $2,004,169 in inventory, of which $983,088 was finished goods and $1,021,081 was raw materials. At December 31, 2020, the Company had $7,995,189 in inventory, of which $598,881 was finished goods and $7,396,308 was raw materials. The Company establishes reserves to reduce low-moving, obsolete, or unusable inventories to their estimated useful or scrap values.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.

 

The Company reviews its long-lived assets, including property and equipment, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.

 

Business Combinations

 

We estimate the fair value of assets acquired and liabilities assumed in a business combination. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable, and as a result, actual results may differ from estimates.

 

Revenue Recognition

 

The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation. Based on the criteria above, the Company typically recognizes revenue upon delivery.

 

The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.

 

Deferred Revenue

 

Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.

 

29

 

 

Research and Development

 

Research and development costs are expensed when incurred. The Company expensed $14,961,916 and $3,185,290 of research and development costs for the years ended December 31, 2021 and 2020, respectively.

 

Stock-based Compensation

 

The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.

 

Income Taxes

 

The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.

 

Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.

 

Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. While the Company believes it has no significant uncertain income tax positions in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.

 

Net Income per Share

 

Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.

 

Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive

 

Concentrations Risk and Significant Customers

 

The Company had certain customers which are each responsible for generating 10% or more of the total revenue for the years ended December 31, 2021 and 2020. Two customers together accounted for approximately 48% and 38% of total revenue for the years ended December 31, 2021 and 2020, respectively.

 

Two customers each accounted for more than 10% of accounts receivable at December 31, 2021 and 2020. These two customers together accounted for approximately 66% and 48% of accounts receivable at December 31, 2021 and 2020, respectively.

 

30

 

 

Recently Issued Accounting Standards

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.

 

As an emerging growth company (“EGC”), the Company has elected to take advantage of the benefits of the extended transition period provided for in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards which allows the Company to defer adoption of certain accounting standards until those standards would otherwise apply to private companies.

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires recognition of leased assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies like us. The Company will use the modified retrospective transition method with the option to recognize a cumulative-effect adjustment at the date of adoption. The Company’s balance sheet will be impacted as it records right-of-use assets and lease liabilities on its consolidated balance sheets, but the Company does not expect the adoption of this standard will have a material impact on its consolidated statements of operations and cash flows.

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for certain financial instruments, which includes the Company’s accounts receivable. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies. The standard requires a cumulative effect adjustment to the balance sheet as of the beginning of the first early reporting period in which the guidance is effective. The Company is evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements but does not expect the adoption of this standard will have a material impact on its consolidated financial statements.

 

Note 3 – Business Combinations

 

On December 31, 2021, the Company completed its acquisition of Advanced Conceptions, Inc. (“ACI”) and Idaho Molecular Inc. (“IdMo”), which were related entities developing, with the Company, an at-home/point-of-care medical diagnostic device. Upon the completion of the acquisition, all outstanding ACI and Idaho Molecular common stock was exchanged for approximately 3.2 million shares of the Company’s common stock and contingent consideration that includes up to approximately 1.4 million shares and approximately 456,000 warrants to purchase shares of the Company’s common stock. The contingent consideration is based on the achievement of certain milestones, which include regulatory approval for identified products, as well as production and net revenue targets. The purchase consideration also includes a payable to a shareholder of ACI of $100,000. In connection with the acquisition, the Company incurred transaction costs of approximately $151,000, which is included in general and administrative expenses. Upon the completion of the acquisition, both ACI and IdMo became 100% wholly-owned subsidiaries of the Company.

 

31

 

 

The fair value of assets acquired and liabilities assumed was based on a preliminary valuation, and our estimates and assumptions are subject to change within the measurement period. The primary area that remains preliminary relates to the evaluation of certain tax-related items and potential minor adjustments to the purchase consideration. The total purchase consideration was allocated to the assets acquired and liabilities assumed as set forth below:

 

Fair value of common shares issued  $25,160,223 
Payable to shareholder   100,000 
Fair value of contingent shares   8,684,669 
Fair value of contingent warrants   1,747,972 
Total fair value of consideration transferred  $35,692,864 
      
Identifiable assets acquired and liabilities assumed     
Cash  $1,196,243 
Accounts receivable   31,170 
Prepaid expenses and other current assets   70,321 
Property and equipment   408,173 
Technology - In-process research and development   26,101,000 
Non-competition agreements   1,094,000 
Accounts payable and accrued other expenses   (1,069,274)
Deferred tax liability   (6,845,587)
Total identifiable net assets   20,986,046 
Goodwill   14,706,818 
Total  $35,692,864 

 

The excess of the purchase price over the net assets acquired was recorded as goodwill. Goodwill generated from the acquisition is primarily attributable to assembled workforce and expected growth from future technologies, sales to future customers and buyer specific synergies. Goodwill will not be amortized but instead will be tested for impairment at least annually and more frequently if certain indicators of impairment are present. As a result of the structure of the transaction, the balance of goodwill is not amortizable for tax purposes.

 

The in-process research and development is considered an indefinite-lived intangible until the completion or abandonment of the research and development activities. The non-competition agreements are being amortized over a range of 1.5 to 3 years.

 

As the acquisition was completed on December 31, 2021, the acquired entities did not contribute to the net revenues or to the net income of the Company during the year ended December 31, 2021. Pro forma revenue and results of operations have not been presented because the historical results of ACI and IdMo are not material to the Company’s consolidated financial statements in any period presented.

 

Note 4 – Fair Value Measurements

 

The Company measures and records certain financial assets and liabilities at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

The following three levels of inputs are used to measure the fair value of financial assets and liabilities:

 

Level 1: Quoted market prices in active markets for identical assets or liabilities.

 

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

 

Level 3: Unobservable inputs that are not corroborated by market data.

 

32

 

 

The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 and December 31, 2020, by level within the fair value hierarchy:

 

   December 31, 2021 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                    
Marketable securities (certificates of deposit)  $-   $1,255,266   $-   $1,255,266 
Total assets measured at fair value  $-   $1,255,266   $-   $1,255,266 
Liabilities:                    
Contingent consideration - common stock  $           -   $      -   $8,684,669   $8,684,669 
Contingent consideration - warrants   -    -    1,747,972    1,747,972 
Total liabilities measured at fair value  $-   $-   $10,432,641   $10,432,641 

 

   December 31, 2020 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                
Marketable securities (certificates of deposit)  $-   $4,335,446   $             -   $4,335,446 
Total assets measured at fair value  $-   $4,335,446   $-   $4,335,446 

 

The Company’s financial instruments that are measured at fair value on a recurring basis consist of certificates of deposit.

 

In connection with the acquisitions of Idaho Molecular, Inc and Advanced Conceptions, Inc. on December 31, 2021, the Company recorded a liability for contingent consideration in the form of shares of common stock and warrants to purchase common stock. The fair value of contingent consideration is calculated using a discounted probability weighted valuation model. Discount rates used in such calculation are a significant assumption that are not observed in the market, and therefore, the resulting fair value represents a Level 3 measurement.

 

The changes for Level 3 items measured at fair value on a recurring basis are as follows:

 

Fair value as of December 31, 2020  $- 
Contingent considered issued for business acquisitions   10,432,641 
Fair value as of December 31, 2021  $10,432,641 

 

The fair value of the contingent consideration is based on the fair value of the contingent consideration-common stock and contingent consideration-warrants. The fair value of the contingent consideration-common stock is equal to the probability-adjusted value of the Company’s common stock as of December 31, 2021. The fair value of the contingent consideration-warrants is equal to the probability adjusted value of a call option with terms consistent with the terms of the warrants as of December 31, 2021. Prior to the probability adjustments, the warrants were valued based on the following inputs:

 

   December 31, 2021 
Stock price  $8.93 
Strike price  $9.13 
Volatility   80.00%
Risk-free rate   1.30%
Expected term   5.0 

 

33

 

 

In order to calculate the probability-adjusted value of the contingent consideration-common stock and contingent consideration-warrants, the Company estimated the probability of achieving certain milestones, which include regulatory approval for identified products, as well as production and net revenue targets. The probability of achieving the milestone related to net revenues was estimated using a Monte Carlo simulation valuation model. The unobservable significant inputs to the valuation model were as follows:

 

   December 31, 2021 
Stock price  $8.93 
Risk-free rate   1.30%
Expected term   5.0 
Weighted-average cost of capital   27.00%
Revenue discount rate   9.50%
Equity volatility   80.00%
Asset volatility   80.00%
Revenue volatility   30.00%

 

Fair Value of Other Financial Instruments

 

The carrying amounts of certain financial instruments, including cash held in banks, accounts receivable, notes receivable, accounts payable, accrued liabilities, and other liabilities approximate fair value due to their short-term maturities and are excluded from the fair value tables above.

 

Note 5 – Property and Equipment

 

Property and equipment, net consisted of the following:

 

  

Estimated

Useful Lives in

   December 31, 
   years   2021   2020 
Lab equipment   3 - 5   $2,476,813   $1,212,561 
Leasehold improvements   3    3,157    3,157 
Office equipment, furniture and other   2 - 5    75,401    38,344 
Less accumulated depreciation and amortization        (622,155)   (304,423)
Fixed assets, net                $1,933,216   $949,639 

 

Note 6 - Goodwill and Intangible Assets

 

Intangible assets, net consisted of the following:

 

  

Estimated

Useful Lives in

  December 31, 
   years  2021   2020 
In-process research and development  Indefinite  $26,101,000   $            - 
Non-competition agreements  1.5 - 3   1,094,000            - 
Less accumulated amortization      -    - 
Intangible assets, net       $27,195,000   $- 

 

34

 

 

The expected future annual amortization expense of the Company’s intangible assets held as of December 31, 2021 is as follows:

 

Year Ending December 31,  Amortization Expense 
2022  $426,660 
2023   364,668 
2024   302,672 
Total  $1,094,000 

 

The Company had goodwill of $14.7 million as of December 31, 2021.

 

Note 7 - Accrued Expenses

 

Accrued expenses consisted of the following:

 

   December 31, 2021   December 31, 2020 
Payroll liabilities  $2,455,694   $1,627,957 
Distributor commissions   509,500    1,070,000 
Sales tax payable   -    52,526 
Other accrued liabilities   894,458    99,020 
Total accrued expenses  $3,859,652   $2,849,503 

 

Note 8 – Revenue

 

The following table sets forth revenue by geographic area:

 

   Years Ended December 31, 
   2021   2020 
United States  $52,185,812   $44,862,751 
Rest of World   45,699,791    29,690,007 
Total  $97,885,603   $74,552,758 
Percentage of revenue by area:          
United States   53%   60%
Rest of World   47%   40%

 

Deferred Revenue

 

Changes in the Company’s deferred revenue balance for the years ended December 31, 2021 and 2020 were as follows:

 

 

Balance as of December 31, 2019  $1,323 
Revenue recognized included in deferred revenue balance at the beginning of the period   (1,323)
Increase due to prepayments from customers   305,307 
Balance as of December 31, 2020   305,307 
Revenue recognized included in deferred revenue balance at the beginning of the period   (256,110)
Increase due to prepayments from customers   79,213 
Increase due to note receivable   150,000 
Decrease due to refunds to customers and application to open balances   (128,410)
Balance as of December 31, 2021  $150,000 

 

The Company expects to perform its performance obligation and recognize the deferred revenue as revenue during the year ended December 31, 2022.

 

35

 

 

Note 9 – Stockholders’ Equity

 

Common Stock

 

During the year ended December 31, 2021, the Company issued 189,225 shares of common stock upon the exercise of options and received $450,398 in proceeds from the exercises.

 

During the year ended December 31, 2021, the Company issued 5,548 shares of common stock for services provided by third parties primarily related to investor relations services.

 

During the year ended December 31, 2021, the Company issued 438,502 shares of common stock upon the vest and release of restricted stock units.

 

During the year ended December 31, 2021, the Company issued 4,628,554 shares of common stock related to the acquisitions of Idaho Molecular, Inc. and Advanced Conceptions, Inc., 1,390,430 of which are subject to forfeiture in favor of the Company if certain milestones are not achieved on or before January 1, 2027.

 

During the year ended December 31, 2020, the Company completed the sale of 3,448,278 shares of the Company’s common stock, par value $0.001 per share, at a purchase price of $1.45 per share in a registered direct offering. The aggregate gross proceeds for the sale of the shares were $5,000,003 and the Company received net proceeds of $4,517,102 after deducting offering costs of $482,901.

 

During the year ended December 31, 2020, the Company completed the sale of 3,324,676 shares of the Company’s common stock, par value $0.001 per share, at a purchase price of $3.08 per share in a registered direct offering. The aggregate gross proceeds for the sale of the shares were $10,240,002 and the Company received net proceeds of $9,612,561 after deducting offering costs of $627,441.

 

During the year ended December 31, 2020, the Company completed the sale of 470,000 shares of the Company’s common stock, par value $0.001 per share, at a purchase price of $9.00 per share in a registered direct offering. The aggregate gross proceeds for the sale of the shares were $4,230,000 and the Company received net proceeds of $3,882,420 after deducting offering costs of $347,580.

 

During the year ended December 31, 2020, the Company issued an aggregate of 2,133,333 shares of common stock upon conversion of all of the Company’s convertible preferred stock outstanding as of December 31, 2019.

 

During the year ended December 31, 2020, the Company issued 856,660 shares of common stock upon the exercise of warrants and received $270,000.

 

During the year ended December 31, 2020, the Company issued 871,229 shares of common stock upon the exercise of options and received $1,460,600.

 

During the year ended December 31, 2020, the Company issued 83,935 shares of common stock for services provided by third parties primarily related to investor relations services.

 

36

 

 

Note 10 – Earnings per Share

 

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for years ended December 31, 2021 and 2020:

 

   2021   2020 
   Years Ended December 31, 
   2021   2020 
Numerator          
Net income, as reported  $36,658,564   $42,478,529 
           
Denominator          
Weighted average shares, basic   28,874,555    26,720,133 
Dilutive effect of stock options, warrants and RSUs   1,029,131    1,280,208 
Shares used to compute diluted earnings per share   29,903,686    28,000,341 
           
Basic earnings per share  $1.27   $1.59 
Diluted earnings per share  $1.23   $1.52 

 

For the years ended December 31, 2021 and 2020, respectively, potentially dilutive securities of 154,644 and 50,000 were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. The computation of diluted earnings per share for the year ended December 31, 2021 also excludes the approximately 1.4 million shares of common stock and approximately 456,000 warrants to purchase shares of common stock mentioned in Note 3 that are contingent upon the achievement of certain milestones.

 

Note 11 – Stock-Based Compensation

 

Stock Incentive Plans

 

The Co-Diagnostics, Inc. 2015 Long Term Incentive Plan (the “Incentive Plan”) reserves an aggregate of 6,000,000 shares of common stock issuable upon the grant of awards under the Incentive Plan. The number of awards available for issuance under the Incentive Plan was 2,095,266 at December 31, 2021.

 

37

 

 

Stock Options

 

The following table summarizes option activity during the years ended December 31, 2021 and 2020:

       Number of Options   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2019    2,021,817   $1.69   $0.83      
Granted    150,000    8.14    4.74          
Expired    -    -    -      
Forfeited/Cancelled    -    -    -      
Exercised    (871,229)   1.68    0.89      
Outstanding at December 31, 2020    1,300,588   $2.44   $1.24      
Granted    -    -    -      
Expired    -    -    -      
Forfeited/Cancelled    -    -    -      
Exercised    (189,225)   2.38    1.12      
Outstanding at December 31, 2021    1,111,363   $2.12   $1.31    6.62 
                      
Exercisable at December 31, 2021    1,094,697   $2.01   $1.18    6.59 

 

The total intrinsic value of options exercised during the years ended December 31, 2021 and 2020 was approximately $1.3 million and $11.8 million, respectively. The aggregate intrinsic value of outstanding options at December 31, 2021 and 2020 was approximately $7.6 million and $7.1 million, respectively. As of December 31, 2021, there were 16,666 unvested options and $78,115 of unrecognized stock-based compensation expense related to options. The unrecognized stock-based compensation expense is expected to be recognized over 0.5 years.

 

Stock-based compensation cost is measured at the grant date based on the fair value of the award granted and recognized as expense over the vesting period using the straight-line method. The Company uses the Black-Scholes model to value options granted. The following weighted average assumptions were used in estimating the grant date fair value of options:

 

   Years Ended December 31, 
   2021   2020 
Risk-free interest rate   -    1.05%
Expected life (years)   -    7.3 
Expected volatility          -    62.82%
Expected dividend yield   -    None 

 

38

 

 

Restricted Stock Units

 

The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the years ended December 31, 2021 and 2020:

 

   Number of RSUs   Weighted Average Grant Date Fair Value 
Unvested at December 31, 2019   -   $- 
Granted   549,500    10.49 
Vested   (27,000)   10.49 
Forfeited/Cancelled   -    - 
Unvested at December 31, 2020   522,500   $10.49 
Granted   1,217,500    9.76 
Vested   (438,502)   10.10 
Forfeited/Cancelled   (34,083)   9.91 
Unvested at December 31, 2021   1,267,415   $9.94 

 

As of December 31, 2021, there was $11.6 million of unrecognized stock-based compensation expense related to outstanding RSUs which is expected to be recognized over a weighted-average period of 2.3 years.

 

Warrants

 

The Company has issued warrants related to financings, acquisitions and as compensation to third parties for services provided. The Company estimates the fair value of issued warrants on the date of issuance as determined using a Black-Scholes pricing model. The Company amortizes the fair value of issued warrants using a vesting schedule based on the terms and conditions of each warrant if granted for services.

 

The following table summarizes warrant activity during the years ended December 31, 2021 and 2020:

 

    Number of Warrants   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2019    983,535   $1.44   $1.03      
Granted    20,000    1.40    15.19      
Expired    (9,090)   6.00    0.17      
Forfeited/Cancelled    -    -    -      
Exercised    (924,445)   1.42    1.43      
Outstanding at December 31, 2020    70,000   $1.83   $5.21    3.3 
Granted    456,281    9.13    3.83      
Expired    -    -    -      
Forfeited/Cancelled    -    -    -      
Exercised    -    -    -      
Outstanding at December 31, 2021    526,281   $8.15   $4.01    4.7 

 

The intrinsic value of warrants exercised during the years ended December 31, 2021 and 2020 was $0 and approximately $9.7 million, respectively. The aggregate intrinsic value of outstanding warrants at December 31, 2021 was approximately $497,000.

 

39

 

 

70,000 warrants are exercisable at December 31, 2021. As discussed in Note 3 and Note 4, approximately 456,000 warrants to purchase shares of the Company’s common stock were issued in connection with the acquisition of ACI and IdMo. The ability to exercise the warrants is contingent upon the achievement of certain development and revenue milestones on or before January 1, 2027. There was no unrecognized stock-based compensation expense related to warrants.

 

See Note 4 for additional information regarding the fair value calculation of the warrants issued during the year ended December 31, 2021. The fair values for the warrants issued during the year ended December 31, 2020 were estimated at the date of grant using the Black Scholes model with the following weighted average assumptions:

 

   Year Ended December 31, 
   2020 
Risk-free interest rate   0.34%
Expected life (years)   5.0 
Expected volatility   61.42%
Expected dividend yield   None 

 

Stock Issued for Services

 

The Company has issued restricted stock to third parties for services provided. The grant date fair value of the restricted stock granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the stock awards. The Company issued 5,548 and 83,935 shares of restricted stock for services during the years ended December 31, 2021 and 2020, respectively, and there was no unrecognized stock-based compensation expense related to restricted stock issued.

 

Stock-Based Compensation Expense

 

The Company recognized stock-based compensation expense related to the types of awards discussed above as follows:

 

   2021   2020 
   Years Ended December 31, 
   2021   2020 
Options  $292,754   $901,345 
Restricted stock units   5,164,750    500,861 
Warrants   -    303,802 
Stock   51,900    1,032,033 
Total stock-based compensation expense  $5,509,404   $2,738,041 

 

40

 

 

Note 12 – Income Taxes

 

The components of the provision for income taxes consists of the following for the years ended December 31, 2021 and 2020:

 

 

   2021   2020 
   Year Ended December 31, 
   2021   2020 
Current:          
Federal  $6,092,730   $- 
State   886,173    637,760 
Total current  $6,978,903   $637,760 
Deferred:          
Federal   1,394,686    (452,544)
State   603,642    (94,680)
Total deferred   1,998,328    (547,224)
Total income tax expense  $8,977,231   $90,536 

 

A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:

 

   2021   2020 
   Year Ended December 31, 
   2021   2020 
Federal income tax expense at statutory rate   21.0%   21.0%
State income tax expense, net of federal tax benefit   3.9    3.3 
Permanent differences:          
- Foreign derived intangible income deduction   (3.5)    (1.7) 
- Stock based compensation   0.2    (8.8) 
- Other permanent differences   0.3    (0.4) 
Research and development credits   (2.6)    (2.0) 
Change in uncertain tax positions   1.4    1.1 
Change in valuation allowance   0.0    (12.1) 
Other   (1.0)    (0.2) 
Effective income tax rate   19.7%   0.2%

 

41

 

 

Net deferred tax assets consist of the following components as of December 31, 2021 and 2020:

 

   2021   2020 
   December 31, 
   2021   2020 
Deferred tax assets:          
Accrued liabilities  $-   $37,898 
Reserves and allowances   166,050    200,049 
Deferred compensation   393,871    241,652 
Research and development credits   -    423,001 
Total deferred tax assets   559,921    902,600 
Deferred tax liabilities:          
Property and equipment, net   (477,542)   (233,951)
Intangibles, net   (6,743,972)   - 
Prepaids   (560,093)   (66,456)
Other   (6,758)   (54,969)
Total deferred tax liabilities   (7,788,365)   (355,376)
Net deferred tax assets (liabilities)   (7,228,444)   547,224 
Less valuation allowance   -    - 
Net deferred tax assets (liabilities)  $(7,228,444)  $547,224 

 

At December 31, 2021, the Company had no federal or state net operating loss carryforwards and no federal or state research and development credit carryforwards.

 

As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December 31, 2020, in part because in that year the Company achieved three years of cumulative pre-tax income, management determined that there was sufficient positive evidence to conclude that it was more likely than not that its deferred taxes were realizable. The Company therefore fully reduced its valuation allowance accordingly by $5,161,500.

 

ASC Topic 740-10-05 requires that the impact of a tax position be recognized in the financial statements if that position is more likely than not of being sustained on audit, based on the technical merits of the position. Our unrecognized tax benefit balances included $1,067,853 at December 31, 2021 and $447,831 at December 31, 2020 of tax positions that, if recognized, would impact our effective tax rate. The Company expects no material changes to the liability for unrecognized tax benefits in the next 12 months. Interest and penalties associated with uncertain tax positions are recorded as a component of income tax expense. A reconciliation of the beginning and ending amount of unrecognized benefits is as follows:

 

   December 31, 
   2021   2020 
Unrecognized tax benefits at the beginning of the year  $447,831   $- 
Gross increases - current year tax positions   770,069    232,145 
Gross increases - prior year tax positions   -    215,686 
Gross decreases - prior year tax positions   (150,047)   - 
Unrecognized tax benefits at end of year  $1,067,853   $447,831 
           
Interest and penalties in year-end balance  $-   $- 

 

42

 

 

The Company is subject to taxation in the United States and other state jurisdictions. The tax years from December 31, 2017 through December 31, 2021 remain open to examination for federal income tax purposes and by the other major taxing jurisdictions to which the Company is subject. The Company is not currently under examination by any taxing authority.

 

Note 13 – Related Party Transactions

 

The Company acquired the exclusive rights to the CoPrimer technology pursuant to an exclusive license agreement, dated April 2014 (the “Exclusive License Agreement”), between the Company and DNA Logix, Inc., which was assigned to Dr. Brent Satterfield, an executive officer, prior to the Company’s acquisition of DNA Logix, Inc. On March 1, 2017, the Company entered into an amendment to its Exclusive License Agreement for its Cooperative Primers (“License”) technology with Dr. Satterfield. The amendment provided in part that all accrued royalties under the License ceased as of January 1, 2017, and the Company agreed to pay to Dr. Satterfield $700,000 of accrued royalties at the rate of $10,000 per month starting in January 2017. At December 31, 2021, the aggregate balance of this related party liability was $0.

 

Note 14 – Commitments and Contingencies

 

Lease Obligations

 

The Company’s offices are located at 2401 S. Foothill Dr., Suite D, Salt Lake City, Utah 84109-1479. In February 2020, the Company entered into a 4-year lease agreement for its office space and in March 2020, the Company entered into an addendum with our landlord for additional space. The aggregate space consists of approximately 13,687 square feet at a monthly rate of $28,825 and expires in February 2024. As a result of business acquisitions during the year ended December 31, 2021, the Company also leases additional laboratory and office space under two month-to-month leases. For the years ended December 31, 2021 and 2020, the Company expensed $346,350 and $311,963, respectively, for rent. The Company’s future minimum lease payments were as follows as of December 31, 2021:

 

Year Ending December 31, 
2022  $293,595 
2023   303,059 
2024   50,774 
Total lease payments   $647,428 

 

Litigation

 

Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.

 

Five different securities class action complaints were filed in July, September and December by certain stockholders of the Company against the Company claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The plaintiffs demand compensatory damages sustained as a result of the Company’s alleged wrongdoing in an amount to be proven at trial. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in these cases. As of the date of this report, the Company does not believe it is probable that these cases will result in an unfavorable outcome; however, if an unfavorable outcome were to occur in these cases, it is possible that the impact could be material to the Company’s results of operations in the period(s) in which any such outcome becomes probable and estimable.

 

43

 

 

Note 15 – Subsequent Events

 

In March 2022, the Company’s Board of Directors authorized a share repurchase program that would allow the Company to repurchase up to $30 million of CODX common stock. The repurchase program does not obligate the Company to acquire any particular amount of common shares, and the repurchase program may be suspended or discontinued at any time at the Company’s discretion. The timing and amount of any share repurchases under the share repurchase program will be determined by Co-Diagnostics’ management at its discretion based on ongoing assessments of the capital needs of the business, the market price of the Company’s common stock, corporate and regulatory requirements, and general market conditions. Share repurchases under the program may be made through a variety of methods, which may include open market purchases, in block trades, accelerated share repurchase transactions, exchange transactions, the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or any combination of such methods.

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

 

None.

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain a set of disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in rules and forms adopted by the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

 

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2021. Based on the evaluation, management has concluded that our disclosure controls and procedures are effective as of December 31, 2021 to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of our financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles.

 

Changes in Internal Control Over Financial Reporting

 

There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a- 15(f) and 15d-15(f) under the Exchange Act) during the fourth quarter of 2021 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

Management’s Annual Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Our management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2021. In making its evaluation, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control – Integrated Framework (2013).

 

Based on this evaluation, management determined that our internal control over financial reporting was effective as of December 31, 2021.

 

44

 

 

This Annual Report does not include an attestation report by our independent registered public accounting firm regarding internal control over financial reporting since we are an emerging growth company. Management’s report was not subject to attestation by our registered public accounting firm pursuant to rules of the SEC that permit emerging growth companies to provide only management’s report in the 10-K.

 

Inherent Limitations on Effectiveness of Controls

 

Our management, including our Chief Executive Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting are intended to be designed to provide reasonable assurance of achieving their objectives. However, our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost–effective control system, misstatements due to error or fraud may occur and not be detected.

 

ITEM 9B. OTHER INFORMATION

 

None.

 

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.

 

None.

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

 

The following table sets forth the names, ages and positions of our executive officers and directors as of March 24, 2022. Our Board of Directors is currently comprised of five members, who are elected annually to serve for one year or until their successor is duly elected and qualified, or until their earlier resignation or removal. Executive officers serve at the discretion of the Board of Directors.

 

Name   Age   Position
Dwight Egan   68   Chief Executive Officer, President and Chairman of the Board
Brian Brown   46   Chief Financial Officer and Secretary
Eugene Durenard   52   Director
James Nelson   69   Director
Richard Serbin   77   Director
Ted Murphy   57   Director

 

Dwight Egan serves as our President and Chief Executive Officer and has been an officer and director of the Company since April 2013. Mr. Egan has been engaged in private investment business from February 1999 to the present. He was a senior executive at Data Broadcasting Corporation, a leading provider of wireless, real-time financial market data, news and sophisticated fixed- income portfolio analytics to 27,000 individual and professional investors from 1995 to 1999. He co-founded and served as CEO and Chairman of the Board of Broadcast International, Inc. from 1984 to 1995, when Data Broadcasting Corporation acquired Broadcast International and created CBS MarketWatch, a leading financial news site and participated in its initial public offering. Mr. Egan’s prior experience in executive leadership positions with public companies and working with capital markets qualifies him to serve as our Chairman, President and Chief Executive Officer.

 

45

 

 

Brian Brown became our Chief Financial Officer in February 2021. From July 2020 until February 2021, Mr. Brown served as the Chief Financial Officer of A-Core Concrete Cutting, Inc. where his duties included overseeing the company’s accounting and finance departments, mergers and acquisitions and responsibility for financial forecasting and budgeting. From August 2019 to December 2019, Mr. Brown served as the Vice President of Accounting, Treasury and Investor Relations at Sportsman’s Warehouse Holdings, Inc., a public company reporting on Nasdaq Global Select under the symbol SPWH, where his duties included overseeing the company’s accounting, treasury and investor relations departments, preparing the company’s annual, quarterly and current reports with the SEC, overseeing all aspects of the company’s annual audit, including, but not limited to, the preparation and review of audit support schedules, preparation of financial statements and footnotes, and providing support to the company’s independent auditors. From October 2009 to August 2019, Mr. Brown served as the Director of Finance of Sportsman’s Warehouse Holdings, Inc. where he assisted with the company’s initial public offering in April 2014 as well as effecting private and secondary public offerings, acquisitions of a group of retail stores and preparing the company’s periodic and current reports with the SEC and complying with the Sarbanes Oxley Act. From May 2005 to October 2009, Mr. Brown served as the Corporate Controller of Franklin Covey Products where he developed and maintained the company’s internal controls over financial reporting structure in accordance with the control standards required under Section 404 of the Sarbanes Oxley Act. From July 2001 to May 2005, Mr. Brown served as an Assurance Senior at KPMG, LLP where he provided audit services to various clients in multiple industries. Mr. Brown holds a Bachelor of Arts in Accounting and Masters of Professional Accountancy from the University of Utah. Mr. Brown is a licensed CPA in Utah.

 

Eugene Durenard has been a member of our Board of Directors since June 2019. Dr. Durenard is the Founder and CEO of Hyperbolic Holdings, a Swiss-based holding, management consulting and strategy advisory company specialized in healthcare. Dr. Durenard brings an investment and entrepreneurial experience spanning 20 years. For the last 7 years he has been working with family offices on direct investments and philanthropy focused on life sciences. He serves on the advisory board of several private companies in the biotech and MedTech sectors as well as an impact venture fund focused on healthcare. After an initial career in proprietary research and trading at Salomon Brothers and Credit Suisse in London, he co-founded Orion Investment Management in Bermuda specializing in quantitative asset and liability management for institutions and private clients. He subsequently sold it to Capital G Bank and co-headed their asset management. Dr. Durenard spent several years establishing personal connections with representatives of 40+ clusters of life science innovation, families operating healthcare businesses and industry leaders globally. He regularly visits labs and incubators, meets with leading scientists and innovators in order to keep abreast of current trends and developments. His advice is based on a thorough analysis that combines in-depth knowledge of science, competitive forces and financial expertise. He has published several articles in asset-liability management industry magazines as well as the book “Professional Automated Trading — Theory and Practice” (Wiley 2013). He has a PhD in Mathematics from Harvard University. Dr. Durenard brings a thorough multi-asset class investment and entrepreneurial experience spanning 20 years to the Company’s Board of Directors.

 

Edward Murphy has been a member of our Board of Directors since June 2019. Mr. Murphy currently serves as a senior vice president and a partner of Dover Investments Ltd., a private investment firm. Throughout his career, Mr. Murphy’s duties have included investment analysis of various types of investment projects in real estate and financial services. Currently, Mr. Murphy serves on the board of directors of several Canadian publicly reporting companies that have interests in various industries. He has been a Director at Empire Minerals Corporation Inc. since January 2016, at Digicrypts Blockchain Solutions Inc. since June 2011, at Lakefield Marketing Corporation since February 2018, CEO/CFO and Director of Credo Resources Inc. since September 2019, and at the Mosport Park Entertainment Corporation since April 30, 1997. He served as a Director at Aurquest Resources from May 2003 to December 2017. Mr. Murphy’s experience in the capital markets outside the United States and his involvement in investment analysis is a benefit to the Board of Directors.

 

46

 

 

Richard Serbin has been a member of our Board of Directors since May 2017. Mr. Serbin currently serves as a consultant to many companies in the healthcare industry. He was the President of Corporate Development and In-House Legal Counsel at Life Science Institute, LLC, from June 1, 2013 to July 15, 2014. Mr. Serbin is a global strategy advisor, pharmacist and entrepreneur with credentials both in pharmacy and law, complemented by more than 40 years of service as an FDA regulatory attorney and patent attorney in the healthcare industry. He was appointed to the Advisory Board of Cure Pharmaceutical in January 2017 and has been a Member of Advisory Board at Prime Access, Inc. since September 2015. Mr. Serbin has been a Director at Rapid Nutrition Plc since November 18, 2014. He served as Director at Viropro Inc. from May 2013 to June 2014. He was Head of Business Advisory Board at Mazal Plant Pharmaceuticals Inc. from October 2006 to September 2007 and also served as its Member of Business Advisory Board. He served as Chief Executive Officer of Optigenex Inc. from July 2002 to September 15, 2005 and a director from July 2004 to September 2005. From January 1999 until July 2002 Mr. Serbin served as a consultant to various pharmaceutical companies. He served as the President of Bradley Pharmaceuticals. He served as Vice President of Corporate Development at Ortho Pharmaceuticals, a Johnson & Johnson subsidiary, and practiced Patent and FDA law at Revlon Johnson & Johnson and Schering-Plough. He served as Patent Attorney for Schering Plough Corporation and Chief FDA Counsel for Revlon Corporation and Johnson and Johnson Corporation. Subsequently, he worked at Revlon Corporation, as its Chief Food, Drug and Cosmetic Counsel. He founded Radius Scientific Corporation. He was J&J’s Vice President of Corporate Development, and later led a successful public offering venture based on technology developed at Stanford Medical School. Mr. Serbin spent a large portion of his career focusing on international markets and clients. While at J&J, Mr. Serbin served on the Board of Directors of 16 US and international subsidiary companies, including Ethicon, Ortho, J&J Consumer Products, Pittman-Moore, Mc Neil, and J&J Development Corporation. He worked on multiple international acquisitions and strategic relationships, and sat on the Board of Directors of several of its international subsidiaries, including those in India, Hong Kong, Japan, Taiwan, Germany, and England. Mr. Serbin has a B.S. and a B. Pharmacy from Rutgers University and Rutgers University College of Pharmacy, a J.D. degree from Seton Hall Law School and a Master’s Degree in Trade Regulations and Law from NYU Law School. Mr. Serbin’s experience in business, law and medicine and knowledge gained as an advisor to the healthcare industry is critical to our Board of Directors as we continue to commercialize our products.

 

James Nelson has been a member of our Board of Directors since June 2019. Mr. Nelson is the retired Chairman and CEO of Sunworks, Inc., a NASDAQ traded commercial, agriculture, and residential solar Integrator which he helped found in October 2010. Mr. Nelson currently serves as strategic advisor to three other publicly traded companies. Jim has spent most of his career working in private equity as a general partner with Peterson Partners and with Millennial Capital Partners. In addition to his investment and financial responsibilities, he served as CEO of two of his firms’ portfolio companies. Prior to his years in private equity, Mr. Nelson served as Vice President of Marketing at Banana Republic, where he managed company-wide marketing, as well as the company’s international expansion initiative. He was also general manager for Banana Republic’s catalog division. He was Vice President of Marketing and Corporate Development at Saga Corporation, a multi-billion-dollar food service company. Jim began his executive career over 35 years ago at Bain and Company, a business strategy consulting firm, where he managed teams of consultants on four continents. Mr. Nelson received his MBA from Brigham Young University, where he graduated summa cum laude and was named the Outstanding Master of Business Administration Graduate. Mr. Nelson’s advice to the Board of Directors from his experiences as a chief executive officer and strategic advisor is useful to the Board of Directors.

 

Involvement in Certain Legal Proceedings

 

To the best of our knowledge, none of our directors or executive officers has been involved in any bankruptcy or criminal proceedings (other than traffic and other minor offenses) or been subject to any of the items set forth under Item 401(f) of Regulation S-K, nor have there been any judgments or injunctions brought against any of our directors or executive officers during the last ten years that we consider material to the evaluation of the ability and integrity of any director or executive officer.

 

Board and Committee Matters

 

Our Board of Directors has five members. The Chairman of the Board and our Chief Executive Officer, Dwight Egan, is a member of the Board and is a full-time employee of the Company, Eugene Durenard, Edward Murphy, James Nelson and Richard Serbin are non-employee directors, and the Board has determined that these persons (who constitute a majority of the Board) are “independent directors” under the criteria set forth in Rule 5605(a)(2) of the Nasdaq Listing Rules. The Board met seven times during the year ended December 31, 2021. All directors attended more than seventy-five percent (75%) of the meetings of the Board and committee meetings of which such director was a member held during 2021.

 

47

 

 

We maintain an audit committee of the board, a compensation committee of the board and a corporate governance/nominating committee of the board, each of which is discussed below. Our board has determined that Messrs. Durenard, Nelson, Murphy and Serbin are “independent” under the definition of independence in the Marketplace Rules of the NASDAQ listing requirements. Our Board of Directors may from time to time establish other standing committees. In addition, from time to time, special committees may be established under the direction of our Board of Directors when necessary to address specific issues.

 

The following table sets forth a description of the three permanent Board committees and the chairpersons and members of those committees, all of whom are independent directors:

 

Committee   Independent Chairperson   Independent Members
         
Audit Committee   Eugene Durenard   Edward Murphy   James Nelson   Richard S. Serbin
                 
Compensation Committee   Richard S. Serbin   Edward Murphy   Eugene Durenard   James Nelson
                 
Governance/Nominating Committee   James Nelson   Edward Murphy   Eugene Durenard   Richard S. Serbin

 

Audit Committee and Financial Expert

 

Our audit committee currently is comprised of Messrs. Durenard, Nelson, Murphy and Serbin with Mr. Durenard serving as chairperson of the audit committee. The functions of the audit committee include engaging an independent registered public accounting firm to audit our annual financial statements, reviewing the independence of our auditors, the financial statements and the auditors’ report, and reviewing management’s administration of our system of internal control over financial reporting and disclosure controls and procedures. The Board of Directors has adopted a written audit committee charter. A current copy of the audit committee charter is available to security holders on our website at www.codiagnostics.com. Our board has determined that all of our directors that are serving on the audit committee are “independent” under the definition of independence in the Marketplace Rules of the NASDAQ listing standards. The Audit Committee met four times during the year ended December 31, 2021. All committee members attended more than seventy-five percent (75%) of the meetings of the Audit Committee held during 2021.

 

Our Board of Directors has determined that Mr. Durenard meets the requirements of an “audit committee financial expert” as defined in applicable SEC regulations.

 

Compensation Committee

 

Our compensation committee currently includes Messrs. Serbin, Nelson, Murphy and Durenard with Mr. Serbin serving as chairperson of the compensation committee. The functions of the compensation committee include reviewing and approving corporate goals relevant to compensation for executive officers, evaluating the effectiveness of our compensation practices, evaluating and approving the compensation of our chief executive officer and other executives, recommending compensation for board members, and reviewing and making recommendations regarding incentive compensation and other employee benefit plans. The Board of Directors has adopted a written compensation committee charter. A current copy of the compensation committee charter is available to shareholders on our website at www.codiagnostics.com. Our board has determined that all of our directors serving on the compensation committee are “independent” under the definition of independence in the Marketplace Rules of the NASDAQ listing standards. The Compensation Committee met four times during the year ended December 31, 2021. All committee members attended more than seventy-five percent (75%) of the meetings of the Compensation Committee held during 2021.

 

48

 

 

Corporate Governance/Nominating Committee

 

Our corporate governance/nominating committee currently include Messrs. Nelson, Murphy, Durenard and Serbin with Mr. Nelson serving as chairperson of the corporate governance/nominating committee. Among other items, the committee is tasked by the Board of Directors to: develop and recommend to the Board the Corporate Governance Guidelines of the Company and oversee compliance therewith; assist the Board in effecting Board organization, membership and function including identifying qualified Board nominees; assist the Board in effecting the organization, membership and function of Board committees including the composition of Board committees and recommending qualified candidates therefor; evaluate and provide successor planning for the Chief Executive Officer and other executive officers; and to develop criteria for Board membership, such as independence, term limits, age limits and ability of former employees to serve on the Board and the evaluation of candidates’ qualifications for nominations to the Board, its committees as well as removal therefrom, respectively. A current copy of the corporate governance/nominating committee charter is available to shareholders on our website at www.codiagnostics.com. Our board has determined all directors serving on the corporate governance committee are “independent” under the definition of independence in the Marketplace Rules of the NASDAQ listing standards. The Corporate Governance/Nominating Committee met four times during the year ended December 31, 2021. All committee members attended more than seventy-five percent (75%) of the meetings of the Audit Committee held during 2021. The nominating committee reviews the qualifications for candidates for the Board of Directors and assists in identifying, interviewing, and recruiting candidates for the Board of Directors.

 

Board Nominations

 

In considering Board candidates, the Board seeks individuals of proven judgment and competence who have strong reputations in their respective fields. Although we do not have a formal diversity policy, the Board considers such factors as experience, education, employment history, special talents or personal attributes, anticipated participation in Board activities, and geographic and diversity factors. The process for identifying and evaluating nominees would include detailed consideration of the recommendations and opinions of members of our Board, our executive officers, and our stockholders. There would be no difference in the process of evaluation of candidates recommended by a stockholder and those recommended by other sources.

 

We do not have a formal policy concerning shareholder recommendations of candidates for board of director membership. Our board views that such a formal policy is not necessary at the present time given the board’s willingness to consider candidates recommended by shareholders. Shareholders may recommend candidates by writing to our Secretary at our principal offices: 2401 S. Foothill Drive, Suite D, Salt Lake City, Utah 84109, giving the candidate’s name, contact information, biographical data and qualifications. A written statement from the candidate consenting to be named as a candidate and, if nominated and elected, to serve as a director should accompany any such recommendation. Shareholders who wish to nominate a director for election are generally advised to submit a shareholder proposal no later than December 31 for the next year’s annual meeting of shareholders.

 

Communication with the Board

 

We have not, to date, developed a formal process for shareholder communications with the board of directors. We believe our current informal process, in which any communication sent to the board of directors, either generally or in care of the chief executive officer, secretary or other corporate officer or director, is forwarded to all members of the board of directors, has served the board’s and the shareholders’ needs.

 

Conflicts of Interests

 

On an annual basis, each director and executive officer is obligated to complete a director and officer questionnaire that requires disclosure of any transactions with our company, including related person transactions reportable under SEC rules, in which the director or executive officer, or any member of his or her immediate family, have a direct or indirect material interest. Under our company’s standards of conduct for employees, all employees, including the executive officers, are expected to avoid conflicts of interest. Pursuant to our code of ethics for the chief executive officer and senior finance officers (as discussed below), such officers are prohibited from engaging in any conflict of interest unless a specific exception has been granted by the board. All of our directors are subject to general fiduciary standards to act in the best interests of our company and our shareholders. Conflicts of interest involving an executive officer or a director are generally resolved by the board.

 

49

 

 

Role of the Board in Risk Oversight

 

Risk is inherent with every business, and how well a business manages risk can ultimately determine its success. Management is responsible for the day-to-day management of the risks that we face, while our Board of Directors, as a whole and through its committees, has responsibility for the oversight of risk management. In its risk oversight role, our Board of Directors is responsible for satisfying itself that the risk management processes designed and implemented by management are adequate and functioning as designed.

 

Our Board of Directors does not have a standing risk management committee, but rather administers this oversight function directly through our Board of Directors as a whole, as well as through various standing committees of the Board of Directors that address risks inherent in their respective areas of oversight. In particular, our Board of Directors is responsible for monitoring and assessing strategic risk exposure, including a determination of the nature and level of risk appropriate for us. Our Audit Committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The Audit Committee also monitors oversight of the performance of our internal audit function. Our Corporate Governance/Nominating Committee monitors the effectiveness of our corporate governance guidelines, including whether they are successful in preventing illegal or improper liability-creating conduct. Our Compensation Committee assesses and monitors whether any of our compensation policies and programs have the potential to encourage excessive risk-taking or promote behaviors contra to our Code of Business Conduct.

 

Delinquent Section 16(a) Reports

 

Section 16(a) of the Exchange Act requires our directors and executive officers, and persons who own more than 10% of our common stock, to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other equity securities. Executive officers, directors and greater than 10% shareholders are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file.

 

The Company prepares these reports for its directors and executive officers who request it on the basis on information obtained from them and the Company’s records. The Company believes that applicable Section 16(a) filing requirements were met during 2021 by its directors and executive officers, except that due to an inadvertent administrative error, one Form 4 for Eugene Durenard was filed late.

 

Code of Ethics

 

We have adopted a code of ethics for our principal executive officer, principal financial officer, controller, or persons performing similar functions. A copy of the code of ethics is included on our website at www.codiagnostics.com.

 

Family Relationships

 

There are no family relationships among our directors and executive officers.

 

ITEM 11. EXECUTIVE COMPENSATION

 

We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 and a “smaller reporting company” as defined in the rules and regulations of the SEC. As an emerging growth company and as a smaller reporting company we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable, in general, to public companies that are not emerging growth companies or smaller reporting companies. Accordingly, this Report includes reduced disclosure about our executive compensation arrangements.

 

Summary Compensation Table

 

The table below summarizes the total compensation paid or earned by each of the named executive officers in their respective capacities for the fiscal years ended December 31, 2021 and 2020. We have omitted in this report certain columns otherwise required to be included because there was no compensation made with respect to such columns, as permitted by applicable SEC regulations.

 

50

 

 

Name and Principal Position  Year   Salary   Bonus (1)   Stock
Awards (2)		   All Other
Comp (3)		   Total
Compensation		 
Dwight Egan
President & Chief Executive Officer		   2021   $350,000   $638,459   $1,208,750   $26,793   $2,224,002 
    2020   $309,375   $350,000   $786,750   $17,500   $1,463,625 
                               
Brian Brown
Chief Financial Officer and Secretary		   2021   $209,731   $475,014   $1,441,600   $

26,793

   $2,153,138 
                               
Reed Benson (4)
Former Chief Financial Officer and Secretary		   2021   $136,250   $154,682   $-   $

26,793

   $317,725 
    2020   $211,458   $225,000   $288,475   $17,500   $742,433 

 

(1)

Bonuses for the year ended December 31, 2021 include accrued bonus payments of $281,597 to Mr. Egan and $223,248 to Mr. Brown that were paid in February 2022. Bonuses for the year ended December 31, 2020 include accrued bonus payments of $272,500 to Mr. Egan and $180,000 to Mr. Benson that were paid in February 2021.

   
(2)

The amounts reported in this column represent the aggregate grant date fair value of the restricted stock units, or RSUs, granted under our 2015 Plan as computed in accordance with FASB ASC Topic 718. Note that the amounts reported in this column reflect the accounting value for these equity awards and do not correspond to the actual economic value that may be received from the equity awards as the RSUs vest over three years.

   
(3) Company profit sharing payments to the Company’s 401 K Plan.
   
(4) Mr. Benson is no longer an executive officer of the Company as of August 2021.

 

51

 

 

Outstanding Equity Awards at Fiscal Year-End 2021

 

The following table contain certain information concerning outstanding equity awards for the Named Executive Officers as of December 31, 2021.

 

   Option Awards   Stock Awards      
   Number of Securities Underlying Unexercised Options (#)   Option Exercise   Option Expiration   Number of Shares or Units of Stock That Have Not   Market Value of Shares or Units of Stock That Have Not Vested    Number of Unearned Shares, Units or Other Rights That Have Not   Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not  
Name  Exercisable   Unexercisable   Price   Date   Vested (#)   ($) (1)    Vested (#)   Vested ($)  
Dwight Egan   50,000    -   $2.63    09/20/28    -     -     -    -  
    50,000    -   $1.10    09/02/29    -     -     -    -  
    -    -    -    -    154,167   $ 1,376,711     -    -  
                                            
Brian Brown   -    -    -    -    103,333   $ 922,764     -    -  
                                            
Reed Benson   41,666    -   $1.10    09/02/29    -     -     -    -  
    -    -    -    -    18,332   $ 163,705     -    -  

 

(1) Based on $8.93 per share which was the closing price of our common stock on December 31, 2021.

 

We do not have written employment agreements with any of our executive officers. All of our executive officers serve on an at-will basis. The base salaries, bonuses and equity awards for our named executive officers were determined by our compensation committee after reviewing a number of factors, including: company performance, achievement of goals, the responsibilities associated with the position, the seniority of the executive’s position, the base salary level in prior years, and our financial position; and for executive officers other than our Chief Executive Officer, recommendations made by our Chief Executive Officer.

 

Potential Payments Upon Termination or Change of Control

 

There is no compensation payable to the named executive officers upon voluntary termination, retirement, involuntary not-for-cause termination, termination following a change of control or in the event of disability or death of the executive.

 

Director Compensation

 

We use a combination of cash and stock-based incentive compensation to attract and retain qualified candidates to serve on its board of directors. In setting director compensation, we consider the significant amount of time that directors expend in fulfilling their duties as well as the skill-level required by our members of the board.

 

52

 

 

Director Summary Compensation Table

 

The table below summarizes the compensation paid or accrued by us to each of our non-employee directors for the fiscal year ended December 31, 2021.

 

Name  Fees Earned or
Paid in Cash		   Stock Awards:
Value of Restricted
 Stock Units (1)		   Total 
Richard Serbin  $100,000   $413,250   $513,250 
James Nelson  $100,000   $413,250   $513,250 
Edward Murphy  $100,000   $413,250   $513,250 
Eugene Durenard  $100,000   $413,250   $513,250 

 

(1) The amounts reported in this column represent the aggregate grant date fair value of the restricted stock units, or RSUs, granted under our 2015 Plan as computed in accordance with FASB ASC Topic 718. Note that the amounts reported in this column reflect the accounting value for these equity awards and do not correspond to the actual economic value that may be received from the equity awards. The RSUs vested immediately upon grant.

 

Our non-employee directors receive cash compensation of $75,000 per year, paid quarterly. The non-employee directors also each received 37,500 RSU’s vesting 1/3rd equally in January 2021, 2022, and 2023. In addition, non-employee directors may be entitled to receive special awards of stock options or RSUs from time to time as determined by the board. During 2021, the non-employee directors were also each awarded an additional $25,000 bonus. The chairman of the board and the chairperson of each of the audit, corporate governance/nomination, and compensation committees receive no additional fees for serving in such capacities. There is no additional compensation for meeting attendance. Directors who are employees of the Company receive no additional compensation for serving as directors. All stock options granted to outside directors are immediately exercisable and expire ten years from the date of grant or 30 days after the date they cease to be directors. Directors are reimbursed for ordinary expenses incurred in connection with attending board and committee meetings.

 

53

 

 

Equity Compensation Plan Information

 

Plan Category  (a) Number of Shares to be Issued upon Exercise of Outstanding Options and Rights   (b) Weighted-average Exercise Price of Outstanding Options and Rights   (c) Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Referenced in Column (a)) 
Equity compensation plans approved by stockholders   2,378,778(1)  $2.12(2)   2,095,266 
Equity compensation plans not approved by stockholders   -   $-    - 
Total   2,378,778(1)  $2.12(2)   2,095,266 

 

(1) Includes options and restricted stock units outstanding under our 2015 Equity Incentive Plan.
   
(2) Represents weighted-average exercise price per share of common stock acquirable upon exercise of outstanding stock options.

 

Equity Incentive Plans

 

Under our Amended and Restated 2015 Long-term Incentive Plan (the “2015 Plan”), the board of directors may issue incentive stock-based awards to employees, directors and consultants of the company. Options awarded generally expire ten years after being granted. Any stock-based awards granted vest in accordance with the vesting schedule determined by the board of directors. Should an employee’s director’s or consultant’s relationship with the company terminate before the vesting period is completed, the unvested portion of each grant is forfeited. We continue to maintain and grant awards under the 2015 Plan which will remain in effect its expiration by its terms.

 

The purpose of our incentive plan is to advance the interests of our stockholders by enhancing our ability to attract, retain and motivate persons who are expected to make important contributions to the company by providing them with both equity ownership opportunities and performance-based incentives intended to align their interests with those of our stockholders. These plans are designed to provide us with flexibility to select from among various equity-based compensation methods, and to be able to address changing accounting and tax rules and corporate governance practices by optimally utilizing stock-based awards.

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

The following table sets forth certain information, as of March 22, 2022, with respect to the holdings of (1) each person who is the beneficial owner of more than 5% of our Common Stock, (2) each of our directors, (3) each named executive officer, and (4) all of our current directors and executive officers as a group.

 

Beneficial ownership of the common stock is determined in accordance with the rules of the Securities and Exchange Commission and includes any shares of common stock over which a person exercises sole or shared voting or investment power, or of which a person has a right to acquire ownership at any time within 60 days of March 22, 2022. Except as otherwise indicated, we believe that the persons named in this table have sole voting and investment power with respect to all shares of common stock held by them. Applicable percentage ownership in the following table is based on 33,965,318 shares of common stock plus, for each individual, any securities that individual has the right to acquire within 60 days of March 22, 2022.

 

54

 

 

To the best of our knowledge, except as otherwise indicated, each of the persons named in the table has sole voting and investment power with respect to the shares of our common stock beneficially owned by such person, except to the extent such power may be shared with a spouse. To our knowledge, none of the shares listed below are held under a voting trust or similar agreement, except as noted. To our knowledge, there is no arrangement, including any pledge by any person of securities of the Company, the operation of which may at a subsequent date result in a change in control of the Company. The information in the tables below is based on information known to us or ascertained by us from public filings made by the stockholders. Except as otherwise indicated in the table below, addresses of the director, executive officers and named beneficial owners are in care of Co-Diagnostics, Inc., 2401 S. Foothill Drive, Suite D, Salt Lake City, Utah 84109.

 

   Number of Shares Beneficially Owned   Percentage
of Class (1)		 
5% Stockholders          
Vanguard Group (1)   1,795,057    5.3%
Named Executive Officers and Directors          
Dwight Egan (2)   124,661    * 
Reed Benson (3)   44,836    * 
Brian Brown   18,459    * 
Edward Murphy (4)   75,000    * 
Eugene Durenard   12,500    * 
James Nelson (5)   62,500    * 
Richard Serbin (6)   35,445    * 
All Directors and Executive Officers as a Group (7 persons)   373,401    1.1%

 

*Represents beneficial ownership of less than 1%.

 

(1) Information obtained from Schedule 13G/A filed with the SEC on February 2, 2022. Vanguard Group has an address of 100 Vanguard Blvd, Malvern, PA, 19355.
(2) Includes exercisable options to acquire 100,000 shares of common stock.
(3) Includes exercisable options to acquire 41,666 shares of common stock.
(4) Includes exercisable options to acquire 50,000 shares of common stock.
(5) Includes exercisable options to acquire 50,000 shares of common stock.
(6) Includes exercisable options to acquire 20,445 shares of common stock.

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

The Company acquired the exclusive rights to the CoPrimer technology pursuant to a license agreement dated April 2014, between us and DNA Logix, Inc., which was assigned to Dr. Satterfield prior to our acquisition of DNA Logix, Inc. Pursuant to the license the Company was to pay Dr. Satterfield minimum royalty payments of $30,000 per month until the Company receives an equity funding of at least $4,000,000, at which time the payments increase to $60,000 per month for the remainder of the year. The payment terms were orally modified to maintain the monthly royalties at $30,000 per month through December 2016. On March 1, 2017, the Company entered into an amendment effective January 1, 2017, to its Exclusive License Agreement for its CoPrimer (“License”) technology with Dr. Satterfield, a former member of our Board of Directors. The amendment provides in part that all royalties under the License cease as of January 1, 2017, and we began in January 2017 to pay $700,000 of accrued royalties at the rate of $10,000 per month. In 2021 and 2020, we paid Dr. Satterfield $150,000 and $120,000, respectively, in payment of the accrued royalties.

 

55

 

 

The Company employs two persons who are related to current or former executive officers. Seth Egan is the Company’s Director of Sales and Marketing, and is the son of Dwight Egan, the Company’s President and Chief Executive Officer. Andrew Benson is the Company’s Director of Investor Relations, and is the son of Reed Benson, the Company’s former Chief Financial Officer and Secretary. During the year ended December 31, 2021, the total compensation paid to or earned by these persons, including salaries, bonuses, and the grant date fair value of equity awards which vest over three years, was $1,512,457 and $1,285,790, respectively. During the year ended December 31, 2020, the total compensation paid to or earned by these persons, including salaries, bonuses, and the grant date fair value of equity awards which vest over three years, was $1,113,440 and $1,109,303, respectively.

 

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

The following table presents aggregate fees for professional services rendered by our independent auditors for the respective periods.

 

   Years Ended December 31, 
   2021   2020 
Audit fees  $113,100   $115,000 
Audit related fees   -    - 
Other consulting fees   -    - 
Tax fees   -    1,000 
Total fees  $113,100   $116,000 

 

Audit fees consist of fees for professional services provided in connection with the audit of our annual consolidated financial statements, review of our quarterly consolidated financial statements and our offerings.

 

Tax fees included fees associated with tax compliance and tax consultations.

 

The audit committee has adopted a policy that requires advance approval of all services performed by the independent auditor when fees are expected to exceed $15,000. The audit committee has delegated to the audit committee chairperson, Mr. Durenard, the authority to approve services, subject to ratification by the audit committee at its next committee meeting. All fees incurred were pre-approved by the audit committee.

 

PART IV

 

Item 15. Exhibits, Financial Statement Schedules.

 

(a) The following documents are filed as part of this Annual Report on Form 10-K:

 

  (1) Financial Statements. The Consolidated Financial Statements filed as part of this Annual Report on Form 10-K are included in Part II, Item 8 of this Annual Report on Form 10-K.
     
  (2) Financial statement schedules. There are no financial statements schedules included because they are either not applicable or the required information is shown in the consolidated financial statements or the notes thereto.
     
  (3) Exhibits. The exhibits required by Item 601 of Regulation S-K and Item 15(b) of this Annual Report are listed in the Exhibit Index below. The exhibits listed in the Exhibit Index are incorporated by reference herein.

 

56

 

 

Exhibit

Number

   Exhibit Description  

Filed with this

Report

  

Incorporated by

Reference herein from Form or Schedule

   Filing Date  

SEC File/Reg.

Number

2.1*+   Agreement and Plan of Merger by and between Co-Diagnostics, Inc, IDMO Acquisition Corp., Idaho Molecular Inc., and Company Representative dated as of December 21, 2021.       Form 8-K (Exhibit 2.1)   12/23/21   001-38148
                     
2.2*+   Agreement and Plan of Merger by and between Co-Diagnostics, Inc, ACI Acquisition Corp., Advanced Conceptions, Inc., and Company Representative dated as of December 21, 2021       Form 8-K (Exhibit 2.2)   12/23/21   001-38148
                     
 3.1    Articles of Incorporation       Draft Registration Statement (Exhibit 3.1)   01/12/17    377-01467
                     
3.1.1   Amendment to the Articles of Incorporation       Draft Registration Statement (Exhibit 3.1.1)   01/12/17   377-01467
                     
3.1.2   Articles of Amendment to Articles of Incorporation       Form 8-K (Exhibit 3.2)   01/03/19   001-38148
                     
3.1.3   Articles of Amendment   X            
                     
3.2   Bylaws       Draft Registration Statement (Exhibit 3.2)   01/12/17   377-01467
                     
4.1   Description of Registrant’s securities   X            
                     
10.1   Exclusive Agreement between Co-Diagnostics, Inc. and DNA Logix, Inc., dated April 18, 2014       Draft Registration Statement (Exhibit 10.2)   01/12/17   377-01467
                     
10.2#   Co-Diagnostics, Inc. Amended and Restated 2015 Long Term Incentive Plan       Form S-8/A   11/20/20   333-237684
                     
10.3   Form of Indemnification Agreement       Form S-1/A (Exhibit 10.13.8)   05/24/17  

333-217542

 

                     
10.4   Shareholders’ Agreement between Co-Diagnostics and Synbiotics Limited, dated January 27, 2017       Form S-1 (Exhibit 10.16)   04/28/17   333-217542
                     
10.5   Amended Exclusive License Agreement between Co-Diagnostics, Brent Satterfield, and DNA Logix, Inc., dated January 1, 2017       Form S-1 (Exhibit 10.17)   04/28/17   333-217542
                     
10.6   Warrant Agreement between Co-Diagnostics, Inc and VStock Transfer, LLC. Dated December 31, 2021 (ACI Warrant)   X            

 

57

 

 

10.7   Warrant Agreement between Co-Diagnostics, Inc and VStock Transfer, LLC. Dated December 31, 2021 (IDMO Warrant)   X            
                     
10.8   Form of Securities Purchase Agreement, dated February 27, 2020       Form 8-K (Exhibit 10.1)   02/27/20   001-38148
                     
10.9   Lease Agreement 2401 Foothill Drive   X            
                     
10.9.1   Amendment #1 to Lease   X            
                     
10.9.2   Amendment #2 to Lease   X            
                     
14.1   Code of Ethics for Senior Financial Officers       Form 10-K (Exhibit 14.1)   03/30/20   001-38148
                     
21.1   Subsidiaries of Registrant   X            
                     
23.1   Consent of Haynie & Company   X            
                     
31.1   Certification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002   X            
                     
31.2   Certification of Principal Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002   X            
                     
32.1   Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002   X            
                     
32.2   Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002   X            
                     
101 SCH   Inline XBRL Taxonomy Extension Schema Document (A)   X            
                     
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document (A)   X            
                     
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document (A)   X            
                     
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document (A)   X            
                     
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document (A)   X            
                     
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)   X            
                     
(A)   iXBRL (INline Extensible Business Reporting Language) information is furnished and not filed for purposes of Section 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934.   X            

 

#Management Contract or Compensatory Plan or Arrangement

 

*Schedules and exhibits to these Exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request.

 

+ Portions of Exhibit 2.1 and Exhibit 2.2 have been omitted as they contain information that (i) is not material and (ii) is the type of information the issuer both customarily and actually treats as private and confidential.

 

58

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  CO-DIAGNOSTICS, INC.
     
Date: March 24, 2022 By: /s/ Dwight Egan
    Dwight Egan
   

Chief Executive Officer, President and Director

(Principal Executive Officer)

     
  By: /s/ Brian Brown
   

Brian Brown

Chief Financial Officer

(Principal Financial and Accounting Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.

 

Signature   Title   Date
         
/s/ Dwight Egan   Chief Executive Officer, President and Director   March 24, 2022
Dwight Egan   (Principal Executive Officer)    
         
/s/ Brian Brown   Chief Financial Officer   March 24, 2022
Brian Brown   (Principal Financial and Accounting Officer)    
         
/s/ Eugen Durenard   Director   March 24, 2022
Eugene Durenard        
         
/s/ Edward Murphy   Director   March 24, 2022
Edward Murphy        
         
/s/ James Nelson   Director   March 24, 2022
James Nelson        
         
/s/ Richard Serbin   Director   March 24, 2022
Richard Serbin        

 

59

 

 EX-3.1.3 2 ex3-1_3.htm

 

Exhibit 3.1.3

 

ARTICLES OF AMENDMENT TO THE

ARTICLES OF INCORPORATION OF CO-DIAGNOSTICS, INC.

 

Pursuant to and in accordance with the provisions of Section 16-10a-1006 of the Utah Revised Business Corporation Act, as amended (the “Act’’), the undersigned, Co-Diagnostics, Inc. (the “Corporation”) hereby declares and certifies the following Articles of Amendment to its Articles of Incorporation.

 

1. The name of the Corporation is Co-Diagnostics, Inc.

 

2. The text of the amendment to the Articles of Incorporation of the Corporation adopted is as follows:

 

Following the final paragraph of ARTICLE ill-CAPITAL STOCK of the Articles of Incorporation, the following text is inserted:

 

“Upon the filing of these Articles of Amendment to the Articles of Incorporation, each share of Common Stock of the Corporation issued and outstanding immediately prior to these Articles of Amendment to the Articles of Incorporation, without further action, will be automatically split and converted into one-eleventh (1/11) of one (1) share of fully paid and nonassessable shares of Common Stock of the Corporation (the “Reverse Stock Split”). No fractional shares shall be issued upon the Reverse Stock Split; rather, each fractional share resulting from the Reverse Stock Split shall be rounded up to the nearest whole number. Each outstanding stock certificate of the Corporation, which prior to the filing of these Articles of Amendment represented one or more shares of Common Stock, shall immediately after such filing represent that number of shares of Common Stock equal to the product of (x) the number of shares of Common Stock represented on such certificates divided by (y) eleven (11) (such adjusted shares, the “Reclassified Shares”), with any resulting fractional shares rounded up to the nearest whole share as set forth above. Any options, warrants or other purchase rights, which prior to the filing of these Articles of Amendment represented the right to acquire one or more shares of the Corporation’s Common Stock, shall immediately after such filing represent the right to acquire one-eleventh (1/11) of one (1) share of the Corporation’s Common Stock for each share of the Corporation’s Common Stock that such option, warrant or other purchase right previously represented the right to acquire. The exercise price of such options, warrants and purchase rights shall be adjusted by multiplying the existing exercise price by eleven (11).

 

The number of authorized shares of Common Stock of the Corporation and the par value of such shares will not be affected by these Articles of Amendment.

 

The Corporation shall, upon the request of each record bolder of a certificate representing shares of Common Stock issued and outstanding immediately prior to the filing of these Articles of Amendment to the Articles of Incorporation, issue and deliver to such holder in exchange for such certificate a new certificate or certificates representing the Reclassified Shares.”

 

3. The amendment specified above was adopted as of May 24, 2017, by the Board of Directors of the Corporation by a unanimous consent resolution for such purpose, and in accordance with the requirements of the Act and the Bylaws of the Corporation.

 

4. The foregoing amendment to the Articles of Incorporation of the Corporation was authorized and approved pursuant to section 16-10a-1003 of the Act by a vote of the majority of the Corporation’s shareholders entitled to vote at an Annual Meeting of the shareholders of the Corporation.

 

5. Pursuant to 16-10a-704 of the Act, this action was approved without meeting with the consent of holders of 64,457,487 shares of the Corporation’s Common Stock equal to 59.3% of the shares entitled to vote on the action

 

IN WITNESS WHEREOF, these Articles of Amendment to the Articles of Incorporation of the Corporation are executed as of June 20, 2017.

 

  Co-Diagnostics, Inc. a Utah corporation
     
  /s/ Reed L. Benson
  Title: Chief Financial Officer
     
     

 

 

 

 EX-4.1 3 ex4-1.htm

 

EXHIBIT 4.1

 

DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED UNDER SECTION 12

OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

 

The following description of our capital stock summarizes certain provisions of articles of incorporation, as amended (the “Articles of Incorporation”), our bylaws (the “Bylaws”), and applicable provisions of law. Such summaries do not purport to be complete and are subject to, and are qualified in their entirety by reference to, all of the provisions of our Articles of Incorporation and our Bylaws, including the definitions therein of certain terms, and all of the applicable provisions of law. Copies of our Articles of Incorporation and our Bylaws are filed or incorporated by reference as exhibits to our Annual Report on Form 10-K.

 

References in this Exhibit to the “Company,” “us,” “we,” and “our” are solely to Co-Diagnostics, Inc. and not to any of its subsidiaries, unless the context requires otherwise.

 

DESCRIPTION OF COMMON STOCK

 

Authorized Capital Stock

 

Pursuant to our Articles of Incorporation, our authorized capital stock presently consists of 100,000,000 shares of Common Stock, par value $0.001 per share, and 5,000,000 shares of “blank check” preferred stock, par value $0.001 per share.

 

Common Stock

 

Fully Paid and Non-Assessable Shares; No Liability for Corporate Obligations

 

All of the outstanding shares of Common Stock are fully paid and non-assessable. A share of Common Stock is fully paid and non-assessable if such share has been issued for consideration legally permissible under the Utah Revised Business Corporation Act with a value at least equal to the par value per share of Common Stock. Holders of fully paid and non-assessable shares of the Common Stock will not be liable for any obligations or liabilities of the Company that the Company may fail to discharge.

 

Voting Rights

 

Each holder of shares of Common Stock is entitled to one vote for each share owned of record on all matters submitted to a vote of shareholders. Except as noted below or as otherwise required by the Utah Revised Business Corporation Act, the vote of shareholders is required to decide any matter brought before a shareholder meeting at which a quorum is present. The holders of a majority of the outstanding shares of our stock must approve any amendments to our Articles of Incorporation, any merger or consolidation to which we are a party (other than parent-subsidiary mergers), any sale of all or substantially all of our assets or our dissolution as a corporation. Our shareholders do not have cumulative voting rights as to the election of directors.

 

Dividends

 

Subject to the preferential rights of any holders of any series of our preferred stock that may be issued in the future, the holders of shares of Common Stock are entitled to such dividends and distributions, whether payable in cash or otherwise, as may be declared from time to time by our board of directors from legally available funds.

 

We have never declared or paid any cash dividends on our capital stock. The payment of dividends on our Common Stock in the future will depend on our earnings, capital requirements, operating and financial condition, and such other factors as our board of directors may consider appropriate. We currently expect to use all available funds to finance the future development and expansion of our business and do not anticipate paying dividends on our Common Stock in the foreseeable future.

 

 

 

 

Liquidation Distributions

 

Subject to the preferential rights of any holders of any series of our preferred stock that may be issued in the future, upon our liquidation, dissolution, or winding-up, and after payment of all prior claims against our assets and our outstanding obligations, the holders’ shares of Common Stock will be entitled to receive, pro rata, all of our remaining assets.

 

Preemptive, Conversion, Redemption, or Similar Rights

 

The holders of shares of Common Stock are not entitled to any preemptive or other similar rights to subscribe for or acquire additional shares of Common Stock or any other securities of the Company. The shares of Common Stock are not subject to conversion or redemption by the Company and the holders of shares of Common Stock do not have any right or option to convert such shares into any other security or property of the Company or to cause the Company to redeem such shares of Common Stock. There are no sinking fund provisions applicable to the Common Stock.

 

Listing

 

Shares of the Common Stock are listed for trading on the NASDAQ Capital Markets under the symbol “CODX.”

 

Transfer Agent and Registrar

 

The transfer agent and registrar for the Common Stock is VStock Transfer Company, Inc. located at 18 Lafayette Pl, Woodmere, New York 11598. Its telephone number is (212) 828-8436.

 

Preferred Stock

 

Shares of our preferred stock are NOT listed for trading. The description herein is provided solely to show the potential effect on our Common Stock.

 

Our Articles of Incorporation authorizes 5,000,000 shares of “blank check” preferred stock, par value $0.001 per share, of which 30,000 have been designated as Series A Convertible Preferred Stock.

 

All 30,000 previously outstanding shares of Series A Preferred Stock were converted into Common Stock during 2020 and 2019. The board of directors of the Company may provide for the issue of any or all of the unissued and undesignated shares of the preferred stock in one or more series, and to fix the number of shares and to determine or alter for each such series, such voting powers, full or limited, or no voting powers, and such designation, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted by the board of directors providing for the issuance of such shares and as may be permitted by law, without shareholder approval.

 

Our board of directors has the right to establish one or more series of preferred stock without shareholder approval. Unless required by law or by any stock exchange on which our Common Stock is listed, the authorized shares of preferred stock will be available for issuance at the discretion of our board of directors without further action by our shareholders. Our board of directors is able to determine, with respect to any series of preferred stock, the terms and rights of that series, including:

 

  ● the designation of the series;
     
  ● the number of shares of the series;
     
  ● whether dividends, if any, will be cumulative or non-cumulative and the dividend rate, if any, of the series;

 

 

 

 

 

  ● the dates at which dividends, if any, will be payable;
     
  ● the redemption rights and price or prices, if any, for shares of the series;
     
  ● the terms and amounts of any sinking fund provided for the purchase or redemption of shares of the series;
     
  ● the amounts payable on shares of the series in the event of any voluntary or involuntary liquidation, dissolution, or winding-up of the affairs of our company;
     
  ● whether the shares of the series will be convertible into shares of any other class or series, or any other security, of our company or any other entity, and, if so, the specification of the other class or series or other security, the conversion price or prices or rate or rates and provisions for any adjustments to such prices or rates, the date or dates as of which the shares will be convertible, and all other terms and conditions upon which the conversion may be made;
     
  ● the ranking of such series with respect to dividends and amounts payable on our liquidation, dissolution, or winding-up, which may include provisions that such series will rank senior to our Common Stock with respect to dividends and those distributions;
     
  ● restrictions on the issuance of shares of the same series or any other class or series; or
     
  ● voting rights, if any, of the holders of the series.

 

The issuance of preferred stock could adversely affect, among other things, the voting power of holders of Common Stock and the likelihood that shareholders will receive dividend payments and payments upon our liquidation, dissolution, or winding up. The issuance of preferred stock could also have the effect of delaying, deferring, or preventing a change in control of us.

 

If we issue shares of preferred stock, the shares will be fully paid and nonassessable and will not have, or be subject to, any preemptive or similar rights.

 

 

 

EX-10.6 4 ex10-6.htm

 

Exhibit 10.6

 

COMPANY WARRANT AGREEMENT

 

THIS WARRANT AGREEMENT (this “Agreement”), dated as of December 31, 2021, is entered into by and between Co-Diagnostics, Inc., a Utah corporation (“Parent” or the “Company”), and VStock Transfer, LLC (the “Warrant Agent”).

 

WHEREAS, Parent consummated a merger (the “Merger”) of its wholly-owned subsidiary, ACI Acquisition Corp. (“Subco”), with and into Advanced Conceptions Inc., a Utah corporation (“Company”), pursuant to an Agreement and Plan of Merger (as such agreement may be amended from time to time, the “Merger Agreement”), by and among Parent, Company, and Subco;

 

WHEREAS, the Merger Agreement provides that the Company will issue warrants to purchase 232,500 shares of the Company’s common stock, par value $0.001 per share, (the “Parent Common Stock”) exercisable subject to satisfaction of certain milestones and over a seven year period at an initial exercise price of $9.125 per share (the “Warrants” or the “Company Warrants”);

 

WHEREAS, the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, transfer, exchange and exercise of the Warrants; and

 

WHEREAS, the Company desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and the respective rights, limitation of rights, and immunities of the Company, the Warrant Agent, and the holders of the Warrants.

 

NOW, THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows:

 

1. Appointment of Warrant Agent and Depository. The Company hereby appoints the Warrant Agent to act as agent for the Company for the Company Warrants, and the Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set forth in this Agreement.

 

2. Warrants.

 

2.1 Issuance of Warrants. Each Company Warrant will be uncertificated and in registered form only, substantially in the form of Exhibit 1, the provisions of which are incorporated herein. Any Warrant so issued shall have the same terms, force and effect as a certificated Warrant that has been duly countersigned by the Warrant Agent in accordance with the terms of this Agreement.

 

2.2 Warrant Register.

 

(a) The Warrant Agent shall maintain books (“Warrant Register”) for the registration of the original issuance and the registration of any subsequent transfer of the Warrants. Upon the initial issuance of the Warrants, the Warrant Agent shall issue and register the Warrants in the names of the respective holders thereof in such denominations and otherwise in accordance with instructions delivered to the Warrant Agent by the Company.

 

 
 

 

(b) Prior to due presentment for registration of transfer of any Warrant in accordance with Section 5.1.1 below, the Company and the Warrant Agent may deem and treat the person in whose name such Warrant is then registered in the Warrant Register (each a “registered holder”) as the absolute owner of such Warrant, for the purpose of any exercise thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.

 

3. Terms and Exercise of Warrants.

 

3.1 Exercise Price. For purposes of this Agreement, “Exercise Price” shall mean the initial exercise price for each Warrant as set forth in the Exhibit 1, subject to adjustment as provided in Exhibit 1.

 

3.2 Duration of Warrants. A Warrant may be exercised only during the period (“Exercise Period”) specified in Exhibit 1 or as the same may be extended as hereinafter provided. Each Warrant not exercised on or before the expiration date, as set forth in Exhibit 1 (the “Expiration Date”), shall become void, and all rights thereunder and all rights in respect thereof under this Agreement shall cease at the close of business on the Expiration Date.

 

3.3 Exercise of Warrants. Warrants may be exercised, at the option of the registered holder of the Warrant, in whole or in part, at any time or from time to time during the Exercise Period, by complying with the Warrant Agent’s procedures relating to the exercise of such book-entry interest in the Warrants. In addition, the registered holder shall deliver to the Warrant Agent (the “Warrant Agent Office”) (i) an exercise form set forth in the Warrant, executed by such registered holder or its duly authorized agent or attorney (the “Exercise Form”) and (ii) payment of the aggregate Exercise Price. In case an exercise of Warrants is in part only, the Warrant Agent shall make an appropriate adjustment to the account of the registered holder to reflect a number of Warrants for the number of shares of Parent Common Stock equal (without giving effect to any adjustment thereof) to the number of such shares called for by such registered holder’s Warrants prior to such exercise, minus the number of shares designated by the registered holder upon such exercise.

 

3.3.1 Payment. Subject to the provisions of the Warrant and this Agreement, a Warrant may be exercised by the registered holder thereof by delivering to the Warrant Agent at its corporate trust department (i) a warrant exercise form properly delivered by the registered holder, and (iii) the payment in full of the Exercise Price for each share of Common Stock as to which the Warrant is exercised as follows:

 

(a) in lawful money of the United States, in certified check or wire payable to the Warrant Agent; or

 

(b) as provided in Section 7.5 hereof.

 

 
 

 

3.3.2 Procedures and Validity.

 

(a) Any exercise of a Warrant by a registered holder pursuant to the terms of this Agreement shall be irrevocable and shall constitute a binding agreement between the registered holder and the Company, enforceable in accordance with its terms.

 

(b) The Warrant Agent shall:

 

(i) examine all Exercise Forms and all other documents delivered to it by or on behalf of registered holders as contemplated hereunder to ascertain whether or not, on their face, such Exercise Forms and any such other documents have been executed and completed in accordance with their terms and the terms hereof;

 

(ii) where an Exercise Form or other document appears on its face to have been improperly completed or executed or some other irregularity in connection with the exercise of the Warrants exists, the Warrant Agent shall endeavor to inform the appropriate parties (including the person submitting such instrument) of the need for fulfillment of all requirements, specifying those requirements which appear to be unfulfilled;

 

(iii) inform the Company of and cooperate with and assist the Company in resolving any reconciliation problems between the Exercise Forms received and the crediting of Warrants to the respective registered holders’ accounts; and

 

(iv) advise the Company no later than two (2) business days after receipt of an Exercise Form, of (i) the receipt of such Exercise Form and the number of Warrants exercised in accordance with the terms and conditions of this Agreement, and (ii) such other information as the Company shall reasonably require.

 

(c) All questions as to the validity, form and sufficiency (including time of receipt) of an exercised Warrant and any Exercise Form will be determined by the Company in good faith. The Company reserves the right to reject any and all Exercise Forms not in proper form or for which any corresponding agreement by the Company to exchange would, in the opinion of the Company, be unlawful. Moreover, the Company reserves the absolute right to waive any of the conditions to the exercise of Warrants or defects in the exercise thereof with regard to any particular exercise of Warrants. Other than as required in Section 3.3.2(b)(ii) above, neither the Company nor the Warrant Agent shall be under any duty to give notice to the registered holders of the Warrants of any irregularities in any exercise of Warrants or any Exercise Form, nor shall it incur any liability for the failure to give such notice.

 

3.3.3 Issuance of Shares. As soon as practicable after the exercise of any Warrant and the clearance of the funds in payment of the Exercise Price, the Company shall cause its Transfer Agent to issue to the registered holder of such Warrant a certificate or certificates, or book entry position, representing the number of full shares of Parent Common Stock to which he, she or it is entitled, registered in such name or names as may be directed by him, her or it. In the event that during the last 20 business days immediately prior to the Expiration Date both (i) a registration statement with respect to the Parent Common Stock underlying the Warrants is not effective or a current prospectus is not available and (ii) the Exercise Price of the Warrants is less than the price at which the Parent Common Stock is trading on NASDAQ (or if the Parent Common Stock is no longer trading on NASDAQ, such other stock exchange on which the shares of Parent Common Stock trades), the Exercise Period shall automatically be extended for a period of 20 business days after the date that the Company causes a registration statement covering the Warrants and the Parent Common Stock underlying the Warrants to be effective and a current prospectus is made available. In no event will the Company be required to “net cash settle” the warrant exercise.

 

 
 

 

3.3.4 Valid Issuance. All shares of Parent Common Stock issued upon the proper exercise of a Warrant in conformity with this Agreement shall be validly issued, fully paid and nonassessable.

 

3.3.5 Date of Issuance. All shares of Parent Common Stock so issued shall be registered in the name of the registered holder or such other name as shall be designated in the Exercise Form delivered by the registered holder. Such shares of Parent Common Stock shall be deemed to have been issued and any person so designated to be named therein shall be deemed to have become the holder of record of such shares of Parent Common Stock as of the date of delivery of the Exercise Form to the Warrant Agent Office duly executed by the registered holder thereof and upon the Company’s receipt of payment of the Exercise Price.

 

4. Adjustments.

 

4.1 Adjustments Generally. The Exercise Price, the number of shares of Parent Common Stock issuable upon exercise of the Warrants and the number of Warrants outstanding are subject to adjustment from time to time upon the occurrence of certain events in accordance with the provisions of Exhibit 1.

 

4.2 Notices of Vesting and Changes in Warrant. Promptly upon the satisfaction of the vesting requirements of the Warrants pursuant to the Merger Agreement, the Company shall deliver written notice of such vesting and exercisability to the Warrant Agent, which notice shall state the date upon which such warrants shall vest and become exercisable. Upon every adjustment of (i) the Exercise Price, (ii) the number of shares of Parent Common Stock issuable upon exercise of the Warrants and (iii) the number of Warrants outstanding, the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Exercise Price resulting from such adjustment and the increase or decrease, if any, in the number of shares purchasable at such price upon the exercise of a Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. Upon the occurrence of any event specified in the Warrant certificate then, in any such event, the Company shall give written notice to each registered holder, at the last address set forth for such registered holder in the Warrant register maintained by the Warrant Agent, of the record date or the effective date of the event. Failure to give such notice, or any defect therein, shall not affect the legality or validity of such event.

 

4.3 No Fractional Shares. Notwithstanding any provision contained in this Agreement to the contrary, the Company shall not issue fractional shares upon exercise of Warrants. If, by reason of any adjustment made pursuant to this Section 4, the registered holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share, the Company shall, upon such exercise, round up or down to the nearest whole number the number of shares of Parent Common Stock to be issued to the registered holder.

 

 
 

 

4.4 Form of Warrant. The form of Warrant certificate need not be changed as a result of any adjustment pursuant to this Section. However, the Company may, at any time, in its sole discretion, make any change in the form of Warrant certificate that the Company may deem appropriate and that does not affect the substance thereof.

 

5. Transfer and Exchange of Warrants.

 

5.1 Exchange and Transfer.

 

5.1.1 The Warrant Agent shall keep, at the Warrant Agent Office, books in which, subject to such reasonable regulations as it may prescribe, it shall register Warrants and exchanges and transfers of outstanding Warrants upon request to exchange or transfer such Warrants, provided, that the Warrant Agent shall have received a written instruction of transfer or exchange in form reasonably satisfactory to the Warrant Agent, duly executed by the registered holder thereof or by its or her or his duly authorized agent or attorney, providing all information required to be delivered hereunder, such signature to be guaranteed by an eligible guarantor institution to the extent required by the Warrant Agent or the Depository. Upon any such registration of transfer, a Warrant Statement shall be issued to the transferee.

 

5.1.2 The Company shall pay for applicable service charges for any exchange or registration of transfer of Warrants; and the Warrant Agent and/or the Company may require payment of a sum sufficient to cover any stamp or other tax or other charge that may be imposed in connection with any such exchange or registration of transfer. Neither the Warrant Agent nor the Company shall be required to pay any stamp or other tax or other charge required to be paid in connection with such transfer, and neither the Warrant Agent nor the Company shall be required to issue or deliver any Warrants until it has been established to the Company’s and the Warrant Agent’s reasonable satisfaction that such tax or other charge has been paid or that no such tax or other charge is due.

 

5.1.3 The Warrant Agent shall not affect any exchange or registration of transfer which will result in the issuance of a Warrant evidencing a fraction of a Warrant or a number of full Warrants and a fraction of a Warrant.

 

5.1.4 All Warrants credited to a registered holder’s or transferee’s account upon any exchange or transfer of Warrants in accordance with the provisions of this Agreement shall be the valid obligations of the Company evidencing the same obligations, and entitled to the same benefits under this Agreement, as the Warrants that were so exchanged or transferred.

 

5.2 Treatment of Holders of Warrants. Each registered holder of Warrants, by accepting the same, consents and agrees with the Company, the Warrant Agent and every subsequent registered holder of such Warrants that until the due presentment for registration of transfer in accordance with Section 5.1.1 of such Warrants, the Company and the Warrant Agent may treat the registered holder of such Warrants as the absolute owner thereof for any purpose and as the person entitled to exercise the rights represented by the Warrants evidenced thereby, any notice to the contrary notwithstanding.

 

 
 

 

5.3 Procedure for Surrender of Warrants. Warrants may be surrendered to the Warrant Agent, either in certificated form or in book entry position, together with a written request for exchange or transfer, and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants, or book entry positions, as requested by the registered holder of the Warrants so surrendered, representing an equal aggregate number of Warrants; provided, however, that in the event that a Warrant surrendered for transfer bears a restrictive legend, the Warrant Agent shall not cancel such Warrant and issue new Warrants in exchange therefor until the Warrant Agent has received an opinion of counsel stating that such transfer may be made and indicating whether the new Warrants must also bear a restrictive legend.

 

5.4 Cancellation of Warrants. Promptly following the Expiration Date or at such earlier time that there are no longer outstanding any Warrants, the Warrant certificate shall be cancelled or destroyed and the Warrant Agent shall deliver a certificate of such cancellation or destruction to the Company.

 

6. [Omitted].

 

7. Other Provisions Relating to Rights of Holders of Warrants.

 

7.1 No Rights as Stockholder. No Warrant shall, and nothing contained in this Agreement, in the Warrant certificate or in the Warrant Statement shall be construed to, entitle the registered holder or any beneficial owner thereof to any of the rights of a holder or beneficial owner of Parent Common Stock, including, without limitation, the right to vote or to consent or to receive notice as a stockholder in respect of any meeting of stockholders for the election of directors of the Company or any other matter, to receive dividends on Parent Common Stock or any rights whatsoever as stockholders of the Company, until such Warrant is duly exercised in accordance with this Agreement and such registered holder is issued the Parent Common Stock to which it is entitled in connection therewith.

 

7.2 Reservation of Common Stock. The Company shall at all times reserve and keep available a number of its authorized but unissued shares of Parent Common Stock that will be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Agreement.

 

7.3 [Omitted].

 

7.4 Limitation on Monetary Damages. In no event shall the registered holder of a Warrant be entitled to receive monetary damages for failure to settle any Warrant exercise if the Parent Common Stock issuable upon exercise of the Warrants has not been registered with the SEC pursuant to an effective registration statement or if a current prospectus is not available for delivery by the Warrant Agent, provided the Company has fulfilled its obligations under Section 7.5 to use its commercially reasonable efforts to effect the registration under the Securities Act of 1933 (the “Securities Act”) of the Parent Common Stock issuable upon exercise of the Warrants.

 

 
 

 

7.5 Registration of Shares of Common Stock; Cashless Exercise at Company’s Option.

 

7.5.1 Registration of the shares of Common Stock. If the Company shall fail to have maintained an effective registration statement covering the issuance of the shares of Common Stock issuable upon exercise of the Warrants as required under the Merger Agreement, the registered holders shall have the right to exercise such Warrants on a “cashless basis,” by exchanging the Warrants (in accordance with Section 3(a)(9) of the Securities Act or another exemption) for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the Warrants, multiplied by the excess of the “Fair Market Value” (as defined below) less the Exercise Price by (y) the Fair Market Value. Solely for purposes of this subsection 7.5.1, “Fair Market Value” shall mean the volume-weighted average price of the shares of Common Stock as reported during the ten (10) trading day period ending on the trading day prior to the date that notice of exercise is received by the Warrant Agent from the registered holder of such Warrants or its securities broker or intermediary. The date that notice of “cashless exercise” is received by the Warrant Agent shall be conclusively determined by the Warrant Agent. In connection with the “cashless exercise” of a Warrant, the Company shall, upon request, provide the Warrant Agent with an opinion of counsel for the Company (which shall be an outside law firm with securities law experience) stating that (i) the exercise of the Warrants on a “cashless basis” in accordance with this subsection 7.5.1 is not required to be registered under the Securities Act and (ii) the shares of Common Stock issued upon such exercise shall be freely tradable under United States federal securities laws by anyone who is not an affiliate (as such term is defined in Rule 144 under the Securities Act) of the Company and, accordingly, shall not be required to bear a restrictive legend. Except as provided in subsection 7.5.2, for the avoidance of doubt, unless and until all of the Warrants have been exercised or have expired, the Company shall continue to be obligated to comply with its registration obligations under the first three sentences of this subsection 7.5.1

 

7.5.1 Cashless Exercise at Company’s Option. If the shares of Common Stock are at the time of any exercise of a Warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, (i) require holders of Warrants who exercise such Warrants to exercise such Warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act as described in subsection 7.5.1 and (ii) in the event the Company so elects, the Company shall (x) not be required to file or maintain in effect a registration statement for the registration, under the Securities Act, of the shares of Common Stock issuable upon exercise of the Warrants, notwithstanding anything in this Agreement to the contrary, and (y) use its commercially reasonable efforts to register or qualify for sale the shares of Common Stock issuable upon exercise of the Warrant under applicable blue sky laws to the extent an exemption is not available..

 

8. Concerning the Warrant Agent and Other Matters.

 

8.1 Payment of Taxes. The Company will from time to time promptly pay all taxes and charges that may be imposed upon the Company or the Warrant Agent in respect of the issuance or delivery of shares of Parent Common Stock upon the exercise of Warrants, but the Company shall not be obligated to pay any transfer taxes in respect of the Warrants or such shares.

 

 
 

 

 

8.2 Resignation, Consolidation, or Merger of Warrant Agent.

 

8.2.1 Appointment of Successor Warrant Agent. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and be discharged from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company and to each registered holder. If the office of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint in writing a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of 30 days after it has been notified in writing of such resignation or incapacity by the Warrant Agent or by any registered holder of a Warrant, then the registered holder of any Warrant may apply to the Supreme Court of the State of New York for the County of New York for the appointment of a successor Warrant Agent at the Company’s cost. Any successor Warrant Agent, whether appointed by the Company or by such court, shall be a corporation organized and existing under the laws of the State of New York, in good standing and having its principal office in the Borough of Manhattan, City and State of New York, and authorized under such laws to exercise corporate trust powers and subject to supervision or examination by federal or state authority. After appointment, any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations of its predecessor Warrant Agent with like effect as if originally named as Warrant Agent hereunder, without any further act or deed; but if for any reason it becomes necessary or appropriate, the predecessor Warrant Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent all the authority, powers, and rights of such predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming to such successor Warrant Agent all such authority, powers, rights, immunities, duties, and obligations.

 

8.2.2 Notice of Successor Warrant Agent. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof to each registered holder, the predecessor Warrant Agent and the transfer agent for the Parent Common Stock not later than the effective date of any such appointment.

 

8.2.3 Merger or Consolidation of Warrant Agent. Any corporation into which the Warrant Agent may be merged or with which it may be consolidated or any corporation resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the successor Warrant Agent under this Agreement without any further act.

 

8.3 Fees and Expenses of Warrant Agent.

 

8.3.1 Remuneration. The Company agrees to pay the Warrant Agent reasonable remuneration for its services as such Warrant Agent hereunder and will reimburse the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably incur in the execution of its duties hereunder.

 

8.3.2 Further Assurances. The Company agrees to perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and delivered all such further and other acts, instruments and assurances as may reasonably be required by the Warrant Agent for the carrying out or performing of the provisions of this Agreement.

 

8.4 Liability of Warrant Agent.

 

8.4.1 Reliance on Company Statement. Whenever in the performance of its duties under this Agreement the Warrant Agent shall deem it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a statement signed by the General Counsel, President or Chairman of the Board of Directors of the Company and delivered to the Warrant Agent. The Warrant Agent may rely upon such statement for any action taken or suffered in good faith by it pursuant to the provisions of this Agreement.

 

 
 

 

8.4.2 Indemnity. The Warrant Agent shall be liable hereunder only for its own gross negligence, willful misconduct or bad faith. The Company agrees to indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, costs and reasonable counsel fees, for anything done or omitted by the Warrant Agent in the execution of this Agreement, except as a result of the Warrant Agent’s gross negligence, willful misconduct or bad faith.

 

8.4.3 Exclusions. The Warrant Agent shall have no responsibility with respect to the validity of this Agreement or with respect to the validity or execution of any Warrant (except its countersignature thereof); nor shall it be responsible for any breach by the Company of any covenant or condition contained in this Agreement or in any Warrant; nor shall it be responsible to make any adjustments required under the provisions of Section 4 hereof or responsible for the manner, method or amount of any such adjustment or the ascertaining of the existence of facts that would require any such adjustment; nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any shares of Parent Common Stock to be issued pursuant to this Agreement or any Warrant or as to whether any shares of Parent Common Stock will when issued be valid and fully paid and nonassessable.

 

8.5 Acceptance of Agency. The Warrant Agent hereby accepts the agency established by this Agreement and agrees to perform the same upon the terms and conditions herein set forth and, among other things, shall account promptly to the Company with respect to Warrants exercised and concurrently account for, and pay to the Company, all moneys received by the Warrant Agent for the purchase of shares of Parent Common Stock through the exercise of Warrants.

 

9. Miscellaneous Provisions.

 

9.1 Successors. All the covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure to the benefit of their respective successors and assigns.

 

9.2 Notices. Any notice, statement or demand authorized by this Agreement to be given or made by the Warrant Agent or by the registered holder of any Warrant to or on the Company shall be delivered by hand or sent by registered or certified mail or overnight courier service, addressed (until another address is filed in writing by the Company with the Warrant Agent) as follows:

 

Co-Diagnostics, Inc.

2401 South Foothill Dr., Suite D

Salt Lake City, UT 84109

Telephone: 801-438-1036

Attention: President

 

 
 

 

Attention: General Counsel

 

Any notice, statement or demand authorized by this Agreement to be given or made by the registered holder of any Warrant or by the Company to or on the Warrant Agent shall be delivered by hand or sent by registered or certified mail or overnight courier service, addressed (until another address is filed in writing by the Company with the Warrant Agent) as follows:

 

VStock Transfer, LLC

18 Lafayette Place

Woodmere, New York 11598

Attn: Compliance Department

 

Any notice, sent pursuant to this Agreement shall be effective, if delivered by hand, upon receipt thereof by the party to whom it is addressed, if sent by overnight courier, on the next business day of the delivery to the courier, and if sent by registered or certified mail on the third day after registration or certification thereof.

 

9.3 Notices to Holders of Warrants. Any notice to registered holders of Warrants which by any provisions of this Warrant Agreement or the Warrant certificate is required or permitted to be given shall be given by first class mail prepaid at such registered holder’s address as it appears on the books of the Warrant Agent.

 

9.4 Applicable Law. The validity, interpretation and performance of this Agreement and of the Warrants shall be governed in all respects by the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. The Company hereby agrees that any action, proceeding or claim against it arising out of or relating in any way to this Agreement shall be brought and enforced in the courts located or situated in New York, New York or the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any such process or summons to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 9.2 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim.

 

9.5 Persons Having Rights under this Agreement. Nothing in this Agreement expressed and nothing that may be implied from any of the provisions hereof is intended, or shall be construed, to confer upon, or give to, any person or corporation other than the parties hereto and the registered holders of the Warrants, any right, remedy, or claim under or by reason of this Agreement or of any covenant, condition, stipulation, promise, or agreement hereof. All covenants, conditions, stipulations, promises, and agreements contained in this Agreement shall be for the sole and exclusive benefit of the parties hereto and their successors and assigns and of the registered holders of the Warrants.

 

 
 

 

9.6 Examination of the Warrant Agreement. A copy of this Agreement shall be available at all reasonable times at the office of the Warrant Agent in the Borough of Manhattan, City and State of New York, for inspection by the registered holder of any Warrant. The Warrant Agent may require any such registered holder to submit his, her or its Warrant Statements for inspection by it.

 

9.7 Counterparts. This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

 

9.8 Effect of Headings. The section headings herein are for convenience only and are not part of this Agreement and shall not affect the interpretation thereof.

 

9.9 Amendments. This Agreement may be amended by the parties hereto without the consent of any registered holder for the purpose of curing any ambiguity, or curing, correcting or supplementing any defective provision contained herein or adding or changing any other provisions with respect to matters or questions arising under this Agreement as the parties may deem necessary or desirable and provided such amendment shall not adversely affect the interest of the registered holders. All other modifications, adjustments or amendments of this Agreement, shall require the written consent of the registered holders of a majority of the then outstanding Warrants provided that no amendment to the Warrant certificate shall be effective to charge any registered holder who has not consented thereto. The Warrant Agent may request from either the Company or the registered holders an opinion of counsel with respect to the validity of any amendment as a condition to its exercise of any amendment.

 

9.10 Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.

 

[Signature page follows]

 

 
 

 

IN WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto as of the day and year first above written.

 

CO-DIAGNOSTICS, INC.  
     
By:  
                            
Name:  
     
VSTOCK TRANSFER, LLC  
     
By:  
     
Name:  
     
[Signature Page to Warrant Agreement]  

 

 
 

 

EXHIBIT 1 TO COMPANY WARRANT AGREEMENT

 

FORM OF GLOBAL WARRANT CERTIFICATE FOR COMPANY WARRANTS

 

EXERCISABLE ONLY IF AUTHENTICATED BY THE WARRANT AGENT AS PROVIDED HEREIN

 

VOID AFTER THE CLOSE OF BUSINESS ON _______________, 20__ OF CO-DIAGNOSTICS, INC.

 

Global Warrant Certificate representing Warrants to purchase __________ shares of common stock, par value $0.001 per share, as described herein

 

NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE SOLD, ASSIGNED, TRANSFERRED, ENCUMBERED, OR OTHERWISE DISPOSED OF, EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED.

 

Each Warrant (each a “Warrant”) represented hereby, entitles the registered holder to purchase one share (the “Warrant Share”) of common stock, $0.001 par value (the “Common Stock”), of Co-Diagnostics, Inc., a Utah corporation, (the “Corporation”) for the benefit of certain registered holders (as defined in the Warrant Agreement) of such Warrants on the following terms. This Global Warrant Certificate represents the number of outstanding Warrants from time to time endorsed hereon and the number of outstanding Warrants represented hereby may from time to time be reduced or increased, as appropriate to reflect exchanges, redemptions, exercises and other similar transactions. This Global Warrant Certificate is issued under and in accordance with that certain Warrant Agreement dated as of December 30, 2021 by and between the Corporation and VStock Transfer, LLC (as such agreement may be amended from time to time, the “Warrant Agreement”), and is subject to the terms and provisions contained therein, all of which terms and provisions the registered holders consent to by acceptance of their book-entry interests in the Global Warrant Certificate. Copies of the Warrant Agreement are on file at the Corporation’s headquarters. In the event of any conflict or inconsistency between this Global Warrant Certificate and the Warrant Agreement, this Global Warrant Certificate shall control. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Warrant Agreement.

 

This Global Warrant Certificate is also issued under and in accordance with that certain Agreement and Plan of Merger (as such agreement may be amended from time to time, the “Merger Agreement”), by and among Co-Diagnostics, Inc., a Utah corporation, Advanced Conceptions, Inc., a Utah corporation, and ACI Acquisition Corp., and is subject to the terms and provisions contained therein. In the event of any conflict or inconsistency between this Global Warrant Certificate and the Merger Agreement, the Merger Agreement shall control.

 

 
 

 

1. Exercise Period. The Warrants shall vest in full and become exercisable immediately following either (i) satisfaction of Milestone 3 as such term is defined in the Merger Agreement or (ii) upon the occurrence of any of the events described in Section 3.1(e) of the Merger Agreement (any such date, the “Vesting Date”). Promptly upon the satisfaction of clauses (i) or (ii), the Corporation shall notify the Warrant Agent that the vesting conditions have been satisfied and the Vesting Date upon which the Warrants shall become fully exercisable pursuant to the notice provision in the Warrant Agreement. Either the Corporation or the registered holder may certify to the Warrant Agent in a form satisfactory to the Warrant Agent the occurrence of the Vesting Date. Notwithstanding anything to the contrary contained herein, the Warrants shall expire at 5:00 p.m. (New York Time) on January 1, 2027 (the “Termination Date”). Parent will provide registered holder at least fifteen (15) days’ written notice prior to the consummation of any of the events described in Section 3.1(e) of the Merger Agreement.

 

2. Exercise of Warrants.

 

(a) The registered holder may, at any time on or after the Vesting Date and prior to the Termination Date, exercise this Warrant in whole or in part at an exercise price per share equal to $9.125 (subject to proportionate adjustment in accordance with Section 6) (the “Exercise Price”), by the delivery of the Warrant Exercise Form annexed hereto duly completed and executed to the Warrant Agent at the Warrant Agent Office or at such other agency or office of the Corporation in the United States of America as the Corporation may designate by notice in writing to the registered holder at the address of such registered holder appearing on the books of the Corporation. Upon any partial exercise of a Warrant, the Warrant Agent shall make an appropriate adjustment to the account of the registered holder to reflect a number of Warrant Shares for the account of the registered holder equal (without giving effect to any adjustment thereof) to the number of Warrant Shares subject to such registered holder’s Warrants prior to such exercise, minus the number of Warrant Shares exercised by the registered holder. In the event of the exercise of the rights represented by any Warrant, a certificate or certificates for the Warrant Shares so purchased, as and if applicable, registered in the name of the registered holder, shall be delivered to the registered holder hereof as soon as practicable after the exercise of such Warrant.

 

(b) Payment to the Corporation of the Exercise Price for each share of Common Stock being purchased shall be made either (i) by wire transfer or cashier’s check drawn on a United States bank payable to the Corporation (to an account as designated by the Warrant Agent by notice in writing to the registered holders); or (ii) by instructing the Warrant Agent to issue Warrant Shares upon exercise of all or any part of this Warrant on a net basis such that, without payment of any cash consideration or other immediately available funds, the registered holder shall surrender this Warrant in exchange for the number of Warrant Shares equal to the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the Warrants, multiplied by the excess of the “Fair Market Value” (as defined below) less the Exercise Price by (y) the Fair Market Value. “Fair Market Value” shall mean the volume-weighted average price of the shares of Common Stock as reported during the ten (10) trading day period ending on the trading day prior to the date that notice of exercise is received by the Warrant Agent from the registered holder of such Warrants or its securities broker or intermediary.

 

 
 

 

3. Reservation of Warrant Shares. The Corporation agrees that, prior to the expiration of this Warrant, it will at all times have authorized and in reserve, and will keep available, solely for issuance or delivery upon the exercise of all outstanding Warrants represented by this Global Warrant Certificate, the number of Warrant Shares as from time to time shall be issuable by the Corporation upon the exercise of this Warrant.

 

4. No Stockholder Rights; No Rights to Net Cash Settled. No Warrant shall entitle the registered holder hereof to any voting rights or other rights as a stockholder of the Corporation.

 

5. Transferability of Warrant and Underlying Shares. Prior to the Termination Date and subject to compliance with applicable Federal and State securities laws, this Warrant and all rights hereunder are transferable, in whole or in part, at the office or agency of the Corporation by the registered holder in person or by duly authorized attorney in accordance with the provisions of the Warrant Agreement and upon delivery of the Assignment Form annexed hereto properly endorsed for transfer. The Corporation or the Warrant Agent shall be entitled to require, as a condition of any such transfer, that the registered holder and the transferee execute or provide such documents and make such representations and warranties as the Corporation or the Warrant Agent may deem appropriate to evidence compliance with applicable Federal and State securities laws.

 

6. Certain Adjustments. With respect to any rights that any registered holder has to exercise any Warrant and convert into shares of Common Stock, registered holder shall be entitled to the following adjustments:

 

(a) Merger or Consolidation. If at any time there shall be a merger or a consolidation of the Corporation with or into another entity when the Corporation is not the surviving corporation, then, as part of such merger or consolidation, lawful provision shall be made so that the registered holder hereof shall thereafter be entitled to receive upon exercise of each Warrant, during the period specified herein and upon payment of the aggregate Exercise Price then in effect, the number of shares of stock or other securities or property (including cash) of the successor corporation resulting from such merger or consolidation, to which the registered holder hereof as the registered holder of the stock deliverable upon exercise of each Warrant would have been entitled in such merger or consolidation if each Warrant had been exercised immediately before such transaction. In any such case, appropriate adjustment shall be made in the application of the provisions of each Warrant with respect to the rights and interests of the registered holder hereof as the registered holder of each Warrant after the merger or consolidation.

 

(b) Reclassification, Recapitalization, etc. If the Corporation at any time shall, by subdivision, combination or reclassification of securities, recapitalization, automatic conversion, or other similar event affecting the number or character of outstanding shares of Common Stock, or otherwise, change any of the securities as to which purchase rights under each Warrant exist into the same or a different number of securities of any other class or classes, each Warrant shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities that were subject to the purchase rights under each Warrant immediately prior to such subdivision, combination, reclassification or other change and the Exercise Price shall be proportionately adjusted.

 

 
 

 

(c) Split or Combination of Common Stock and Stock Dividend. In case the Corporation shall at any time subdivide, redivide, recapitalize, split (forward) or change its outstanding shares of Common Stock into a greater number of shares or declare a dividend upon its Common Stock payable solely in shares of Common Stock, the Exercise Price shall be proportionately reduced and the number of Warrant Shares proportionately increased. Conversely, in case of a reverse stock split or the outstanding shares of Common Stock of the Corporation shall be combined into a smaller number of shares, the Exercise Price shall be proportionately increased and the number of Warrant Shares proportionately reduced.

 

(d) Notices of Changes in Warrant. Upon every adjustment of (i) the Exercise Price, (ii) the number of shares of Parent Common Stock issuable upon exercise of this Global Warrant Certificate and (iii) the number of Warrants outstanding, the Corporation shall give written notice thereof to the registered holder, which notice shall state the Exercise Price resulting from such adjustment and the increase or decrease, if any, in the number of shares purchasable at such price upon the exercise of this Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. Upon the occurrence of any event specified in this Global Warrant Certificate then, in any such event, the Corporation shall give written notice to the registered holder, at the last address set forth for such registered holder in the Warrant register maintained by the Warrant Agent, of the record date or the effective date of the event. Failure to give such notice, or any defect therein, shall not affect the legality or validity of such event.

 

7. Compliance with Securities Laws; Legend and Stop Transfer Orders. Unless the Warrant Shares are subject to an effective registration statement under the Securities Act, upon exercise of any part of any Warrant represented hereby, (i) the Corporation shall be entitled to require that the registered holder make such representations and warranties as may be reasonably required by the Corporation to assure that the issuance of Warrant Shares is exempt from the registration requirements of applicable securities laws and (ii) the Corporation shall instruct its transfer agent to enter stop transfer orders with respect to such Warrant Shares, and the Warrant Shares shall bear on the face thereof substantially the following legend:

 

THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE SOLD, ASSIGNED, TRANSFERRED, ENCUMBERED, OR OTHERWISE DISPOSED OF, EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED.

 

8. Miscellaneous. This Global Warrant Certificate and each Warrant represented hereby shall be governed by and construed in accordance with the laws of the State of Utah. All the covenants and provisions of this Global Warrant Certificate and each Warrant by or for the benefit of the Corporation shall bind and inure to the benefit of its successors and assigns hereunder. Nothing in this global Warrant Certificate shall be construed to give to any person or corporation other than the Corporation and the registered holder of each Warrant represented hereby any legal or equitable right, remedy, or claim under this Global Warrant Certificate and each Warrant represented hereby. This Global Warrant Certificate and each Warrant represented hereby shall be for the sole and exclusive benefit of the Corporation and the registered holder. The section headings herein are for convenience only and are not part of this Global Warrant Certificate and shall not affect the interpretation hereof.

 

9. Validity. This Warrant Certificate shall not be valid or obligatory for any purpose until authenticated by the Warrant Agent.

 

IN WITNESS WHEREOF, the Corporation has caused this Global Warrant Certificate to be executed by its duly authorized officer, this _____ day of __________ 2021.

 

CO-DIAGNOSTICS, INC.
     
By:                      
Name:             
Title: Chief Executive Officer

 

 
 

 

Certificate of Authentication

 

This is the Global Warrant Certificate for the Warrants referred to in the within-mentioned Warrant Agreement.

 

VSTOCK TRANSFER, LLC, as Warrant Agent

 

By:

 

Authorized Signature

 

[TO BE ATTACHED TO GLOBAL WARRANT CERTIFICATE] SCHEDULE OF INCREASES OR DECREASES IN WARRANT CERTIFICATE

 

The following increases or decreases in this Warrant have been made:

 

Date

 

Amount of decrease in the number of Warrants represented by this Warrant

 

Amount of increase in number of Warrants represented by this Warrant

 

Number of Warrants represented by this Warrant following such decrease or increase.

 

Signature of authorized officer of the depository

 

 
 

 

FORM OF EXERCISE FORM

 

To Be Executed by the registered holder in Order to Exercise Company Warrant

 

The undersigned hereby irrevocably elects to exercise the right, represented by the book-entry Warrant(s), to purchase shares of the Common Stock of Co-Diagnostics, Inc. (the “Warrant Shares”) and the undersigned herewith makes payment of the full purchase price for such shares at the price per share provided for in such Warrant in accordance with the terms of the Warrant Agreement. Such payment takes the form of $__________ in lawful money of the United States.

 

In the event that the registered holder wishes to exercise through cashless exercise (i) the number of Warrant Shares that this Warrant is exercisable for would be determined in accordance with Section 2(b) of this Global Warrant Certificate which allows for such cashless exercise and (ii) the registered holder hereof shall complete the following: The undersigned hereby irrevocably elects to exercise the right, represented by this Global Warrant Certificate, through the cashless exercise provisions hereof, to receive Warrant Shares.

 

The undersigned hereby requests that certificates for the Warrant Shares purchased be issued in the name of:

 

(please print or type name and address)

 

(please insert social security or other identifying number)

 

and be delivered as follows:

 

(please print or type name and address)

 

(please insert social security or other identifying number)

 

and if such number of shares of Common Stock shall not be all the shares evidenced by this Global Warrant Certificate, that a new Warrant for the balance of such shares be registered in the name of, and delivered to, registered holder.

 

Signature of Holder

 

SIGNATURE GUARANTEE:

 

This Warrant may be exercised by delivering the Exercise Form to VStock Transfer, LLC at the following addresses:

 

By mail at

___________

[       ]

 

 
 

 

[FORM OF ASSIGNMENT]

 

(TO BE EXECUTED TO TRANSFER THE WARRANT)

 

For value received, hereby sells, assigns and transfers unto the Assignee(s) named below the rights represented by such number of Company Warrants listed opposite the respective name(s) of the Assignee(s) named below and all other rights of the registered holder with respect to such Warrants, and does hereby irrevocably constitute and appoint _______________ attorney, to transfer said Warrant on the books of the Depositary and/or the Warrant Agent with respect to the number of Warrants set forth below, with full power of substitution:

 

Name(s) of

 

Assignee(s) Address No. of Warrants

 

Dated: _____________

 

Signature

 

(Signed exactly as name appears in the records of the Depositary)

 

Signature Guarantee:

  

 

 

 EX-10.7 5 ex10-7.htm

 

Exhibit 10.7

 

COMPANY WARRANT AGREEMENT

 

THIS WARRANT AGREEMENT (this “Agreement”), dated as of December 31, 2021, is entered into by and between Co-Diagnostics, Inc., a Utah corporation (“Parent” or the “Company”), and VStock Transfer, LLC (the “Warrant Agent”).

 

WHEREAS, Parent consummated a merger (the “Merger”) of its wholly-owned subsidiary, IDMO Acquisition Corporation, Inc. (“Subco”), with and into Idaho Molecular Inc., an Idaho corporation (“Company”), pursuant to an Agreement and Plan of Merger (as such agreement may be amended from time to time, the “Merger Agreement”), by and among Parent, Company, and Subco;

 

WHEREAS, the Merger Agreement provides that the Company will issue warrants to purchase 232,500 shares of the Company’s common stock, par value $0.001 per share, (the “Parent Common Stock”) exercisable subject to satisfaction of certain milestones and over a seven year period at an initial exercise price of $9.125 per share (the “Warrants” or the “Company Warrants”);

 

WHEREAS, the Company desires the Warrant Agent to act on behalf of the Company, and the Warrant Agent is willing to so act, in connection with the issuance, transfer, exchange and exercise of the Warrants; and

 

WHEREAS, the Company desires to provide for the form and provisions of the Warrants, the terms upon which they shall be issued and exercised, and the respective rights, limitation of rights, and immunities of the Company, the Warrant Agent, and the holders of the Warrants.

 

NOW, THEREFORE, in consideration of the mutual agreements herein contained, the parties hereto agree as follows:

 

1. Appointment of Warrant Agent and Depository. The Company hereby appoints the Warrant Agent to act as agent for the Company for the Company Warrants, and the Warrant Agent hereby accepts such appointment and agrees to perform the same in accordance with the terms and conditions set forth in this Agreement.

 

2. Warrants.

 

2.1 Issuance of Warrants. Each Company Warrant will be uncertificated and in registered form only, substantially in the form of Exhibit 1, the provisions of which are incorporated herein. Any Warrant so issued shall have the same terms, force and effect as a certificated Warrant that has been duly countersigned by the Warrant Agent in accordance with the terms of this Agreement.

 

2.2 Warrant Register.

 

(a) The Warrant Agent shall maintain books (“Warrant Register”) for the registration of the original issuance and the registration of any subsequent transfer of the Warrants. Upon the initial issuance of the Warrants, the Warrant Agent shall issue and register the Warrants in the names of the respective holders thereof in such denominations and otherwise in accordance with instructions delivered to the Warrant Agent by the Company.

 

 

 

 

(b) Prior to due presentment for registration of transfer of any Warrant in accordance with Section 5.1.1 below, the Company and the Warrant Agent may deem and treat the person in whose name such Warrant is then registered in the Warrant Register (each a “registered holder”) as the absolute owner of such Warrant, for the purpose of any exercise thereof, and for all other purposes, and neither the Company nor the Warrant Agent shall be affected by any notice to the contrary.

 

3. Terms and Exercise of Warrants.

 

3.1 Exercise Price. For purposes of this Agreement, “Exercise Price” shall mean the initial exercise price for each Warrant as set forth in the Exhibit 1, subject to adjustment as provided in Exhibit 1.

 

3.2 Duration of Warrants. A Warrant may be exercised only during the period (“Exercise Period”) specified in Exhibit 1 or as the same may be extended as hereinafter provided. Each Warrant not exercised on or before the expiration date, as set forth in Exhibit 1 (the “Expiration Date”), shall become void, and all rights thereunder and all rights in respect thereof under this Agreement shall cease at the close of business on the Expiration Date.

 

3.3 Exercise of Warrants. Warrants may be exercised, at the option of the registered holder of the Warrant, in whole or in part, at any time or from time to time during the Exercise Period, by complying with the Warrant Agent’s procedures relating to the exercise of such book-entry interest in the Warrants. In addition, the registered holder shall deliver to the Warrant Agent (the “Warrant Agent Office”) (i) an exercise form set forth in the Warrant, executed by such registered holder or its duly authorized agent or attorney (the “Exercise Form”) and (ii) payment of the aggregate Exercise Price. In case an exercise of Warrants is in part only, the Warrant Agent shall make an appropriate adjustment to the account of the registered holder to reflect a number of Warrants for the number of shares of Parent Common Stock equal (without giving effect to any adjustment thereof) to the number of such shares called for by such registered holder’s Warrants prior to such exercise, minus the number of shares designated by the registered holder upon such exercise.

 

3.3.1 Payment. Subject to the provisions of the Warrant and this Agreement, a Warrant may be exercised by the registered holder thereof by delivering to the Warrant Agent at its corporate trust department (i) a warrant exercise form properly delivered by the registered holder, and (iii) the payment in full of the Exercise Price for each share of Common Stock as to which the Warrant is exercised as follows:

 

(a) in lawful money of the United States, in certified check or wire payable to the Warrant Agent; or

 

(b) as provided in Section 7.5 hereof.

 

 

 

 

3.3.2 Procedures and Validity.

 

(a) Any exercise of a Warrant by a registered holder pursuant to the terms of this Agreement shall be irrevocable and shall constitute a binding agreement between the registered holder and the Company, enforceable in accordance with its terms.

 

(b) The Warrant Agent shall:

 

(i) examine all Exercise Forms and all other documents delivered to it by or on behalf of registered holders as contemplated hereunder to ascertain whether or not, on their face, such Exercise Forms and any such other documents have been executed and completed in accordance with their terms and the terms hereof;

 

(ii) where an Exercise Form or other document appears on its face to have been improperly completed or executed or some other irregularity in connection with the exercise of the Warrants exists, the Warrant Agent shall endeavor to inform the appropriate parties (including the person submitting such instrument) of the need for fulfillment of all requirements, specifying those requirements which appear to be unfulfilled;

 

(iii) inform the Company of and cooperate with and assist the Company in resolving any reconciliation problems between the Exercise Forms received and the crediting of Warrants to the respective registered holders’ accounts; and

 

(iv) advise the Company no later than two (2) business days after receipt of an Exercise Form, of (i) the receipt of such Exercise Form and the number of Warrants exercised in accordance with the terms and conditions of this Agreement, and (ii) such other information as the Company shall reasonably require.

 

(c) All questions as to the validity, form and sufficiency (including time of receipt) of an exercised Warrant and any Exercise Form will be determined by the Company in good faith. The Company reserves the right to reject any and all Exercise Forms not in proper form or for which any corresponding agreement by the Company to exchange would, in the opinion of the Company, be unlawful. Moreover, the Company reserves the absolute right to waive any of the conditions to the exercise of Warrants or defects in the exercise thereof with regard to any particular exercise of Warrants. Other than as required in Section 3.3.2(b)(ii) above, neither the Company nor the Warrant Agent shall be under any duty to give notice to the registered holders of the Warrants of any irregularities in any exercise of Warrants or any Exercise Form, nor shall it incur any liability for the failure to give such notice.

 

3.3.3 Issuance of Shares. As soon as practicable after the exercise of any Warrant and the clearance of the funds in payment of the Exercise Price, the Company shall cause its Transfer Agent to issue to the registered holder of such Warrant a certificate or certificates, or book entry position, representing the number of full shares of Parent Common Stock to which he, she or it is entitled, registered in such name or names as may be directed by him, her or it. In the event that during the last 20 business days immediately prior to the Expiration Date both (i) a registration statement with respect to the Parent Common Stock underlying the Warrants is not effective or a current prospectus is not available and (ii) the Exercise Price of the Warrants is less than the price at which the Parent Common Stock is trading on NASDAQ (or if the Parent Common Stock is no longer trading on NASDAQ, such other stock exchange on which the shares of Parent Common Stock trades), the Exercise Period shall automatically be extended for a period of 20 business days after the date that the Company causes a registration statement covering the Warrants and the Parent Common Stock underlying the Warrants to be effective and a current prospectus is made available. In no event will the Company be required to “net cash settle” the warrant exercise.

 

 

 

 

3.3.4 Valid Issuance. All shares of Parent Common Stock issued upon the proper exercise of a Warrant in conformity with this Agreement shall be validly issued, fully paid and nonassessable.

 

3.3.5 Date of Issuance. All shares of Parent Common Stock so issued shall be registered in the name of the registered holder or such other name as shall be designated in the Exercise Form delivered by the registered holder. Such shares of Parent Common Stock shall be deemed to have been issued and any person so designated to be named therein shall be deemed to have become the holder of record of such shares of Parent Common Stock as of the date of delivery of the Exercise Form to the Warrant Agent Office duly executed by the registered holder thereof and upon the Company’s receipt of payment of the Exercise Price.

 

4. Adjustments.

 

4.1 Adjustments Generally. The Exercise Price, the number of shares of Parent Common Stock issuable upon exercise of the Warrants and the number of Warrants outstanding are subject to adjustment from time to time upon the occurrence of certain events in accordance with the provisions of Exhibit 1.

 

4.2 Notices of Vesting and Changes in Warrant. Promptly upon the satisfaction of the vesting requirements of the Warrants pursuant to the Merger Agreement, the Company shall deliver written notice of such vesting and exercisability to the Warrant Agent, which notice shall state the date upon which such warrants shall vest and become exercisable. Upon every adjustment of (i) the Exercise Price, (ii) the number of shares of Parent Common Stock issuable upon exercise of the Warrants and (iii) the number of Warrants outstanding, the Company shall give written notice thereof to the Warrant Agent, which notice shall state the Exercise Price resulting from such adjustment and the increase or decrease, if any, in the number of shares purchasable at such price upon the exercise of a Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. Upon the occurrence of any event specified in the Warrant certificate then, in any such event, the Company shall give written notice to each registered holder, at the last address set forth for such registered holder in the Warrant register maintained by the Warrant Agent, of the record date or the effective date of the event. Failure to give such notice, or any defect therein, shall not affect the legality or validity of such event.

 

4.3 No Fractional Shares. Notwithstanding any provision contained in this Agreement to the contrary, the Company shall not issue fractional shares upon exercise of Warrants. If, by reason of any adjustment made pursuant to this Section 4, the registered holder of any Warrant would be entitled, upon the exercise of such Warrant, to receive a fractional interest in a share, the Company shall, upon such exercise, round up or down to the nearest whole number the number of shares of Parent Common Stock to be issued to the registered holder.

 

 

 

 

4.4 Form of Warrant. The form of Warrant certificate need not be changed as a result of any adjustment pursuant to this Section. However, the Company may, at any time, in its sole discretion, make any change in the form of Warrant certificate that the Company may deem appropriate and that does not affect the substance thereof.

 

5. Transfer and Exchange of Warrants.

 

5.1 Exchange and Transfer.

 

5.1.1 The Warrant Agent shall keep, at the Warrant Agent Office, books in which, subject to such reasonable regulations as it may prescribe, it shall register Warrants and exchanges and transfers of outstanding Warrants upon request to exchange or transfer such Warrants, provided, that the Warrant Agent shall have received a written instruction of transfer or exchange in form reasonably satisfactory to the Warrant Agent, duly executed by the registered holder thereof or by its or her or his duly authorized agent or attorney, providing all information required to be delivered hereunder, such signature to be guaranteed by an eligible guarantor institution to the extent required by the Warrant Agent or the Depository. Upon any such registration of transfer, a Warrant Statement shall be issued to the transferee.

 

5.1.2 The Company shall pay for applicable service charges for any exchange or registration of transfer of Warrants; and the Warrant Agent and/or the Company may require payment of a sum sufficient to cover any stamp or other tax or other charge that may be imposed in connection with any such exchange or registration of transfer. Neither the Warrant Agent nor the Company shall be required to pay any stamp or other tax or other charge required to be paid in connection with such transfer, and neither the Warrant Agent nor the Company shall be required to issue or deliver any Warrants until it has been established to the Company’s and the Warrant Agent’s reasonable satisfaction that such tax or other charge has been paid or that no such tax or other charge is due.

 

5.1.3 The Warrant Agent shall not affect any exchange or registration of transfer which will result in the issuance of a Warrant evidencing a fraction of a Warrant or a number of full Warrants and a fraction of a Warrant.

 

5.1.4 All Warrants credited to a registered holder’s or transferee’s account upon any exchange or transfer of Warrants in accordance with the provisions of this Agreement shall be the valid obligations of the Company evidencing the same obligations, and entitled to the same benefits under this Agreement, as the Warrants that were so exchanged or transferred.

 

5.2 Treatment of Holders of Warrants. Each registered holder of Warrants, by accepting the same, consents and agrees with the Company, the Warrant Agent and every subsequent registered holder of such Warrants that until the due presentment for registration of transfer in accordance with Section 5.1.1 of such Warrants, the Company and the Warrant Agent may treat the registered holder of such Warrants as the absolute owner thereof for any purpose and as the person entitled to exercise the rights represented by the Warrants evidenced thereby, any notice to the contrary notwithstanding.

 

 

 

 

5.3 Procedure for Surrender of Warrants. Warrants may be surrendered to the Warrant Agent, either in certificated form or in book entry position, together with a written request for exchange or transfer, and thereupon the Warrant Agent shall issue in exchange therefor one or more new Warrants, or book entry positions, as requested by the registered holder of the Warrants so surrendered, representing an equal aggregate number of Warrants; provided, however, that in the event that a Warrant surrendered for transfer bears a restrictive legend, the Warrant Agent shall not cancel such Warrant and issue new Warrants in exchange therefor until the Warrant Agent has received an opinion of counsel stating that such transfer may be made and indicating whether the new Warrants must also bear a restrictive legend.

 

5.4 Cancellation of Warrants. Promptly following the Expiration Date or at such earlier time that there are no longer outstanding any Warrants, the Warrant certificate shall be cancelled or destroyed and the Warrant Agent shall deliver a certificate of such cancellation or destruction to the Company.

 

6. [Omitted].

 

7. Other Provisions Relating to Rights of Holders of Warrants.

 

7.1 No Rights as Stockholder. No Warrant shall, and nothing contained in this Agreement, in the Warrant certificate or in the Warrant Statement shall be construed to, entitle the registered holder or any beneficial owner thereof to any of the rights of a holder or beneficial owner of Parent Common Stock, including, without limitation, the right to vote or to consent or to receive notice as a stockholder in respect of any meeting of stockholders for the election of directors of the Company or any other matter, to receive dividends on Parent Common Stock or any rights whatsoever as stockholders of the Company, until such Warrant is duly exercised in accordance with this Agreement and such registered holder is issued the Parent Common Stock to which it is entitled in connection therewith.

 

7.2 Reservation of Common Stock. The Company shall at all times reserve and keep available a number of its authorized but unissued shares of Parent Common Stock that will be sufficient to permit the exercise in full of all outstanding Warrants issued pursuant to this Agreement.

 

7.3 [Omitted].

 

7.4 Limitation on Monetary Damages. In no event shall the registered holder of a Warrant be entitled to receive monetary damages for failure to settle any Warrant exercise if the Parent Common Stock issuable upon exercise of the Warrants has not been registered with the SEC pursuant to an effective registration statement or if a current prospectus is not available for delivery by the Warrant Agent, provided the Company has fulfilled its obligations under Section 7.5 to use its commercially reasonable efforts to effect the registration under the Securities Act of 1933 (the “Securities Act”) of the Parent Common Stock issuable upon exercise of the Warrants.

 

 

 

 

7.5 Registration of Shares of Common Stock; Cashless Exercise at Company’s Option.

 

7.5.1 Registration of the shares of Common Stock. If the Company shall fail to have maintained an effective registration statement covering the issuance of the shares of Common Stock issuable upon exercise of the Warrants as required under the Merger Agreement, the registered holders shall have the right to exercise such Warrants on a “cashless basis,” by exchanging the Warrants (in accordance with Section 3(a)(9) of the Securities Act or another exemption) for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the Warrants, multiplied by the excess of the “Fair Market Value” (as defined below) less the Exercise Price by (y) the Fair Market Value. Solely for purposes of this subsection 7.5.1, “Fair Market Value” shall mean the volume-weighted average price of the shares of Common Stock as reported during the ten (10) trading day period ending on the trading day prior to the date that notice of exercise is received by the Warrant Agent from the registered holder of such Warrants or its securities broker or intermediary. The date that notice of “cashless exercise” is received by the Warrant Agent shall be conclusively determined by the Warrant Agent. In connection with the “cashless exercise” of a Warrant, the Company shall, upon request, provide the Warrant Agent with an opinion of counsel for the Company (which shall be an outside law firm with securities law experience) stating that (i) the exercise of the Warrants on a “cashless basis” in accordance with this subsection 7.5.1 is not required to be registered under the Securities Act and (ii) the shares of Common Stock issued upon such exercise shall be freely tradable under United States federal securities laws by anyone who is not an affiliate (as such term is defined in Rule 144 under the Securities Act) of the Company and, accordingly, shall not be required to bear a restrictive legend. Except as provided in subsection 7.5.2, for the avoidance of doubt, unless and until all of the Warrants have been exercised or have expired, the Company shall continue to be obligated to comply with its registration obligations under the first three sentences of this subsection 7.5.1

 

7.5.1 Cashless Exercise at Company’s Option. If the shares of Common Stock are at the time of any exercise of a Warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at its option, (i) require holders of Warrants who exercise such Warrants to exercise such Warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act as described in subsection 7.5.1 and (ii) in the event the Company so elects, the Company shall (x) not be required to file or maintain in effect a registration statement for the registration, under the Securities Act, of the shares of Common Stock issuable upon exercise of the Warrants, notwithstanding anything in this Agreement to the contrary, and (y) use its commercially reasonable efforts to register or qualify for sale the shares of Common Stock issuable upon exercise of the Warrant under applicable blue sky laws to the extent an exemption is not available..

 

8. Concerning the Warrant Agent and Other Matters.

 

8.1 Payment of Taxes. The Company will from time to time promptly pay all taxes and charges that may be imposed upon the Company or the Warrant Agent in respect of the issuance or delivery of shares of Parent Common Stock upon the exercise of Warrants, but the Company shall not be obligated to pay any transfer taxes in respect of the Warrants or such shares.

 

 

 

 

8.2 Resignation, Consolidation, or Merger of Warrant Agent.

 

8.2.1 Appointment of Successor Warrant Agent. The Warrant Agent, or any successor to it hereafter appointed, may resign its duties and be discharged from all further duties and liabilities hereunder after giving sixty (60) days’ notice in writing to the Company and to each registered holder. If the office of the Warrant Agent becomes vacant by resignation or incapacity to act or otherwise, the Company shall appoint in writing a successor Warrant Agent in place of the Warrant Agent. If the Company shall fail to make such appointment within a period of 30 days after it has been notified in writing of such resignation or incapacity by the Warrant Agent or by any registered holder of a Warrant, then the registered holder of any Warrant may apply to the Supreme Court of the State of New York for the County of New York for the appointment of a successor Warrant Agent at the Company’s cost. Any successor Warrant Agent, whether appointed by the Company or by such court, shall be a corporation organized and existing under the laws of the State of New York, in good standing and having its principal office in the Borough of Manhattan, City and State of New York, and authorized under such laws to exercise corporate trust powers and subject to supervision or examination by federal or state authority. After appointment, any successor Warrant Agent shall be vested with all the authority, powers, rights, immunities, duties, and obligations of its predecessor Warrant Agent with like effect as if originally named as Warrant Agent hereunder, without any further act or deed; but if for any reason it becomes necessary or appropriate, the predecessor Warrant Agent shall execute and deliver, at the expense of the Company, an instrument transferring to such successor Warrant Agent all the authority, powers, and rights of such predecessor Warrant Agent hereunder; and upon request of any successor Warrant Agent the Company shall make, execute, acknowledge, and deliver any and all instruments in writing for more fully and effectually vesting in and confirming to such successor Warrant Agent all such authority, powers, rights, immunities, duties, and obligations.

 

8.2.2 Notice of Successor Warrant Agent. In the event a successor Warrant Agent shall be appointed, the Company shall give notice thereof to each registered holder, the predecessor Warrant Agent and the transfer agent for the Parent Common Stock not later than the effective date of any such appointment.

 

8.2.3 Merger or Consolidation of Warrant Agent. Any corporation into which the Warrant Agent may be merged or with which it may be consolidated or any corporation resulting from any merger or consolidation to which the Warrant Agent shall be a party shall be the successor Warrant Agent under this Agreement without any further act.

 

8.3 Fees and Expenses of Warrant Agent.

 

8.3.1 Remuneration. The Company agrees to pay the Warrant Agent reasonable remuneration for its services as such Warrant Agent hereunder and will reimburse the Warrant Agent upon demand for all expenditures that the Warrant Agent may reasonably incur in the execution of its duties hereunder.

 

8.3.2 Further Assurances. The Company agrees to perform, execute, acknowledge and deliver or cause to be performed, executed, acknowledged and delivered all such further and other acts, instruments and assurances as may reasonably be required by the Warrant Agent for the carrying out or performing of the provisions of this Agreement.

 

8.4 Liability of Warrant Agent.

 

8.4.1 Reliance on Company Statement. Whenever in the performance of its duties under this Agreement the Warrant Agent shall deem it necessary or desirable that any fact or matter be proved or established by the Company prior to taking or suffering any action hereunder, such fact or matter (unless other evidence in respect thereof be herein specifically prescribed) may be deemed to be conclusively proved and established by a statement signed by the General Counsel, President or Chairman of the Board of Directors of the Company and delivered to the Warrant Agent. The Warrant Agent may rely upon such statement for any action taken or suffered in good faith by it pursuant to the provisions of this Agreement.

 

 

 

 

8.4.2 Indemnity. The Warrant Agent shall be liable hereunder only for its own gross negligence, willful misconduct or bad faith. The Company agrees to indemnify the Warrant Agent and save it harmless against any and all liabilities, including judgments, costs and reasonable counsel fees, for anything done or omitted by the Warrant Agent in the execution of this Agreement, except as a result of the Warrant Agent’s gross negligence, willful misconduct or bad faith.

 

8.4.3 Exclusions. The Warrant Agent shall have no responsibility with respect to the validity of this Agreement or with respect to the validity or execution of any Warrant (except its countersignature thereof); nor shall it be responsible for any breach by the Company of any covenant or condition contained in this Agreement or in any Warrant; nor shall it be responsible to make any adjustments required under the provisions of Section 4 hereof or responsible for the manner, method or amount of any such adjustment or the ascertaining of the existence of facts that would require any such adjustment; nor shall it by any act hereunder be deemed to make any representation or warranty as to the authorization or reservation of any shares of Parent Common Stock to be issued pursuant to this Agreement or any Warrant or as to whether any shares of Parent Common Stock will when issued be valid and fully paid and nonassessable.

 

8.5 Acceptance of Agency. The Warrant Agent hereby accepts the agency established by this Agreement and agrees to perform the same upon the terms and conditions herein set forth and, among other things, shall account promptly to the Company with respect to Warrants exercised and concurrently account for, and pay to the Company, all moneys received by the Warrant Agent for the purchase of shares of Parent Common Stock through the exercise of Warrants.

 

9. Miscellaneous Provisions.

 

9.1 Successors. All the covenants and provisions of this Agreement by or for the benefit of the Company or the Warrant Agent shall bind and inure to the benefit of their respective successors and assigns.

 

9.2 Notices. Any notice, statement or demand authorized by this Agreement to be given or made by the Warrant Agent or by the registered holder of any Warrant to or on the Company shall be delivered by hand or sent by registered or certified mail or overnight courier service, addressed (until another address is filed in writing by the Company with the Warrant Agent) as follows:

 

Co-Diagnostics, Inc.

2401 South Foothill Dr., Suite D

Salt Lake City, UT 84109

Telephone: 801-438-1036

Attention: President

Attention: General Counsel

 

 

 

 

Any notice, statement or demand authorized by this Agreement to be given or made by the registered holder of any Warrant or by the Company to or on the Warrant Agent shall be delivered by hand or sent by registered or certified mail or overnight courier service, addressed (until another address is filed in writing by the Company with the Warrant Agent) as follows:

 

VStock Transfer, LLC

18 Lafayette Place

Woodmere, New York 11598

Attn: Compliance Department

 

Any notice, sent pursuant to this Agreement shall be effective, if delivered by hand, upon receipt thereof by the party to whom it is addressed, if sent by overnight courier, on the next business day of the delivery to the courier, and if sent by registered or certified mail on the third day after registration or certification thereof.

 

9.3 Notices to Holders of Warrants. Any notice to registered holders of Warrants which by any provisions of this Warrant Agreement or the Warrant certificate is required or permitted to be given shall be given by first class mail prepaid at such registered holder’s address as it appears on the books of the Warrant Agent.

 

9.4 Applicable Law. The validity, interpretation and performance of this Agreement and of the Warrants shall be governed in all respects by the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction. The Company hereby agrees that any action, proceeding or claim against it arising out of or relating in any way to this Agreement shall be brought and enforced in the courts located or situated in New York, New York or the United States District Court for the Southern District of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any such process or summons to be served upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 9.2 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim.

 

9.5 Persons Having Rights under this Agreement. Nothing in this Agreement expressed and nothing that may be implied from any of the provisions hereof is intended, or shall be construed, to confer upon, or give to, any person or corporation other than the parties hereto and the registered holders of the Warrants, any right, remedy, or claim under or by reason of this Agreement or of any covenant, condition, stipulation, promise, or agreement hereof. All covenants, conditions, stipulations, promises, and agreements contained in this Agreement shall be for the sole and exclusive benefit of the parties hereto and their successors and assigns and of the registered holders of the Warrants.

 

 

 

 

9.6 Examination of the Warrant Agreement. A copy of this Agreement shall be available at all reasonable times at the office of the Warrant Agent in the Borough of Manhattan, City and State of New York, for inspection by the registered holder of any Warrant. The Warrant Agent may require any such registered holder to submit his, her or its Warrant Statements for inspection by it.

 

9.7 Counterparts. This Agreement may be executed in any number of original or facsimile counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument.

 

9.8 Effect of Headings. The section headings herein are for convenience only and are not part of this Agreement and shall not affect the interpretation thereof.

 

9.9 Amendments. This Agreement may be amended by the parties hereto without the consent of any registered holder for the purpose of curing any ambiguity, or curing, correcting or supplementing any defective provision contained herein or adding or changing any other provisions with respect to matters or questions arising under this Agreement as the parties may deem necessary or desirable and provided such amendment shall not adversely affect the interest of the registered holders. All other modifications, adjustments or amendments of this Agreement, shall require the written consent of the registered holders of a majority of the then outstanding Warrants provided that no amendment to the Warrant certificate shall be effective to charge any registered holder who has not consented thereto. The Warrant Agent may request from either the Company or the registered holders an opinion of counsel with respect to the validity of any amendment as a condition to its exercise of any amendment.

 

9.10 Severability. Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.

 

[Signature page follows]

 

 

 

 

IN WITNESS WHEREOF, this Agreement has been duly executed by the parties hereto as of the day and year first above written.

 

CO-DIAGNOSTICS, INC.  
     
By:    
     
Name:    
     
VSTOCK TRANSFER, LLC  
     
By:                            
     
Name:    

 

[Signature Page to Warrant Agreement]

 

 

 

 

EXHIBIT 1 TO COMPANY WARRANT AGREEMENT

 

FORM OF GLOBAL WARRANT CERTIFICATE FOR COMPANY WARRANTS

 

EXERCISABLE ONLY IF AUTHENTICATED BY THE WARRANT AGENT AS PROVIDED HEREIN

 

VOID AFTER THE CLOSE OF BUSINESS ON _______________, 20__ OF CO-DIAGNOSTICS, INC.

 

Global Warrant Certificate representing Warrants to purchase __________ shares of common stock, par value $0.001 per share, as described herein

 

NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE SOLD, ASSIGNED, TRANSFERRED, ENCUMBERED, OR OTHERWISE DISPOSED OF, EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED.

 

Each Warrant (each a “Warrant”) represented hereby, entitles the registered holder to purchase one share (the “Warrant Share”) of common stock, $0.001 par value (the “Common Stock”), of Co-Diagnostics, Inc., a Utah corporation, (the “Corporation”) for the benefit of certain registered holders (as defined in the Warrant Agreement) of such Warrants on the following terms. This Global Warrant Certificate represents the number of outstanding Warrants from time to time endorsed hereon and the number of outstanding Warrants represented hereby may from time to time be reduced or increased, as appropriate to reflect exchanges, redemptions, exercises and other similar transactions. This Global Warrant Certificate is issued under and in accordance with that certain Warrant Agreement dated as of December 30, 2021 by and between the Corporation and VStock Transfer, LLC (as such agreement may be amended from time to time, the “Warrant Agreement”), and is subject to the terms and provisions contained therein, all of which terms and provisions the registered holders consent to by acceptance of their book-entry interests in the Global Warrant Certificate. Copies of the Warrant Agreement are on file at the Corporation’s headquarters. In the event of any conflict or inconsistency between this Global Warrant Certificate and the Warrant Agreement, this Global Warrant Certificate shall control. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Warrant Agreement.

 

This Global Warrant Certificate is also issued under and in accordance with that certain Agreement and Plan of Merger (as such agreement may be amended from time to time, the “Merger Agreement”), by and among Co-Diagnostics, Inc., a Utah corporation, Idaho Molecular Inc., an Idaho corporation, and IDMO Acquisition Corporation, Inc., and is subject to the terms and provisions contained therein. In the event of any conflict or inconsistency between this Global Warrant Certificate and the Merger Agreement, the Merger Agreement shall control.

 

 

 

 

1. Exercise Period. The Warrants shall vest in full and become exercisable immediately following either (i) satisfaction of Milestone 3 as such term is defined in the Merger Agreement or (ii) upon the occurrence of any of the events described in Section 3.1(e) of the Merger Agreement (any such date, the “Vesting Date”). Promptly upon the satisfaction of clauses (i) or (ii), the Corporation shall notify the Warrant Agent that the vesting conditions have been satisfied and the Vesting Date upon which the Warrants shall become fully exercisable pursuant to the notice provision in the Warrant Agreement. Either the Corporation or the registered holder may certify to the Warrant Agent in a form satisfactory to the Warrant Agent the occurrence of the Vesting Date. Notwithstanding anything to the contrary contained herein, the Warrants shall expire at 5:00 p.m. (New York Time) on January 1, 2027 (the “Termination Date”). Parent will provide registered holder at least fifteen (15) days’ written notice prior to the consummation of any of the events described in Section 3.1(e) of the Merger Agreement.

 

2. Exercise of Warrants.

 

(a) The registered holder may, at any time on or after the Vesting Date and prior to the Termination Date, exercise this Warrant in whole or in part at an exercise price per share equal to $9.125 (subject to proportionate adjustment in accordance with Section 6) (the “Exercise Price”), by the delivery of the Warrant Exercise Form annexed hereto duly completed and executed to the Warrant Agent at the Warrant Agent Office or at such other agency or office of the Corporation in the United States of America as the Corporation may designate by notice in writing to the registered holder at the address of such registered holder appearing on the books of the Corporation. Upon any partial exercise of a Warrant, the Warrant Agent shall make an appropriate adjustment to the account of the registered holder to reflect a number of Warrant Shares for the account of the registered holder equal (without giving effect to any adjustment thereof) to the number of Warrant Shares subject to such registered holder’s Warrants prior to such exercise, minus the number of Warrant Shares exercised by the registered holder. In the event of the exercise of the rights represented by any Warrant, a certificate or certificates for the Warrant Shares so purchased, as and if applicable, registered in the name of the registered holder, shall be delivered to the registered holder hereof as soon as practicable after the exercise of such Warrant.

 

(b) Payment to the Corporation of the Exercise Price for each share of Common Stock being purchased shall be made either (i) by wire transfer or cashier’s check drawn on a United States bank payable to the Corporation (to an account as designated by the Warrant Agent by notice in writing to the registered holders); or (ii) by instructing the Warrant Agent to issue Warrant Shares upon exercise of all or any part of this Warrant on a net basis such that, without payment of any cash consideration or other immediately available funds, the registered holder shall surrender this Warrant in exchange for the number of Warrant Shares equal to the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the Warrants, multiplied by the excess of the “Fair Market Value” (as defined below) less the Exercise Price by (y) the Fair Market Value. “Fair Market Value” shall mean the volume-weighted average price of the shares of Common Stock as reported during the ten (10) trading day period ending on the trading day prior to the date that notice of exercise is received by the Warrant Agent from the registered holder of such Warrants or its securities broker or intermediary.

 

 

 

 

3. Reservation of Warrant Shares. The Corporation agrees that, prior to the expiration of this Warrant, it will at all times have authorized and in reserve, and will keep available, solely for issuance or delivery upon the exercise of all outstanding Warrants represented by this Global Warrant Certificate, the number of Warrant Shares as from time to time shall be issuable by the Corporation upon the exercise of this Warrant.

 

4. No Stockholder Rights; No Rights to Net Cash Settled. No Warrant shall entitle the registered holder hereof to any voting rights or other rights as a stockholder of the Corporation.

 

5. Transferability of Warrant and Underlying Shares. Prior to the Termination Date and subject to compliance with applicable Federal and State securities laws, this Warrant and all rights hereunder are transferable, in whole or in part, at the office or agency of the Corporation by the registered holder in person or by duly authorized attorney in accordance with the provisions of the Warrant Agreement and upon delivery of the Assignment Form annexed hereto properly endorsed for transfer. The Corporation or the Warrant Agent shall be entitled to require, as a condition of any such transfer, that the registered holder and the transferee execute or provide such documents and make such representations and warranties as the Corporation or the Warrant Agent may deem appropriate to evidence compliance with applicable Federal and State securities laws.

 

6. Certain Adjustments. With respect to any rights that any registered holder has to exercise any Warrant and convert into shares of Common Stock, registered holder shall be entitled to the following adjustments:

 

(a) Merger or Consolidation. If at any time there shall be a merger or a consolidation of the Corporation with or into another entity when the Corporation is not the surviving corporation, then, as part of such merger or consolidation, lawful provision shall be made so that the registered holder hereof shall thereafter be entitled to receive upon exercise of each Warrant, during the period specified herein and upon payment of the aggregate Exercise Price then in effect, the number of shares of stock or other securities or property (including cash) of the successor corporation resulting from such merger or consolidation, to which the registered holder hereof as the registered holder of the stock deliverable upon exercise of each Warrant would have been entitled in such merger or consolidation if each Warrant had been exercised immediately before such transaction. In any such case, appropriate adjustment shall be made in the application of the provisions of each Warrant with respect to the rights and interests of the registered holder hereof as the registered holder of each Warrant after the merger or consolidation.

 

(b) Reclassification, Recapitalization, etc. If the Corporation at any time shall, by subdivision, combination or reclassification of securities, recapitalization, automatic conversion, or other similar event affecting the number or character of outstanding shares of Common Stock, or otherwise, change any of the securities as to which purchase rights under each Warrant exist into the same or a different number of securities of any other class or classes, each Warrant shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities that were subject to the purchase rights under each Warrant immediately prior to such subdivision, combination, reclassification or other change and the Exercise Price shall be proportionately adjusted.

 

 

 

 

(c) Split or Combination of Common Stock and Stock Dividend. In case the Corporation shall at any time subdivide, redivide, recapitalize, split (forward) or change its outstanding shares of Common Stock into a greater number of shares or declare a dividend upon its Common Stock payable solely in shares of Common Stock, the Exercise Price shall be proportionately reduced and the number of Warrant Shares proportionately increased. Conversely, in case of a reverse stock split or the outstanding shares of Common Stock of the Corporation shall be combined into a smaller number of shares, the Exercise Price shall be proportionately increased and the number of Warrant Shares proportionately reduced.

 

(d) Notices of Changes in Warrant. Upon every adjustment of (i) the Exercise Price, (ii) the number of shares of Parent Common Stock issuable upon exercise of this Global Warrant Certificate and (iii) the number of Warrants outstanding, the Corporation shall give written notice thereof to the registered holder, which notice shall state the Exercise Price resulting from such adjustment and the increase or decrease, if any, in the number of shares purchasable at such price upon the exercise of this Warrant, setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. Upon the occurrence of any event specified in this Global Warrant Certificate then, in any such event, the Corporation shall give written notice to the registered holder, at the last address set forth for such registered holder in the Warrant register maintained by the Warrant Agent, of the record date or the effective date of the event. Failure to give such notice, or any defect therein, shall not affect the legality or validity of such event.

 

7. Compliance with Securities Laws; Legend and Stop Transfer Orders. Unless the Warrant Shares are subject to an effective registration statement under the Securities Act, upon exercise of any part of any Warrant represented hereby, (i) the Corporation shall be entitled to require that the registered holder make such representations and warranties as may be reasonably required by the Corporation to assure that the issuance of Warrant Shares is exempt from the registration requirements of applicable securities laws and (ii) the Corporation shall instruct its transfer agent to enter stop transfer orders with respect to such Warrant Shares, and the Warrant Shares shall bear on the face thereof substantially the following legend:

 

THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS. NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE SOLD, ASSIGNED, TRANSFERRED, ENCUMBERED, OR OTHERWISE DISPOSED OF, EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED.

 

8. Miscellaneous. This Global Warrant Certificate and each Warrant represented hereby shall be governed by and construed in accordance with the laws of the State of Utah. All the covenants and provisions of this Global Warrant Certificate and each Warrant by or for the benefit of the Corporation shall bind and inure to the benefit of its successors and assigns hereunder. Nothing in this global Warrant Certificate shall be construed to give to any person or corporation other than the Corporation and the registered holder of each Warrant represented hereby any legal or equitable right, remedy, or claim under this Global Warrant Certificate and each Warrant represented hereby. This Global Warrant Certificate and each Warrant represented hereby shall be for the sole and exclusive benefit of the Corporation and the registered holder. The section headings herein are for convenience only and are not part of this Global Warrant Certificate and shall not affect the interpretation hereof.

 

 

 

 

9. Validity. This Warrant Certificate shall not be valid or obligatory for any purpose until authenticated by the Warrant Agent.

 

IN WITNESS WHEREOF, the Corporation has caused this Global Warrant Certificate to be executed by its duly authorized officer, this _____ day of __________ 2021.

 

  CO-DIAGNOSTICS, INC.  
       
  By:    
  Name:    
  Title: Chief Executive Officer  

 

 

 

 

Certificate of Authentication

 

This is the Global Warrant Certificate for the Warrants referred to in the within-mentioned Warrant Agreement.

 

VSTOCK TRANSFER, LLC, as Warrant Agent

 

By:

 

Authorized Signature

 

[TO BE ATTACHED TO GLOBAL WARRANT CERTIFICATE] SCHEDULE OF INCREASES OR DECREASES IN WARRANT CERTIFICATE

 

The following increases or decreases in this Warrant have been made:

 

Date

 

Amount of decrease in the number of Warrants represented by this Warrant

 

Amount of increase in number of Warrants represented by this Warrant

 

Number of Warrants represented by this Warrant following such decrease or increase.

 

Signature of authorized officer of the depository

 

 

 

 

FORM OF EXERCISE FORM

 

To Be Executed by the registered holder in Order to Exercise Company Warrant

 

The undersigned hereby irrevocably elects to exercise the right, represented by the book-entry Warrant(s), to purchase shares of the Common Stock of Co-Diagnostics, Inc. (the “Warrant Shares”) and the undersigned herewith makes payment of the full purchase price for such shares at the price per share provided for in such Warrant in accordance with the terms of the Warrant Agreement. Such payment takes the form of $__________ in lawful money of the United States.

 

In the event that the registered holder wishes to exercise through cashless exercise (i) the number of Warrant Shares that this Warrant is exercisable for would be determined in accordance with Section 2(b) of this Global Warrant Certificate which allows for such cashless exercise and (ii) the registered holder hereof shall complete the following: The undersigned hereby irrevocably elects to exercise the right, represented by this Global Warrant Certificate, through the cashless exercise provisions hereof, to receive Warrant Shares.

 

The undersigned hereby requests that certificates for the Warrant Shares purchased be issued in the name of:

 

(please print or type name and address)

 

(please insert social security or other identifying number)

 

and be delivered as follows:

 

(please print or type name and address)

 

(please insert social security or other identifying number)

 

and if such number of shares of Common Stock shall not be all the shares evidenced by this Global Warrant Certificate, that a new Warrant for the balance of such shares be registered in the name of, and delivered to, registered holder.

 

Signature of Holder

 

SIGNATURE GUARANTEE:

 

This Warrant may be exercised by delivering the Exercise Form to VStock Transfer, LLC at the following addresses:

 

By mail at

___________

[       ]

 

 

 

 

[FORM OF ASSIGNMENT]

 

(TO BE EXECUTED TO TRANSFER THE WARRANT)

 

For value received, hereby sells, assigns and transfers unto the Assignee(s) named below the rights represented by such number of Company Warrants listed opposite the respective name(s) of the Assignee(s) named below and all other rights of the registered holder with respect to such Warrants, and does hereby irrevocably constitute and appoint _______________ attorney, to transfer said Warrant on the books of the Depositary and/or the Warrant Agent with respect to the number of Warrants set forth below, with full power of substitution:

 

Name(s) of

 

Assignee(s) Address No. of Warrants

 

Dated: _____________

 

Signature

 

(Signed exactly as name appears in the records of the Depositary)

 

Signature Guarantee:

 

 

 

 EX-10.9 6 ex10-9.htm

 

Exhibit 10.9

 

LEASE AGREEMENT

2401 FOOTHILL DRIVE

 

THIS LEASE AGREEMENT (this “Lease”) is entered into as of the __ day of June, 2018, between YESCO Properties, LLC, a Utah company (“Landlord”), whose address is 2401 Foothill Dr., SLC, UT 84109, and Co-Diagnostics, a Utah company (“Tenant”), whose address is 2401 Foothill Drive, SLC, UT 84109.

 

Landlord and Tenant agree as follows:

 

1. Definitions. As used in this Lease, each of the following terms will have the meaning indicated:

 

1.1. “Basic Monthly Rent” means:

 

Period(s)  Basic Monthly Rent  Rented Square feet
       
Feb. 1, 2018 through May 31, 2018  $11,399.30 per month  7,209
       
June. 1, 2018 through January 31, 2019  $14,399.30 per month  10,273
       
Feb. 1, 2019 through Jan 31, 2020  $14,831.25 per month  10,273
       
__________ through    $n/a, per month  n.a..
__________, inclusive      
       
__________ through    $n.a., per month  n.a.
__________, inclusive      

 

* June 2018 Rent will be discounted by $1500.

 

1.2. “Building” means the building with the street address of see above , in ______ County,______ , (The Building includes, without limitation, all heating, air-conditioning, mechanical, electrical, and plumbing systems, the roof and all walls, foundations and fixtures constituting a part of the Building.)

 

1.3. “Commencement Date” means Feb 1, 2018.

 

1.4. Expiration Date” means the date that is_ years after the Commencement Date, plus any partial calendar month occurring between the Commencement Date and the first day of the first full calendar month following the Commencement Date, if the Commencement Date does not occur on the first day of a calendar month, as the same may be extended pursuant to Paragraph 2.2.

 

1.5. “Occupants” means any assignee, subtenant, employee, agent, licensee, invitee, patient or resident of Tenant.

 

1.6. “Permitted Use” means typical office and labs use only, and no other purpose.

 

1.7. “Personaltv” means the following:

 

1.7.1. all goods, equipment, machinery, inventory, materials, supplies, fixtures, furniture, furnishings, tools, appliances and other tangible personal property now owned or acquired after the date of this Agreement by Landlord and located in the Building: and

 

1.7.2. all trademarks, trade names, telephone numbers, logos, contract rights, escrow accounts. accounts receivable, chattel paper, insurance policies, agreements, instruments, documents of title, general intangibles, business records, plans. specifications, drawings, options, declarations, surveys, studies, architectural renderings, diagrams, maps, permits, licenses, certificates, zoning and subdivision development applications, filings and approvals and other intangible personal property now owned or acquired after the date of this Agreement by Landlord and used in connection with the ownership or operation of the Building or any businesses located on the Building.

 

 

 

 

1.8. “Premises” means the portion of the Building that is leased to Tenant as identified on Exhibit A

 

1.9. “Security Deposit” means $11,744.25

 

1.10 “Term” means the period commencing at 12:01 a.m. of the Commencement Date and expiring at midnight of the Expiration Date.

 

2. Agreement of Lease. Landlord leases the Premises to Tenant and Tenant leases the Premises from Landlord for the Term, together with such non-exclusive rights of ingress and egress over and across the Landlord’s land upon which the: Building is located, and such portions of the Building as are designated on Exhibit A as “Common Areas” that are reasonably necessary for the use of the Premises, in accordance with the provisions set forth in this Lease. Tenant acknowledges that it has had an opportunity to inspect the Premises, and agrees that it accepts the Premises as-is and with all faults.

 

3. Basic Monthly Rent. Tenant covenants to pay to Landlord without abatement, deduction, offset, prior notice or demand the: Basic Monthly Rent in lawful money of the United States in equal consecutive monthly installments at such place as Landlord may designate, in advance on or before the first day of each calendar month during the: Term, commencing on the Commencement Date. If the Commencement Date occurs on a day other than the first day of a calendar month, on or before the Commencement Date the Basic Monthly Rent will be paid for the initial fractional calendar month prorated on a per diem basis and for the first full calendar month occurring after the Commencement Date. If this Lease: expires or terminates on a day other than the last day of a calendar month, the Basic Monthly Rent for such fractional month will be prorated on a per diem basis.

 

4. Property Taxes. Landlord will pay all property taxes applicable to the Building during the Term. Tenant is responsible for the payment of all other taxes arising in in connection with the use and occupancy of the Premises.

 

5. Use. Tenant will not use or occupy or permit the: Premises to be used or occupied for any purpose other than for the Permitted Use, and will not do or permit anything to be done: by Tenant’s Occupants which may (a) violate the provisions of any insurance carried, with respect to the Premises, (b) create a public or private nuisance or commit waste. (c) overload the floors or otherwise damage the structure: of the Building. or (d) violate any present or future laws, ordinances, regulations, permits, licenses or requirements or any covenants. conditions and restrictions existing with respect to the Premises. Tenant \.\·ill, at Tenant’s sole cost, (w) use the Premises in a careful, safe and proper manner, (x) comply with all present and future laws, ordinances, regulations. permits. licenses, and requirements and any covenants, conditions and restrictions existing with respect to the Premises. including. without limitation, those relating to chemicals. hazardous materials. hazardous substances, hazardous wastes, pollutants or contaminants, and those relating to access by disabled persons. (y) comply with the: requirements of any board of fire underwriters or other similar body relating to the Premises, and (z} not inventory, store, use: or dispose of any chemicals, hazardous materials. hazardous substances, hazardous wastes, pollutants or contaminants on the Premises, except in accordance with applicable laws, ordinances, regulations, permits, licenses and requirements. Except as set forth in this Lease, no representation or warranty has been made to, or relied on by, Tenant concerning the Premises. including, without limitation, the fitness or suitability of the Premises for the conduct of Tenant’s business, nor has Landlord agreed to undertake any modification, alteration or improvement of the Premises.

 

2

 

 

6. Security Deposit. On the date of this Lease, Tenant shall deposit with Landlord the Security Deposit as security for the faithful performance by Tenant under this Lease. The Security Deposit shall be returned (without interest) to Tennant (or, at Landlord’s option, to the last assignee of Tenant’s interest under this Lease) after the expiration of the Tern or sooner termination of this Lease and delivery of possession of the Premises to Landlord in accordance with Paragraph l 6 if, at such time. Tenant is not in default under this lease. If Landlord’s interest in this Lease is conveyed, transferred or assigned, Landlord shall transfer or credit the Security Deposit to Landlord’s successor in interest. and Landlord shall be released from any liability for the return of the Security Deposit. Landlord may intermingle the Security Deposit with Landlord’s own funds, and shall not be deemed to be a trustee of the Security Deposit. If Tenant fails to pay or perform in a timely manner any obligation under this Lease, Landlord may, prior to. concurrently with or subsequent to, exercising any other right or remedy, use, apply or retain all or any part of the Security Deposit for the payment of any monetary obligation due under this Lease, or to compensate landlord for any other expense, loss or damage that Landlord may incur by reason of Tenant’s failure, including any damage or deficiency in the reletting of the Premises. If all or any portion of the Security Deposit is so used, applied or retained, Tennant shall immediately deposit with landlord cash in an amount sufficient to restore the Security Deposit to the original amount. The Security Deposit is not a limitation on Landlord’s damages or other rights under this lease, a payment of liquidated damages or prepaid rent and shall not be applied by Tenant to the rent for the last (or any) month of the Term, or to any other amount due under this Lease. If this Lease is terminated due to any default of Tenant, any portion of the Security Deposit remaining at the time of such termination shall immediately inure to the benefit of Landlord as partial compensation for the costs and expenses incurred by Landlord in connection with this Lease, and shall be in addition to any other damages to which Landlord is otherwise entitled.

 

7. Utilities. Landlord will provide to the Premises during the Term basic water, gas, electric, and sewer services for Tenant. Tenant is responsible for all increased and differential costs for basic water, gas, electric, and sewer services associated with Tenant’s use of the Premises for non-office uses; such additional costs shall be paid in addition to the Basic Monthly Rent. Tenant agrees to pay all costs associated with any other utility services it desires, including its own telecommunications, security, fire alarm, [internet services, or other desired utilities. Tenant shall pay for such services directly to the providers. If any utility or service to the Premises is interrupted for any reason (including the occurrence of any “brown outs” that interfere with Tenant’s operations in any way), Landlord will not be liable to Tenant for such interruption, such interruption will not be deemed to be an eviction or interference with Tenant’s use and occupancy of the Premises, and the Basic Monthly Rent and other amounts required to be paid by Tenant under this lease will not be abated as a result of such interruption. Tenant waives any claims of any kind against Landlord related to or arising out of in any way any such interruption and takes full responsibility for operation of all of their specialty equipment and ensuring against any power outages. Landlord and Tenant will cooperate in taking reasonable steps to re-instate any interrupted service.

 

8. Maintenance and Repairs: Alterations: Signs: Access to Premises.

 

8.1. Maintenance and Repairs. Landlord to provide general repairs, maintenance and janitorial service typical for office use. Tenant will keep Premises neat and tidy and in good repair and use reasonable care in use of the Building. Except for normal wear and tear, Tenant will pay for damage to the Premises or Building caused by their negligent or otherwise wrongful acts or omissions. All such repairs and replacements will be in quality and class equal to or better than the original work or installations. Tenant to provide maintenance, repairs, and replacement of specialized equipment used by Tenant such as auxiliary power generators, security systems other than keyed door locks, heating and air conditioning equipment used to maintain specified temperature ranges for lab space (if applicable), inventory, servers and other temperature sensitive items. Tenant also to provide other equipment or facilities to protect any property with any other specified environmental requirements, including moisture requirements. Tenant will also provide janitorial for lab areas (if applicable).

 

3

 

 

8.2. Alterations. Tenant will not make any change. addition or improvement to the Premises, unless such change, addition or improvement (a) utilizes only new and firstgrade materials, (b) is in conformity with all applicable laws, ordinances, regulations and requirements, and is made after obtaining any required permits and licenses, (c) is made with the prior written consent of Landlord, (d) is made pursuant to plans and specifications approved in writing in advance by Landlord, (e) is made after Tenant has provided to Landlord such indemnification or bonds, including, without limitation, a performance and completion bond, in such form and amount as may be satisfactory to Landlord, to protect against claims and liens for labor performed and materials furnished, and to insure the completion of any change, addition or improvement, and (f) is carried out by persons approved in writing by Landlord, who, if required by Landlord, deliver to Landlord before commencement of their work proof of such insurance coverage as Landlord may reasonably require, with Landlord named as an additional insured. Any such change, addition or improvement will immediately become the property of Landlord. Tenant will promptly pay the entire cost of any such change, addition or improvement. Tenant will indemnify, defend and hold harmless Landlord from and against all liens, claims, damages, losses, liabilities and expenses, including attorneys’ fees, which may arise out of, or be connected in any way with, any such change, addition or improvement. Within ten (10) days following the imposition of any lien resulting from any such change, addition or improvement, Tenant will cause such lien to be released of record by payment of money or posting of a proper bond.

 

8.3. Signs. Tenant shall not make any changes to the exterior of the Premises, install any exterior lights, decorations, balloons, flags, pennants, banners, or painting, or erect or install any signs, windows or door lettering, placards, decorations, or advertising media of any type which can be viewed from the exterior of the Premises, without Landlord’s prior written consent, which consent may be withheld in Landlord’s sole discretion. Tenant acknowledges that the West elevation of the Building is not available to Tenant for the installation of any signs. Upon surrender or vacation of the Premises, Tenant shall have removed all signs and repair, paint, and/or replace the building facia surface to which its signs are attached. Tenant shall obtain all applicable governmental permits and approvals for sign and exterior treatments. All signs, decorations, advertising media, blinds, draperies and other window treatment or bars or other security installations visible from outside the Premises shall be subject to Landlord’s approval and conform in all respects to Landlord’s requirements.

 

8.4. Access to Premises. Landlord and Landlord’s agents, employees and contractors may enter the Premises at reasonable times on reasonable notice to Tenant for the purpose of inspecting the Premises and ascertaining compliance with the provisions of this Lease by Tenant. Landlord will have free access to the Premises in an emergency. Landlord may also show the Premises to prospective purchasers, tenants or mortgagees at reasonable times. Tenant waives any claim for any damage, injury or inconvenience to, or interference with, Tenant’s business, occupancy or quiet enjoyment of the Premises and other loss occasioned by such entry, unless caused by Landlord’s willful misconduct or gross negligence. Landlord will at all times have a key with which to unlock all of the doors in the Premises (excluding Tenant’s vaults, safes and similar areas designated in writing by Tenant in advance). During the six (6) months prior to the expiration of the Term or other termination of this Lease, Landlord may place on the Premises “To Let,” “For Sale” or other similar signs.

 

9. Assignment.

 

9.1. Prohibition. Tenant will not, either voluntarily or by operation of law, assign, transfer, mortgage, encumber, pledge or hypothecate this Lease or Tenant’s interest in this Lease, in whole or in part, or sublease the Premises or any part of the Premises, without the prior written consent of Landlord, which will not be unreasonably withheld, conditioned or delayed. Any transfer of this Lease from Tenant by merger, consolidation, liquidation or transfer of assets will constitute an assignment for the purposes of this Lease. If Tenant is a corporation, an unincorporated association or a partnership, the assignment, transfer, mortgage, encumbrance, pledge or hypothecation of any stock or interest in such corporation, association or partnership in the aggregate in excess of forty-nine percent (49%) ,.vii! be deemed an assignment within the meaning of this Paragraph. Consent to any assignment or subleasing will not operate as a waiver of the necessity for consent to any subsequent assignment or subleasing and the terms of such consent will be binding on any person holding by, through or under Tenant. At Landlord’s option, any assignment or sublease without Landlord’s prior written consent will be void ab initio.

 

4

 

 

9.2. Landlord’s Rights. If this Lease is assigned or if all or any portion of the Premises is subleased or occupied by any person other than Tenant without obtaining Landlord’s consent, Landlord may collect rent and other charges from such assignee or other party, and apply the amount collected to the rent and other charges payable under this Lease, but such collection will not constitute consent or waiver of the necessity of consent to such assignment or subleasing, nor will such collection constitute the recognition of such assignee or subtenant as Tenant under this Lease or a release of Tenant from the further performance of all of the covenants and obligations of Tenant contained in this Lease. No consent by Landlord to any assignment or subleasing by Tenant will relieve Tenant of any obligation to be paid or performed by Tenant under this Lease, whether occurring before or after such consent, assignment or subleasing, but rather Tenant and Tenant’s assignee or subtenant, as the case may be, will be jointly and severally primarily liable for such payment and performance. Tenant will reimburse Landlord for Landlord’s attorneys’ and other fees and costs incurred in connection with both determining whether to give consent and giving consent. No assignment or subleasing under this Lease will be effective unless and until Tenant provides to Landlord an executed counterpart of the assignment or sublease agreement, which will specifically state that (a) such agreement is subject to all of the provisions of this Lease, (b) in the case of an assignment, the assignee assumes and agrees to perform all of Tenant’s obligations under this Lease, (c) the assignee or subtenant, as the case may be, may not further assign such agreement, or allow the Premises to be used by others, without the prior written consent of Landlord in each instance, (d) a consent by Landlord to such assignment or subleasing will not be deemed or construed to modify, amend or affect the provisions of this Lease or Tenant’s obligations under this Lease, which will continue to apply to the Premises and the occupants of the Premises as if the assignment or sublease had not been made, (e) if Tenant defaults in the payment of any amounts due under this Lease, Landlord is authorized to collect any rents or other amounts due from any assignee, subtenant or other occupant of the Premises and to apply the net amounts collected to the sums payable under this Lease, and (t) the receipt by Landlord of any amounts from an assignee, subtenant or other occupant of any pan of the Premises will not be deemed or construed as releasing Tenant from Tenant’s obligations under this Lease or the acceptance of that party as a direct tenant. If all or any portion of the Premises is assigned or subleased and the compensation to be received by Tenant exceeds the Basic Monthly Rent (or pro rata portion of the Basic Monthly Rent, as the case may be) applicable to the portion being assigned or subleased, Tenant \viii pay such excess to Landlord on the first day of each calendar month.

 

10. Indemnity: Waiver and Release.

 

10.1. lndemnitv. Tenant will indemnify, defend and hold harmless Landlord and Landlord’s employees and agents from and against all demands, claims, causes of action, judgments, losses, damages, liabilities, fines, penalties, costs and expenses, including attorneys’ fees, arising from the occupancy or use of the Premises by Tenant or Tenant’s Occupants, any chemicals, hazardous materials, hazardous substances, hazardous wastes, pollutants or contaminants generated, manufactured, used, inventoried, deposited, released or stored by Tenant or Tenant’s Occupants on the Premises, the conduct of Tenant’s business on the Premises, any act or omission done, permitted or suffered by Tenant or any of Tenant’s Occupants, any default or nonperformance by Tenant under this Lease, any injury or damage to the person, property or business of Tenant or Tenant’s Occupants or any litigation commenced by or against Tenant to which Landlord is made a party without willful misconduct or gross negligence on the part of Landlord. If any action or proceeding is brought against Landlord or Landlord’s employees or agents by reason of any of the matters set forth in the preceding sentence, Tenant, on notice from Landlord, will defend Landlord at Tenant’s expense with counsel reasonably satisfactory to Landlord. The provisions of this Paragraph 10.1 will survive the expiration of the Term or sooner termination of this Lease.

 

10.2. Waiver and Release. Tenant waives and releases all claims against Landlord and Landlord’s employees and agents with respect to all matters for which Landlord has disclaimed liability or responsibility pursuant to the provisions of this Lease. In addition, Landlord and Landlord’s employees and agents will not be liable for any loss, injury, death or damage to persons, property or Tenant’s business resulting from any theft, act of God, public enemy, injunction, riot, strike, insurrection, war, court order, requisition, order of governmental body or authority, fire. explosion, falling object, steam, water, rain, snow, ice, wind and other weather-related occurrences, breakage, leakage, obstruction or other defects of pipes, sprinklers, wires. appliances. plumbing, air-conditioning or lighting fixtures, construction, repair or alteration of the Premises or other cause beyond Landlord’s reasonable control.

 

5

 

 

11. Insurance. On or before the Commencement Date, Tenant will, at Tenant’s sole cost. procure and continue in force the following insurance coverage: (a} commercial general liability insurance with a $1,000,000 limit per occurrence for bodily injury and property damage, $2,000,000 general aggregate, and $2,000,000 products and completed operation aggregate coverage that includes without limitation, contractual liability coverage for the performance by Tenant of the indemnity agreement invitees or customers are kept in, or about the, Premises, Tennant shall maintain ,warehouser’s legal liability or bailee customers insurance for the full value of the property of such invitees or customers as determined by the warehouse contract between Tenant and its customer; (b) automobile insurance with a combined single limit of not less than $1,000,000 per occurrence insuring Tenant against liability arising out of the ownership maintenance or use of any owned, hired or borrowed automobiles, (c) all risk or special form property insurance covering all property and improvements installed or placed in the Premises by Tenant, including special causes of loss with theft coverage, insuring against fire, extended coverage risks, vandalism and malicious mischief, and including boiler and sprinkler leakage coverage, in an amount equal to the full replacement cost (without deduction for depreciation) of all furnishings, trade fixtures, leasehold improvements, equipment and other personal property from time to time situated in or on the Premises; and (d) workers’ compensation insurance satisfying Tenant’s obligations under the workers’ compensation laws of the state in which the Premises are located. Any company writing any of Tenant’s insurance shall have an A.M. Best rating of not less than A-VIII. Tenant agrees that the liability and automobile insurance will name Landlord and any other person specified from time to time by Landlord as an additional insured and the property insurance will name Landlord as loss payee as Landlord’s interests may appear. All liability policies maintained by Tenant will contain a provision that Landlord and any other additional insured, although named as an insured, will nevertheless be entitled to recover under such policies for any loss sustained by Landlord and Landlord’s agents and employees as a result of the acts or omissions of Tenant. Tenant will furnish Landlord with certificates of coverage. No such policy will be cancelable or subject to reduction of coverage or other modification except after thirty (30) days’ prior written notice to Landlord by the insurer. All such policies will be written as primary policies, not contributing with and not in excess of the coverage that Landlord may carry, and will only be subject to such deductibles as may be approved in writing in advance by Landlord. Tenant will, at least ten (10) days prior to the expiration of such policies, furnish Landlord with renewals of, or binders for, such policies. Landlord and Tenant waive all rights to recover against each other, against any other tenant or occupant of the Building and against the officers, directors, shareholders, partners, joint venturers, employees, agents’ customers, invitees or business visitors of each other or of any other tenant or occupant of the Building, for any loss or damage arising from any cause covered by any insurance carried by the waiving party, but only to the extent that such loss or damage is actually covered. Landlord and Tenant will cause their respective insurance carriers to issue appropriate waivers of subrogation rights endorsements to all policies of insurance carried in connection with the Premises or the contents of the Premises. Any mortgage lender making a loan with respect to any part of the Premises may, at Landlord’s option, be afforded coverage under any policy required to be secured by Tenant under this Lease by use of a mortgagee’s endorsement to the policy concerned. Notwithstanding the foregoing provisions of this Paragraph, if the holder of any mortgage then affecting Landlord’s interest in the Premises requires that Landlord make monthly or other periodic payments to an escrow or reserve for use in paying insurance premiums as they fall due, Tenant will, on being so advised by Landlord and at the time of Tenant’s making the monthly payments of Basic Monthly Rent required under Paragraph 3, remit to Landlord the monthly or other periodic payments required to be paid by Landlord to such holder, and Landlord will in tum remit such payments to such holder.

 

6

 

 

12. Damage or Destruction. If the Premises are damaged or destroyed by any casualty other than a casualty caused by Tenant, Landlord will promptly repair the Premises to substantially the condition in which the Premises were immediately prior to such damage or destruction. All proceeds payable under any insurance policy maintained by Tenant pursuant to Paragraph l l(c) will be paid directly to Landlord, and not to Landlord and Tenant jointly. During such repair, the Basic Monthly Rent will not abate. If (a) by reason of such occurrence the Premises are rendered wholly untenantable, (b) the Premises are damaged in ,whole or in part during the last twelve (12) months of the Term, or (c) the Premises are damaged to the extent of twenty percent (20%) or more of the then replacement value of the Premises or to the extent that it would take, in Landlord’s opinion, in excess of ninety (90) days to complete the requisite repairs, Landlord may either elect for Tenant to repair the damage or cancel this Lease by notice of cancellation within sixty (60) days after such event. On such notice of cancellation, Tenant will vacate and surrender the Premises to Landlord and Landlord may retain all insurance proceeds. Tenant will have no claim against Landlord for any loss suffered by reason of any such damage, destruction, repair or restoration, nor may Tenant terminate this Lease as the result of any statutory provision in effect on or after the date of this Lease pertaining to the damage and destruction of the Premises. Landlord will not be required to repair any damage to, or to make any restoration or replacement of, the Premises or any furnishings, trade fixtures, leasehold improvements, equipment or other personal property installed in the Premises. Unless this Lease is terminated by Landlord pursuant to this Paragraph, Tenant will be required to restore and replace the Premises and such furnishings. trade fixtures, leasehold improvements, equipment and other personal property on damage or destruction in at least a condition equal to that existing prior to such event, and Landlord will make available to Tenant all or a portion of the insurance proceeds (if any), as necessary for Tenant to complete such restoration and replacement. If made, the disbursement of such proceeds will be made to Tenant from an escrow account controlled by Landlord in accordance with disbursement procedures typically used by construction lenders in the metropolitan area in which the Premises are located.

 

3. Condemnation. As used in this Paragraph, the term “Condemnation Proceedings” means any actions or proceedings in which any interest in the Premises is taken for any public or quasipublic purpose by any lawful authority through exercise of the power of eminent domain or by purchase or other means in lieu of such exercise. If the whole of the Premises is taken through Condemnation Proceedings, this Lease will automatically terminate as of the date of the taking. The phrase “as of the date of the taking:” means the date of taking actual physical possession by the condemning authority or such earlier date as the condemning authority gives notice that it is deemed to have taken possession. Landlord or Tenant may terminate this Lease if more than twenty-five percent (25%) of the Premises is taken or any portion of the Premises is taken that substantially interferes with Tenant’s ability to operate or use the Premises for the purposes for which the Premises were intended. Any such termination must be accomplished through written notice given no later than thirty (30) days after, and will be effective as of, the date of such taking. In all other cases, or if neither Landlord nor Tenant exercises its right to terminate, this Lease will remain in effect, and Tenant will promptly repair and restore the Premises as nearly as possible to the nature and character that existed immediately prior to such taking. If a portion of the Premises is taken and this Lease is not terminated, the Basic monthly Rent will be reduced in the proportion that the Building floor area taken bears to the total floor area of the Building leased by Tenant immediately prior to the taking. Whether or not this Lease is terminated as a consequence of Condemnation Proceedings, all damages or compensation awarded for a partial or total taking, including any award for severance damage and any sums compensating for diminution in the value of or deprivation of the leasehold estate under this Lease, will be the sole and exclusive property of Landlord; provided, however, that if (but only it) (a) this Lease is not terminated as a consequence of Condemnation Proceedings, and (b) Landlord receives an award in such Condemnation Proceedings expressly designated for the repair and restoration of the Premises, Landlord will make available to Tenant all or a portion of the award so designated, as necessary, for Tenant to complete its obligations of repair and restoration under this Paragraph. If made, the disbursement of such portion of the award will be made by Landlord to Tenant in accordance with disbursement procedures typically used by construction lenders in the metropolitan area in which the Premises are located. Other than as expressly set forth in the immediately preceding two sentences, Tenant will be absolutely responsible, at its sole cost and expense, to repair and restore the Premises as nearly as possible to the nature and character that existed prior to such taking if this Lease is not terminated pursuant to this Paragraph. Tenant will have no claim against Landlord for the occurrence of any Condemnation Proceedings, or for the termination of this Lease or a reduction in the Premises as a result of any Condemnation Proceedings

 

7

 

 

14. Landlord’s Financing. This Lease will be subordinate to any existing or future first mortgage, first deed of trust, ground lease and declaration of covenants, conditions, easements and restrictions encumbering the Premises, and all renewals, modifications, amendments, consolidations, replacements and extensions of any such instruments. No documentation other than this Lease will be required to evidence such subordination. [f the holder of any mortgage or deed of mist elects to have this Lease superior to the lien of its mortgage or deed of trust and gives written notice of such election to Tenant, this Lease will be deemed prior to such mortgage or deed of trust. Tenant will execute such documents as may be required by Landlord to confirm such subordination or priority within ten (l0) days after request. Tenant will from time to time if so requested by Landlord and if doing so will not materially and adversely affect Tenant’s economic interests under this Lease, join with Landlord in amending this Lease so as to meet the needs or requirements of any lender that is considering making or that has made a loan secured by all or any portion of the Premises. Any sale, assignment or transfer of Landlord’s interest under this Lease or in the Premises, including any such disposition resulting from Landlord’s default under a debt obligation, will be subject to this Lease and Tenant will attorn to Landlord’s successors and assigns and will recognize such successors or assigns as Landlord under this Lease. regardless of any law of law to the contrary or absence of privity of contract.

 

15. Default.

 

15.1. Default bv Tenant. The occurrence of any of the following events will constitute a d fault by Tenant under this Lease: (a) Tenant fails to pay in a timely manner any installment of Basic monthly Rent or any other sum clue under this Lease within three (3) business clays after written notice is given to Tenant that the same is past due; (b) Tenant fails to observe or perform in a timely manner any other term, covenant or condition to be observed or performed by Tenant under this Lease within ten ( l 0) business days after written notice is given to Tenant of such failure; provided, however, that if more than ten (10) business days is reasonably required to cure such failure, Tenant will not be in default if Tenant commences such cure within such ten (l 0) day period and diligently prosecutes such cure to completion; (c) Tenant files a petition in bankruptcy, becomes insolvent, has taken against Tenant in any court, pursuant to state or federal statute, a petition in bankruptcy or insolvency or for reorganization or appointment of a receiver or trustee, petitions for or enters into an arrangement for the benefit of creditors or suffers this Lease to become subject to a writ of execution; or (d) Tenant vacates or abandons the Premises.

 

15.2. Remedies. On any default by Tenant under this Lease, Landlord may at any time, without waiving or limiting any other right or remedy available to Landlord, (a) perform in Tenant’s stead any obligation that Ten::int has failed to perform, and Landlord will be reimbursed promptly for any cost incurred by Landlord with interest from the date of such expenditure until paid in full at the greater of the prime rate then charged by Wells Fargo Bank, N.A. (or any other bank designated by Landlord), plus four percent (4%), or eighteen percent (18%) per annum (the “Interest Rate”), (b) terminate Tenant’s rights under this Lease by written notice, (c) reenter and take possession of the Premises by any lawful means (with or without terminating this Lease), or (d) pursue any other remedy allowed by law. Tenant will pay to Landlord the cost of recovering possession of the Premises, all costs of reletting, including reasonable renovation, remodeling and alteration of the Premises, the amount of any commissions paid by Landlord in connection with such reletting, and all other costs and damages arising out of Tenant’s default, including attorneys’ fees and costs. Notwithstanding any termination or reentry, the liability of Tenant for the rent payable under this Lease will not be extinguished for the balance of the Term, and Tenant agrees to compensate Landlord on demand for any deficiency, whether arising from (v) reletting the Premises at a lesser rent than applies under this Lease, (w) reletting the Premises for a term shorter than the remaining Term, (x) reletting less than all of the Premises, (y) any default in the payment of rent by any person to whom Landlord relets the Premises, or (z) any other cause whatsoever. No reentry to or taking possession of the Premises or other action by Landlord or its agents on or following the occurrence of any default by Tenant ,viii be construed as an election by Landlord to terminate this Lease or as an acceptance of any surrender of the Premises, unless Landlord provides Tenant written notice of such termination or acceptance.

 

8

 

 

15.3. Past Due Amounts: Obligations Independent. If Tenant fails to pay when due any amount required to be paid by Tenant under this Lease, such unpaid amount will bear interest at the Interest Rate from the due date of such amount to the date of payment in full, with interest. In addition, Landlord may also charge a sum of five percent (5%) of such unpaid amount as a service fee. This late payment charge is intended to compensate Landlord for Landlord’s additional administrative costs resulting from Tenant’s failure to perform in a timely manner Tenant’s obligations under this Lease, and has been agreed on by Landlord and Tenant after negotiation as a reasonable estimate of the additional administrative costs which will be incurred by Landlord as a result of such failure. The actual cost in each instance is extremely difficult, if not impossible, to determine. This late payment charge will constitute liquidated damages and will be paid to Landlord together with such unpaid amount. The payment of this late payment charge will not constitute a waiver by Landlord of any default by Tenant under this Lease. All amounts due: under this Lease are and will be deemed to be rent or additional rent, and will be paid without abatement, deduction, offset, prior notice or demand (unless expressly provided by the terms of this Lease). Landlord will have the same remedies for a default in the payment of any amount due under this Lease as Landlord has for a default in the payment of Basic Monthly Rent. The obligations of Tenant to pay Basic Monthly Rent and all other amounts due under this Lease, and to perform all of Tenant’s other obligations under this Lease, are severable from and independent of any obligation of Landlord under this lease.

 

14.4. Default bv Landlord. Landlord will not be in default under this Lease unless Landlord fails to perform an obligation required of Landlord under this Lease within thirty (30) days after written notice by Tenant to Landlord and the holder of any mortgage or deed of trust covering the Premises whose name and address have been furnished to Tenant in writing, specifying the respects in which Landlord has failed to perform such obligation, and such holder fails to perform such obligation with.in a second thirty (30) day period commencing on the expiration of such first thirty (30) day period. [f the nature of such obligation is such that more than thirty (30) days are reasonably required for performance or cure. Landlord will not be in default if Landlord or such holder commences performance within their respective thirty (30) clay periods and after such commencement diligently prosecutes the same to completion. In no event may Tenant terminate this Lease or withhold the payment of rent or other charges provided for in this Lease as a result of Landlord’s default.

 

16. Expiration or· Termination.

 

16.1. Surrender of Premises. On the expiration of the Term or sooner termination of this Lease, Tenant will, at Tenant’s sole cost, promptly and peaceably surrender the Premises to Landlord in good order and condition, and deliver all keys to the Premises to Landlord. All personal property, trade fixtures and other property then located on the Premises will remain on the Premises and may be used, sold or otherwise disposed of by Landlord. No sun-ender of the Premises will be effected by Landlord’s acceptance of the keys or of the rent or by any other means without Landlord’s written acknowledgement of such acceptance as a surrender. All accounts receivable and accounts payable will be allocated between Landlord and Tenant as of the date of the expiration of the Term or sooner termination of this Lease, and Landlord and Tenant will each cooperate with the other in such allocation and the related payment and collection.

 

16.2. Holding Over. Tenant will indemnify, defend and hold harmless Landlord from and against all claims, liabilities and expenses, including attorneys’ fees, resulting from delay by Tenant in surrendering the Premises in accordance with the provisions of this Lease. If Tenant remains in possession of the Premises after the expiration of the Tern, or sooner termination of this Lease with the prior written consent of Landlord, such occupancy will be a tenancy from month to month at a rental (and not as a penalty) in the amount of one hundred fifty percent ( l 50%) of the last monthly rental, plus all other charges payable under this Lease, and on all of the terms of this Lease applicable to a month to month tenancy.

 

16.3. Survival. The provisions of this Paragraph 16 will survive the expiration of the Term or sooner termination of this Lease.

 

9

 

 

17. Estoppel Certificate. Tenant will, within ten (10) days after Landlord’s request, execute and deliver to Landlord an estoppel certificate in favor of Landlord and such other persons as Landlord will request setting forth the following: (a) a ratification of this Lease; (b) the Commencement Date and Expiration Date; (c) that this Lease is in full force and effect and has not been assigned, modified, supplemented or amended (except by such writing as will be stated); (d) that all conditions under this Lease to be performed by Landlord have been satisfied, or, in the alternative, those claimed by Tenant to be unsatisfied; (e) that no defenses or offsets exist against the enforcement of this Lease by Landlord. or, in the alternative. those claimed by Tenant to exist; (t) the amount of advance rent, if any (or none if such is the case), paid by Tenant; (g) the date to which rent has been paid: and (h) such other information as Landlord may request. Landlord ·s mortgage lenders and purchasers will be entitled to rely on any estoppel certificate executed by Tenant.

 

18. General Provisions.

 

18.1. No Partnership. landlord does not by this Lease, in any way or for any purpose, become a partner or joint venturer of Tenant in the conduct of Tenant’s business or otherwise.

 

18.2. Force Majeure If either Landlord or Tenant is delayed or hindered in or prevented from the performance of any act required under this Lease by reason of acts of God, strikes, lockouts, other labor troubles, inability to procure labor or m::tterials, fire, accident, failure of power, restrictive governmental laws. ordinances, regulations or requirements of general applicability, riots, civil commotion, insurrection, war or other reason not the fault of the party delayed, hindered or prevented and beyond the control of such party (financial inability excepted), performance of the action in question will be excused for the period of delay and the period for the performance of such act will be extended for a period equivalent to the period of such delay. The provisions of this Paragraph, will not, however, operate to excuse Tenant from the prompt payment of rent or any other amounts required to be paid under this Lease.

 

18.3. Notices. Any notice or demand to be given by Landlord or Tenant to the other will be given in writing by personal service, telegram, express mail, Federal Express, DHL or any other similar form of collier or delivery service, or mailing in the United States mail, postage prepaid, certified, return receipt requested and addressed to such party as set forth ar the outset of this Lease. Either Landlord or Tenant may change the address at which such patty desires to receive notice on written notice of such change to the other party. Any such notice will be deemed to have been given, and will be effective, on delivery to the notice address then applicable for the party to which the notice is directed: provided, however, that refusal to accept delivery of a notice or the inability to deliver a notice because of an address change which was not properly communicated will not defeat or delay the giving of a notice.

 

18.4. Severability. If any provision of this Lease or the application of any provision of this Lease to any person or circumstance will to any extent be invalid, the remainder of this Lease or the application of such provision to persons or circumstances other than those as to which such provision is held invalid will not be affected by such invalidity. Each provision of this Lease will be valid and enforceable to the fullest extent permitted by law.

 

18.5. Brokerage Commissions. Except as agreed in writing by Landlord, Tenant represents and warrants that no claims exist for brokerage commissions or finder’s f.;:es in connection with this Lease and agrees to indemnify, defend and hold harmless Landlord from and against all claims, liabilities and expenses, including attorneys’ fees, arising from any such brokerage commissions or finder’s fees.

 

18.6. Use of Pronouns. The use of the neuter singular pronoun to refer to Landlord or Tenant will be deemed a proper reference even though Landlord or Tenant may be an individual, partnership, association, limited liability company, corporation or a group of two or more individuals, partnerships, associations, limited liability companies or corporations. The necessary grammatical changes required to make the provisions of this Lease apply in the plural sense where more than one Landlord or Tenant exists and to individuals, partnerships, associations, limited liability companies, corporations, males or females, will in all instances be assumed as though in each case fully expressed.

 

18.7. Successors. Except as otherwise provided in this Lease, all provisions contained in this Lease wilt be binding on and will inure to the benefit of Landlord and Tenant and their respective successors and assigns. On any sale or assignment (except for purposes of security or collateral) by Landlord of the Premises or this Lease, Landlord will, on and after such sale or assignment, be relieved entirely of all of Landlord’s obligations under this Lease and such obligations wilt, as of the time of such sale or assignment, automatically pass to Landlord’s successor in interest.

 

10

 

 

18.8. Recourse bv Tenant. Anything in this Lease to the contrary notwithstanding, Tenant will look solely to the equity of Landlord in the Premises, subject to the prior rights of the holder of any mortgage or deed of trust, for the collection of any judgment (or other judicial process) requiring the payment of money by Landlord on any default or breach by Landlord with respect to any of the terms. covenants and conditions of this Lease to be observed or performed by Landlord, and no other asset of Landlord or any other person will be subject to levy, execution or other procedure for the satisfaction of Tenant’s remedies.

 

18.9. Quiet Enjoyment. On Tenant paying the rent payable under this Lease land observing and performing all of the terms, covenants and conditions on Tenant’s part to be observed and performed under this Lease, Tenant will have quiet enjoyment of the Premises for the Term without interference from Landlord, or anyone claiming by, through or under Landlord, subject to all of the provisions of this Lease.

 

18.10. Waiver. No failure by any party to insist on the strict performance of any covenant, duty or condition of this Lease or to exercise any right or remedy consequent on a breach of this Lease will constitute a waiver of any such breach or of such or any other covenant, duty or condition. Any party may, by notice delivered in the manner provided in this Lease, but will be: under no obligation to. waive any of its rights or any conditions to its obligations under this Lease, or any covenant or duty of any other party. No waiver will affect or alter the remainder of this Lease but each other covenant. duty and condition of this Lease will continue in full force and effect with respect to any other then existing or subsequently occurring breach.

 

18.11. Rights and Remedies. The rights and remedies of Landlord and Tenant will not be mutually exclusive and the exercise of one or more of the provisions of this Lease will not preclude the exercise of any other provisions. The parties confirm that damages at law may be an inadequate remedy for a breach or threatened breach by any patty of any of the provisions of this Lease. The parties’ respective rights and obligations under this Lease will be enforceable by specific performance, injunction or any other equitable remedy.

 

18.12. Authorization. Each individual executing this Lease does represent and warrant to each other so signing (and each other entity for which another person may be signing) that he has been duly authorized to deliver this Lease in the capacity and for the entity set forth where he signs.

 

18.13. Attorneys’ Fees. If any action is brought to recover any rent or other amount under this Lease because of any default under this Lease, to enforce or interpret any of the provisions of this Lease, or for recovery of possession of the Premises, the party prevailing in such action will be entitled to recover from the other party reasonable attorneys’ fees (including those incurred in connection with any appeal), the amount of which will be fixed by the court and made a part of any judgment rendered. Tenant will be responsible for all expenses, including, without limitation, attorneys’ fees, incurred by Landlord in any case or proceeding involving Tenant or any assignee or subtenant of Tenant under or related to any bankruptcy or insolvency law. The foregoing provisions of this Paragraph 18.13 will survive the expiration of the Term or sooner termination of this Lease.

 

18.14. Merger. The surrender of this Lease by Tenant, the cancellation of this Lease by agreement of Landlord and Tenant or the termination of this Lease on account of Tenant’s default will not work a merger, and will, at Landlord’s option, either terminate any subleases of part or all of the Premises or operate as an assignment to Landlord of any of those subleases. Landlord’s option under this Paragraph 18.14 may be exercised by notice to Tenant and all known subtenants in the Premises.

 

18.15. Miscellaneous. The captions to the Paragraphs of this Lease are for convenience of reference only and will not be deemed relevant in resolving questions of construction or interpretation under this Lease. Tenant will not record this Lease or a memorandum or notice of this Lease without the prior written consent of Landlord. This Lease constitutes the entire agreement between the parties. No amendment to this Lease will be binding on Landlord or Tenant unless reduced to writing and signed by both parties. Unless otherwise set forth in this Lease, all references to Paragraphs are to Paragraphs in this Lease. Each provision to be performed by Tenant will be construed to be both a covenant and a condition. This Lease will be governed by and construed and interpreted in accordance with the laws of the state in which the Premises are located. LANDLORD AND TENANT WAIVE TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY EITHER OF THEM AGAINST THE OTHER ON ALL MATTERS ARISING OUT OF THIS LEASE OR THE USE AND OCCUPANCY OF THE PREMISES. Time is of the essence of each provision of this Lease.

 

11

 

 

LANDLORD AND TENANT have executed this Lease on the respective dates set forth below, to be effective as of the date first set forth above.

 

  LANDLORD:
  YESCO Properties LLC
   
  By:  
  Name:  
  Its:  
   
  Date: Jul 5, 2018
   
  TENANT:
  Co-Diagnostics
   
  By:  
  Name:  
  Its:  
   
  Date: 6/29/18

 

12

 

 

ADDENDUM #1

TO

LEASE AGREEMENT

 

That certain Lease Agreement dated        June 5, 2018        between YESCO Properties LLC, a Utah limited liability company (“Landlord”) and Co-Diagnostics, Inc. (“Tenant”) (the “Lease”) is by this Addendum #1 to the Lease (this “Addendum”) amended. Capitalized terms not defined in this Addendum shall have the meaning as set forth in the Lease. Notwithstanding any provision of the Lease to the contrary, the following provisions control:

 

1.Tenant acknowledges that Landlord never approved the Sublease Agreement between Tenant and Isomeric Pharmacy Solutions, LLC (“Isomeric”), which was required by the terms of the lease between Landlord and Isomeric. Due to continuing events of default under Landlord’s lease with Isomeric, Landlord is exercising its right under its lease with Isomeric to declare any sublease between Isomeric and Tenant void from the beginning.

 

2.Landlord agrees that all payments previously made pursuant to the sublease between Tenant and Isomeric shall be deposited towards Tenant’s obligations under the Lease.

 

3.Tenant acknowledges that certain office furnishings and lab fixtures situated in the Premises are the property of Isomeric. Tenant agrees that the terms of the use of such furnishings and equipment is a matter between Tenant and Isomeric, and Tenant agrees to hold Landlord harmless from any claims resulting from the use of any property belonging to Isomeric. Tenant acknowledges that it is solely responsible for negotiating an agreement for the use of such property, which includes the items referred on Exhibit A attached hereto. Tenant further acknowledges and agrees that in connection with the settlement of claims between YESCO and Isomeric, Isomeric has agreed to lease the equipment identified on Exhibit A to Tenant for $1,000 for the term of the Lease and that all payments for use of the equipment is payable to Landlord for the remaining term of the Lease. Tenant agrees to pay Landlord $1,000 per month in addition to the Basic Monthly Rent during the Term of the Lease in accordance with such settlement.

 

Except as modified by this Addendum, the Lease remains in full force and effect. This Addendum is effective as of the date of the Lease.

 

Date Signed:_

 

Co-Diagnostics, inc.   YESCO LLC.
     
By:                          By:  
Title:     Title:  
Date Signed:     Date Signed:  

 

13

 EX-10.9.1 7 ex10-9_1.htm

 

Exhibit 10.9.1

 

AMENDMENT #1

TO LEASE

 

That certain Lease with a Commencement Date of February 1, 2018 between YESCO Properties, LLC, a Utah Limited Liability Company (“Landlord”) and Co-Diagnostics, Inc., a Utah Corporation (“Tenant”) (the “Lease”) as amended by that First Lease Addendum dated June 5, 2018, is by this Amendment #1 to the Lease (this “Amendment”) modified. This Amendment is dated March 26, 2020. Capitalized terms not defined in this Addendum shall have the meaning as set forth in the Lease. Notwithstanding any provision of the Lease to the contrary, the following provisions control:

 

Expiration Date: February 29, 2024.

 

Basic Monthly Rent:

 

Period  Rentable Square Feet   Basic Monthly Rent   Less: Monthly Settlement
Discount		 
March 1, 2020  Through  March 31, 2020   10,213   $19,689.92   ($1,822.92)
April I, 2020  Through  February 28, 2021   13,687   $24,900.92   ($1,822.92)
March I, 2021  Through  February 28, 2022   13,687   $25,647.95   ($1,822.92)
March 1, 2022  Through  February 28, 2023   13,687   $26,417.39   ($1 822.92)
March 1, 2023  Through  February 29, 2024   13,687   $27,209.91   ($1,822.92)

 

Additional Space: Commencing on April 1, 2020, Tenant agrees to rent additional space as described on Exhibit A.

 

Settlement Agreement: Landlord and Tenant are entering into a settlement agreement with Isomeric Pharmacy Solutions, LLC (“Isomeric) in connection with th.is Amendment. Pursuant to the settlement agreement, Isomeric is transferring all of its property located at the Premises in exchange for a payment of $175,000.00 from Tenant to Isomeric. Landlord and Tenant agree to distribute the Isomeric property as follows: I) Tenant will have all right, title and interest to the items referenced on Exhibit B; 2) Landlord has all right, title, and interest in the items referenced on Exhibit C; and 3) If Landlord sells the items referenced on Exhibit D, 100% of the proceeds go to the Landlord. Landlord agrees not to disrupt current production in the removal of items to be sold. If Tenant is able to sell the items referenced on Exhibit D prior to the Expiration Date it will distribute one-half of the proceeds to Landlord.

 

In consideration of Tenant’s settlement payment to Isomeric, so long as Tenant timely and completely fulfils its obligations under the Lease and this Amendment, Landlord agrees to discount the Basic Monthly Rent by $1,822.92 each month. In the event that Tenant defaults in any of its obligations under the Lease and this Amendment, no further credit, abatement, or accommodation will be provided by Landlord and Tenant shall be liable for the remaining Basic Monthly Rent without discount and the items referenced on Exhibit B shall become the sole property of Landlord.

 

Except as modified by this Amendment, the Lease remains in full force and effect.

 

Co-Diagnostics, Inc., a Utah Corporation   YESCO Properties, LLC
         
By:                 By:                  

         
Title:            Title:

 

Date Signed:     Date Signed:

 

 

 EX-10.9.2 8 ex10-9_2.htm

 

Exhibit 10.9.2

 

AMENDMENT #2

TO

LEASE

 

That certain Lease with a Commencement Date of February 1, 2018 between YESCO Properties; LLC, a Utah Limited Liability Company (“Landlord”) and Co-Diagnostics, Inc., a Utah Corporation (“Tenant”) (the “Lease”) as amended by that First Lease Addendum dated June 5, 2018, and Amendment to Lease #1 dated March 26, 2020 (Amendment #1) is by this Amendment #2 to the Lease (this “Amendment”) modified. This Amendment is dated May 26; 2020. Capitalized terms not defined in this Addendum shall have the meaning as set forth in the Lease. Notwithstanding any provision of the Lease to the contrary, the following provisions control:

 

Additional Space: Commencing on June 1, 2020 and until August 31, 2020, Tenant agrees to rent additional space as described on Exhibit A. Rent will increase $1860.37 a month.

 

Basic Monthly Rent included in Amendment #1 and this Amendment:

 

Period  Rentable Square Feet   Basic Monthly Rent   Less: Monthly
Settlement Discount		   Monthly Amount
Due		 
March l, 2020  Through  March 31, 2020   10,213   $19,689.92   ($1,822.92)  $17,867.00 
April 1, 2020  Through  February 28, 2021   13,687   $24,900.92   ($1,822.92)  $23,078.00 
June 1, 2020  Through  August 31, 2020   14,658   $26,761.29   ($1,822.92)  $24,938.37 
September 1, 2020  Through  February 28, 2021   13,687   $24,900.92   ($1,822.92)  $23,078.00 
March l, 2021  Through  February 28, 2022   13,687   $25,647.95   ($1,822.92)  $23,825.03 
March I, 2022  Through  February 28, 2023   13,687   $26,417.39   ($1,822.92)  $24,594.47 
March 1, 2023  Through  February 29, 2024   13,687   $27,209.91   ($1,822.92)  $25,386.99 

 

Except as modified by this Amendment, the Lease and Amendment #1 remain in full force and effect.

 

Co-Diagnostics, Inc., a Utah Corporation   YESCO Properties, LLC
         
By:                 By:                  

         
Title:            Title:

 

Date Signed:     Date Signed:

 

 

 EX-21.1 9 ex21-1.htm

 

Exhibit 21.1

 

List of Subsidiaries

 

LIST OF SUBSIDIARIES

 

Co-Diagnostics, Inc. (the “Company”) has the following direct and indirect subsidiaries:

 

Subsidiary Name  Jurisdiction of Formation   Percentage of Ownership 
         
DNA Logix, Inc.   Utah    100%
           
Idaho Molecular, Inc.   Idaho    100%
           
Advanced Conceptions, Inc.   Utah    100%

 

 

 EX-23.1 10 ex23-1.htm

 

EXHIBIT 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in Registration Statements No. 333-226835 and 333-249651 on Form S-3 and 333-237684 on Form S-8 of Co-Diagnostics, Inc. of our report dated March 24, 2022, relating to our audits of the consolidated financial statements which appear in this Annual Report on Form 10-K of Co-Diagnostics, Inc. for the years ended December 31, 2021 and 2020.

 

Haynie & Company

Salt Lake City, Utah

March 24, 2022

 

 

 

 EX-31.1 11 ex31-1.htm

 

EXHIBIT 31.1

 

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13A-14 OF THE EXCHANGE ACT OF 1934

 

CERTIFICATION

 

I, Dwight Egan, certify that:

 

1. I have reviewed this annual report on Form 10-K of Co-Diagnostics, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 24, 2022 /s/ Dwight Egan
  Dwight Egan
  Chief Executive Officer, President and Principal Executive Officer

 

 

 

 EX-31.2 12 ex31-2.htm

 

EXHIBIT 31.2

 

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13A-14 OF THE EXCHANGE ACT OF 1934

 

CERTIFICATION

 

I, Brian Brown, certify that:

 

1. I have reviewed this annual report on Form 10-K of Co-Diagnostics, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:

 

  a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 24, 2022 /s/ Brian Brown
  Brian Brown
  Chief Financial Officer and Principal Financial and Accounting Officer

 

 

 

 EX-32.1 13 ex32-1.htm

 

EXHIBIT 32.1

 

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S. C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Co-Diagnostics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dwight Egan, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

(1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 24, 2022 /s/ Dwight Egan
  Dwight Egan
  Chief Executive Officer, President and Principal Executive Officer

 

 

 

 EX-32.2 14 ex32-2.htm

 

EXHIBIT 32.2

 

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S. C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Co-Diagnostics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Brian Brown, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

 

(1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and
   
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 24, 2022 /s/ Brian Brown
  Brian Brown
  Chief Financial Officer and Principal Financial and Accounting Officer

 

 

 

 EX-101.SCH 15 codx-20211231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statement of Changes in Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statements of cash Flows link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Overview and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Earnings per Share link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Business Combinations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Schedule of Assets and Liabilities assumed (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Business Combinations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Schedule of Fair Value Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Schedule of Changes in Fair Value Measurement (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Schedule of Contingent Consideration Common Stock and Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Schedule of Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Summary of Revenue by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Schedule of Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Stockholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Schedule of Basic and Diluted Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Earnings per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Schedule of Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Schedule of Fair Value of Options Weighted Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Schedule of Outstanding Restricted Stock Units and Related Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Schedule of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Schedule of Fair Value of Warrants Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Schedule of Recognized Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Schedule of Components Income Tax Provision (Details) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Schedule of Benefit from Income Taxes and Effective Tax Rates (Details) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Schedule of Deferred Tax Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Schedule of Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - Schedule of Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 16 codx-20211231_cal.xml XBRL CALCULATION FILE EX-101.DEF 17 codx-20211231_def.xml XBRL DEFINITION FILE EX-101.LAB 18 codx-20211231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Convertible Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Sale of Stock [Axis] IPO [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Customer [Axis] Two Customers Together [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Accounts Receivable [Member] Business Acquisition [Axis] Advanced Conceptions, Inc. and Idaho Molecular, Inc. [Member] Advanced Conceptions Inc [Member] Measurement Frequency [Axis] Fair Value, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value By Fair Value Hierarchy Level Ax [Axis] Measurement Input Type [Axis] Measurement Input, Share Price [Member] Measurement Input Strike Price [Member] Measurement Input, Price Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Term [Member] Measurement Input Cost of Capital [Member] Measurement Input, Discount Rate [Member] Measurement Input Equity Volatility [Member] Measurement Input Asset Volatility [Member] Measurement Input Revenue Volatility [Member] Long-Lived Tangible Asset [Axis] Equipment [Member] Leaseholds and Leasehold Improvements [Member] Leasehold Improvements [Member] Office Equipment [Member] Finite-Lived Intangible Assets by Major Class [Axis] In Process Research and Development [Member] Noncompete Agreements [Member] Geographical [Axis] Americas [Member] Rest of World [Member] Geographic Concentration Risk [Member] Options [Member] Title of Individual [Axis] Third Parties [Member] Common Stock Three [Member] Common Stock One [Member] Common Stock Two [Member] Antidilutive Securities [Axis] Warrant [Member] Product and Service [Axis] Investment Relations Services [Member] Plan Name [Axis] 2015 Long Term Incentive Plan [Member] Award Type [Axis] Stock Options [Member] Restricted Stock Units (RSUs) [Member] Restricted Stock [Member] Measurement Input, Option Volatility [Member] Measurement Input, Expected Dividend Rate [Member] Share-based Payment Arrangement, Option [Member] Share-based Payment Arrangement [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Exclusive License Agreement [Member] Dr. Brent Satterfield [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] Assets Current assets Cash and cash equivalents Marketable investment securities Accounts receivable, net Inventory Prepaid expenses Note receivable Total current assets Property and equipment, net Goodwill Intangible assets, net Investment in joint venture Deferred tax asset Note receivable Total assets Liabilities and stockholders’ equity Current liabilities Accounts payable Accrued expenses, current Accrued expenses (related party), current Contingent consideration liabilities, current Income taxes payable Deferred revenue Total current liabilities Long-term liabilities Income taxes payable Deferred tax liability Contingent consideration liabilities Accrued expenses (related party), noncurrent Total long-term liabilities Total liabilities Commitments and contingencies (Note 14) Stockholders’ equity Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2021 and December 31, 2020 Common stock, $0.001 par value; 100,000,000 shares authorized; 33,819,862 and 28,558,033 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively Additional paid-in capital Accumulated earnings Total stockholders’ equity Total liabilities and stockholders’ equity Convertible preferred stock, par value Convertible preferred stock , shares authorized Convertible preferred stock, shares issued Convertible preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Cost of revenue Gross profit Operating expenses Sales and marketing General and administrative Research and development Depreciation and amortization Total operating expenses Income from operations Other income (expense) Interest income Loss on disposition of assets Gain (loss) on equity method investment in joint venture Total other income (expense) Income before income taxes Income tax provision Net income Earnings per common share: Basic Diluted Weighted average shares outstanding: Basic Diluted Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares Public offering, net of offering costs of $1,457,922 Public offering, net of offering costs, shares Common stock issued for warrant exercises Common stock issued for warrant exercises, shares Common stock issued for option exercises Common stock issued for option exercises, shares Stock-based compensation expense Stock-based compensation expense, shares Conversion of preferred stock to common Conversion of preferred stock to common, shares Common stock issued for acquisitions Common stock issued for acquisitions, shares Net income Ending balance, value Ending balance, shares Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Public offering costs Statement of Cash Flows [Abstract] Cash flows from operating activities Adjustments to reconcile net income to cash used in operating activities: Stock-based compensation expense Loss (gain) from equity method investment Loss on disposition of assets Deferred income taxes Bad debt expense Changes in assets and liabilities: Accounts receivable Prepaid expenses Inventory Deferred revenue Income taxes payable Accounts payable and accrued expenses Net cash provided by operating activities Cash flows from investing activities Purchases of property and equipment Purchases of marketable investment securities Proceeds from maturities of marketable investment securities Investment in joint venture Business combinations, net of cash acquired Net cash provided by (used in) investing activities Cash flows from financing activities Proceeds from sale of common stock Proceeds from exercise of options and warrants Payment of offering costs Net cash provided by financing activities Net increase in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of cash flow information Interest paid Income taxes paid Supplemental disclosure of non-cash investing and financing transactions Inventory moved to property, plant and equipment Fair value of common stock issued as consideration for business acquisitions Fair value of contingent common stock and warrants issued as consideration for business acquisitions Accounting Policies [Abstract] Overview and Basis of Presentation Summary of Significant Accounting Policies Business Combination and Asset Acquisition [Abstract] Business Combinations Fair Value Disclosures [Abstract] Fair Value Measurements Property, Plant and Equipment [Abstract] Property and Equipment Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Payables and Accruals [Abstract] Accrued Expenses Revenue from Contract with Customer [Abstract] Revenue Equity [Abstract] Stockholders’ Equity Earnings Per Share [Abstract] Earnings per Share Share-based Payment Arrangement [Abstract] Stock-Based Compensation Income Tax Disclosure [Abstract] Income Taxes Related Party Transactions [Abstract] Related Party Transactions Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Reclassifications Cash and Cash Equivalents Marketable Investment Securities Accounts Receivable Equity-Method Investments Inventory Property and Equipment Business Combinations Revenue Recognition Deferred Revenue Research and Development Stock-based Compensation Income Taxes Net Income per Share Concentrations Risk and Significant Customers Recently Issued Accounting Standards Schedule of Assets and Liabilities assumed Schedule of Fair Value Assets and Liabilities Schedule of Changes in Fair Value Measurement Schedule of Contingent Consideration Common Stock and Warrants Schedule of Property and Equipment Schedule of Intangible Assets Schedule of Future Amortization Expense Schedule of Accrued Expenses Summary of Revenue by Geographic Area Schedule of Deferred Revenue Schedule of Basic and Diluted Earnings Per Share Schedule of Option Activity Schedule of Fair Value of Options Weighted Average Assumptions Schedule of Outstanding Restricted Stock Units and Related Activity Schedule of Warrant Activity Schedule of Fair Value of Warrants Assumptions Schedule of Recognized Stock-based Compensation Expense Schedule of Components Income Tax Provision Schedule of Benefit from Income Taxes and Effective Tax Rates Schedule of Deferred Tax Assets Schedule of Unrecognized Tax Benefits Schedule of Future Minimum Lease Payments Schedule of Product Information [Table] Product Information [Line Items] Accounts receivable Doubtful accounts Inventory finished goods Inventory raw materials Estimated useful life of property Research and development costs Concentration risk percentage Stock issued during period, value acquisitions Payable to shareholders Fair value of contingent shares Fair value of contingent warrants Business combination, consideration transferred Cash Accounts receivables Prepaid expenses and other current assets Property and equipments Research and development in process Non competition agreements Accounts payable and accrued other expenses Deferred tax liability Total indentifiable net assets Total Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Number of shares exchanged Number of shares on contingent consideration Warrants to purchase shares of common stock General and administrative expense Equity method investment ownership percentage Finite lived intangible assets remaining amortization period Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] FairValueByFairValueHierarchyLevelAxAxis [Axis] Marketable securities (certificates of deposit) Total assets measured at fair value Contingent consideration common stock Contingent consideration warrants Total liabilities measured at fair value Asset acquisition contingent consideration liability noncurrent Contingent considered issued for business acquisitions Asset acquisition contingent consideration liability noncurrent Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Warrants measurement input Warrants measurement, term Business combination,contingent consideration Business combination,contingent consideration, term Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property and equipment estimated useful lives Property and equipment, gross Less: accumulated depreciation Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Estimated useful lives in years, term Intangible assets, gross Estimated useful lives in years Less accumulated amortization 2022 2023 2024 Total Payroll liabilities Distributor commissions Sales tax payable Other accrued liabilities Total accrued expenses Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Revenue Percentage of revenue Deferred revenue, beginning balance Revenue recognized included in deferred revenue balance at the beginning of the period Increase due to prepayments from customers Increase due to note receivable Decrease due to refunds to customers and application to open balances Deferred revenue, Ending balance Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Number of shares issued for exercise of options Number of shares issued for exercise of options, value Number of shares issued for services Vest and restricted stock units Stock Issued During Period, Shares, Acquisitions [custom:StockIssuedDuringPeriodSharesForfeited] Number of common stock issued Sale of common stock purchase price per shares Issuance of common stock gross proceeds Net proceeds from issuance of common stock Offering costs Potentially dilutive shares Net income, as reported Weighted average shares, basic Dilutive effect of stock options, warrants and RSUs Shares used to compute diluted earnings per share Basic earnings per share Diluted earnings per share Securities excluded from computation of diluted earnings per share Number of Options Outstanding, Beginning Weighted Average Exercise Price Outstanding, Beginning Weighted Average Fair Value Outstanding, Beginning Number of Options Outstanding, Granted Weighted Average Exercise Price Granted Weighted Average Fair Value Granted Number of Options Outstanding, Expired Weighted Average Exercise Price Expired Weighted Average Fair Value Expired Number of Options Outstanding, Forfeited/Cancelled Weighted Average Exercise Price Forfeited/Cancelled Weighted Average Fair Value Forfeited/Cancelled Number of Options Outstanding, Exercised Weighted Average Exercise Price Exercised Weighted Average Fair Value Exercised Number of Options Outstanding, Ending Weighted Average Exercise Price Outstanding, Ending Weighted Average Fair Value Outstanding, Ending Weighted-average Remaining Contractual Life (years) Outstanding, Ending Number of Options Exercisable Ending Weighted Average Exercise Price, Exercisable Ending Weighted Average Fair Value, Exercisable Ending Weighted-average Remaining Contractual Life (years), Exercisable Ending Risk-free interest rate Expected life (years) Expected volatility Expected dividend yield Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Restricted Stock Units, Outstanding Beginning Weighted Average Grant Date Fair Value, Outstanding Beginning Number of Restricted Stock Units, Granted Weighted Average Grant Date Fair Value, Granted Number of Restricted Stock Units, Vested Weighted Average Grant Date Fair Value, Vested Number of Restricted Stock Units, Forfeited/Cancelled Weighted Average Grant Date Fair Value, Forfeited/Cancelled Number of Restricted Stock Units, Outstanding Ending Weighted Average Grant Date Fair Value, Outstanding Ending Number of Warrants Outstanding, Beginning Weighted Average Exercise Price, Beginning Weighted Average Fair Value, Beginning Number of Warrants Outstanding, Granted Weighted Average Exercise Price, Granted Weighted Average Fair Value, Granted Number of Warrants Outstanding, Expired Weighted Average Exercise Price, Expired Weighted Average Fair Value, Expired Number of Warrants Outstanding, Forfeited/Cancelled Weighted Average Exercise Price, Forfeited/Cancelled Weighted Average Fair Value, Forfeited/Cancelled Number of Warrants Outstanding, Exercised Weighted Average Exercise Price, Exercised Weighted Average Fair Value, Exercised Weighted-average Remaining Contractual Life (Years) Outstanding, Beginning Number of Warrants Outstanding, Ending Weighted Average Exercise Price, Ending Weighted Average Fair Value, Ending Weighted-average Remaining Contractual Life (Years) Outstanding, Ending Warrants outstanding, measurement input Warrants, expected life Total stock-based compensation expense Aggregate number of common shares reserved Number of common shares availalble for issuance Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Intrinsic value of options outstanding Unvested options Unrecognized stock-based compensation Unrecognized stock-based compensation recognition period Intrinsic value of warrants exercised Warrants exercisable Warrants purchase Current: Federal State Total current Deferred: Federal State Total deferred Total income tax expense Federal income tax expense at statutory rate State income tax expense, net of federal tax benefit Permanent differences: - Foreign derived intangible income deduction - Stock based compensation - Other permanent differences Research and development credits Change in uncertain tax positions Change in valuation allowance Other Effective income tax rate Deferred tax assets: Accrued liabilities Reserves and allowances Deferred compensation Research and development credits Total deferred tax assets Deferred tax liabilities: Property and equipment, net Intangibles, net Prepaids Other Total deferred tax liabilities Net deferred tax assets (liabilities) Less valuation allowance Net deferred tax assets (liabilities) Net deferred tax assets (liabilities) Unrecognized tax benefits at the beginning of the year Gross increases - current year tax positions Gross increases - prior year tax positions Gross decreases- prior year tax positions Unrecognized tax benefits at end of year Interest and penalities in year- end balance Net operating loss carry-forwards Research and development credit carry forwards Deferred tax valuation allowance Unrecognized tax benefits that would impact effective tax rate Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Accrued royalties Payment for royalties per month Due to related party 2022 2023 2024 Total lease payments Operating lease, term Area of land Payments for rent Lease expiration date Rent expenses Subsequent Event [Table] Subsequent Event [Line Items] Employee stock purchase plan Rest of World [Member] Increase due to prepayments from customers. Increase due to note receivable. Decrease due to refunds to customers and application to open balances. Options [Member] Payments to acquire interest in joint ventures. Proceeds from exercise of options and warrants. Non cash or part non cash inventory moved to property plant and equipment. Third Parties [Member] Investment Relations Services [Member] Fair value of contingent common stock and warrants issued as consideration for business acquisitions. Net proceeds from issuance of common stock. Common Stock One [Member] Two Customers Together [Member] Common Stock Two [Member] Idaho Molecular [Member] Advanced Conceptions [Member] Weighted average number of basic shares outstanding. Earnings basic per share. 2015 Long Term Incentive Plan [Member] Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercised. Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercisable. Stock Options [Member] Business combination recognized identifiable assets acquired and liabilities non competition agreements. Payments to share holders value acquisitions. Weighted average exercise price, beginning. Fair value of contingent consideration to common stock. Fair value by fair value hierachy level axis. Weighted Average Fair Value, Beginning. Weighted Average Exercise Price, Granted. Weighted Average Fair Value, Forfeited/Cancelled. Fair value of contigent consideration to warrants. Weighted average price at which grantees could have acquired the underlying shares with respect to non-options of the plan that expired. Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercised. Weighted Average Exercise Price, Forfeited/Cancelled. Weighted Average Exercise Price, Forfeited/Cancelled. Weighted Average Fair Value, Exercised. Contingent considered issued for business acquisitions. Weighted average price at which grantees can acquire the shares reserved for issuance under the non-option plan. Share-based compensation arrangement by share-based payment award, non-option, granted in period, weighted average exercise price. Weighted-average Remaining Contractual Life (Years) Outstanding, Beginning. Weighted-average Remaining Contractual Life (Years) Outstanding, Ending. Measurement Input Strike Price [Member] Intrinsic value of warrants exercised. Measurement Input Cost of Capital [Member] Schedule of Fair Values Warrants Assumptions [Table text block] Measurement Input Equity Volatility [Member] Measurement Input Asset Volatility [Member] Measurement Input Revenue Volatility [Member] Advanced Conceptions, Inc. and Idaho Molecular, Inc. [Member] Stock issued during period shares contingent consideration. Class of warrant exercisable. Advanced Conceptions Inc [Member] Stock issued during period shares issued for vest and restricted stock units. Taxes payable non current. Indefinite lived intangible asset useful life. Common Stock Three [Member] Effective income tax rate reconcilation foreign derived intangible income deduction. Effective income tax rate reconciliation change in valuation allowance. Exclusive License Agreement [Member] Dr. Satterfield [Member] Dr. Brent Satterfield [Member] Value of input, expected term used to measure contingent consideration liability from business combination. Number of shares forfeited during period. Number of share options (or share units) exercised during the current period. Assets, Current Accounts Receivable, after Allowance for Credit Loss, Noncurrent Assets [Default Label] Liabilities, Current TaxesPayableNoncurrent Liabilities, Noncurrent Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Weighted Average Number of Shares Outstanding, Basic Shares, Outstanding Share-based Payment Arrangement, Noncash Expense Gain (Loss) on Sale of Investments Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense Increase (Decrease) in Inventories Increase (Decrease) in Contract with Customer, Liability Increase (Decrease) in Income Taxes Payable Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Payments to Acquire Marketable Securities PaymentsToAcquireInterestInJointVentures Payments to Acquire Businesses, Net of Cash Acquired Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Revenue from Contract with Customer [Text Block] Inventory, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Business Combinations Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Business Combination, Contingent Consideration, Liability, Noncurrent Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Finite-Lived Intangible Assets, Net Revenue from Contract with Customer, Including Assessed Tax Contract with Customer, Liability Contract with Customer, Liability, Revenue Recognized DecreaseDueToRefundsToCustomersAndApplicationToOpenBalances Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price StockIssuedDuringPeriodSharesStockOptionsExercised1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice Current Federal, State and Local, Tax Expense (Benefit) Deferred Federal Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Deferred Federal, State and Local, Tax Expense (Benefit) Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent Deferred Tax Assets, Gross Deferred Tax Liabilities, Property, Plant and Equipment Deferred Tax Liabilities, Intangible Assets Deferred Tax Liabilities, Prepaid Expenses Deferred Tax Liabilities, Other Deferred Tax Liabilities, Gross Deferred Tax Assets, Net of Valuation Allowance Unrecognized Tax Benefits Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Unrecognized Tax Benefits, Income Tax Penalties Accrued Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year Two Lessee, Operating Lease, Liability, to be Paid, Year Three Lessee, Operating Lease, Liability, to be Paid EX-101.PRE 19 codx-20211231_pre.xml XBRL PRESENTATION FILE XML 20 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2021
Mar. 23, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2021    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2021    
Current Fiscal Year End Date --12-31    
Entity File Number 001-38148    
Entity Registrant Name CO-DIAGNOSTICS, INC.    
Entity Central Index Key 0001692415    
Entity Tax Identification Number 46-2609396    
Entity Incorporation, State or Country Code UT    
Entity Address, Address Line One 2401 S. Foothill Drive    
Entity Address, City or Town Salt Lake City    
Entity Address, State or Province UT    
Entity Address, Postal Zip Code 84109    
City Area Code (801)    
Local Phone Number 438-1036    
Title of 12(b) Security Common Stock    
Trading Symbol CODX    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 229,000,000
Entity Common Stock, Shares Outstanding   33,965,318  
ICFR Auditor Attestation Flag false    
Auditor Firm ID 457    
Auditor Name Haynie & Company    
Auditor Location Salt Lake City, Utah    
XML 21 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Current assets    
Cash and cash equivalents $ 88,607,234 $ 42,976,713
Marketable investment securities 1,255,266 4,335,446
Accounts receivable, net 20,839,182 12,136,833
Inventory 2,004,169 7,995,189
Prepaid expenses 2,338,444 369,028
Note receivable 75,000
Total current assets 115,119,295 67,813,209
Property and equipment, net 1,933,216 949,639
Goodwill 14,706,818
Intangible assets, net 27,195,000
Investment in joint venture 1,004,953 1,927,125
Deferred tax asset 547,224
Note receivable 75,000
Total assets 160,034,282 71,237,197
Current liabilities    
Accounts payable 607,506 598,318
Accrued expenses, current 3,859,652 2,849,503
Accrued expenses (related party), current 120,000
Contingent consideration liabilities, current 5,767,304
Income taxes payable 2,213,088 189,729
Deferred revenue 150,000 305,307
Total current liabilities 12,597,550 4,062,857
Long-term liabilities    
Income taxes payable 1,067,853 447,831
Deferred tax liability 7,228,444
Contingent consideration liabilities 4,665,337
Accrued expenses (related party), noncurrent 30,000
Total long-term liabilities 12,961,634 477,831
Total liabilities 25,559,184 4,540,688
Commitments and contingencies (Note 14)
Stockholders’ equity    
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2021 and December 31, 2020
Common stock, $0.001 par value; 100,000,000 shares authorized; 33,819,862 and 28,558,033 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively 33,820 28,558
Additional paid-in capital 80,271,999 49,157,236
Accumulated earnings 54,169,279 17,510,715
Total stockholders’ equity 134,475,098 66,696,509
Total liabilities and stockholders’ equity $ 160,034,282 $ 71,237,197
XML 22 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Convertible preferred stock, par value $ 0.001 $ 0.001
Convertible preferred stock , shares authorized 5,000,000 5,000,000
Convertible preferred stock, shares issued 0 0
Convertible preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 33,819,862 28,558,033
Common stock, shares outstanding 33,819,862 28,558,033
XML 23 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]    
Revenue $ 97,885,603 $ 74,552,758
Cost of revenue 11,574,944 16,591,346
Gross profit 86,310,659 57,961,412
Operating expenses    
Sales and marketing 13,397,813 4,665,113
General and administrative 11,550,615 8,278,734
Research and development 14,961,916 3,185,290
Depreciation and amortization 335,363 138,635
Total operating expenses 40,245,707 16,267,772
Income from operations 46,064,952 41,693,640
Other income (expense)    
Interest income 45,631 97,215
Loss on disposition of assets (44,355) (175)
Gain (loss) on equity method investment in joint venture (430,433) 778,385
Total other income (expense) (429,157) 875,425
Income before income taxes 45,635,795 42,569,065
Income tax provision 8,977,231 90,536
Net income $ 36,658,564 $ 42,478,529
Earnings per common share:    
Basic $ 1.27 $ 1.59
Diluted $ 1.23 $ 1.52
Weighted average shares outstanding:    
Basic 28,874,555 26,720,133
Diluted 29,903,686 28,000,341
XML 24 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statement of Changes in Stockholders' Equity - USD ($)
Convertible Preferred Stock [Member]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2019 $ 26 $ 17,343 $ 26,687,701 $ (24,967,814) $ 1,737,256
Beginning balance, shares at Dec. 31, 2019 25,600 17,342,922      
Public offering, net of offering costs of $1,457,922 $ 7,243 18,004,840 18,012,083
Public offering, net of offering costs, shares   7,242,954      
Common stock issued for warrant exercises $ 857 269,143 270,000
Common stock issued for warrant exercises, shares   856,660      
Common stock issued for option exercises $ 871 1,459,729 1,460,600
Common stock issued for option exercises, shares   871,229      
Stock-based compensation expense $ 111 2,737,930 2,738,041
Stock-based compensation expense, shares   110,935      
Conversion of preferred stock to common $ (26) $ 2,133 (2,107)
Conversion of preferred stock to common, shares (25,600) 2,133,333      
Common stock issued for acquisitions        
Net income 42,478,529 42,478,529
Ending balance, value at Dec. 31, 2020 $ 28,558 49,157,236 17,510,715 66,696,509
Ending balance, shares at Dec. 31, 2020 28,558,033      
Common stock issued for option exercises $ 189 450,209 450,398
Common stock issued for option exercises, shares   189,225      
Stock-based compensation expense $ 444 5,508,960 5,509,404
Stock-based compensation expense, shares   444,050      
Common stock issued for acquisitions $ 4,629 25,155,594 25,160,223
Common stock issued for acquisitions, shares   4,628,554      
Net income 36,658,564 36,658,564
Ending balance, value at Dec. 31, 2021 $ 33,820 $ 80,271,999 $ 54,169,279 $ 134,475,098
Ending balance, shares at Dec. 31, 2021 33,819,862      
XML 25 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statement of Changes in Stockholders' Equity (Parenthetical)
 12 Months Ended
Dec. 31, 2020
USD ($)
Subsidiary, Sale of Stock [Line Items]  
Public offering costs $ 1,457,921
IPO [Member]  
Subsidiary, Sale of Stock [Line Items]  
Public offering costs $ 1,457,922
XML 26 R7.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities    
Net income $ 36,658,564 $ 42,478,529
Adjustments to reconcile net income to cash used in operating activities:    
Depreciation and amortization 335,363 138,635
Stock-based compensation expense 5,509,404 2,738,041
Loss (gain) from equity method investment 430,433 (778,385)
Loss on disposition of assets 44,355 175
Deferred income taxes 930,081 (547,224)
Bad debt expense 69,672 954,804
Changes in assets and liabilities:    
Accounts receivable (8,740,851) (12,960,255)
Prepaid expenses (2,049,095) (6,462)
Inventory 5,705,361 (7,915,241)
Deferred revenue (155,307) 303,984
Income taxes payable 2,643,381
Accounts payable and accrued expenses (299,937) 3,758,634
Net cash provided by operating activities 41,081,424 28,165,235
Cash flows from investing activities    
Purchases of property and equipment (669,463) (774,397)
Purchases of marketable investment securities (9,310,000)
Proceeds from maturities of marketable investment securities 3,080,180 4,974,554
Investment in joint venture 491,739 (714,500)
Business combinations, net of cash acquired 1,196,243
Net cash provided by (used in) investing activities 4,098,699 (5,824,343)
Cash flows from financing activities    
Proceeds from sale of common stock 19,470,005
Proceeds from exercise of options and warrants 450,398 1,730,599
Payment of offering costs (1,457,921)
Net cash provided by financing activities 450,398 19,742,683
Net increase in cash and cash equivalents 45,630,521 42,083,575
Cash and cash equivalents at beginning of period 42,976,713 893,138
Cash and cash equivalents at end of period 88,607,234 42,976,713
Supplemental disclosure of cash flow information    
Interest paid
Income taxes paid 5,403,769
Supplemental disclosure of non-cash investing and financing transactions    
Inventory moved to property, plant and equipment 285,659 117,220
Fair value of common stock issued as consideration for business acquisitions 25,160,223
Fair value of contingent common stock and warrants issued as consideration for business acquisitions $ 10,432,641
XML 27 R8.htm IDEA: XBRL DOCUMENT v3.22.1
Overview and Basis of Presentation
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Overview and Basis of Presentation

Note 1 – Overview and Basis of Presentation

 

Description of Business

 

Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CODX”), is developing robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The Company develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA). In connection with the sale of these tests, the Company may sell diagnostic equipment and supplies from other manufacturers.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include receivables and other long-lived assets, legal and regulatory contingencies, income taxes, share based arrangements, and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates.

 

Basis of Presentation

 

The accompanying audited consolidated financial statements of Co-Diagnostics, Inc. and its wholly owned subsidiaries have been prepared to reflect the financial position, results of operations and cash flows of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated.

 
XML 28 R9.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

 

Reclassifications

 

Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.

 

Cash and Cash Equivalents

 

Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of December 31, 2021 and December 31, 2020. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.

 

Marketable Investment Securities

 

The Company’s marketable investment securities are comprised of investments in certificates of deposit. The Company determines the appropriate classification of its marketable investment securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable investment securities as available-for-sale securities as the Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. As a result, the Company classifies its marketable investment securities, including securities with stated maturities beyond twelve months, within current assets in the consolidated balance sheets. Any unrealized gains or losses are immaterial.

 

Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At December 31, 2021 total accounts receivable was $21,508,779 with an allowance for uncollectable accounts of $669,597 resulting in a net amount of $20,839,182. At December 31, 2020 total accounts receivable was $12,928,633 with an allowance for uncollectable accounts of $791,800 resulting in a net amount of $12,136,833.

 

 

Equity-Method Investments

 

Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.

 

Inventory

 

Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At December 31, 2021, the Company had $2,004,169 in inventory, of which $983,088 was finished goods and $1,021,081 was raw materials. At December 31, 2020, the Company had $7,995,189 in inventory, of which $598,881 was finished goods and $7,396,308 was raw materials. The Company establishes reserves to reduce low-moving, obsolete, or unusable inventories to their estimated useful or scrap values.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.

 

The Company reviews its long-lived assets, including property and equipment, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.

 

Business Combinations

 

We estimate the fair value of assets acquired and liabilities assumed in a business combination. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable, and as a result, actual results may differ from estimates.

 

Revenue Recognition

 

The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation. Based on the criteria above, the Company typically recognizes revenue upon delivery.

 

The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.

 

Deferred Revenue

 

Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.

 

 

Research and Development

 

Research and development costs are expensed when incurred. The Company expensed $14,961,916 and $3,185,290 of research and development costs for the years ended December 31, 2021 and 2020, respectively.

 

Stock-based Compensation

 

The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.

 

Income Taxes

 

The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.

 

Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.

 

Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. While the Company believes it has no significant uncertain income tax positions in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.

 

Net Income per Share

 

Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.

 

Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive

 

Concentrations Risk and Significant Customers

 

The Company had certain customers which are each responsible for generating 10% or more of the total revenue for the years ended December 31, 2021 and 2020. Two customers together accounted for approximately 48% and 38% of total revenue for the years ended December 31, 2021 and 2020, respectively.

 

Two customers each accounted for more than 10% of accounts receivable at December 31, 2021 and 2020. These two customers together accounted for approximately 66% and 48% of accounts receivable at December 31, 2021 and 2020, respectively.

 

 

Recently Issued Accounting Standards

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.

 

As an emerging growth company (“EGC”), the Company has elected to take advantage of the benefits of the extended transition period provided for in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards which allows the Company to defer adoption of certain accounting standards until those standards would otherwise apply to private companies.

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires recognition of leased assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies like us. The Company will use the modified retrospective transition method with the option to recognize a cumulative-effect adjustment at the date of adoption. The Company’s balance sheet will be impacted as it records right-of-use assets and lease liabilities on its consolidated balance sheets, but the Company does not expect the adoption of this standard will have a material impact on its consolidated statements of operations and cash flows.

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for certain financial instruments, which includes the Company’s accounts receivable. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies. The standard requires a cumulative effect adjustment to the balance sheet as of the beginning of the first early reporting period in which the guidance is effective. The Company is evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements but does not expect the adoption of this standard will have a material impact on its consolidated financial statements.

 
XML 29 R10.htm IDEA: XBRL DOCUMENT v3.22.1
Business Combinations
 12 Months Ended
Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]  
Business Combinations

Note 3 – Business Combinations

 

On December 31, 2021, the Company completed its acquisition of Advanced Conceptions, Inc. (“ACI”) and Idaho Molecular Inc. (“IdMo”), which were related entities developing, with the Company, an at-home/point-of-care medical diagnostic device. Upon the completion of the acquisition, all outstanding ACI and Idaho Molecular common stock was exchanged for approximately 3.2 million shares of the Company’s common stock and contingent consideration that includes up to approximately 1.4 million shares and approximately 456,000 warrants to purchase shares of the Company’s common stock. The contingent consideration is based on the achievement of certain milestones, which include regulatory approval for identified products, as well as production and net revenue targets. The purchase consideration also includes a payable to a shareholder of ACI of $100,000. In connection with the acquisition, the Company incurred transaction costs of approximately $151,000, which is included in general and administrative expenses. Upon the completion of the acquisition, both ACI and IdMo became 100% wholly-owned subsidiaries of the Company.

 

 

The fair value of assets acquired and liabilities assumed was based on a preliminary valuation, and our estimates and assumptions are subject to change within the measurement period. The primary area that remains preliminary relates to the evaluation of certain tax-related items and potential minor adjustments to the purchase consideration. The total purchase consideration was allocated to the assets acquired and liabilities assumed as set forth below:

 

Fair value of common shares issued  $25,160,223 
Payable to shareholder   100,000 
Fair value of contingent shares   8,684,669 
Fair value of contingent warrants   1,747,972 
Total fair value of consideration transferred  $35,692,864 
      
Identifiable assets acquired and liabilities assumed     
Cash  $1,196,243 
Accounts receivable   31,170 
Prepaid expenses and other current assets   70,321 
Property and equipment   408,173 
Technology - In-process research and development   26,101,000 
Non-competition agreements   1,094,000 
Accounts payable and accrued other expenses   (1,069,274)
Deferred tax liability   (6,845,587)
Total identifiable net assets   20,986,046 
Goodwill   14,706,818 
Total  $35,692,864 

 

The excess of the purchase price over the net assets acquired was recorded as goodwill. Goodwill generated from the acquisition is primarily attributable to assembled workforce and expected growth from future technologies, sales to future customers and buyer specific synergies. Goodwill will not be amortized but instead will be tested for impairment at least annually and more frequently if certain indicators of impairment are present. As a result of the structure of the transaction, the balance of goodwill is not amortizable for tax purposes.

 

The in-process research and development is considered an indefinite-lived intangible until the completion or abandonment of the research and development activities. The non-competition agreements are being amortized over a range of 1.5 to 3 years.

 

As the acquisition was completed on December 31, 2021, the acquired entities did not contribute to the net revenues or to the net income of the Company during the year ended December 31, 2021. Pro forma revenue and results of operations have not been presented because the historical results of ACI and IdMo are not material to the Company’s consolidated financial statements in any period presented.

 
XML 30 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements

Note 4 – Fair Value Measurements

 

The Company measures and records certain financial assets and liabilities at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

 

The following three levels of inputs are used to measure the fair value of financial assets and liabilities:

 

Level 1: Quoted market prices in active markets for identical assets or liabilities.

 

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

 

Level 3: Unobservable inputs that are not corroborated by market data.

 

 

The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 and December 31, 2020, by level within the fair value hierarchy:

 

   December 31, 2021 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                    
Marketable securities (certificates of deposit)  $-   $1,255,266   $-   $1,255,266 
Total assets measured at fair value  $-   $1,255,266   $-   $1,255,266 
Liabilities:                    
Contingent consideration - common stock  $           -   $      -   $8,684,669   $8,684,669 
Contingent consideration - warrants   -    -    1,747,972    1,747,972 
Total liabilities measured at fair value  $-   $-   $10,432,641   $10,432,641 

 

   December 31, 2020 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                
Marketable securities (certificates of deposit)  $-   $4,335,446   $             -   $4,335,446 
Total assets measured at fair value  $-   $4,335,446   $-   $4,335,446 

 

The Company’s financial instruments that are measured at fair value on a recurring basis consist of certificates of deposit.

 

In connection with the acquisitions of Idaho Molecular, Inc and Advanced Conceptions, Inc. on December 31, 2021, the Company recorded a liability for contingent consideration in the form of shares of common stock and warrants to purchase common stock. The fair value of contingent consideration is calculated using a discounted probability weighted valuation model. Discount rates used in such calculation are a significant assumption that are not observed in the market, and therefore, the resulting fair value represents a Level 3 measurement.

 

The changes for Level 3 items measured at fair value on a recurring basis are as follows:

 

Fair value as of December 31, 2020  $- 
Contingent considered issued for business acquisitions   10,432,641 
Fair value as of December 31, 2021  $10,432,641 

 

The fair value of the contingent consideration is based on the fair value of the contingent consideration-common stock and contingent consideration-warrants. The fair value of the contingent consideration-common stock is equal to the probability-adjusted value of the Company’s common stock as of December 31, 2021. The fair value of the contingent consideration-warrants is equal to the probability adjusted value of a call option with terms consistent with the terms of the warrants as of December 31, 2021. Prior to the probability adjustments, the warrants were valued based on the following inputs:

 

   December 31, 2021 
Stock price  $8.93 
Strike price  $9.13 
Volatility   80.00%
Risk-free rate   1.30%
Expected term   5.0 

 

 

In order to calculate the probability-adjusted value of the contingent consideration-common stock and contingent consideration-warrants, the Company estimated the probability of achieving certain milestones, which include regulatory approval for identified products, as well as production and net revenue targets. The probability of achieving the milestone related to net revenues was estimated using a Monte Carlo simulation valuation model. The unobservable significant inputs to the valuation model were as follows:

 

   December 31, 2021 
Stock price  $8.93 
Risk-free rate   1.30%
Expected term   5.0 
Weighted-average cost of capital   27.00%
Revenue discount rate   9.50%
Equity volatility   80.00%
Asset volatility   80.00%
Revenue volatility   30.00%

 

Fair Value of Other Financial Instruments

 

The carrying amounts of certain financial instruments, including cash held in banks, accounts receivable, notes receivable, accounts payable, accrued liabilities, and other liabilities approximate fair value due to their short-term maturities and are excluded from the fair value tables above.

 
XML 31 R12.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Property and Equipment

Note 5 – Property and Equipment

 

Property and equipment, net consisted of the following:

 

  

Estimated

Useful Lives in

   December 31, 
   years   2021   2020 
Lab equipment   3 - 5   $2,476,813   $1,212,561 
Leasehold improvements   3    3,157    3,157 
Office equipment, furniture and other   2 - 5    75,401    38,344 
Less accumulated depreciation and amortization        (622,155)   (304,423)
Fixed assets, net                $1,933,216   $949,639 

 
XML 32 R13.htm IDEA: XBRL DOCUMENT v3.22.1
Goodwill and Intangible Assets
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets

Note 6 - Goodwill and Intangible Assets

 

Intangible assets, net consisted of the following:

 

  

Estimated

Useful Lives in

  December 31, 
   years  2021   2020 
In-process research and development  Indefinite  $26,101,000   $            - 
Non-competition agreements  1.5 - 3   1,094,000            - 
Less accumulated amortization      -    - 
Intangible assets, net       $27,195,000   $- 

 

 

The expected future annual amortization expense of the Company’s intangible assets held as of December 31, 2021 is as follows:

 

Year Ending December 31,  Amortization Expense 
2022  $426,660 
2023   364,668 
2024   302,672 
Total  $1,094,000 

 

The Company had goodwill of $14.7 million as of December 31, 2021.

 
XML 33 R14.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Expenses
 12 Months Ended
Dec. 31, 2021
Payables and Accruals [Abstract]  
Accrued Expenses

Note 7 - Accrued Expenses

 

Accrued expenses consisted of the following:

 

   December 31, 2021   December 31, 2020 
Payroll liabilities  $2,455,694   $1,627,957 
Distributor commissions   509,500    1,070,000 
Sales tax payable   -    52,526 
Other accrued liabilities   894,458    99,020 
Total accrued expenses  $3,859,652   $2,849,503 

 
XML 34 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue
 12 Months Ended
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]  
Revenue

Note 8 – Revenue

 

The following table sets forth revenue by geographic area:

 

   Years Ended December 31, 
   2021   2020 
United States  $52,185,812   $44,862,751 
Rest of World   45,699,791    29,690,007 
Total  $97,885,603   $74,552,758 
Percentage of revenue by area:          
United States   53%   60%
Rest of World   47%   40%

 

Deferred Revenue

 

Changes in the Company’s deferred revenue balance for the years ended December 31, 2021 and 2020 were as follows:

 

 

Balance as of December 31, 2019  $1,323 
Revenue recognized included in deferred revenue balance at the beginning of the period   (1,323)
Increase due to prepayments from customers   305,307 
Balance as of December 31, 2020   305,307 
Revenue recognized included in deferred revenue balance at the beginning of the period   (256,110)
Increase due to prepayments from customers   79,213 
Increase due to note receivable   150,000 
Decrease due to refunds to customers and application to open balances   (128,410)
Balance as of December 31, 2021  $150,000 

 

The Company expects to perform its performance obligation and recognize the deferred revenue as revenue during the year ended December 31, 2022.

 

 
XML 35 R16.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders’ Equity
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Stockholders’ Equity

Note 9 – Stockholders’ Equity

 

Common Stock

 

During the year ended December 31, 2021, the Company issued 189,225 shares of common stock upon the exercise of options and received $450,398 in proceeds from the exercises.

 

During the year ended December 31, 2021, the Company issued 5,548 shares of common stock for services provided by third parties primarily related to investor relations services.

 

During the year ended December 31, 2021, the Company issued 438,502 shares of common stock upon the vest and release of restricted stock units.

 

During the year ended December 31, 2021, the Company issued 4,628,554 shares of common stock related to the acquisitions of Idaho Molecular, Inc. and Advanced Conceptions, Inc., 1,390,430 of which are subject to forfeiture in favor of the Company if certain milestones are not achieved on or before January 1, 2027.

 

During the year ended December 31, 2020, the Company completed the sale of 3,448,278 shares of the Company’s common stock, par value $0.001 per share, at a purchase price of $1.45 per share in a registered direct offering. The aggregate gross proceeds for the sale of the shares were $5,000,003 and the Company received net proceeds of $4,517,102 after deducting offering costs of $482,901.

 

During the year ended December 31, 2020, the Company completed the sale of 3,324,676 shares of the Company’s common stock, par value $0.001 per share, at a purchase price of $3.08 per share in a registered direct offering. The aggregate gross proceeds for the sale of the shares were $10,240,002 and the Company received net proceeds of $9,612,561 after deducting offering costs of $627,441.

 

During the year ended December 31, 2020, the Company completed the sale of 470,000 shares of the Company’s common stock, par value $0.001 per share, at a purchase price of $9.00 per share in a registered direct offering. The aggregate gross proceeds for the sale of the shares were $4,230,000 and the Company received net proceeds of $3,882,420 after deducting offering costs of $347,580.

 

During the year ended December 31, 2020, the Company issued an aggregate of 2,133,333 shares of common stock upon conversion of all of the Company’s convertible preferred stock outstanding as of December 31, 2019.

 

During the year ended December 31, 2020, the Company issued 856,660 shares of common stock upon the exercise of warrants and received $270,000.

 

During the year ended December 31, 2020, the Company issued 871,229 shares of common stock upon the exercise of options and received $1,460,600.

 

During the year ended December 31, 2020, the Company issued 83,935 shares of common stock for services provided by third parties primarily related to investor relations services.

 

 
XML 36 R17.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings per Share
 12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Earnings per Share

Note 10 – Earnings per Share

 

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for years ended December 31, 2021 and 2020:

 

   2021   2020 
   Years Ended December 31, 
   2021   2020 
Numerator          
Net income, as reported  $36,658,564   $42,478,529 
           
Denominator          
Weighted average shares, basic   28,874,555    26,720,133 
Dilutive effect of stock options, warrants and RSUs   1,029,131    1,280,208 
Shares used to compute diluted earnings per share   29,903,686    28,000,341 
           
Basic earnings per share  $1.27   $1.59 
Diluted earnings per share  $1.23   $1.52 

 

For the years ended December 31, 2021 and 2020, respectively, potentially dilutive securities of 154,644 and 50,000 were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. The computation of diluted earnings per share for the year ended December 31, 2021 also excludes the approximately 1.4 million shares of common stock and approximately 456,000 warrants to purchase shares of common stock mentioned in Note 3 that are contingent upon the achievement of certain milestones.

 
XML 37 R18.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation

Note 11 – Stock-Based Compensation

 

Stock Incentive Plans

 

The Co-Diagnostics, Inc. 2015 Long Term Incentive Plan (the “Incentive Plan”) reserves an aggregate of 6,000,000 shares of common stock issuable upon the grant of awards under the Incentive Plan. The number of awards available for issuance under the Incentive Plan was 2,095,266 at December 31, 2021.

 

 

Stock Options

 

The following table summarizes option activity during the years ended December 31, 2021 and 2020:

       Number of Options   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2019    2,021,817   $1.69   $0.83      
Granted    150,000    8.14    4.74          
Expired    -    -    -      
Forfeited/Cancelled    -    -    -      
Exercised    (871,229)   1.68    0.89      
Outstanding at December 31, 2020    1,300,588   $2.44   $1.24      
Granted    -    -    -      
Expired    -    -    -      
Forfeited/Cancelled    -    -    -      
Exercised    (189,225)   2.38    1.12      
Outstanding at December 31, 2021    1,111,363   $2.12   $1.31    6.62 
                      
Exercisable at December 31, 2021    1,094,697   $2.01   $1.18    6.59 

 

The total intrinsic value of options exercised during the years ended December 31, 2021 and 2020 was approximately $1.3 million and $11.8 million, respectively. The aggregate intrinsic value of outstanding options at December 31, 2021 and 2020 was approximately $7.6 million and $7.1 million, respectively. As of December 31, 2021, there were 16,666 unvested options and $78,115 of unrecognized stock-based compensation expense related to options. The unrecognized stock-based compensation expense is expected to be recognized over 0.5 years.

 

Stock-based compensation cost is measured at the grant date based on the fair value of the award granted and recognized as expense over the vesting period using the straight-line method. The Company uses the Black-Scholes model to value options granted. The following weighted average assumptions were used in estimating the grant date fair value of options:

 

   Years Ended December 31, 
   2021   2020 
Risk-free interest rate   -    1.05%
Expected life (years)   -    7.3 
Expected volatility          -    62.82%
Expected dividend yield   -    None 

 

 

Restricted Stock Units

 

The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the years ended December 31, 2021 and 2020:

 

   Number of RSUs   Weighted Average Grant Date Fair Value 
Unvested at December 31, 2019   -   $- 
Granted   549,500    10.49 
Vested   (27,000)   10.49 
Forfeited/Cancelled   -    - 
Unvested at December 31, 2020   522,500   $10.49 
Granted   1,217,500    9.76 
Vested   (438,502)   10.10 
Forfeited/Cancelled   (34,083)   9.91 
Unvested at December 31, 2021   1,267,415   $9.94 

 

As of December 31, 2021, there was $11.6 million of unrecognized stock-based compensation expense related to outstanding RSUs which is expected to be recognized over a weighted-average period of 2.3 years.

 

Warrants

 

The Company has issued warrants related to financings, acquisitions and as compensation to third parties for services provided. The Company estimates the fair value of issued warrants on the date of issuance as determined using a Black-Scholes pricing model. The Company amortizes the fair value of issued warrants using a vesting schedule based on the terms and conditions of each warrant if granted for services.

 

The following table summarizes warrant activity during the years ended December 31, 2021 and 2020:

 

    Number of Warrants   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2019    983,535   $1.44   $1.03      
Granted    20,000    1.40    15.19      
Expired    (9,090)   6.00    0.17      
Forfeited/Cancelled    -    -    -      
Exercised    (924,445)   1.42    1.43      
Outstanding at December 31, 2020    70,000   $1.83   $5.21    3.3 
Granted    456,281    9.13    3.83      
Expired    -    -    -      
Forfeited/Cancelled    -    -    -      
Exercised    -    -    -      
Outstanding at December 31, 2021    526,281   $8.15   $4.01    4.7 

 

The intrinsic value of warrants exercised during the years ended December 31, 2021 and 2020 was $0 and approximately $9.7 million, respectively. The aggregate intrinsic value of outstanding warrants at December 31, 2021 was approximately $497,000.

 

 

70,000 warrants are exercisable at December 31, 2021. As discussed in Note 3 and Note 4, approximately 456,000 warrants to purchase shares of the Company’s common stock were issued in connection with the acquisition of ACI and IdMo. The ability to exercise the warrants is contingent upon the achievement of certain development and revenue milestones on or before January 1, 2027. There was no unrecognized stock-based compensation expense related to warrants.

 

See Note 4 for additional information regarding the fair value calculation of the warrants issued during the year ended December 31, 2021. The fair values for the warrants issued during the year ended December 31, 2020 were estimated at the date of grant using the Black Scholes model with the following weighted average assumptions:

 

   Year Ended December 31, 
   2020 
Risk-free interest rate   0.34%
Expected life (years)   5.0 
Expected volatility   61.42%
Expected dividend yield   None 

 

Stock Issued for Services

 

The Company has issued restricted stock to third parties for services provided. The grant date fair value of the restricted stock granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the stock awards. The Company issued 5,548 and 83,935 shares of restricted stock for services during the years ended December 31, 2021 and 2020, respectively, and there was no unrecognized stock-based compensation expense related to restricted stock issued.

 

Stock-Based Compensation Expense

 

The Company recognized stock-based compensation expense related to the types of awards discussed above as follows:

 

   2021   2020 
   Years Ended December 31, 
   2021   2020 
Options  $292,754   $901,345 
Restricted stock units   5,164,750    500,861 
Warrants   -    303,802 
Stock   51,900    1,032,033 
Total stock-based compensation expense  $5,509,404   $2,738,041 

 

 
XML 38 R19.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes

Note 12 – Income Taxes

 

The components of the provision for income taxes consists of the following for the years ended December 31, 2021 and 2020:

 

 

   2021   2020 
   Year Ended December 31, 
   2021   2020 
Current:          
Federal  $6,092,730   $- 
State   886,173    637,760 
Total current  $6,978,903   $637,760 
Deferred:          
Federal   1,394,686    (452,544)
State   603,642    (94,680)
Total deferred   1,998,328    (547,224)
Total income tax expense  $8,977,231   $90,536 

 

A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:

 

   2021   2020 
   Year Ended December 31, 
   2021   2020 
Federal income tax expense at statutory rate   21.0%   21.0%
State income tax expense, net of federal tax benefit   3.9    3.3 
Permanent differences:          
- Foreign derived intangible income deduction   (3.5)    (1.7) 
- Stock based compensation   0.2    (8.8) 
- Other permanent differences   0.3    (0.4) 
Research and development credits   (2.6)    (2.0) 
Change in uncertain tax positions   1.4    1.1 
Change in valuation allowance   0.0    (12.1) 
Other   (1.0)    (0.2) 
Effective income tax rate   19.7%   0.2%

 

 

Net deferred tax assets consist of the following components as of December 31, 2021 and 2020:

 

   2021   2020 
   December 31, 
   2021   2020 
Deferred tax assets:          
Accrued liabilities  $-   $37,898 
Reserves and allowances   166,050    200,049 
Deferred compensation   393,871    241,652 
Research and development credits   -    423,001 
Total deferred tax assets   559,921    902,600 
Deferred tax liabilities:          
Property and equipment, net   (477,542)   (233,951)
Intangibles, net   (6,743,972)   - 
Prepaids   (560,093)   (66,456)
Other   (6,758)   (54,969)
Total deferred tax liabilities   (7,788,365)   (355,376)
Net deferred tax assets (liabilities)   (7,228,444)   547,224 
Less valuation allowance   -    - 
Net deferred tax assets (liabilities)  $(7,228,444)  $547,224 

 

At December 31, 2021, the Company had no federal or state net operating loss carryforwards and no federal or state research and development credit carryforwards.

 

As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December 31, 2020, in part because in that year the Company achieved three years of cumulative pre-tax income, management determined that there was sufficient positive evidence to conclude that it was more likely than not that its deferred taxes were realizable. The Company therefore fully reduced its valuation allowance accordingly by $5,161,500.

 

ASC Topic 740-10-05 requires that the impact of a tax position be recognized in the financial statements if that position is more likely than not of being sustained on audit, based on the technical merits of the position. Our unrecognized tax benefit balances included $1,067,853 at December 31, 2021 and $447,831 at December 31, 2020 of tax positions that, if recognized, would impact our effective tax rate. The Company expects no material changes to the liability for unrecognized tax benefits in the next 12 months. Interest and penalties associated with uncertain tax positions are recorded as a component of income tax expense. A reconciliation of the beginning and ending amount of unrecognized benefits is as follows:

 

   December 31, 
   2021   2020 
Unrecognized tax benefits at the beginning of the year  $447,831   $- 
Gross increases - current year tax positions   770,069    232,145 
Gross increases - prior year tax positions   -    215,686 
Gross decreases - prior year tax positions   (150,047)   - 
Unrecognized tax benefits at end of year  $1,067,853   $447,831 
           
Interest and penalties in year-end balance  $-   $- 

 

 

The Company is subject to taxation in the United States and other state jurisdictions. The tax years from December 31, 2017 through December 31, 2021 remain open to examination for federal income tax purposes and by the other major taxing jurisdictions to which the Company is subject. The Company is not currently under examination by any taxing authority.

 
XML 39 R20.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions
 12 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]  
Related Party Transactions

Note 13 – Related Party Transactions

 

The Company acquired the exclusive rights to the CoPrimer technology pursuant to an exclusive license agreement, dated April 2014 (the “Exclusive License Agreement”), between the Company and DNA Logix, Inc., which was assigned to Dr. Brent Satterfield, an executive officer, prior to the Company’s acquisition of DNA Logix, Inc. On March 1, 2017, the Company entered into an amendment to its Exclusive License Agreement for its Cooperative Primers (“License”) technology with Dr. Satterfield. The amendment provided in part that all accrued royalties under the License ceased as of January 1, 2017, and the Company agreed to pay to Dr. Satterfield $700,000 of accrued royalties at the rate of $10,000 per month starting in January 2017. At December 31, 2021, the aggregate balance of this related party liability was $0.

 
XML 40 R21.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 14 – Commitments and Contingencies

 

Lease Obligations

 

The Company’s offices are located at 2401 S. Foothill Dr., Suite D, Salt Lake City, Utah 84109-1479. In February 2020, the Company entered into a 4-year lease agreement for its office space and in March 2020, the Company entered into an addendum with our landlord for additional space. The aggregate space consists of approximately 13,687 square feet at a monthly rate of $28,825 and expires in February 2024. As a result of business acquisitions during the year ended December 31, 2021, the Company also leases additional laboratory and office space under two month-to-month leases. For the years ended December 31, 2021 and 2020, the Company expensed $346,350 and $311,963, respectively, for rent. The Company’s future minimum lease payments were as follows as of December 31, 2021:

 

Year Ending December 31, 
2022  $293,595 
2023   303,059 
2024   50,774 
Total lease payments   $647,428 

 

Litigation

 

Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.

 

Five different securities class action complaints were filed in July, September and December by certain stockholders of the Company against the Company claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The plaintiffs demand compensatory damages sustained as a result of the Company’s alleged wrongdoing in an amount to be proven at trial. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in these cases. As of the date of this report, the Company does not believe it is probable that these cases will result in an unfavorable outcome; however, if an unfavorable outcome were to occur in these cases, it is possible that the impact could be material to the Company’s results of operations in the period(s) in which any such outcome becomes probable and estimable.

 

 
XML 41 R22.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events
 12 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]  
Subsequent Events

Note 15 – Subsequent Events

 

In March 2022, the Company’s Board of Directors authorized a share repurchase program that would allow the Company to repurchase up to $30 million of CODX common stock. The repurchase program does not obligate the Company to acquire any particular amount of common shares, and the repurchase program may be suspended or discontinued at any time at the Company’s discretion. The timing and amount of any share repurchases under the share repurchase program will be determined by Co-Diagnostics’ management at its discretion based on ongoing assessments of the capital needs of the business, the market price of the Company’s common stock, corporate and regulatory requirements, and general market conditions. Share repurchases under the program may be made through a variety of methods, which may include open market purchases, in block trades, accelerated share repurchase transactions, exchange transactions, the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or any combination of such methods.
XML 42 R23.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Reclassifications

Reclassifications

 

Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of December 31, 2021 and December 31, 2020. The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.

 
Marketable Investment Securities

Marketable Investment Securities

 

The Company’s marketable investment securities are comprised of investments in certificates of deposit. The Company determines the appropriate classification of its marketable investment securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable investment securities as available-for-sale securities as the Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. As a result, the Company classifies its marketable investment securities, including securities with stated maturities beyond twelve months, within current assets in the consolidated balance sheets. Any unrealized gains or losses are immaterial.

 
Accounts Receivable

Accounts Receivable

 

Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At December 31, 2021 total accounts receivable was $21,508,779 with an allowance for uncollectable accounts of $669,597 resulting in a net amount of $20,839,182. At December 31, 2020 total accounts receivable was $12,928,633 with an allowance for uncollectable accounts of $791,800 resulting in a net amount of $12,136,833.

 

 
Equity-Method Investments

Equity-Method Investments

 

Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.

 
Inventory

Inventory

 

Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At December 31, 2021, the Company had $2,004,169 in inventory, of which $983,088 was finished goods and $1,021,081 was raw materials. At December 31, 2020, the Company had $7,995,189 in inventory, of which $598,881 was finished goods and $7,396,308 was raw materials. The Company establishes reserves to reduce low-moving, obsolete, or unusable inventories to their estimated useful or scrap values.

 
Property and Equipment

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from three to five years. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.

 

The Company reviews its long-lived assets, including property and equipment, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.

 
Business Combinations

Business Combinations

 

We estimate the fair value of assets acquired and liabilities assumed in a business combination. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable, and as a result, actual results may differ from estimates.

 
Revenue Recognition

Revenue Recognition

 

The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation. Based on the criteria above, the Company typically recognizes revenue upon delivery.

 

The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.

 
Deferred Revenue

Deferred Revenue

 

Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.

 

 
Research and Development

Research and Development

 

Research and development costs are expensed when incurred. The Company expensed $14,961,916 and $3,185,290 of research and development costs for the years ended December 31, 2021 and 2020, respectively.

 
Stock-based Compensation

Stock-based Compensation

 

The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.

 
Income Taxes

Income Taxes

 

The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, deferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.

 

Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.

 

Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. While the Company believes it has no significant uncertain income tax positions in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.

 
Net Income per Share

Net Income per Share

 

Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.

 

Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive

 
Concentrations Risk and Significant Customers

Concentrations Risk and Significant Customers

 

The Company had certain customers which are each responsible for generating 10% or more of the total revenue for the years ended December 31, 2021 and 2020. Two customers together accounted for approximately 48% and 38% of total revenue for the years ended December 31, 2021 and 2020, respectively.

 

Two customers each accounted for more than 10% of accounts receivable at December 31, 2021 and 2020. These two customers together accounted for approximately 66% and 48% of accounts receivable at December 31, 2021 and 2020, respectively.

 

 
Recently Issued Accounting Standards

Recently Issued Accounting Standards

 

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.

 

As an emerging growth company (“EGC”), the Company has elected to take advantage of the benefits of the extended transition period provided for in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards which allows the Company to defer adoption of certain accounting standards until those standards would otherwise apply to private companies.

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires recognition of leased assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies like us. The Company will use the modified retrospective transition method with the option to recognize a cumulative-effect adjustment at the date of adoption. The Company’s balance sheet will be impacted as it records right-of-use assets and lease liabilities on its consolidated balance sheets, but the Company does not expect the adoption of this standard will have a material impact on its consolidated statements of operations and cash flows.

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for certain financial instruments, which includes the Company’s accounts receivable. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies. The standard requires a cumulative effect adjustment to the balance sheet as of the beginning of the first early reporting period in which the guidance is effective. The Company is evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements but does not expect the adoption of this standard will have a material impact on its consolidated financial statements.

 
XML 43 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Business Combinations (Tables)
 12 Months Ended
Dec. 31, 2021
Business Combination and Asset Acquisition [Abstract]  
Schedule of Assets and Liabilities assumed

The fair value of assets acquired and liabilities assumed was based on a preliminary valuation, and our estimates and assumptions are subject to change within the measurement period. The primary area that remains preliminary relates to the evaluation of certain tax-related items and potential minor adjustments to the purchase consideration. The total purchase consideration was allocated to the assets acquired and liabilities assumed as set forth below:

 

Fair value of common shares issued  $25,160,223 
Payable to shareholder   100,000 
Fair value of contingent shares   8,684,669 
Fair value of contingent warrants   1,747,972 
Total fair value of consideration transferred  $35,692,864 
      
Identifiable assets acquired and liabilities assumed     
Cash  $1,196,243 
Accounts receivable   31,170 
Prepaid expenses and other current assets   70,321 
Property and equipment   408,173 
Technology - In-process research and development   26,101,000 
Non-competition agreements   1,094,000 
Accounts payable and accrued other expenses   (1,069,274)
Deferred tax liability   (6,845,587)
Total identifiable net assets   20,986,046 
Goodwill   14,706,818 
Total  $35,692,864 
XML 44 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Schedule of Fair Value Assets and Liabilities

The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 and December 31, 2020, by level within the fair value hierarchy:

 

   December 31, 2021 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                    
Marketable securities (certificates of deposit)  $-   $1,255,266   $-   $1,255,266 
Total assets measured at fair value  $-   $1,255,266   $-   $1,255,266 
Liabilities:                    
Contingent consideration - common stock  $           -   $      -   $8,684,669   $8,684,669 
Contingent consideration - warrants   -    -    1,747,972    1,747,972 
Total liabilities measured at fair value  $-   $-   $10,432,641   $10,432,641 

 

   December 31, 2020 
   (Level 1)   (Level 2)   (Level 3)   Total 
Assets:                
Marketable securities (certificates of deposit)  $-   $4,335,446   $             -   $4,335,446 
Total assets measured at fair value  $-   $4,335,446   $-   $4,335,446 
Schedule of Changes in Fair Value Measurement

The changes for Level 3 items measured at fair value on a recurring basis are as follows:

 

Fair value as of December 31, 2020  $- 
Contingent considered issued for business acquisitions   10,432,641 
Fair value as of December 31, 2021  $10,432,641 
Schedule of Contingent Consideration Common Stock and Warrants

 

   December 31, 2021 
Stock price  $8.93 
Strike price  $9.13 
Volatility   80.00%
Risk-free rate   1.30%
Expected term   5.0 

 

 

In order to calculate the probability-adjusted value of the contingent consideration-common stock and contingent consideration-warrants, the Company estimated the probability of achieving certain milestones, which include regulatory approval for identified products, as well as production and net revenue targets. The probability of achieving the milestone related to net revenues was estimated using a Monte Carlo simulation valuation model. The unobservable significant inputs to the valuation model were as follows:

 

   December 31, 2021 
Stock price  $8.93 
Risk-free rate   1.30%
Expected term   5.0 
Weighted-average cost of capital   27.00%
Revenue discount rate   9.50%
Equity volatility   80.00%
Asset volatility   80.00%
Revenue volatility   30.00%
XML 45 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment

Property and equipment, net consisted of the following:

 

  

Estimated

Useful Lives in

   December 31, 
   years   2021   2020 
Lab equipment   3 - 5   $2,476,813   $1,212,561 
Leasehold improvements   3    3,157    3,157 
Office equipment, furniture and other   2 - 5    75,401    38,344 
Less accumulated depreciation and amortization        (622,155)   (304,423)
Fixed assets, net                $1,933,216   $949,639 

 
XML 46 R27.htm IDEA: XBRL DOCUMENT v3.22.1
Goodwill and Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets

Intangible assets, net consisted of the following:

 

  

Estimated

Useful Lives in

  December 31, 
   years  2021   2020 
In-process research and development  Indefinite  $26,101,000   $            - 
Non-competition agreements  1.5 - 3   1,094,000            - 
Less accumulated amortization      -    - 
Intangible assets, net       $27,195,000   $- 
Schedule of Future Amortization Expense

The expected future annual amortization expense of the Company’s intangible assets held as of December 31, 2021 is as follows:

 

Year Ending December 31,  Amortization Expense 
2022  $426,660 
2023   364,668 
2024   302,672 
Total  $1,094,000 
XML 47 R28.htm IDEA: XBRL DOCUMENT v3.22.1
Accrued Expenses (Tables)
 12 Months Ended
Dec. 31, 2021
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses consisted of the following:

 

   December 31, 2021   December 31, 2020 
Payroll liabilities  $2,455,694   $1,627,957 
Distributor commissions   509,500    1,070,000 
Sales tax payable   -    52,526 
Other accrued liabilities   894,458    99,020 
Total accrued expenses  $3,859,652   $2,849,503 
XML 48 R29.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue (Tables)
 12 Months Ended
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]  
Summary of Revenue by Geographic Area

The following table sets forth revenue by geographic area:

 

   Years Ended December 31, 
   2021   2020 
United States  $52,185,812   $44,862,751 
Rest of World   45,699,791    29,690,007 
Total  $97,885,603   $74,552,758 
Percentage of revenue by area:          
United States   53%   60%
Rest of World   47%   40%
Schedule of Deferred Revenue

Changes in the Company’s deferred revenue balance for the years ended December 31, 2021 and 2020 were as follows:

 

 

Balance as of December 31, 2019  $1,323 
Revenue recognized included in deferred revenue balance at the beginning of the period   (1,323)
Increase due to prepayments from customers   305,307 
Balance as of December 31, 2020   305,307 
Revenue recognized included in deferred revenue balance at the beginning of the period   (256,110)
Increase due to prepayments from customers   79,213 
Increase due to note receivable   150,000 
Decrease due to refunds to customers and application to open balances   (128,410)
Balance as of December 31, 2021  $150,000 
XML 49 R30.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings per Share (Tables)
 12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Earnings Per Share

The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for years ended December 31, 2021 and 2020:

 

   2021   2020 
   Years Ended December 31, 
   2021   2020 
Numerator          
Net income, as reported  $36,658,564   $42,478,529 
           
Denominator          
Weighted average shares, basic   28,874,555    26,720,133 
Dilutive effect of stock options, warrants and RSUs   1,029,131    1,280,208 
Shares used to compute diluted earnings per share   29,903,686    28,000,341 
           
Basic earnings per share  $1.27   $1.59 
Diluted earnings per share  $1.23   $1.52 
XML 50 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Option Activity

The following table summarizes option activity during the years ended December 31, 2021 and 2020:

       Number of Options   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2019    2,021,817   $1.69   $0.83      
Granted    150,000    8.14    4.74          
Expired    -    -    -      
Forfeited/Cancelled    -    -    -      
Exercised    (871,229)   1.68    0.89      
Outstanding at December 31, 2020    1,300,588   $2.44   $1.24      
Granted    -    -    -      
Expired    -    -    -      
Forfeited/Cancelled    -    -    -      
Exercised    (189,225)   2.38    1.12      
Outstanding at December 31, 2021    1,111,363   $2.12   $1.31    6.62 
                      
Exercisable at December 31, 2021    1,094,697   $2.01   $1.18    6.59 
Schedule of Fair Value of Options Weighted Average Assumptions

 

   Years Ended December 31, 
   2021   2020 
Risk-free interest rate   -    1.05%
Expected life (years)   -    7.3 
Expected volatility          -    62.82%
Expected dividend yield   -    None 
Schedule of Outstanding Restricted Stock Units and Related Activity

The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the years ended December 31, 2021 and 2020:

 

   Number of RSUs   Weighted Average Grant Date Fair Value 
Unvested at December 31, 2019   -   $- 
Granted   549,500    10.49 
Vested   (27,000)   10.49 
Forfeited/Cancelled   -    - 
Unvested at December 31, 2020   522,500   $10.49 
Granted   1,217,500    9.76 
Vested   (438,502)   10.10 
Forfeited/Cancelled   (34,083)   9.91 
Unvested at December 31, 2021   1,267,415   $9.94 
Schedule of Warrant Activity

The following table summarizes warrant activity during the years ended December 31, 2021 and 2020:

 

    Number of Warrants   Weighted Average Exercise Price   Weighted Average Fair Value   Weighted Average Remaining Contractual Life (Years) 
Outstanding at December 31, 2019    983,535   $1.44   $1.03      
Granted    20,000    1.40    15.19      
Expired    (9,090)   6.00    0.17      
Forfeited/Cancelled    -    -    -      
Exercised    (924,445)   1.42    1.43      
Outstanding at December 31, 2020    70,000   $1.83   $5.21    3.3 
Granted    456,281    9.13    3.83      
Expired    -    -    -      
Forfeited/Cancelled    -    -    -      
Exercised    -    -    -      
Outstanding at December 31, 2021    526,281   $8.15   $4.01    4.7 
Schedule of Fair Value of Warrants Assumptions

 

   Year Ended December 31, 
   2020 
Risk-free interest rate   0.34%
Expected life (years)   5.0 
Expected volatility   61.42%
Expected dividend yield   None 
Schedule of Recognized Stock-based Compensation Expense

The Company recognized stock-based compensation expense related to the types of awards discussed above as follows:

 

   2021   2020 
   Years Ended December 31, 
   2021   2020 
Options  $292,754   $901,345 
Restricted stock units   5,164,750    500,861 
Warrants   -    303,802 
Stock   51,900    1,032,033 
Total stock-based compensation expense  $5,509,404   $2,738,041 
XML 51 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Schedule of Components Income Tax Provision

The components of the provision for income taxes consists of the following for the years ended December 31, 2021 and 2020:

 

 

   2021   2020 
   Year Ended December 31, 
   2021   2020 
Current:          
Federal  $6,092,730   $- 
State   886,173    637,760 
Total current  $6,978,903   $637,760 
Deferred:          
Federal   1,394,686    (452,544)
State   603,642    (94,680)
Total deferred   1,998,328    (547,224)
Total income tax expense  $8,977,231   $90,536 
Schedule of Benefit from Income Taxes and Effective Tax Rates

A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:

 

   2021   2020 
   Year Ended December 31, 
   2021   2020 
Federal income tax expense at statutory rate   21.0%   21.0%
State income tax expense, net of federal tax benefit   3.9    3.3 
Permanent differences:          
- Foreign derived intangible income deduction   (3.5)    (1.7) 
- Stock based compensation   0.2    (8.8) 
- Other permanent differences   0.3    (0.4) 
Research and development credits   (2.6)    (2.0) 
Change in uncertain tax positions   1.4    1.1 
Change in valuation allowance   0.0    (12.1) 
Other   (1.0)    (0.2) 
Effective income tax rate   19.7%   0.2%
Schedule of Deferred Tax Assets

Net deferred tax assets consist of the following components as of December 31, 2021 and 2020:

 

   2021   2020 
   December 31, 
   2021   2020 
Deferred tax assets:          
Accrued liabilities  $-   $37,898 
Reserves and allowances   166,050    200,049 
Deferred compensation   393,871    241,652 
Research and development credits   -    423,001 
Total deferred tax assets   559,921    902,600 
Deferred tax liabilities:          
Property and equipment, net   (477,542)   (233,951)
Intangibles, net   (6,743,972)   - 
Prepaids   (560,093)   (66,456)
Other   (6,758)   (54,969)
Total deferred tax liabilities   (7,788,365)   (355,376)
Net deferred tax assets (liabilities)   (7,228,444)   547,224 
Less valuation allowance   -    - 
Net deferred tax assets (liabilities)  $(7,228,444)  $547,224 
Schedule of Unrecognized Tax Benefits

 

   December 31, 
   2021   2020 
Unrecognized tax benefits at the beginning of the year  $447,831   $- 
Gross increases - current year tax positions   770,069    232,145 
Gross increases - prior year tax positions   -    215,686 
Gross decreases - prior year tax positions   (150,047)   - 
Unrecognized tax benefits at end of year  $1,067,853   $447,831 
           
Interest and penalties in year-end balance  $-   $- 
XML 52 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Future Minimum Lease Payments

 

Year Ending December 31, 
2022  $293,595 
2023   303,059 
2024   50,774 
Total lease payments   $647,428 
XML 53 R34.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Product Information [Line Items]    
Accounts receivable $ 21,508,779 $ 12,928,633
Doubtful accounts 669,597 791,800
Accounts receivable, net 20,839,182 12,136,833
Inventory 2,004,169 7,995,189
Inventory finished goods 983,088 598,881
Inventory raw materials 1,021,081 7,396,308
Research and development costs $ 14,961,916 $ 3,185,290
Two Customers Together [Member] | Customer Concentration Risk [Member] | Revenue Benchmark [Member]    
Product Information [Line Items]    
Concentration risk percentage 48.00% 38.00%
Two Customers Together [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]    
Product Information [Line Items]    
Concentration risk percentage 66.00% 48.00%
Minimum [Member]    
Product Information [Line Items]    
Estimated useful life of property 3 years  
Maximum [Member]    
Product Information [Line Items]    
Estimated useful life of property 5 years  
XML 54 R35.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Assets and Liabilities assumed (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Business Combination and Asset Acquisition [Abstract]    
Stock issued during period, value acquisitions $ 25,160,223
Payable to shareholders 100,000  
Fair value of contingent shares 8,684,669  
Fair value of contingent warrants 1,747,972  
Business combination, consideration transferred 35,692,864  
Cash 1,196,243  
Accounts receivables 31,170  
Prepaid expenses and other current assets 70,321  
Property and equipments 408,173  
Research and development in process 26,101,000  
Non competition agreements 1,094,000  
Accounts payable and accrued other expenses (1,069,274)  
Deferred tax liability (6,845,587)  
Total indentifiable net assets 20,986,046  
Goodwill 14,706,818
Total $ 35,692,864  
XML 55 R36.htm IDEA: XBRL DOCUMENT v3.22.1
Business Combinations (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Business Acquisition [Line Items]      
Warrants to purchase shares of common stock 456,000 456,000  
Payable to shareholders   $ 100,000  
General and administrative expense   $ 11,550,615 $ 8,278,734
Minimum [Member]      
Business Acquisition [Line Items]      
Finite lived intangible assets remaining amortization period   1 year 6 months  
Maximum [Member]      
Business Acquisition [Line Items]      
Finite lived intangible assets remaining amortization period   3 years  
Advanced Conceptions, Inc. and Idaho Molecular, Inc. [Member]      
Business Acquisition [Line Items]      
Number of shares exchanged 3,200,000    
Number of shares on contingent consideration 1,400,000    
Warrants to purchase shares of common stock 456,000 456,000  
General and administrative expense $ 151,000    
Equity method investment ownership percentage 100.00% 100.00%  
Advanced Conceptions Inc [Member]      
Business Acquisition [Line Items]      
Payable to shareholders   $ 100,000  
XML 56 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Fair Value Assets and Liabilities (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total liabilities measured at fair value $ 10,432,641  
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total liabilities measured at fair value  
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total liabilities measured at fair value  
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total liabilities measured at fair value 10,432,641  
Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets measured at fair value
Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets measured at fair value 1,255,266 4,335,446
Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total assets measured at fair value
Fair Value, Recurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities (certificates of deposit) 1,255,266 4,335,446
Total assets measured at fair value 1,255,266 4,335,446
Contingent consideration common stock 8,684,669  
Contingent consideration warrants 1,747,972  
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration common stock  
Contingent consideration warrants  
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration common stock  
Contingent consideration warrants  
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration common stock 8,684,669  
Contingent consideration warrants 1,747,972  
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities (certificates of deposit)
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities (certificates of deposit) 1,255,266 4,335,446
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Marketable securities (certificates of deposit)
XML 57 R38.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Changes in Fair Value Measurement (Details)
 12 Months Ended
Dec. 31, 2021
USD ($)
Fair Value Disclosures [Abstract]  
Asset acquisition contingent consideration liability noncurrent
Contingent considered issued for business acquisitions 10,432,641
Asset acquisition contingent consideration liability noncurrent $ 10,432,641
XML 58 R39.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Contingent Consideration Common Stock and Warrants (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement, term 5 years  
Measurement Input, Share Price [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input 8.93  
Business combination,contingent consideration 8.93  
Measurement Input Strike Price [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input 9.13  
Measurement Input, Price Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input 80.00  
Measurement Input, Risk Free Interest Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement input 1.30 0.34
Business combination,contingent consideration 1.30  
Measurement Input, Expected Term [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants measurement, term   5 years
Business combination,contingent consideration, term 5 years  
Measurement Input Cost of Capital [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Business combination,contingent consideration 27.00  
Measurement Input, Discount Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Business combination,contingent consideration 9.50  
Measurement Input Equity Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Business combination,contingent consideration 80.00  
Measurement Input Asset Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Business combination,contingent consideration 80.00  
Measurement Input Revenue Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Business combination,contingent consideration 30.00  
XML 59 R40.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Property and Equipment (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Less: accumulated depreciation $ (622,155) $ (304,423)
Property and equipment, net $ 1,933,216 949,639
Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment estimated useful lives 3 years  
Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment estimated useful lives 5 years  
Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 2,476,813 1,212,561
Equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment estimated useful lives 3 years  
Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment estimated useful lives 5 years  
Leaseholds and Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment estimated useful lives 3 years  
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 3,157 3,157
Office Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 75,401 $ 38,344
Office Equipment [Member] | Minimum [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment estimated useful lives 2 years  
Office Equipment [Member] | Maximum [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment estimated useful lives 5 years  
XML 60 R41.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Intangible Assets (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]    
Less accumulated amortization
Intangible assets, net $ 27,195,000
In Process Research and Development [Member]    
Finite-Lived Intangible Assets [Line Items]    
Estimated useful lives in years, term Indefinite  
Intangible assets, gross $ 26,101,000
Noncompete Agreements [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, gross $ 1,094,000
Noncompete Agreements [Member] | Minimum [Member]    
Finite-Lived Intangible Assets [Line Items]    
Estimated useful lives in years 1 year 6 months  
Noncompete Agreements [Member] | Maximum [Member]    
Finite-Lived Intangible Assets [Line Items]    
Estimated useful lives in years 3 years  
XML 61 R42.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Future Amortization Expense (Details)
Dec. 31, 2021
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2022 $ 426,660
2023 364,668
2024 302,672
Total $ 1,094,000
XML 62 R43.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Accrued Expenses (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Payroll liabilities $ 2,455,694 $ 1,627,957
Distributor commissions 509,500 1,070,000
Sales tax payable 52,526
Other accrued liabilities 894,458 99,020
Total accrued expenses $ 3,859,652 $ 2,849,503
XML 63 R44.htm IDEA: XBRL DOCUMENT v3.22.1
Summary of Revenue by Geographic Area (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Disaggregation of Revenue [Line Items]    
Revenue $ 97,885,603 $ 74,552,758
Americas [Member]    
Disaggregation of Revenue [Line Items]    
Revenue $ 52,185,812 $ 44,862,751
Americas [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]    
Disaggregation of Revenue [Line Items]    
Percentage of revenue 53.00% 60.00%
Rest of World [Member]    
Disaggregation of Revenue [Line Items]    
Revenue $ 45,699,791 $ 29,690,007
Rest of World [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]    
Disaggregation of Revenue [Line Items]    
Percentage of revenue 47.00% 40.00%
XML 64 R45.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Deferred Revenue (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Revenue from Contract with Customer [Abstract]    
Deferred revenue, beginning balance $ 305,307 $ 1,323
Revenue recognized included in deferred revenue balance at the beginning of the period (256,110) (1,323)
Increase due to prepayments from customers 79,213 305,307
Increase due to note receivable 150,000  
Decrease due to refunds to customers and application to open balances (128,410)  
Deferred revenue, Ending balance $ 150,000 $ 305,307
XML 65 R46.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders’ Equity (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Number of shares issued for exercise of options, value   $ 450,398 $ 1,460,600
Vest and restricted stock units   438,502  
Common stock, par value $ 0.001 $ 0.001 $ 0.001
Issuance of common stock gross proceeds   $ 19,470,005
Offering costs   $ 1,457,921
Potentially dilutive shares   154,644 50,000
Investment Relations Services [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Number of shares issued for services     83,935
Convertible Preferred Stock [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Potentially dilutive shares     2,133,333
Advanced Conceptions, Inc. and Idaho Molecular, Inc. [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Stock Issued During Period, Shares, Acquisitions   4,628,554  
[custom:StockIssuedDuringPeriodSharesForfeited]   1,390,430  
Number of common stock issued 3,200,000    
Third Parties [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Number of shares issued for services   5,548  
Options [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Number of shares issued for exercise of options   189,225 871,229
Number of shares issued for exercise of options, value   $ 450,398 $ 1,460,600
Common Stock Three [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Number of common stock issued     3,448,278
Common stock, par value     $ 0.001
Sale of common stock purchase price per shares     $ 1.45
Issuance of common stock gross proceeds     $ 5,000,003
Net proceeds from issuance of common stock     4,517,102
Offering costs     $ 482,901
Common Stock One [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Number of common stock issued     3,324,676
Common stock, par value     $ 0.001
Sale of common stock purchase price per shares     $ 3.08
Issuance of common stock gross proceeds     $ 10,240,002
Net proceeds from issuance of common stock     9,612,561
Offering costs     $ 627,441
Common Stock Two [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Number of common stock issued     470,000
Common stock, par value     $ 0.001
Sale of common stock purchase price per shares     $ 9.00
Issuance of common stock gross proceeds     $ 4,230,000
Net proceeds from issuance of common stock     3,882,420
Offering costs     $ 347,580
Warrant [Member]      
Accumulated Other Comprehensive Income (Loss) [Line Items]      
Number of shares issued for exercise of options     856,660
Number of shares issued for exercise of options, value     $ 270,000
Potentially dilutive shares   456,000  
XML 66 R47.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Basic and Diluted Earnings Per Share (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Earnings Per Share [Abstract]    
Net income, as reported $ 36,658,564 $ 42,478,529
Weighted average shares, basic 28,874,555 26,720,133
Dilutive effect of stock options, warrants and RSUs 1,029,131 1,280,208
Shares used to compute diluted earnings per share 29,903,686 28,000,341
Basic earnings per share $ 1.27 $ 1.59
Diluted earnings per share $ 1.23 $ 1.52
XML 67 R48.htm IDEA: XBRL DOCUMENT v3.22.1
Earnings per Share (Details Narrative) - shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Securities excluded from computation of diluted earnings per share 154,644 50,000
Common Stock [Member]    
Securities excluded from computation of diluted earnings per share 1,400,000  
Warrant [Member]    
Securities excluded from computation of diluted earnings per share 456,000  
XML 68 R49.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Option Activity (Details) - $ / shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]    
Number of Options Outstanding, Beginning 1,300,588 2,021,817
Weighted Average Exercise Price Outstanding, Beginning $ 2.44 $ 1.69
Weighted Average Fair Value Outstanding, Beginning $ 1.24 $ 0.83
Number of Options Outstanding, Granted 150,000
Weighted Average Exercise Price Granted $ 8.14
Weighted Average Fair Value Granted $ 4.74
Number of Options Outstanding, Expired
Weighted Average Exercise Price Expired
Weighted Average Fair Value Expired
Number of Options Outstanding, Forfeited/Cancelled
Weighted Average Exercise Price Forfeited/Cancelled
Weighted Average Fair Value Forfeited/Cancelled
Number of Options Outstanding, Exercised (189,225) (871,229)
Weighted Average Exercise Price Exercised $ 2.38 $ 1.68
Weighted Average Fair Value Exercised $ 1.12 $ 0.89
Number of Options Outstanding, Ending 1,111,363 1,300,588
Weighted Average Exercise Price Outstanding, Ending $ 2.12 $ 2.44
Weighted Average Fair Value Outstanding, Ending $ 1.31 $ 1.24
Weighted-average Remaining Contractual Life (years) Outstanding, Ending 6 years 7 months 13 days  
Number of Options Exercisable Ending 1,094,697  
Weighted Average Exercise Price, Exercisable Ending $ 2.01  
Weighted Average Fair Value, Exercisable Ending $ 1.18  
Weighted-average Remaining Contractual Life (years), Exercisable Ending 6 years 7 months 2 days  
XML 69 R50.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Fair Value of Options Weighted Average Assumptions (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]    
Risk-free interest rate 1.05%
Expected life (years) 7 years 3 months 18 days
Expected volatility 62.82%
Expected dividend yield 0.00%
XML 70 R51.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Outstanding Restricted Stock Units and Related Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of Restricted Stock Units, Outstanding Beginning 522,500
Weighted Average Grant Date Fair Value, Outstanding Beginning $ 10.49
Number of Restricted Stock Units, Granted 1,217,500 549,500
Weighted Average Grant Date Fair Value, Granted $ 9.76 $ 10.49
Number of Restricted Stock Units, Vested (438,502) (27,000)
Weighted Average Grant Date Fair Value, Vested $ 10.10 $ 10.49
Number of Restricted Stock Units, Forfeited/Cancelled (34,083)
Weighted Average Grant Date Fair Value, Forfeited/Cancelled $ 9.91
Number of Restricted Stock Units, Outstanding Ending 1,267,415 522,500
Weighted Average Grant Date Fair Value, Outstanding Ending $ 9.94 $ 10.49
XML 71 R52.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Warrant Activity (Details) - $ / shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]    
Number of Warrants Outstanding, Beginning 70,000 983,535
Weighted Average Exercise Price, Beginning $ 1.83 $ 1.44
Weighted Average Fair Value, Beginning $ 5.21 $ 1.03
Number of Warrants Outstanding, Granted 456,281 20,000
Weighted Average Exercise Price, Granted $ 9.13 $ 1.40
Weighted Average Fair Value, Granted $ 3.83 $ 15.19
Number of Warrants Outstanding, Expired (9,090)
Weighted Average Exercise Price, Expired $ 6.00
Weighted Average Fair Value, Expired $ 0.17
Number of Warrants Outstanding, Forfeited/Cancelled
Weighted Average Exercise Price, Forfeited/Cancelled
Weighted Average Fair Value, Forfeited/Cancelled
Number of Warrants Outstanding, Exercised (924,445)
Weighted Average Exercise Price, Exercised $ 1.42
Weighted Average Fair Value, Exercised $ 1.43
Weighted-average Remaining Contractual Life (Years) Outstanding, Beginning   3 years 3 months 18 days
Number of Warrants Outstanding, Ending 526,281 70,000
Weighted Average Exercise Price, Ending $ 8.15  
Weighted Average Fair Value, Ending $ 4.01 $ 5.21
Weighted-average Remaining Contractual Life (Years) Outstanding, Ending 4 years 8 months 12 days  
XML 72 R53.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Fair Value of Warrants Assumptions (Details)
Dec. 31, 2021
Dec. 31, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants, expected life 5 years  
Measurement Input, Risk Free Interest Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants outstanding, measurement input 1.30 0.34
Measurement Input, Expected Term [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants, expected life   5 years
Measurement Input, Option Volatility [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants outstanding, measurement input   61.42
Measurement Input, Expected Dividend Rate [Member]    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Warrants outstanding, measurement input   0
XML 73 R54.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Recognized Stock-based Compensation Expense (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense $ 5,509,404 $ 2,738,041
Warrant [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense 303,802
Share-based Payment Arrangement, Option [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense 292,754 901,345
Restricted Stock Units (RSUs) [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense 5,164,750 500,861
Share-based Payment Arrangement [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation expense $ 51,900 $ 1,032,033
XML 74 R55.htm IDEA: XBRL DOCUMENT v3.22.1
Stock-Based Compensation (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Warrants exercisable 70,000  
Warrants purchase 456,000  
Third Parties [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares issued for services 5,548  
Warrant [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Intrinsic value of options outstanding $ 497,000  
Stock Options [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 1,300,000 $ 11,800,000
Intrinsic value of options outstanding $ 7,600,000 7,100,000
Unvested options 16,666  
Unrecognized stock-based compensation $ 78,115  
Unrecognized stock-based compensation recognition period 6 months  
Intrinsic value of warrants exercised $ 0 $ 9,700,000
Restricted Stock Units (RSUs) [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Unrecognized stock-based compensation $ 11,600,000  
Unrecognized stock-based compensation recognition period 2 years 3 months 18 days  
Restricted Stock [Member] | Third Parties [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Number of shares issued for services 5,548 83,935
2015 Long Term Incentive Plan [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Aggregate number of common shares reserved 6,000,000  
Number of common shares availalble for issuance 2,095,266  
XML 75 R56.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Components Income Tax Provision (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Current:    
Federal $ 6,092,730
State 886,173 637,760
Total current 6,978,903 637,760
Deferred:    
Federal 1,394,686 (452,544)
State 603,642 (94,680)
Total deferred 1,998,328 (547,224)
Total income tax expense $ 8,977,231 $ 90,536
XML 76 R57.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Benefit from Income Taxes and Effective Tax Rates (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Federal income tax expense at statutory rate 21.00% 21.00%
State income tax expense, net of federal tax benefit 3.90% 3.30%
Permanent differences:    
- Foreign derived intangible income deduction (3.50%) (1.70%)
- Stock based compensation 0.20% (8.80%)
- Other permanent differences 0.30% (0.40%)
Research and development credits (2.60%) (2.00%)
Change in uncertain tax positions 1.40% 1.10%
Change in valuation allowance 0.00% (12.10%)
Other (1.00%) (0.20%)
Effective income tax rate 19.70% 0.20%
XML 77 R58.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Deferred Tax Assets (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Deferred tax assets:    
Accrued liabilities $ 37,898
Reserves and allowances 166,050 200,049
Deferred compensation 393,871 241,652
Research and development credits 423,001
Total deferred tax assets 559,921 902,600
Deferred tax liabilities:    
Property and equipment, net (477,542) (233,951)
Intangibles, net (6,743,972)
Prepaids (560,093) (66,456)
Other (6,758) (54,969)
Total deferred tax liabilities (7,788,365) (355,376)
Net deferred tax assets (liabilities) (7,228,444) 547,224
Less valuation allowance
Net deferred tax assets (liabilities) (7,228,444) (547,224)
Net deferred tax assets (liabilities) $ 7,228,444 $ 547,224
XML 78 R59.htm IDEA: XBRL DOCUMENT v3.22.1
Schedule of Unrecognized Tax Benefits (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Unrecognized tax benefits at the beginning of the year $ 447,831
Gross increases - current year tax positions 770,069 232,145
Gross increases - prior year tax positions 215,686
Gross decreases- prior year tax positions (150,047)
Unrecognized tax benefits at end of year 1,067,853 447,831
Interest and penalities in year- end balance
XML 79 R60.htm IDEA: XBRL DOCUMENT v3.22.1
Income Taxes (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Net operating loss carry-forwards   $ 0
Research and development credit carry forwards $ 423,001
Deferred tax valuation allowance 5,161,500  
Unrecognized tax benefits that would impact effective tax rate $ 447,831 $ 1,067,853
XML 80 R61.htm IDEA: XBRL DOCUMENT v3.22.1
Related Party Transactions (Details Narrative) - Exclusive License Agreement [Member] - Dr. Brent Satterfield [Member] - USD ($)
 1 Months Ended
Jan. 30, 2017
Dec. 31, 2021
Jan. 01, 2017
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Accrued royalties     $ 700,000
Payment for royalties per month $ 10,000    
Due to related party   $ 0  
XML 81 R62.htm IDEA: XBRL DOCUMENT v3.22.1
Commitments and Contingencies (Details Narrative)
 12 Months Ended
Dec. 31, 2021
USD ($)
a
Dec. 31, 2020
USD ($)
Feb. 29, 2020
Commitments and Contingencies Disclosure [Abstract]      
Operating lease, term     4 years
Area of land | a 13,687    
Payments for rent $ 28,825    
Lease expiration date Feb. 29, 2024    
Rent expenses $ 346,350 $ 311,963  
XML 82 R63.htm IDEA: XBRL DOCUMENT v3.22.1
Subsequent Events (Details Narrative)
$ in Millions
 1 Months Ended
Mar. 31, 2022
USD ($)
Subsequent Event [Member] | Common Stock [Member] | Maximum [Member]  
Subsequent Event [Line Items]  
Employee stock purchase plan $ 30.0
XML 83 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001692415 2021-01-01 2021-12-31 0001692415 2021-06-30 0001692415 2022-03-23 0001692415 2021-12-31 0001692415 2020-12-31 0001692415 2020-01-01 2020-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001692415 us-gaap:CommonStockMember 2019-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001692415 us-gaap:RetainedEarningsMember 2019-12-31 0001692415 2019-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001692415 us-gaap:CommonStockMember 2020-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001692415 us-gaap:RetainedEarningsMember 2020-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001692415 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001692415 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001692415 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001692415 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001692415 us-gaap:CommonStockMember 2021-12-31 0001692415 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001692415 us-gaap:RetainedEarningsMember 2021-12-31 0001692415 us-gaap:IPOMember 2020-01-01 2020-12-31 0001692415 srt:MinimumMember 2021-01-01 2021-12-31 0001692415 srt:MaximumMember 2021-01-01 2021-12-31 0001692415 CODX:TwoCustomersTogetherMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001692415 CODX:TwoCustomersTogetherMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001692415 CODX:TwoCustomersTogetherMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001692415 CODX:TwoCustomersTogetherMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001692415 CODX:AdvancedConceptionsIncAndIdahoMolecularIncMember 2021-12-30 2021-12-31 0001692415 CODX:AdvancedConceptionsIncAndIdahoMolecularIncMember 2021-12-31 0001692415 CODX:AdvancedConceptionsIncMember 2021-01-01 2021-12-31 0001692415 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001692415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001692415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001692415 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001692415 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001692415 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001692415 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001692415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001692415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001692415 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001692415 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001692415 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001692415 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001692415 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001692415 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001692415 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001692415 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001692415 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001692415 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001692415 us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001692415 CODX:MeasurementInputStrikePriceMember 2021-12-31 0001692415 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001692415 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001692415 us-gaap:MeasurementInputExpectedTermMember 2021-01-01 2021-12-31 0001692415 CODX:MeasurementInputCostOfCapitalMember 2021-12-31 0001692415 us-gaap:MeasurementInputDiscountRateMember 2021-12-31 0001692415 CODX:MeasurementInputEquityVolatilityMember 2021-12-31 0001692415 CODX:MeasurementInputAssetVolatilityMember 2021-12-31 0001692415 CODX:MeasurementInputRevenueVolatilityMember 2021-12-31 0001692415 srt:MinimumMember us-gaap:EquipmentMember 2021-01-01 2021-12-31 0001692415 srt:MaximumMember us-gaap:EquipmentMember 2021-01-01 2021-12-31 0001692415 us-gaap:EquipmentMember 2021-12-31 0001692415 us-gaap:EquipmentMember 2020-12-31 0001692415 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2021-01-01 2021-12-31 0001692415 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001692415 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001692415 srt:MinimumMember us-gaap:OfficeEquipmentMember 2021-01-01 2021-12-31 0001692415 srt:MaximumMember us-gaap:OfficeEquipmentMember 2021-01-01 2021-12-31 0001692415 us-gaap:OfficeEquipmentMember 2021-12-31 0001692415 us-gaap:OfficeEquipmentMember 2020-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2021-01-01 2021-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2021-12-31 0001692415 us-gaap:InProcessResearchAndDevelopmentMember 2020-12-31 0001692415 srt:MinimumMember us-gaap:NoncompeteAgreementsMember 2021-01-01 2021-12-31 0001692415 srt:MaximumMember us-gaap:NoncompeteAgreementsMember 2021-01-01 2021-12-31 0001692415 us-gaap:NoncompeteAgreementsMember 2021-12-31 0001692415 us-gaap:NoncompeteAgreementsMember 2020-12-31 0001692415 srt:AmericasMember 2021-01-01 2021-12-31 0001692415 srt:AmericasMember 2020-01-01 2020-12-31 0001692415 CODX:RestOfWorldMember 2021-01-01 2021-12-31 0001692415 CODX:RestOfWorldMember 2020-01-01 2020-12-31 0001692415 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0001692415 srt:AmericasMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-12-31 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-12-31 0001692415 CODX:RestOfWorldMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-12-31 0001692415 CODX:OptionsMember 2021-01-01 2021-12-31 0001692415 CODX:ThirdPartiesMember 2021-01-01 2021-12-31 0001692415 CODX:AdvancedConceptionsIncAndIdahoMolecularIncMember 2021-01-01 2021-12-31 0001692415 CODX:CommonStockThreeMember 2020-01-01 2020-12-31 0001692415 CODX:CommonStockThreeMember 2020-12-31 0001692415 CODX:CommonStockOneMember 2020-01-01 2020-12-31 0001692415 CODX:CommonStockOneMember 2020-12-31 0001692415 CODX:CommonStockTwoMember 2020-01-01 2020-12-31 0001692415 CODX:CommonStockTwoMember 2020-12-31 0001692415 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001692415 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001692415 CODX:OptionsMember 2020-01-01 2020-12-31 0001692415 CODX:InvestmentRelationsServicesMember 2020-01-01 2020-12-31 0001692415 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001692415 CODX:TwoThousandFifteenLongTermIncentivePlanMember 2021-12-31 0001692415 CODX:StockOptionsMember 2021-01-01 2021-12-31 0001692415 CODX:StockOptionsMember 2020-01-01 2020-12-31 0001692415 CODX:StockOptionsMember 2021-12-31 0001692415 CODX:StockOptionsMember 2020-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0001692415 us-gaap:WarrantMember 2021-12-31 0001692415 CODX:ThirdPartiesMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001692415 CODX:ThirdPartiesMember us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001692415 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001692415 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001692415 us-gaap:MeasurementInputExpectedTermMember 2020-12-31 0001692415 us-gaap:MeasurementInputOptionVolatilityMember 2020-12-31 0001692415 us-gaap:MeasurementInputExpectedDividendRateMember 2020-12-31 0001692415 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001692415 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001692415 us-gaap:StockCompensationPlanMember 2021-01-01 2021-12-31 0001692415 us-gaap:StockCompensationPlanMember 2020-01-01 2020-12-31 0001692415 CODX:DrBrentSatterfieldMember CODX:ExclusiveLicenseAgreementMember 2017-01-01 0001692415 CODX:DrBrentSatterfieldMember CODX:ExclusiveLicenseAgreementMember 2017-01-01 2017-01-30 0001692415 CODX:DrBrentSatterfieldMember CODX:ExclusiveLicenseAgreementMember 2021-12-31 0001692415 2020-02-29 0001692415 srt:MaximumMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2022-03-01 2022-03-31 iso4217:USD shares iso4217:USD shares pure utr:acre 0001692415 false FY P3Y 2024-02-29 10-K true 2021-12-31 --12-31 2021 false 001-38148 CO-DIAGNOSTICS, INC. UT 46-2609396 2401 S. Foothill Drive Salt Lake City UT 84109 (801) 438-1036 Common Stock CODX NASDAQ No No Yes Yes Non-accelerated Filer true true false false false 229000000 33965318 457 Haynie & Company Salt Lake City, Utah 88607234 42976713 1255266 4335446 20839182 12136833 2004169 7995189 2338444 369028 75000 115119295 67813209 1933216 949639 14706818 27195000 1004953 1927125 547224 75000 160034282 71237197 607506 598318 3859652 2849503 120000 5767304 2213088 189729 150000 305307 12597550 4062857 1067853 447831 7228444 4665337 30000 12961634 477831 25559184 4540688 0.001 0.001 5000000 5000000 0 0 0 0 0.001 0.001 100000000 100000000 33819862 33819862 28558033 28558033 33820 28558 80271999 49157236 54169279 17510715 134475098 66696509 160034282 71237197 97885603 74552758 11574944 16591346 86310659 57961412 13397813 4665113 11550615 8278734 14961916 3185290 335363 138635 40245707 16267772 46064952 41693640 45631 97215 -44355 -175 -430433 778385 -429157 875425 45635795 42569065 8977231 90536 36658564 42478529 1.27 1.59 1.23 1.52 28874555 26720133 29903686 28000341 25600 26 17342922 17343 26687701 -24967814 1737256 1457922 7242954 7243 18004840 18012083 856660 857 269143 270000 871229 871 1459729 1460600 110935 111 2737930 2738041 -25600 -26 2133333 2133 -2107 42478529 42478529 28558033 28558 49157236 17510715 66696509 189225 189 450209 450398 444050 444 5508960 5509404 4628554 4629 25155594 25160223 36658564 36658564 33819862 33820 80271999 54169279 134475098 36658564 42478529 335363 138635 5509404 2738041 -430433 778385 -44355 -175 930081 -547224 69672 954804 8740851 12960255 2049095 6462 -5705361 7915241 -155307 303984 2643381 -299937 3758634 41081424 28165235 669463 774397 9310000 3080180 4974554 -491739 714500 -1196243 4098699 -5824343 19470005 450398 1730599 1457921 450398 19742683 45630521 42083575 42976713 893138 88607234 42976713 5403769 285659 117220 25160223 10432641 <p id="xdx_803_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zViDTTJzsjn1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_826_zVZX3WS0IVqh">Overview and Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description of Business</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 27.35pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CODX”), is developing robust and innovative molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The Company develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA). In connection with the sale of these tests, the Company may sell diagnostic equipment and supplies from other manufacturers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Such estimates include receivables and other long-lived assets, legal and regulatory contingencies, income taxes, share based arrangements, and others. These estimates and assumptions are based on management’s best estimates and judgments. Actual amounts and results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis of Presentation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying audited consolidated financial statements of Co-Diagnostics, Inc. and its wholly owned subsidiaries have been prepared to reflect the financial position, results of operations and cash flows of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). All intercompany balances and transactions have been eliminated.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zZvbhRl4Iz1e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 – <span id="xdx_821_zU6BuBbOGXhg">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span> </span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span/></b></span></p> <p id="xdx_84B_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zi8aFsvzRVve" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zAoIg8kWVcdk">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zAEuygpiqKti" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_ziYlQl5jWyil">Cash and Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of December 31, 2021 and December 31, 2020. <span style="background-color: white">The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--MarketableSecuritiesPolicy_zEkaO0DuWUV1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z8zyii7eq2Dg">Marketable Investment Securities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s marketable investment securities are comprised of investments in certificates of deposit. The Company determines the appropriate classification of its marketable investment securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable investment securities as available-for-sale securities as the Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. <span style="background-color: white">As a result, the Company classifies its marketable investment securities, including securities with stated maturities beyond twelve months, within current assets in the consolidated balance sheets. Any unrealized gains or losses are immaterial.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zL1H9FQgXxu6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zS9Rdy5AqzQ4">Accounts Receivable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At December 31, 2021 total accounts receivable was $<span id="xdx_901_eus-gaap--AccountsReceivableGrossCurrent_iI_c20211231_zOAQgcFKeBYb" title="Accounts receivable">21,508,779</span> with an allowance for uncollectable accounts of $<span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20211231_zImDyFlHgufj" title="Doubtful accounts">669,597</span> resulting in a net amount of $<span id="xdx_908_eus-gaap--AccountsReceivableNetCurrent_iI_c20211231_z7PGGylXtnzf" title="Accounts receivable, net">20,839,182</span>. At December 31, 2020 total accounts receivable was $<span id="xdx_905_eus-gaap--AccountsReceivableGrossCurrent_iI_c20201231_z4a7LOTJeLE7" title="Accounts receivable">12,928,633</span> with an allowance for uncollectable accounts of $<span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20201231_zCx8z6rWx1a7" title="Doubtful accounts">791,800</span> resulting in a net amount of $<span id="xdx_90A_eus-gaap--AccountsReceivableNetCurrent_iI_c20201231_zXZfHRrSF902" title="Accounts receivable, net">12,136,833</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84D_eus-gaap--EquityMethodInvestmentsPolicy_ztbBNvBVoR8j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zFn8BCB5naEa">Equity-Method Investments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--InventoryPolicyTextBlock_zJSxdKriX1Ci" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zWipfv52qduc">Inventory</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At December 31, 2021, the Company had $<span id="xdx_903_eus-gaap--InventoryNet_iI_c20211231_zV3jP1EBL2Mb" title="Inventory">2,004,169</span> in inventory, of which $<span id="xdx_90F_eus-gaap--InventoryFinishedGoods_iI_c20211231_zNGFDafzIySh" title="Inventory finished goods">983,088</span> was finished goods and $<span id="xdx_905_eus-gaap--InventoryRawMaterials_iI_c20211231_zRZL4rZ6qlq8" title="Inventory raw materials">1,021,081</span> was raw materials. At December 31, 2020, the Company had $<span id="xdx_902_eus-gaap--InventoryNet_iI_pp0p0_c20201231_zkIsHkOENCVj" title="Inventory">7,995,189</span> in inventory, of which $<span id="xdx_904_eus-gaap--InventoryFinishedGoods_iI_c20201231_zhhvjQt001Tl" title="Inventory finished goods">598,881</span> was finished goods and $<span id="xdx_901_eus-gaap--InventoryRawMaterials_iI_c20201231_zQytWTMDTJh1" title="Inventory raw materials">7,396,308</span> was raw materials. The Company establishes reserves to reduce low-moving, obsolete, or unusable inventories to their estimated useful or scrap values.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zyNrfAjMIfzd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zYPmYxw5nTv">Property and Equipment</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from <span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_za0xhBcz5AD5" title="Estimated useful life of property::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0552">three</span></span> to <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zUqkJ543Nmrc" title="Estimated useful life of property">five years</span>. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews its long-lived assets, including property and equipment, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--BusinessCombinationsPolicy_zTCL6gqF6Rp" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zcbUrRrw8YHd">Business Combinations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We estimate the fair value of assets acquired and liabilities assumed in a business combination. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable, and as a result, actual results may differ from estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--RevenueRecognitionPolicyTextBlock_z3JAUr1XuWyc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zganBGX8MqZ">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation. Based on the criteria above, the Company typically recognizes revenue upon delivery.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zsoZvNpjt0Bg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_z0uMxqmiKJ93">Deferred Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_ztREKtIsiORl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z8fievGR2Eid">Research and Development</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs are expensed when incurred. The Company expensed $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231_zD31grYExex" title="Research and development costs">14,961,916</span> and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231_zgepmEXfZlw2" title="Research and development costs">3,185,290</span> of research and development costs for the years ended December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zp8VINkOnaL4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zfB04oP1hJfg">Stock-based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. <span style="background-color: white">When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zTeCsQ39ZPFe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zP3LKUDC7qK8">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, d</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">eferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. While the Company believes it has no significant uncertain income tax positions in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zayB3iewlqZh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zJfGUtsg9uCh">Net Income per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zYmv9p6Ni7H6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zqsZadBcpIh">Concentrations Risk and Significant Customers</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company had certain customers which are each responsible for generating 10% or more of the total revenue for the years ended December 31, 2021 and 2020. Two customers together accounted for approximately <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zXaRhfoyQkEg" title="Concentration risk percentage">48</span>% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z1BK5OEfUokd" title="Concentration risk percentage">38</span>% of total revenue for the years ended December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Two customers each accounted for more than 10% of accounts receivable at December 31, 2021 and 2020. These two customers together accounted for approximately <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z1A6UaIYLXXj" title="Concentration risk percentage">66</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zJm7LCpDZZgi" title="Concentration risk percentage">48</span>% of accounts receivable at December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqf5gUrlXHAe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zmlRakIHjUGl">Recently Issued Accounting Standards</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As an emerging growth company (“EGC”), the Company has elected to take advantage of the benefits of the extended transition period provided for in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards which allows the Company to defer adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires recognition of leased assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies like us. The Company will use the modified retrospective transition method with the option to recognize a cumulative-effect adjustment at the date of adoption. The Company’s balance sheet will be impacted as it records right-of-use assets and lease liabilities on its consolidated balance sheets, but the Company does not expect the adoption of this standard will have a material impact on its consolidated statements of operations and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for certain financial instruments, which includes the Company’s accounts receivable. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies. The standard requires a cumulative effect adjustment to the balance sheet as of the beginning of the first early reporting period in which the guidance is effective. The Company is evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements but does not expect the adoption of this standard will have a material impact on its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zi8aFsvzRVve" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zAoIg8kWVcdk">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zAEuygpiqKti" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_ziYlQl5jWyil">Cash and Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents consist of cash on hand, money market funds and highly liquid investments with an original maturity date of 90 days or less from the date of purchase. The fair value of cash equivalents approximated their carrying value as of December 31, 2021 and December 31, 2020. <span style="background-color: white">The Company has its cash and cash equivalents with a large creditworthy financial institution and the balance exceeded federally insured limits. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on cash and cash equivalents.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--MarketableSecuritiesPolicy_zEkaO0DuWUV1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_z8zyii7eq2Dg">Marketable Investment Securities</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s marketable investment securities are comprised of investments in certificates of deposit. The Company determines the appropriate classification of its marketable investment securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable investment securities as available-for-sale securities as the Company may sell these securities at any time for use in its current operations or for other purposes, even prior to maturity. <span style="background-color: white">As a result, the Company classifies its marketable investment securities, including securities with stated maturities beyond twelve months, within current assets in the consolidated balance sheets. Any unrealized gains or losses are immaterial.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zL1H9FQgXxu6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zS9Rdy5AqzQ4">Accounts Receivable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade accounts receivable are recorded at the invoiced amount (net of allowance) and do not bear interest. The Company maintains an allowance for doubtful accounts for amounts the Company does not expect to collect. In establishing the required allowance, management considers historical losses, current market condition, customers’ financial condition, the age of receivables, and current payment patterns. Account balances are written off against the allowance once the receivable is deemed uncollectible. Recoveries of trade receivables previously written off are recorded when collected. At December 31, 2021 total accounts receivable was $<span id="xdx_901_eus-gaap--AccountsReceivableGrossCurrent_iI_c20211231_zOAQgcFKeBYb" title="Accounts receivable">21,508,779</span> with an allowance for uncollectable accounts of $<span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20211231_zImDyFlHgufj" title="Doubtful accounts">669,597</span> resulting in a net amount of $<span id="xdx_908_eus-gaap--AccountsReceivableNetCurrent_iI_c20211231_z7PGGylXtnzf" title="Accounts receivable, net">20,839,182</span>. At December 31, 2020 total accounts receivable was $<span id="xdx_905_eus-gaap--AccountsReceivableGrossCurrent_iI_c20201231_z4a7LOTJeLE7" title="Accounts receivable">12,928,633</span> with an allowance for uncollectable accounts of $<span id="xdx_905_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20201231_zCx8z6rWx1a7" title="Doubtful accounts">791,800</span> resulting in a net amount of $<span id="xdx_90A_eus-gaap--AccountsReceivableNetCurrent_iI_c20201231_zXZfHRrSF902" title="Accounts receivable, net">12,136,833</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 21508779 669597 20839182 12928633 791800 12136833 <p id="xdx_84D_eus-gaap--EquityMethodInvestmentsPolicy_ztbBNvBVoR8j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zFn8BCB5naEa">Equity-Method Investments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our equity method investments are initially recorded at cost and are included in other long-term assets in the accompanying consolidated balance sheet. We adjust the carrying value of our investment based on our share of the earnings or losses in the periods which they are reported by the investee until the carrying amount is zero. The earnings or losses are included in other income (expense) in the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--InventoryPolicyTextBlock_zJSxdKriX1Ci" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zWipfv52qduc">Inventory</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory is stated at the lower of cost or net-realizable value. Inventory cost is determined on a first-in first-out basis that approximates average cost in accordance with ASC 330-10-30-12. At December 31, 2021, the Company had $<span id="xdx_903_eus-gaap--InventoryNet_iI_c20211231_zV3jP1EBL2Mb" title="Inventory">2,004,169</span> in inventory, of which $<span id="xdx_90F_eus-gaap--InventoryFinishedGoods_iI_c20211231_zNGFDafzIySh" title="Inventory finished goods">983,088</span> was finished goods and $<span id="xdx_905_eus-gaap--InventoryRawMaterials_iI_c20211231_zRZL4rZ6qlq8" title="Inventory raw materials">1,021,081</span> was raw materials. At December 31, 2020, the Company had $<span id="xdx_902_eus-gaap--InventoryNet_iI_pp0p0_c20201231_zkIsHkOENCVj" title="Inventory">7,995,189</span> in inventory, of which $<span id="xdx_904_eus-gaap--InventoryFinishedGoods_iI_c20201231_zhhvjQt001Tl" title="Inventory finished goods">598,881</span> was finished goods and $<span id="xdx_901_eus-gaap--InventoryRawMaterials_iI_c20201231_zQytWTMDTJh1" title="Inventory raw materials">7,396,308</span> was raw materials. The Company establishes reserves to reduce low-moving, obsolete, or unusable inventories to their estimated useful or scrap values.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 2004169 983088 1021081 7995189 598881 7396308 <p id="xdx_846_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zyNrfAjMIfzd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zYPmYxw5nTv">Property and Equipment</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the property, generally from <span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtYxL_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_za0xhBcz5AD5" title="Estimated useful life of property::XDX::P3Y"><span style="-sec-ix-hidden: xdx2ixbrl0552">three</span></span> to <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dc_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zUqkJ543Nmrc" title="Estimated useful life of property">five years</span>. Repairs and maintenance costs are expensed as incurred except when such repairs significantly add to the useful life or productive capacity of the asset, in which case the repairs are capitalized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company reviews its long-lived assets, including property and equipment, for impairment whenever an event or change in facts and circumstances indicates that their carrying amounts may not be recoverable. Recoverability of these assets is measured by comparing the carrying amount to the estimated undiscounted future cash flows expected to be generated. If the carrying amount exceeds the undiscounted cash flows, the assets are determined to be impaired and an impairment charge is recognized as the amount by which the carrying amount exceeds fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P5Y <p id="xdx_846_eus-gaap--BusinessCombinationsPolicy_zTCL6gqF6Rp" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zcbUrRrw8YHd">Business Combinations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We estimate the fair value of assets acquired and liabilities assumed in a business combination. Goodwill as of the acquisition date is measured as the excess of consideration transferred over the net of the acquisition date fair values of the assets acquired and the liabilities assumed. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable, and as a result, actual results may differ from estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--RevenueRecognitionPolicyTextBlock_z3JAUr1XuWyc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zganBGX8MqZ">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company generates revenue from product sales and license sales. The Company recognizes revenue when all of the following criteria are satisfied: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when, or as the Company satisfies each performance obligation. Based on the criteria above, the Company typically recognizes revenue upon delivery.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as deferred revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zsoZvNpjt0Bg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_z0uMxqmiKJ93">Deferred Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred revenue primarily consists of payments received from customers prior to the Company fulfilling its performance obligation of providing the product. When this occurs, the Company records a contract liability as deferred revenue. Deferred revenue is recognized as revenue as the related performance obligations are satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_ztREKtIsiORl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z8fievGR2Eid">Research and Development</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs are expensed when incurred. The Company expensed $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20211231_zD31grYExex" title="Research and development costs">14,961,916</span> and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20201231_zgepmEXfZlw2" title="Research and development costs">3,185,290</span> of research and development costs for the years ended December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 14961916 3185290 <p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zp8VINkOnaL4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zfB04oP1hJfg">Stock-based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has granted stock-based awards, including restricted stock, stock options, stock warrants and restricted stock units (“RSUs”), to its employees, certain consultants and members of its board of directors. The Company records stock-based compensation based on the grant date fair value of the awards and recognizes the fair value of those awards as expense using the straight-line method over the requisite service period of the award. The Company estimates the grant date fair value of stock options using the Black-Scholes option-pricing model. <span style="background-color: white">When an award is forfeited prior to the vesting date, the Company recognizes an adjustment for the previously recognized expense in the period of the forfeiture.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zTeCsQ39ZPFe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zP3LKUDC7qK8">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company accounts for income taxes in accordance with the liability method of accounting for income taxes. Under this method, d</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">eferred income tax assets and deferred income tax liabilities represent the tax effect of temporary differences between financial reporting and tax reporting measured at enacted tax rates in effect for the year in which the differences are expected to reverse. The Company recognizes only the impact of tax positions that, based on their technical merits, are more likely than not to be sustained upon an audit by the taxing authority.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowances are provided when it is more-likely-than-not that some or all of the deferred income tax assets may not be realized. In assessing the need for a valuation allowance, the Company has considered its historical levels of income, expectations of future taxable income and ongoing tax planning strategies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify; text-indent: 35.65pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing the provision for income taxes, including the effective tax rate and analysis of potential tax exposure items, if any, requires significant judgment and expertise in federal and state income tax laws, regulations and strategies, including the determination of deferred income tax assets and liabilities and any estimated valuation allowances deemed necessary to value deferred income tax assets. Judgments and tax strategies are subject to audit by various taxing authorities. While the Company believes it has no significant uncertain income tax positions in the consolidated financial statements, adverse determinations by these taxing authorities could have a material adverse effect on the consolidated financial positions, result of operations, or cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zayB3iewlqZh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zJfGUtsg9uCh">Net Income per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic net income or loss per common share is computed by dividing net income or loss applicable to common shareholders by the weighted average number of shares outstanding during each period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted net income or loss per share is computed by dividing net income or loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period increased by common shares that could be issued upon conversion or exercise of other outstanding securities to the extent those additional common shares would be dilutive. The dilutive effect of potentially dilutive securities is reflected in diluted net income or loss per share by application of the treasury stock method. During periods when the Company is in a net loss position, basic net loss per share is the same as diluted net loss per share as the effects of potentially dilutive securities are anti-dilutive</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zYmv9p6Ni7H6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zqsZadBcpIh">Concentrations Risk and Significant Customers</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company had certain customers which are each responsible for generating 10% or more of the total revenue for the years ended December 31, 2021 and 2020. Two customers together accounted for approximately <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zXaRhfoyQkEg" title="Concentration risk percentage">48</span>% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_z1BK5OEfUokd" title="Concentration risk percentage">38</span>% of total revenue for the years ended December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Two customers each accounted for more than 10% of accounts receivable at December 31, 2021 and 2020. These two customers together accounted for approximately <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z1A6UaIYLXXj" title="Concentration risk percentage">66</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zJm7LCpDZZgi" title="Concentration risk percentage">48</span>% of accounts receivable at December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 0.48 0.38 0.66 0.48 <p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zqf5gUrlXHAe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zmlRakIHjUGl">Recently Issued Accounting Standards</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company’s financial statements upon adoption.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As an emerging growth company (“EGC”), the Company has elected to take advantage of the benefits of the extended transition period provided for in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards which allows the Company to defer adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which requires recognition of leased assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. This update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies like us. The Company will use the modified retrospective transition method with the option to recognize a cumulative-effect adjustment at the date of adoption. The Company’s balance sheet will be impacted as it records right-of-use assets and lease liabilities on its consolidated balance sheets, but the Company does not expect the adoption of this standard will have a material impact on its consolidated statements of operations and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for certain financial instruments, which includes the Company’s accounts receivable. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss methodology, which will result in more timely recognition of credit losses. The update is effective for annual periods and interim periods with those periods beginning after December 15, 2021, for public EGC companies. The standard requires a cumulative effect adjustment to the balance sheet as of the beginning of the first early reporting period in which the guidance is effective. The Company is evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements but does not expect the adoption of this standard will have a material impact on its consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_801_eus-gaap--BusinessCombinationDisclosureTextBlock_zg4dAP4st03c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 – <span id="xdx_828_zSijg2TlSQJj">Business Combinations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 31, 2021, the Company completed its acquisition of Advanced Conceptions, Inc. (“ACI”) and Idaho Molecular Inc. (“IdMo”), which were related entities developing, with the Company, an at-home/point-of-care medical diagnostic device. Upon the completion of the acquisition, all outstanding ACI and Idaho Molecular common stock was exchanged for approximately <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20211230__20211231__us-gaap--BusinessAcquisitionAxis__custom--AdvancedConceptionsIncAndIdahoMolecularIncMember_zyJnNDdWy6gj" title="Number of shares exchanged">3.2 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million shares of the Company’s common stock and contingent consideration that includes up to approximately <span id="xdx_905_ecustom--StockIssuedDuringPeriodSharesContingentConsideration_pn5n6_c20211230__20211231__us-gaap--BusinessAcquisitionAxis__custom--AdvancedConceptionsIncAndIdahoMolecularIncMember_zEwYAOgdY56h" title="Number of shares on contingent consideration">1.4 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million shares and approximately <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231__us-gaap--BusinessAcquisitionAxis__custom--AdvancedConceptionsIncAndIdahoMolecularIncMember_zIGTs6YST2wi" title="Warrants to purchase shares of common stock">456,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants to purchase shares of the Company’s common stock. The contingent consideration is based on the achievement of certain milestones, which include regulatory approval for identified products, as well as production and net revenue targets. The purchase consideration also includes a payable to a shareholder of ACI of $<span id="xdx_90A_ecustom--PaymentsToShareHoldersValueAcquisitions_pp0p0_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--AdvancedConceptionsIncMember_zl1KWMGqaIrb" title="Payable to shareholders">100,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. In connection with the acquisition, the Company incurred transaction costs of approximately $<span id="xdx_902_eus-gaap--GeneralAndAdministrativeExpense_c20211230__20211231__us-gaap--BusinessAcquisitionAxis__custom--AdvancedConceptionsIncAndIdahoMolecularIncMember_zKMIc0OgmdF1" title="General and administrative expense">151,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, which is included in general and administrative expenses. Upon the completion of the acquisition, both ACI and IdMo became <span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20211231__us-gaap--BusinessAcquisitionAxis__custom--AdvancedConceptionsIncAndIdahoMolecularIncMember_zmv1xruS6QLc" style="font: 10pt Times New Roman, Times, Serif" title="Equity method investment ownership percentage">100</span>% wholly-owned subsidiaries of the Company</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_zMyaT089AjJl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of assets acquired and liabilities assumed was based on a preliminary valuation, and our estimates and assumptions are subject to change within the measurement period. The primary area that remains preliminary relates to the evaluation of certain tax-related items and potential minor adjustments to the purchase consideration. The total purchase consideration was allocated to the assets acquired and liabilities assumed as set forth below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zeoPe8gqz1z8" style="display: none">Schedule of Assets and Liabilities assumed</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 80%">Fair value of common shares issued</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20210101__20211231_zSIcX0lehjo7" style="width: 16%; text-align: right" title="Stock issued during period, value acquisitions">25,160,223</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Payable to shareholder</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--PaymentsToShareHoldersValueAcquisitions_c20210101__20211231_zi5fQ801MlCl" style="text-align: right" title="Payable to shareholders">100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Fair value of contingent shares</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ContingentConsiderationClassifiedAsEquityFairValueDisclosure_iI_c20211231_zbGT0x0sHfO6" style="text-align: right" title="Fair value of contingent shares">8,684,669</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Fair value of contingent warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--WarrantsNotSettleableInCashFairValueDisclosure_iI_c20211231_zg5LBND20pgi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of contingent warrants">1,747,972</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total fair value of consideration transferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--BusinessCombinationConsiderationTransferred1_c20210101__20211231_zqy6Oz1sPUT8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Business combination, consideration transferred">35,692,864</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Identifiable assets acquired and liabilities assumed</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Cash</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_c20211231_zGNojNKtPf72" style="text-align: right" title="Cash">1,196,243</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Accounts receivable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_c20211231_ze2sYQxhW1ke" style="text-align: right" title="Accounts receivables">31,170</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other current assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_iI_c20211231_zGXKFTbAYHW7" style="text-align: right" title="Prepaid expenses and other current assets">70,321</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Property and equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_c20211231_zi1OLYEu7oh7" style="text-align: right" title="Property and equipments">408,173</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Technology - In-process research and development</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities_iI_c20211231_zTnyCjuBKxf2" style="text-align: right" title="Research and development in process">26,101,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Non-competition agreements</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesNonCompetitionAgreements_iI_c20211231_zGl0giuVRrzj" style="text-align: right" title="Non competition agreements">1,094,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Accounts payable and accrued other expenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_iNI_di_c20211231_zqxRfssFTrC5" style="text-align: right" title="Accounts payable and accrued other expenses">(1,069,274</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Deferred tax liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_iNI_di_c20211231_z6VgxFRsjupb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deferred tax liability">(6,845,587</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total identifiable net assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20211231_zJ4NWXt1iuhe" style="text-align: right" title="Total indentifiable net assets">20,986,046</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--Goodwill_iI_c20211231_zeRGg1Z3UsIb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill">14,706,818</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_c20211231_zmsfl4YhDPm4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">35,692,864</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zOc46Aygogt7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The excess of the purchase price over the net assets acquired was recorded as goodwill. Goodwill generated from the acquisition is primarily attributable to assembled workforce and expected growth from future technologies, sales to future customers and buyer specific synergies. Goodwill will not be amortized but instead will be tested for impairment at least annually and more frequently if certain indicators of impairment are present. As a result of the structure of the transaction, the balance of goodwill is not amortizable for tax purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The in-process research and development is considered an indefinite-lived intangible until the completion or abandonment of the research and development activities. The non-competition agreements are being amortized over a range of <span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20210101__20211231__srt--RangeAxis__srt--MinimumMember_zVtQOn4WrEk6" title="Finite lived intangible assets remaining amortization period">1.5</span> to <span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zEYmOMI4xljc" title="Finite lived intangible assets remaining amortization period">3</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As the acquisition was completed on December 31, 2021, the acquired entities did not contribute to the net revenues or to the net income of the Company during the year ended December 31, 2021. Pro forma revenue and results of operations have not been presented because the historical results of ACI and IdMo are not material to the Company’s consolidated financial statements in any period presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3200000 1400000 456000 100000 151000 1 <p id="xdx_890_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_zMyaT089AjJl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of assets acquired and liabilities assumed was based on a preliminary valuation, and our estimates and assumptions are subject to change within the measurement period. The primary area that remains preliminary relates to the evaluation of certain tax-related items and potential minor adjustments to the purchase consideration. The total purchase consideration was allocated to the assets acquired and liabilities assumed as set forth below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BA_zeoPe8gqz1z8" style="display: none">Schedule of Assets and Liabilities assumed</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 80%">Fair value of common shares issued</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodValueAcquisitions_c20210101__20211231_zSIcX0lehjo7" style="width: 16%; text-align: right" title="Stock issued during period, value acquisitions">25,160,223</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Payable to shareholder</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--PaymentsToShareHoldersValueAcquisitions_c20210101__20211231_zi5fQ801MlCl" style="text-align: right" title="Payable to shareholders">100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Fair value of contingent shares</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ContingentConsiderationClassifiedAsEquityFairValueDisclosure_iI_c20211231_zbGT0x0sHfO6" style="text-align: right" title="Fair value of contingent shares">8,684,669</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Fair value of contingent warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--WarrantsNotSettleableInCashFairValueDisclosure_iI_c20211231_zg5LBND20pgi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Fair value of contingent warrants">1,747,972</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Total fair value of consideration transferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--BusinessCombinationConsiderationTransferred1_c20210101__20211231_zqy6Oz1sPUT8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Business combination, consideration transferred">35,692,864</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Identifiable assets acquired and liabilities assumed</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Cash</td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_c20211231_zGNojNKtPf72" style="text-align: right" title="Cash">1,196,243</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Accounts receivable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_iI_c20211231_ze2sYQxhW1ke" style="text-align: right" title="Accounts receivables">31,170</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other current assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_iI_c20211231_zGXKFTbAYHW7" style="text-align: right" title="Prepaid expenses and other current assets">70,321</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Property and equipment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_c20211231_zi1OLYEu7oh7" style="text-align: right" title="Property and equipments">408,173</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Technology - In-process research and development</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities_iI_c20211231_zTnyCjuBKxf2" style="text-align: right" title="Research and development in process">26,101,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Non-competition agreements</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesNonCompetitionAgreements_iI_c20211231_zGl0giuVRrzj" style="text-align: right" title="Non competition agreements">1,094,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Accounts payable and accrued other expenses</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_iNI_di_c20211231_zqxRfssFTrC5" style="text-align: right" title="Accounts payable and accrued other expenses">(1,069,274</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Deferred tax liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_iNI_di_c20211231_z6VgxFRsjupb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Deferred tax liability">(6,845,587</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total identifiable net assets</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_c20211231_zJ4NWXt1iuhe" style="text-align: right" title="Total indentifiable net assets">20,986,046</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--Goodwill_iI_c20211231_zeRGg1Z3UsIb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Goodwill">14,706,818</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Total</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_iI_c20211231_zmsfl4YhDPm4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">35,692,864</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 25160223 100000 8684669 1747972 35692864 1196243 31170 70321 408173 26101000 1094000 1069274 6845587 20986046 14706818 35692864 P1Y6M P3Y <p id="xdx_806_eus-gaap--FairValueDisclosuresTextBlock_z1iCfsL3Q5Rj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 – <span id="xdx_823_zkSlaXpyiyE6">Fair Value Measurements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures and records certain financial assets and liabilities at fair value on a recurring basis. Fair value is based on the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following three levels of inputs are used to measure the fair value of financial assets and liabilities:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1: Quoted market prices in active markets for identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3: Unobservable inputs that are not corroborated by market data.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zg3518j0zJu6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 and December 31, 2020, by level within the fair value hierarchy:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zk6XPsLODpu4" style="display: none">Schedule of Fair Value Assets and Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1.5pt">Marketable securities (certificates of deposit)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecurities_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zm7IeHnuO84l" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Marketable securities (certificates of deposit)"><span style="-sec-ix-hidden: xdx2ixbrl0642">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--MarketableSecurities_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCqDuq7BltPl" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Marketable securities (certificates of deposit)">1,255,266</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7wCOg6TwcJi" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Marketable securities (certificates of deposit)"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--MarketableSecurities_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z6Xoq3Z3h7je" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Marketable securities (certificates of deposit)">1,255,266</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z6HnSJMIP3mj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0650">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLfFapCIYSqc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">1,255,266</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zynnaJbelf5d" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxvCqoqI6Dy9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">1,255,266</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Contingent consideration - common stock</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_ecustom--FairValueOfContingentConsiderationToCommonStock_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__custom--FairValueByFairValueHierarchyLevelAxAxis__us-gaap--FairValueInputsLevel1Member_zYk3TzBox34f" style="text-align: right" title="Contingent consideration common stock">          <span style="-sec-ix-hidden: xdx2ixbrl0658"> </span>-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_ecustom--FairValueOfContingentConsiderationToCommonStock_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__custom--FairValueByFairValueHierarchyLevelAxAxis__us-gaap--FairValueInputsLevel2Member_zeZSA6wQIdpj" style="text-align: right" title="Contingent consideration common stock">     <span style="-sec-ix-hidden: xdx2ixbrl0660"> </span>-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--FairValueOfContingentConsiderationToCommonStock_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__custom--FairValueByFairValueHierarchyLevelAxAxis__us-gaap--FairValueInputsLevel3Member_z4QZ151PvwFd" style="text-align: right" title="Contingent consideration common stock">8,684,669</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--FairValueOfContingentConsiderationToCommonStock_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdqcT2CDIQme" style="text-align: right" title="Contingent consideration common stock">8,684,669</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Contingent consideration - warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_ecustom--FairValueOfContingentConsiderationToWarrants_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__custom--FairValueByFairValueHierarchyLevelAxAxis__us-gaap--FairValueInputsLevel1Member_zlHrQECDYw94" style="border-bottom: Black 1.5pt solid; text-align: right" title="Contingent consideration warrants"><span style="-sec-ix-hidden: xdx2ixbrl0666">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--FairValueOfContingentConsiderationToWarrants_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__custom--FairValueByFairValueHierarchyLevelAxAxis__us-gaap--FairValueInputsLevel2Member_ztTWsXCnviIi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Contingent consideration warrants"><span style="-sec-ix-hidden: xdx2ixbrl0668">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_ecustom--FairValueOfContingentConsiderationToWarrants_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__custom--FairValueByFairValueHierarchyLevelAxAxis__us-gaap--FairValueInputsLevel3Member_zJcjuEjSz3Cb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Contingent consideration warrants">1,747,972</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--FairValueOfContingentConsiderationToWarrants_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzP0EQYdyFqe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Contingent consideration warrants">1,747,972</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20211231__custom--FairValueByFairValueHierarchyLevelAxAxis__us-gaap--FairValueInputsLevel1Member_zYRGy7WS1HRk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20211231__custom--FairValueByFairValueHierarchyLevelAxAxis__us-gaap--FairValueInputsLevel2Member_z3seBkcPLFj9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0676">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20211231__custom--FairValueByFairValueHierarchyLevelAxAxis__us-gaap--FairValueInputsLevel3Member_zbuLevT9KIs1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities measured at fair value">10,432,641</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20211231_zyrzveZsO1g2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities measured at fair value">10,432,641</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1.5pt">Marketable securities (certificates of deposit)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecurities_iI_c20201231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zPH6PGBvZ6Df" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Marketable securities (certificates of deposit)"><span style="-sec-ix-hidden: xdx2ixbrl0682">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_pp0p0_c20201231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9waNpLhGPM2" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Marketable securities (certificates of deposit)">4,335,446</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecurities_iI_c20201231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUg4dE2FzKYh" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Marketable securities (certificates of deposit)">            <span style="-sec-ix-hidden: xdx2ixbrl0686"> </span>-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--MarketableSecurities_iI_c20201231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQdEXYyHuO3k" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Marketable securities (certificates of deposit)">4,335,446</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zl7q8y6J9524" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0690">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQU0EDOER2Yb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">4,335,446</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh2fpC3Hn111" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0694">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20201231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zOoP6mVLysw6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">4,335,446</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zG1dlgIKWdCa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments that are measured at fair value on a recurring basis consist of certificates of deposit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the acquisitions of Idaho Molecular, Inc and Advanced Conceptions, Inc. on December 31, 2021, the Company recorded a liability for contingent consideration in the form of shares of common stock and warrants to purchase common stock. The fair value of contingent consideration is calculated using a discounted probability weighted valuation model. Discount rates used in such calculation are a significant assumption that are not observed in the market, and therefore, the resulting fair value represents a Level 3 measurement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zGT36wByptkd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The changes for Level 3 items measured at fair value on a recurring basis are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 60pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zVVMJuliFhc4" style="display: none">Schedule of Changes in Fair Value Measurement</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Fair value as of December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iS_c20210101__20211231_z49DilL36i9d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Asset acquisition contingent consideration liability noncurrent"><span style="-sec-ix-hidden: xdx2ixbrl0700">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 70%; text-align: left; padding-bottom: 1.5pt">Contingent considered issued for business acquisitions</td><td style="width: 10%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98C_ecustom--ContingentConsideredIssuedForBusinessAcquisitions_c20210101__20211231_z8ovD4Tn2RPb" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Contingent considered issued for business acquisitions">10,432,641</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Fair value as of December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iE_c20210101__20211231_z5RrSc3eUMj1" style="border-bottom: Black 2.5pt double; text-align: right" title="Asset acquisition contingent consideration liability noncurrent">10,432,641</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zEzlIbdnJhUl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the contingent consideration is based on the fair value of the contingent consideration-common stock and contingent consideration-warrants. The fair value of the contingent consideration-common stock is equal to the probability-adjusted value of the Company’s common stock as of December 31, 2021. The fair value of the contingent consideration-warrants is equal to the probability adjusted value of a call option with terms consistent with the terms of the warrants as of December 31, 2021. Prior to the probability adjustments, the warrants were valued based on the following inputs:</span></p> <p id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zpiccZIH1lX8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> <span id="xdx_8BF_zg3exvZ9JGB1" style="display: none">Schedule of Contingent Consideration Common Stock and Warrants</span></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zpuruaDolIf3" style="width: 16%; text-align: right" title="Warrants measurement input">8.93</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Strike price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputStrikePriceMember_zK3cVOifFAp2" style="text-align: right" title="Warrants measurement input">9.13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zDS5whyEkeba" style="text-align: right" title="Warrants measurement input">80.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zzLfu533sbb1" style="text-align: right" title="Warrants measurement input">1.30</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231_zYjxs60AwO13" style="text-align: right" title="Warrants measurement, term">5.0</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In order to calculate the probability-adjusted value of the contingent consideration-common stock and contingent consideration-warrants, the Company estimated the probability of achieving certain milestones, which include regulatory approval for identified products, as well as production and net revenue targets. The probability of achieving the milestone related to net revenues was estimated using a Monte Carlo simulation valuation model. The unobservable significant inputs to the valuation model were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zqLXGv2Ta1o1" style="width: 16%; text-align: right" title="Business combination,contingent consideration">8.93</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zByYSoOk6oQg" style="text-align: right" title="Business combination,contingent consideration">1.30</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--BusinessCombinationContingentConsiderationLiabilityMeasurementInputExpectedTerm_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zhxoYlmhDPb6" style="text-align: right" title="Business combination,contingent consideration, term">5.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average cost of capital</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputCostOfCapitalMember_zhImkEGhNGik" style="text-align: right" title="Business combination,contingent consideration">27.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenue discount rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zfdaih8MKiT" style="text-align: right" title="Business combination,contingent consideration">9.50</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Equity volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEquityVolatilityMember_z3wiMDKAyeYl" style="text-align: right" title="Business combination,contingent consideration">80.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Asset volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputAssetVolatilityMember_zKh26MPjAQJf" style="text-align: right" title="Business combination,contingent consideration">80.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Revenue volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRevenueVolatilityMember_zIA2hopBBqu5" style="text-align: right" title="Business combination,contingent consideration">30.00</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AB_zXl1kPOQIsf9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value of Other Financial Instruments</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts of certain financial instruments, including cash held in banks, accounts receivable, notes receivable, accounts payable, accrued liabilities, and other liabilities approximate fair value due to their short-term maturities and are excluded from the fair value tables above.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zg3518j0zJu6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the assets and liabilities measured at fair value on a recurring basis as of December 31, 2021 and December 31, 2020, by level within the fair value hierarchy:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zk6XPsLODpu4" style="display: none">Schedule of Fair Value Assets and Liabilities</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1.5pt">Marketable securities (certificates of deposit)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--MarketableSecurities_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zm7IeHnuO84l" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Marketable securities (certificates of deposit)"><span style="-sec-ix-hidden: xdx2ixbrl0642">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--MarketableSecurities_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCqDuq7BltPl" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Marketable securities (certificates of deposit)">1,255,266</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7wCOg6TwcJi" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Marketable securities (certificates of deposit)"><span style="-sec-ix-hidden: xdx2ixbrl0646">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--MarketableSecurities_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z6Xoq3Z3h7je" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Marketable securities (certificates of deposit)">1,255,266</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z6HnSJMIP3mj" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0650">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLfFapCIYSqc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">1,255,266</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zynnaJbelf5d" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0654">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zxvCqoqI6Dy9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">1,255,266</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Contingent consideration - common stock</td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_ecustom--FairValueOfContingentConsiderationToCommonStock_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__custom--FairValueByFairValueHierarchyLevelAxAxis__us-gaap--FairValueInputsLevel1Member_zYk3TzBox34f" style="text-align: right" title="Contingent consideration common stock">          <span style="-sec-ix-hidden: xdx2ixbrl0658"> </span>-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_ecustom--FairValueOfContingentConsiderationToCommonStock_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__custom--FairValueByFairValueHierarchyLevelAxAxis__us-gaap--FairValueInputsLevel2Member_zeZSA6wQIdpj" style="text-align: right" title="Contingent consideration common stock">     <span style="-sec-ix-hidden: xdx2ixbrl0660"> </span>-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--FairValueOfContingentConsiderationToCommonStock_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__custom--FairValueByFairValueHierarchyLevelAxAxis__us-gaap--FairValueInputsLevel3Member_z4QZ151PvwFd" style="text-align: right" title="Contingent consideration common stock">8,684,669</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_ecustom--FairValueOfContingentConsiderationToCommonStock_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zdqcT2CDIQme" style="text-align: right" title="Contingent consideration common stock">8,684,669</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Contingent consideration - warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_ecustom--FairValueOfContingentConsiderationToWarrants_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__custom--FairValueByFairValueHierarchyLevelAxAxis__us-gaap--FairValueInputsLevel1Member_zlHrQECDYw94" style="border-bottom: Black 1.5pt solid; text-align: right" title="Contingent consideration warrants"><span style="-sec-ix-hidden: xdx2ixbrl0666">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_980_ecustom--FairValueOfContingentConsiderationToWarrants_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__custom--FairValueByFairValueHierarchyLevelAxAxis__us-gaap--FairValueInputsLevel2Member_ztTWsXCnviIi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Contingent consideration warrants"><span style="-sec-ix-hidden: xdx2ixbrl0668">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_ecustom--FairValueOfContingentConsiderationToWarrants_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__custom--FairValueByFairValueHierarchyLevelAxAxis__us-gaap--FairValueInputsLevel3Member_zJcjuEjSz3Cb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Contingent consideration warrants">1,747,972</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_ecustom--FairValueOfContingentConsiderationToWarrants_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zzP0EQYdyFqe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Contingent consideration warrants">1,747,972</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total liabilities measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20211231__custom--FairValueByFairValueHierarchyLevelAxAxis__us-gaap--FairValueInputsLevel1Member_zYRGy7WS1HRk" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0674">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20211231__custom--FairValueByFairValueHierarchyLevelAxAxis__us-gaap--FairValueInputsLevel2Member_z3seBkcPLFj9" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0676">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20211231__custom--FairValueByFairValueHierarchyLevelAxAxis__us-gaap--FairValueInputsLevel3Member_zbuLevT9KIs1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities measured at fair value">10,432,641</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20211231_zyrzveZsO1g2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total liabilities measured at fair value">10,432,641</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Assets:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 40%; text-align: left; padding-bottom: 1.5pt">Marketable securities (certificates of deposit)</td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--MarketableSecurities_iI_c20201231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zPH6PGBvZ6Df" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Marketable securities (certificates of deposit)"><span style="-sec-ix-hidden: xdx2ixbrl0682">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--MarketableSecurities_iI_pp0p0_c20201231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9waNpLhGPM2" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Marketable securities (certificates of deposit)">4,335,446</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--MarketableSecurities_iI_c20201231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUg4dE2FzKYh" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Marketable securities (certificates of deposit)">            <span style="-sec-ix-hidden: xdx2ixbrl0686"> </span>-</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--MarketableSecurities_iI_c20201231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zQdEXYyHuO3k" style="border-bottom: Black 1.5pt solid; width: 11%; text-align: right" title="Marketable securities (certificates of deposit)">4,335,446</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total assets measured at fair value</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_iI_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zl7q8y6J9524" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0690">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zQU0EDOER2Yb" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">4,335,446</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zh2fpC3Hn111" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value"><span style="-sec-ix-hidden: xdx2ixbrl0694">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AssetsFairValueDisclosure_iI_c20201231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zOoP6mVLysw6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets measured at fair value">4,335,446</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1255266 1255266 1255266 1255266 8684669 8684669 1747972 1747972 10432641 10432641 4335446 4335446 4335446 4335446 <p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_zGT36wByptkd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The changes for Level 3 items measured at fair value on a recurring basis are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 60pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zVVMJuliFhc4" style="display: none">Schedule of Changes in Fair Value Measurement</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Fair value as of December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iS_c20210101__20211231_z49DilL36i9d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Asset acquisition contingent consideration liability noncurrent"><span style="-sec-ix-hidden: xdx2ixbrl0700">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 70%; text-align: left; padding-bottom: 1.5pt">Contingent considered issued for business acquisitions</td><td style="width: 10%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td id="xdx_98C_ecustom--ContingentConsideredIssuedForBusinessAcquisitions_c20210101__20211231_z8ovD4Tn2RPb" style="border-bottom: Black 1.5pt solid; width: 18%; text-align: right" title="Contingent considered issued for business acquisitions">10,432,641</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Fair value as of December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--BusinessCombinationContingentConsiderationLiabilityNoncurrent_iE_c20210101__20211231_z5RrSc3eUMj1" style="border-bottom: Black 2.5pt double; text-align: right" title="Asset acquisition contingent consideration liability noncurrent">10,432,641</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 10432641 10432641 <p id="xdx_892_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_zpiccZIH1lX8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> <span id="xdx_8BF_zg3exvZ9JGB1" style="display: none">Schedule of Contingent Consideration Common Stock and Warrants</span></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zpuruaDolIf3" style="width: 16%; text-align: right" title="Warrants measurement input">8.93</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Strike price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputStrikePriceMember_zK3cVOifFAp2" style="text-align: right" title="Warrants measurement input">9.13</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zDS5whyEkeba" style="text-align: right" title="Warrants measurement input">80.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zzLfu533sbb1" style="text-align: right" title="Warrants measurement input">1.30</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20211231_zYjxs60AwO13" style="text-align: right" title="Warrants measurement, term">5.0</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In order to calculate the probability-adjusted value of the contingent consideration-common stock and contingent consideration-warrants, the Company estimated the probability of achieving certain milestones, which include regulatory approval for identified products, as well as production and net revenue targets. The probability of achieving the milestone related to net revenues was estimated using a Monte Carlo simulation valuation model. The unobservable significant inputs to the valuation model were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zqLXGv2Ta1o1" style="width: 16%; text-align: right" title="Business combination,contingent consideration">8.93</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zByYSoOk6oQg" style="text-align: right" title="Business combination,contingent consideration">1.30</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--BusinessCombinationContingentConsiderationLiabilityMeasurementInputExpectedTerm_dtY_c20210101__20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zhxoYlmhDPb6" style="text-align: right" title="Business combination,contingent consideration, term">5.0</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average cost of capital</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputCostOfCapitalMember_zhImkEGhNGik" style="text-align: right" title="Business combination,contingent consideration">27.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Revenue discount rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember_zfdaih8MKiT" style="text-align: right" title="Business combination,contingent consideration">9.50</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Equity volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputEquityVolatilityMember_z3wiMDKAyeYl" style="text-align: right" title="Business combination,contingent consideration">80.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Asset volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputAssetVolatilityMember_zKh26MPjAQJf" style="text-align: right" title="Business combination,contingent consideration">80.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Revenue volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--BusinessCombinationContingentConsiderationLiabilityMeasurementInput_iI_uPure_c20211231__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputRevenueVolatilityMember_zIA2hopBBqu5" style="text-align: right" title="Business combination,contingent consideration">30.00</td><td style="text-align: left">%</td></tr> </table> 8.93 9.13 80.00 1.30 P5Y 8.93 1.30 P5Y 27.00 9.50 80.00 80.00 30.00 <p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zJjfcIilwCad" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5 – <span id="xdx_829_zzQlfl7DAI3j">Property and Equipment</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zzfakGPSbbZ7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zy1zjPnolAQ5" style="display: none">Schedule of Property and Equipment</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Estimated</p> <p style="margin-top: 0; margin-bottom: 0">Useful Lives in</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Lab equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zNniGUOQicck" title="Property and equipment estimated useful lives">3</span> - <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zJGJROUIiIW4" title="Property and equipment estimated useful lives">5</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zyxa7hrqCF5a" style="width: 14%; text-align: right" title="Property and equipment, gross">2,476,813</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zUlt3xTtZVyc" style="width: 14%; text-align: right" title="Property and equipment, gross">1,212,561</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdsAndLeaseholdImprovementsMember_zNULZkEtwQrb" title="Property and equipment estimated useful lives">3</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zzhrcHbgJoW2" style="text-align: right" title="Property and equipment, gross">3,157</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zpFDJhQEo1L2" style="text-align: right" title="Property and equipment, gross">3,157</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office equipment, furniture and other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zncZHGcsMuUa" title="Property and equipment estimated useful lives">2</span> - <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zRH8d9wLg5Ie" title="Property and equipment estimated useful lives">5</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z85W0rrp8qb2" style="text-align: right" title="Property and equipment, gross">75,401</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zHchHySF6Cle" style="text-align: right" title="Property and equipment, gross">38,344</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20211231_zBLmx7MmkOsb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: accumulated depreciation">(622,155</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20201231_zpeyTiXyNv0j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: accumulated depreciation">(304,423</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Fixed assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">          </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20211231_zDONMh3Xgju6" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">1,933,216</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20201231_z37SNkZS9PWc" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">949,639</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zzfakGPSbbZ7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zy1zjPnolAQ5" style="display: none">Schedule of Property and Equipment</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Estimated</p> <p style="margin-top: 0; margin-bottom: 0">Useful Lives in</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> years</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Lab equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MinimumMember_zNniGUOQicck" title="Property and equipment estimated useful lives">3</span> - <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember__srt--RangeAxis__srt--MaximumMember_zJGJROUIiIW4" title="Property and equipment estimated useful lives">5</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zyxa7hrqCF5a" style="width: 14%; text-align: right" title="Property and equipment, gross">2,476,813</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zUlt3xTtZVyc" style="width: 14%; text-align: right" title="Property and equipment, gross">1,212,561</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdsAndLeaseholdImprovementsMember_zNULZkEtwQrb" title="Property and equipment estimated useful lives">3</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zzhrcHbgJoW2" style="text-align: right" title="Property and equipment, gross">3,157</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zpFDJhQEo1L2" style="text-align: right" title="Property and equipment, gross">3,157</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Office equipment, furniture and other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zncZHGcsMuUa" title="Property and equipment estimated useful lives">2</span> - <span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_zRH8d9wLg5Ie" title="Property and equipment estimated useful lives">5</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z85W0rrp8qb2" style="text-align: right" title="Property and equipment, gross">75,401</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20201231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zHchHySF6Cle" style="text-align: right" title="Property and equipment, gross">38,344</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated depreciation and amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20211231_zBLmx7MmkOsb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: accumulated depreciation">(622,155</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_c20201231_zpeyTiXyNv0j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less: accumulated depreciation">(304,423</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Fixed assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right">          </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20211231_zDONMh3Xgju6" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">1,933,216</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20201231_z37SNkZS9PWc" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment, net">949,639</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> P3Y P5Y 2476813 1212561 P3Y 3157 3157 P2Y P5Y 75401 38344 622155 304423 1933216 949639 <p id="xdx_805_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zPFt9bNwaaqf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6 - <span id="xdx_822_zOaAf6VKzWjd">Goodwill and Intangible Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zeNyMQmly8Jg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zfSS8lkfInfh" style="display: none">Schedule of Intangible Assets </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Estimated</p> <p style="margin-top: 0; margin-bottom: 0">Useful Lives in</p></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> years</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">In-process research and development</td><td style="width: 2%"> </td> <td style="width: 14%; text-align: center"><span id="xdx_900_ecustom--IndefiniteLivedIntangibleAssetUsefulLife_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zZkP100aPyHj" title="Estimated useful lives in years, term">Indefinite</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zFFc1TBbJ6V2" style="width: 14%; text-align: right" title="In-process research and development">26,101,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zx0JyuIxVM0l" style="width: 14%; text-align: right" title="In-process research and development">           <span style="-sec-ix-hidden: xdx2ixbrl0776"> </span>-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-competition agreements</td><td> </td> <td style="text-align: center"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember__srt--RangeAxis__srt--MinimumMember_z0nE4Iciziyh" title="Estimated useful lives in years">1.5</span> - <span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember__srt--RangeAxis__srt--MaximumMember_zVCzUdDeh1X6" title="Estimated useful lives in years">3</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_z0ct4haYeGdh" style="text-align: right" title="Intangible assets, gross">1,094,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zSWyJSmq9b11" style="text-align: right" title="Intangible assets, gross">       <span style="-sec-ix-hidden: xdx2ixbrl0784"> </span>-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231_zGxKLBIPuvC7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl0786">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20201231_z1WvsPw8pgU2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl0788">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Intangible assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">   </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20211231_zMlPqCzdqqMc" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">27,195,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20201231_zaIAespoONp6" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net"><span style="-sec-ix-hidden: xdx2ixbrl0792">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zPTFb18WFdQi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zOKhJOm1KDea" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expected future annual amortization expense of the Company’s intangible assets held as of December 31, 2021 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zhPshHDKSjQ" style="display: none">Schedule of Future Amortization Expense </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Year Ending December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_497_20211231_zfXPLwjYghHl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization Expense</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzZiM_zkzwNNo6wvHc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 82%; text-align: justify">2022</td><td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">426,660</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzZiM_zsNyTlL51H4l" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">2023</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">364,668</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzZiM_zEDuaMmD2ij3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify">2024</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">302,672</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzZiM_zYX5bQAZUU7f" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: justify">Total</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,094,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zkTIvoBIJfKk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had goodwill of $14.7 million as of December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zeNyMQmly8Jg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible assets, net consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zfSS8lkfInfh" style="display: none">Schedule of Intangible Assets </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Estimated</p> <p style="margin-top: 0; margin-bottom: 0">Useful Lives in</p></td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> years</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">In-process research and development</td><td style="width: 2%"> </td> <td style="width: 14%; text-align: center"><span id="xdx_900_ecustom--IndefiniteLivedIntangibleAssetUsefulLife_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zZkP100aPyHj" title="Estimated useful lives in years, term">Indefinite</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zFFc1TBbJ6V2" style="width: 14%; text-align: right" title="In-process research and development">26,101,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zx0JyuIxVM0l" style="width: 14%; text-align: right" title="In-process research and development">           <span style="-sec-ix-hidden: xdx2ixbrl0776"> </span>-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-competition agreements</td><td> </td> <td style="text-align: center"><span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember__srt--RangeAxis__srt--MinimumMember_z0nE4Iciziyh" title="Estimated useful lives in years">1.5</span> - <span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember__srt--RangeAxis__srt--MaximumMember_zVCzUdDeh1X6" title="Estimated useful lives in years">3</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_z0ct4haYeGdh" style="text-align: right" title="Intangible assets, gross">1,094,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zSWyJSmq9b11" style="text-align: right" title="Intangible assets, gross">       <span style="-sec-ix-hidden: xdx2ixbrl0784"> </span>-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231_zGxKLBIPuvC7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl0786">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20201231_z1WvsPw8pgU2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less accumulated amortization"><span style="-sec-ix-hidden: xdx2ixbrl0788">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Intangible assets, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt">   </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20211231_zMlPqCzdqqMc" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net">27,195,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20201231_zaIAespoONp6" style="border-bottom: Black 2.5pt double; text-align: right" title="Intangible assets, net"><span style="-sec-ix-hidden: xdx2ixbrl0792">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Indefinite 26101000 P1Y6M P3Y 1094000 27195000 <p id="xdx_89B_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zOKhJOm1KDea" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expected future annual amortization expense of the Company’s intangible assets held as of December 31, 2021 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zhPshHDKSjQ" style="display: none">Schedule of Future Amortization Expense </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Year Ending December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" id="xdx_497_20211231_zfXPLwjYghHl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amortization Expense</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_maFLIANzZiM_zkzwNNo6wvHc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 82%; text-align: justify">2022</td><td style="width: 1%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">426,660</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_maFLIANzZiM_zsNyTlL51H4l" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">2023</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">364,668</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_maFLIANzZiM_zEDuaMmD2ij3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify">2024</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">302,672</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzZiM_zYX5bQAZUU7f" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: justify">Total</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,094,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 426660 364668 302672 1094000 <p id="xdx_80B_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zFtms4aNHs8h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7 - <span id="xdx_821_ziSvSWd3xiG3">Accrued Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zWQp8db5wvEa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zDDUqS16gCb8" style="display: none">Schedule of Accrued Expenses </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20211231_zl6ck8a2cjxj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20201231_zi31yqBf6Ou6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--AccruedPayrollTaxesCurrent_iI_maALCzYz0_zx42ewj43lcc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Payroll liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,455,694</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,627,957</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccruedSalesCommissionCurrent_iI_maALCzYz0_zfJD04nhz7ph" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Distributor commissions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">509,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,070,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_maALCzYz0_zhE8UR6SOb8e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Sales tax payable</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0814"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,526</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzYz0_zVSFpBgVk595" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other accrued liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">894,458</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">99,020</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iI_mtALCzYz0_zQjgyzUd6S43" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,859,652</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,849,503</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zHqE8YTmaKZa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zWQp8db5wvEa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BB_zDDUqS16gCb8" style="display: none">Schedule of Accrued Expenses </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20211231_zl6ck8a2cjxj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20201231_zi31yqBf6Ou6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--AccruedPayrollTaxesCurrent_iI_maALCzYz0_zx42ewj43lcc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Payroll liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,455,694</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,627,957</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccruedSalesCommissionCurrent_iI_maALCzYz0_zfJD04nhz7ph" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Distributor commissions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">509,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,070,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_maALCzYz0_zhE8UR6SOb8e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Sales tax payable</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0814"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,526</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maALCzYz0_zVSFpBgVk595" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other accrued liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">894,458</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">99,020</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iI_mtALCzYz0_zQjgyzUd6S43" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,859,652</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,849,503</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2455694 1627957 509500 1070000 52526 894458 99020 3859652 2849503 <p id="xdx_801_eus-gaap--RevenueFromContractWithCustomerTextBlock_zorGJIRAl7F8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8 – <span id="xdx_82E_zQkTW0C0r8lc">Revenue</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zpip6n1ibdk7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth revenue by geographic area:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_z9EhQeIhXaL" style="display: none">Summary of Revenue by Geographic Area </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20211231__srt--StatementGeographicalAxis__srt--AmericasMember_zpwoleb2rDB5" style="width: 16%; text-align: right" title="Revenue">52,185,812</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200101__20201231__srt--StatementGeographicalAxis__srt--AmericasMember_zyrCmUYDzw1c" style="width: 16%; text-align: right" title="Revenue">44,862,751</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Rest of World</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20211231__srt--StatementGeographicalAxis__custom--RestOfWorldMember_zyZkp1E9pYjj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">45,699,791</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200101__20201231__srt--StatementGeographicalAxis__custom--RestOfWorldMember_zPti5VVvAdS" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">29,690,007</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20211231_zuARGY6k0p5k" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">97,885,603</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200101__20201231_zH7M22x6oZw6" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">74,552,758</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Percentage of revenue by area:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">United States</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--StatementGeographicalAxis__srt--AmericasMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zJazHFVJeNog" style="text-align: right" title="Percentage of revenue">53</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__srt--StatementGeographicalAxis__srt--AmericasMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_z0skdzkf6pv1" style="text-align: right" title="Percentage of revenue">60</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Rest of World</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zZcS9rKfGLzf" style="text-align: right" title="Percentage of revenue">47</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zRaUBOXchH1h" style="text-align: right" title="Percentage of revenue">40</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8AE_z13JKgCFvti8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deferred Revenue</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zsvRzQTqXeyj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in the Company’s deferred revenue balance for the years ended December 31, 2021 and 2020 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B8_zNakCKApdiZe" style="display: none">Schedule of Deferred Revenue</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance as of December 31, 2019</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ContractWithCustomerLiability_iS_c20200101__20201231_zUENGvoZtdNa" style="width: 16%; text-align: right" title="Deferred revenue, beginning balance">1,323</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Revenue recognized included in deferred revenue balance at the beginning of the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_iN_di_c20200101__20201231_zRVBGf26lXMg" style="text-align: right" title="Revenue recognized included in deferred revenue balance at the beginning of the period">(1,323</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Increase due to prepayments from customers</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_ecustom--IncreaseDueToPrepaymentsFromCustomers_c20200101__20201231_zqdmOB9VOj21" style="border-bottom: Black 1.5pt solid; text-align: right" title="Increase due to prepayments from customers">305,307</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance as of December 31, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ContractWithCustomerLiability_iS_c20210101__20211231_zNvzN7EmUmq2" style="text-align: right" title="Deferred revenue, beginning balance">305,307</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Revenue recognized included in deferred revenue balance at the beginning of the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_iN_di_c20210101__20211231_z5acRrjLtM6e" style="text-align: right" title="Revenue recognized included in deferred revenue balance at the beginning of the period">(256,110</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Increase due to prepayments from customers</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--IncreaseDueToPrepaymentsFromCustomers_c20210101__20211231_ztHqSI9pUlYf" style="text-align: right" title="Increase due to prepayments from customers">79,213</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Increase due to note receivable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--IncreaseDueToNoteReceivable_c20210101__20211231_zePfxnIws6wj" style="text-align: right" title="Increase due to note receivable">150,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Decrease due to refunds to customers and application to open balances</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_ecustom--DecreaseDueToRefundsToCustomersAndApplicationToOpenBalances_iN_di_c20210101__20211231_zhcNQNX5TXfa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Decrease due to refunds to customers and application to open balances">(128,410</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ContractWithCustomerLiability_iE_c20210101__20211231_z9H33Mb2t3Sh" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred revenue, Ending balance">150,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zlvNd94oh9nj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expects to perform its performance obligation and recognize the deferred revenue as revenue during the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_894_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_zpip6n1ibdk7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth revenue by geographic area:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_z9EhQeIhXaL" style="display: none">Summary of Revenue by Geographic Area </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20211231__srt--StatementGeographicalAxis__srt--AmericasMember_zpwoleb2rDB5" style="width: 16%; text-align: right" title="Revenue">52,185,812</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200101__20201231__srt--StatementGeographicalAxis__srt--AmericasMember_zyrCmUYDzw1c" style="width: 16%; text-align: right" title="Revenue">44,862,751</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Rest of World</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20211231__srt--StatementGeographicalAxis__custom--RestOfWorldMember_zyZkp1E9pYjj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">45,699,791</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200101__20201231__srt--StatementGeographicalAxis__custom--RestOfWorldMember_zPti5VVvAdS" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">29,690,007</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20210101__20211231_zuARGY6k0p5k" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">97,885,603</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200101__20201231_zH7M22x6oZw6" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">74,552,758</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Percentage of revenue by area:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">United States</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--StatementGeographicalAxis__srt--AmericasMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zJazHFVJeNog" style="text-align: right" title="Percentage of revenue">53</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__srt--StatementGeographicalAxis__srt--AmericasMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_z0skdzkf6pv1" style="text-align: right" title="Percentage of revenue">60</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Rest of World</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zZcS9rKfGLzf" style="text-align: right" title="Percentage of revenue">47</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__srt--StatementGeographicalAxis__custom--RestOfWorldMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--GeographicConcentrationRiskMember_zRaUBOXchH1h" style="text-align: right" title="Percentage of revenue">40</td><td style="text-align: left">%</td></tr> </table> 52185812 44862751 45699791 29690007 97885603 74552758 0.53 0.60 0.47 0.40 <p id="xdx_899_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zsvRzQTqXeyj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in the Company’s deferred revenue balance for the years ended December 31, 2021 and 2020 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B8_zNakCKApdiZe" style="display: none">Schedule of Deferred Revenue</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Balance as of December 31, 2019</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ContractWithCustomerLiability_iS_c20200101__20201231_zUENGvoZtdNa" style="width: 16%; text-align: right" title="Deferred revenue, beginning balance">1,323</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Revenue recognized included in deferred revenue balance at the beginning of the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_iN_di_c20200101__20201231_zRVBGf26lXMg" style="text-align: right" title="Revenue recognized included in deferred revenue balance at the beginning of the period">(1,323</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Increase due to prepayments from customers</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_ecustom--IncreaseDueToPrepaymentsFromCustomers_c20200101__20201231_zqdmOB9VOj21" style="border-bottom: Black 1.5pt solid; text-align: right" title="Increase due to prepayments from customers">305,307</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Balance as of December 31, 2020</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ContractWithCustomerLiability_iS_c20210101__20211231_zNvzN7EmUmq2" style="text-align: right" title="Deferred revenue, beginning balance">305,307</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Revenue recognized included in deferred revenue balance at the beginning of the period</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_iN_di_c20210101__20211231_z5acRrjLtM6e" style="text-align: right" title="Revenue recognized included in deferred revenue balance at the beginning of the period">(256,110</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Increase due to prepayments from customers</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--IncreaseDueToPrepaymentsFromCustomers_c20210101__20211231_ztHqSI9pUlYf" style="text-align: right" title="Increase due to prepayments from customers">79,213</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Increase due to note receivable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--IncreaseDueToNoteReceivable_c20210101__20211231_zePfxnIws6wj" style="text-align: right" title="Increase due to note receivable">150,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Decrease due to refunds to customers and application to open balances</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_ecustom--DecreaseDueToRefundsToCustomersAndApplicationToOpenBalances_iN_di_c20210101__20211231_zhcNQNX5TXfa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Decrease due to refunds to customers and application to open balances">(128,410</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Balance as of December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ContractWithCustomerLiability_iE_c20210101__20211231_z9H33Mb2t3Sh" style="border-bottom: Black 2.5pt double; text-align: right" title="Deferred revenue, Ending balance">150,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1323 1323 305307 305307 256110 79213 150000 128410 150000 <p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z48NcTXgWjXj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 – <span id="xdx_828_ze2cvoPCZrp8">Stockholders’ Equity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--OptionsMember_zLqBdEy1tMql">189,225 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock upon the exercise of options and received $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__custom--OptionsMember_zcUwNNIx9Cqd">450,398 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in proceeds from the exercises.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ThirdPartiesMember_z1DKFm6dXw4i" title="Number of shares issued for services">5,548</span> shares of common stock for services provided by third parties primarily related to investor relations services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company issued <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesIssuedForVestAndRestrictedStockUnits_c20210101__20211231_zGxhjGbvD5Vj" title="Vest and restricted stock units">438,502</span> shares of common stock upon the vest and release of restricted stock units.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--AdvancedConceptionsIncAndIdahoMolecularIncMember_zOSUkQtjXoUc">4,628,554 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock related to the acquisitions of Idaho Molecular, Inc. and Advanced Conceptions, Inc., <span id="xdx_90D_ecustom--StockIssuedDuringPeriodSharesForfeited_c20210101__20211231__us-gaap--BusinessAcquisitionAxis__custom--AdvancedConceptionsIncAndIdahoMolecularIncMember_zLdSlms7NrFf">1,390,430 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of which are subject to forfeiture in favor of the Company if certain milestones are not achieved on or before January 1, 2027.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company completed the sale of <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockThreeMember_zlSbnq7H0Kof" title="Number of common stock issued">3,448,278</span> shares of the Company’s common stock, par value $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockThreeMember_zlZDEnJOMvEc" title="Common stock, par value">0.001</span> per share, at a purchase price of $<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_c20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockThreeMember_zkLxeM85Aymb" title="Sale of common stock purchase price per shares">1.45</span> per share in a registered direct offering. The aggregate gross proceeds for the sale of the shares were $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockThreeMember_z2wEgbbM3iyd" title="Issuance of common stock gross proceeds">5,000,003</span> and the Company received net proceeds of $<span id="xdx_909_ecustom--NetProceedsFromIssuanceOfCommonStock_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockThreeMember_zACC5RFATpwj" title="Net proceeds from issuance of common stock">4,517,102</span> after deducting offering costs of $<span id="xdx_901_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockThreeMember_zYzJODETjTc4" title="Offering costs">482,901</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company completed the sale of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember_zpkpnaTlhdvf" title="Number of common stock issued">3,324,676</span> shares of the Company’s common stock, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember_zZgoJlDFdRba" title="Common stock, par value">0.001</span> per share, at a purchase price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember_z5XsTcrWurD2" title="Sale of common stock purchase price per shares">3.08</span> per share in a registered direct offering. The aggregate gross proceeds for the sale of the shares were $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember_zgDrmqSDjG04" title="Issuance of common stock gross proceeds">10,240,002</span> and the Company received net proceeds of $<span id="xdx_90B_ecustom--NetProceedsFromIssuanceOfCommonStock_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember_zIbC0SuOLBS9" title="Net proceeds from issuance of common stock">9,612,561</span> after deducting offering costs of $<span id="xdx_90C_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockOneMember_zodV0FCCw68l" title="Offering costs">627,441</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company completed the sale of <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockTwoMember_zkcHULtzhQY2" title="Number of common stock issued">470,000</span> shares of the Company’s common stock, par value $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockTwoMember_zGB5ILDff8G2" title="Common stock, par value">0.001</span> per share, at a purchase price of $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockTwoMember_zUw8cHWquFme" title="Sale of common stock purchase price per shares">9.00</span> per share in a registered direct offering. The aggregate gross proceeds for the sale of the shares were $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockTwoMember_zLrXHfEtQJw3" title="Issuance of common stock gross proceeds">4,230,000</span> and the Company received net proceeds of $<span id="xdx_90F_ecustom--NetProceedsFromIssuanceOfCommonStock_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockTwoMember_zHxGU7Jd0vZb" title="Net proceeds from issuance of common stock">3,882,420</span> after deducting offering costs of $<span id="xdx_904_eus-gaap--PaymentsOfStockIssuanceCosts_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--CommonStockTwoMember_zjk8UNZ7qztl" title="Offering costs">347,580</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company issued an aggregate of <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertiblePreferredStockMember_zRkvveTDvmT4" title="Potentially dilutive shares"><span title="Potentially dilutive shares">2,133,333</span></span> shares of common stock upon conversion of all of the Company’s convertible preferred stock outstanding as of December 31, 2019.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zz5zH3mbLDil" title="Number of shares issued for exercise of options">856,660</span> shares of common stock upon the exercise of warrants and received $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z2lgDEI3Zf85" title="Number of shares issued for exercise of options, value">270,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company issued <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--OptionsMember_zX2gmtVSn0hf">871,229 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock upon the exercise of options and received $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pp0p0_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__custom--OptionsMember_zl1ciwHuKjFl">1,460,600</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__srt--ProductOrServiceAxis__custom--InvestmentRelationsServicesMember_zytGZOucaNGa" title="Number of shares issued for services">83,935</span> shares of common stock for services provided by third parties primarily related to investor relations services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 189225 450398 5548 438502 4628554 1390430 3448278 0.001 1.45 5000003 4517102 482901 3324676 0.001 3.08 10240002 9612561 627441 470000 0.001 9.00 4230000 3882420 347580 2133333 856660 270000 871229 1460600 83935 <p id="xdx_80B_eus-gaap--EarningsPerShareTextBlock_zPlO6JEBOXA1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10 – <span id="xdx_822_zvurEZf7HrH2">Earnings per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zvjSVyVnsKN7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for years ended December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zuko8FVVHRHe" style="display: none">Schedule of Basic and Diluted Earnings Per Share </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20210101__20211231_zZGyLnlyehR1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20200101__20201231_z5rflwldMre6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLoss_zFxZyDWSm9Tj" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Net income, as reported</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">36,658,564</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">42,478,529</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WeightedAverageNumberOfBasicSharesOutstanding_z9rDjysXCQjl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28,874,555</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,720,133</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_zeyOWIHhGcR" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive effect of stock options, warrants and RSUs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,029,131</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,280,208</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_z1WOt8gJsnCg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Shares used to compute diluted earnings per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">29,903,686</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">28,000,341</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--EarningsBasicPerShare_pid_zwjmKUucUBMk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Basic earnings per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.27</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.59</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareDiluted_pid_zu3nZxnifDu1" style="vertical-align: bottom; background-color: White"> <td>Diluted earnings per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.23</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.52</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A1_zqVbragJJJdf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the years ended December 31, 2021 and 2020, respectively, potentially dilutive securities of <span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zdl5scLQdEdb" title="Securities excluded from computation of diluted earnings per share">154,644 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_zxI5n202v1vh" title="Securities excluded from computation of diluted earnings per share">50,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. The computation of diluted earnings per share for the year ended December 31, 2021 also excludes the approximately <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn5n6_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwEZQeLBALWe" title="Securities excluded from computation of diluted earnings per share">1.4</span> million shares of common stock and approximately <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1rWnBfHdjtl" title="Securities excluded from computation of diluted earnings per share">456,000</span> warrants to purchase shares of common stock mentioned in Note 3 that are contingent upon the achievement of certain milestones.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zvjSVyVnsKN7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share for years ended December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zuko8FVVHRHe" style="display: none">Schedule of Basic and Diluted Earnings Per Share </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20210101__20211231_zZGyLnlyehR1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20200101__20201231_z5rflwldMre6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Numerator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--NetIncomeLoss_zFxZyDWSm9Tj" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: left; padding-bottom: 2.5pt">Net income, as reported</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">36,658,564</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 16%; text-align: right">42,478,529</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold">Denominator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--WeightedAverageNumberOfBasicSharesOutstanding_z9rDjysXCQjl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted average shares, basic</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">28,874,555</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,720,133</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--WeightedAverageNumberDilutedSharesOutstandingAdjustment_zeyOWIHhGcR" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Dilutive effect of stock options, warrants and RSUs</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,029,131</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,280,208</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_z1WOt8gJsnCg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Shares used to compute diluted earnings per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">29,903,686</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">28,000,341</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--EarningsBasicPerShare_pid_zwjmKUucUBMk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Basic earnings per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.27</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.59</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareDiluted_pid_zu3nZxnifDu1" style="vertical-align: bottom; background-color: White"> <td>Diluted earnings per share</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.23</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1.52</td><td style="text-align: left"> </td></tr> </table> 36658564 42478529 28874555 26720133 1029131 1280208 29903686 28000341 1.27 1.59 1.23 1.52 154644 50000 1400000 456000 <p id="xdx_804_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zqgYsPW32A6d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11 – <span id="xdx_82B_zmXv6YJ17NRb">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Incentive Plans</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Co-Diagnostics, Inc. 2015 Long Term Incentive Plan (the “Incentive Plan”) reserves an aggregate of <span id="xdx_90F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20211231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenLongTermIncentivePlanMember_zQYDjqMWpgvk" title="Aggregate number of common shares reserved">6,000,000</span> shares of common stock issuable upon the grant of awards under the Incentive Plan. The number of awards available for issuance under the Incentive Plan was <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20211231__us-gaap--PlanNameAxis__custom--TwoThousandFifteenLongTermIncentivePlanMember_zVvIVWFIoF1l" title="Number of common shares availalble for issuance">2,095,266</span> at December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Options</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zMfb86rXn0r7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes option activity during the years ended December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_z03x74Z7fs93" style="display: none">Schedule of Option Activity </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify">    </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2019</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_ztdVRq5N7rE8" style="width: 12%; text-align: right" title="Number of Options Outstanding, Beginning">2,021,817</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200101__20201231_zZWf6QXaooHk" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning">1.69</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20200101__20201231_zf1NGllhgP23" style="width: 12%; text-align: right" title="Weighted Average Fair Value Outstanding, Beginning">0.83</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20200101__20201231_z59B0Xpb03oc" style="text-align: right" title="Number of Options Outstanding, Granted">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_znF4tsjzrcUh" style="text-align: right" title="Weighted Average Exercise Price Granted">8.14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231_zWjTCvmZ7Mwk" style="text-align: right" title="Weighted Average Fair Value Granted">4.74</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">     </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Expired</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20200101__20201231_zT3WstzYKuwf" style="text-align: right" title="Number of Options Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zmP4Yj006WC3" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl0975">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20200101__20201231_z0JCWPwmbCAj" style="text-align: right" title="Weighted Average Fair Value Expired"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Forfeited/Cancelled</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20200101__20201231_zsFbtyYEgiH2" style="text-align: right" title="Number of Options Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0979">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231_zLYxE78b8gDf" style="text-align: right" title="Weighted Average Exercise Price Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0981">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20200101__20201231_zRwwh1Ig0Wc5" style="text-align: right" title="Weighted Average Fair Value Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify">Exercised</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_iN_di_c20200101__20201231_zHmP1kvljX9b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding, Exercised">(871,229</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zWfbptXIaKW2" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price Exercised">1.68</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised_iE_pid_c20200101__20201231_z4PGQSkTTkNc" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value Exercised">0.89</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2020</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zWqhIAv9C4pk" style="text-align: right" title="Number of Options Outstanding, Beginning">1,300,588</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zJAhXB8AAiQ3" style="text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning">2.44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20210101__20211231_zlFwd1sRp1V2" style="text-align: right" title="Weighted Average Fair Value Outstanding, Beginning">1.24</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20211231_zDDDwxugm0vd" style="text-align: right" title="Number of Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0997">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zjOw7uQYPt3h" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="-sec-ix-hidden: xdx2ixbrl0999">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231_z5RLnB4mfnCi" style="text-align: right" title="Weighted Average Fair Value Granted"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Expired</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20210101__20211231_zwUUtk5ntwy9" style="text-align: right" title="Number of Options Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1003">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zOJoZ0jOMXB7" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl1005">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20210101__20211231_z53mqZjkAmVg" style="text-align: right" title="Weighted Average Fair Value Expired"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Forfeited/Cancelled</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210101__20211231_zegbUITxxHAi" style="text-align: right" title="Number of Options Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1009">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_za8NHKjNXDy" style="text-align: right" title="Weighted Average Exercise Price Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1011">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20210101__20211231_zpW4uc6RxFL1" style="text-align: right" title="Weighted Average Fair Value Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1013">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify">Exercised</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_iN_di_c20210101__20211231_z13yGKE6Lmmh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding, Exercised">(189,225</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zXTl5utKRtvc" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price Exercised">2.38</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised_iE_pid_c20210101__20211231_zWUmpRzg3FPl" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value Exercised">1.12</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2021</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231_zF3A17QbjeMb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending">1,111,363</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zseBZ53bLYsc" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending">2.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20210101__20211231_zbhLRzuALPce" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value Outstanding, Ending">1.31</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20210101__20211231_zugm00qLGxK1" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average Remaining Contractual Life (years) Outstanding, Ending">6.62</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at December 31, 2021</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210101__20211231_z3URBBN68syl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable Ending">1,094,697</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zmeQJBC1ofd4" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Exercisable Ending">2.01</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_iE_pid_c20210101__20211231_zaXDswJXKuHl" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value, Exercisable Ending">1.18</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zhvOZgXRUVD3" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average Remaining Contractual Life (years), Exercisable Ending">6.59</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zE1OF3F2TfXj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total intrinsic value of options exercised during the years ended December 31, 2021 and 2020 was approximately $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zxy1zRKyprVb">1.3 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z5PMaPorwI71">11.8 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively. The aggregate intrinsic value of outstanding options at December 31, 2021 and 2020 was approximately $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn5n6_c20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z0tPjF3tE3Hl">7.6 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pn5n6_c20201231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zCDasHp5jsf8">7.1 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, respectively. As of December 31, 2021, there were <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zrGZd6zl9eVb" title="Unvested options">16,666 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unvested options and $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pip0_c20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_z2sZOlVw1Usj" title="Unrecognized stock-based compensation">78,115 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of unrecognized stock-based compensation expense related to options. The unrecognized stock-based compensation expense is expected to be recognized over <span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zqfFLx4WXpgf" title="Unrecognized stock-based compensation recognition period">0.5 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation cost is measured at the grant date based on the fair value of the award granted and recognized as expense over the vesting period using the straight-line method. The Company uses the Black-Scholes model to value options granted. The following weighted average assumptions were used in estimating the grant date fair value of options:</span></p> <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zuQMSoTypzkk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B5_zGZYUBOR4y57" style="display: none">Schedule of Fair Value of Options Weighted Average Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20210101__20211231_zXvOiKUIXLSg" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zqFi97nu0QEk" title="Risk-free interest rate">1.05</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c20210101__20211231_z4MN2Gzt3Mq7" title="Expected life (years)"><span style="-sec-ix-hidden: xdx2ixbrl1053">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_z9SGo41sCH01" title="Expected life (years)">7.3</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">       <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20210101__20211231_z3M9emPm5qn4" title="Expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1057">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_z7SXVIPxgUl1" title="Expected volatility">62.82</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dpxL_uPure_c20210101__20211231_z9xxifgwo94f" style="text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1061">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dpn_uPure_c20200101__20201231_zhbbCav9JuG2" style="text-align: right" title="Expected dividend yield"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A1_zxbuYX5Y3Gil" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restricted Stock Units</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zdxbdHWLfY52" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the years ended December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zSPdVrsBLCA9" style="display: none">Schedule of Outstanding Restricted Stock Units and Related Activity </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested at December 31, 2019</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKj7oMdvTZS" style="text-align: right" title="Number of Restricted Stock Units, Outstanding Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1067">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2KO0l2hhhge" style="text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1069">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: justify">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztHOH8AexPU" style="width: 16%; text-align: right" title="Number of Restricted Stock Units, Granted">549,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRD8wDeHFPVg" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Granted">10.49</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0d2hrhaDSQ6" style="text-align: right" title="Number of Restricted Stock Units, Vested">(27,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHwkNVsfq80e" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">10.49</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXhA4vanc5Sb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Restricted Stock Units, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1079">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdpgeWJJSZtc" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1081">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested at December 31, 2020</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpIxJz52LHOa" style="text-align: right" title="Number of Restricted Stock Units, Outstanding Beginning">522,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0k7esXOm9I9" style="text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Beginning">10.49</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOcWgmeoo1q7" style="text-align: right" title="Number of Restricted Stock Units, Granted">1,217,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0lhzF20z274" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">9.76</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zU59ccI4xKZ7" style="text-align: right" title="Number of Restricted Stock Units, Vested">(438,502</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zj4OBMLUd9i6" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">10.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8wTTKHzZV6d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Restricted Stock Units, Forfeited/Cancelled">(34,083</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfunQIOUTEY9" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited/Cancelled">9.91</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested at December 31, 2021</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znJYHW8cebcg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Restricted Stock Units, Outstanding Ending">1,267,415</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqEk7mxbcjJ3" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Ending">9.94</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zYgWVVCbjhS" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, there was $<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOvpm3yhiKf8" title="Unrecognized stock-based compensation">11.6</span> million of unrecognized stock-based compensation expense related to outstanding RSUs which is expected to be recognized over a weighted-average period of <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znc4A15m5KW" title="Unrecognized stock-based compensation recognition period">2.3</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has issued warrants related to financings, acquisitions and as compensation to third parties for services provided. The Company estimates the fair value of issued warrants on the date of issuance as determined using a Black-Scholes pricing model. The Company amortizes the fair value of issued warrants using a vesting schedule based on the terms and conditions of each warrant if granted for services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zoc3OClcrw9c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes warrant activity during the years ended December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zDPlnfi3RWNk" style="display: none">Schedule of Warrant Activity </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2019</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20201231_zgSmBBhNcfH7" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning">983,535</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_zTTpPpAxtjFg" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning">1.44</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue_iS_c20200101__20201231_zhaJPvQ9a8q1" style="width: 12%; text-align: right" title="Weighted Average Fair Value, Beginning">1.03</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231_zz8Ugk0nrQRl" style="text-align: right" title="Number of Warrants Outstanding, Granted">20,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zSBS8JTaKKuj" style="text-align: right" title="Weighted Average Exercise Price, Granted">1.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231_zYedL0cnZYEk" style="text-align: right" title="Weighted Average Fair Value, Granted">15.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Expired</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20200101__20201231_zHSZza5Q46Gg" style="text-align: right" title="Number of Warrants Outstanding, Expired">(9,090</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="text-align: right" title="Weighted Average Exercise Price, Expired">6.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue_c20200101__20201231_pdd" style="text-align: right" title="Weighted Average Fair Value, Expired">0.17</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Forfeited/Cancelled</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20201231_pdd" style="text-align: right" title="Number of Warrants Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1127">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="text-align: right" title="Weighted Average Exercise Price, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1129">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue_c20200101__20201231_pdd" style="text-align: right" title="Weighted Average Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1131">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify">Exercised</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20200101__20201231_zcPYfJXd5BX1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Exercised">(924,445</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Exercised">1.42</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231_z9m0ZiGZGdE6" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value, Exercised">1.43</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2020</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231_z8A0MfXBQMs3" style="text-align: right" title="Number of Warrants Outstanding, Beginning">70,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zlJurqfxwpL1" style="text-align: right" title="Weighted Average Exercise Price, Beginning">1.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue_iS_c20210101__20211231_zFA1Kkjk4hve" style="text-align: right" title="Weighted Average Fair Value, Beginning">5.21</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231_zPqMwsByDKX1" title="Weighted-average Remaining Contractual Life (Years) Outstanding, Beginning">3.3</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231_zpEOrU0KXted" style="text-align: right" title="Number of Warrants Outstanding, Granted">456,281</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_z93lk9ynJ1Ra" style="text-align: right" title="Weighted Average Exercise Price, Granted">9.13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231_zbwuFdjcDFX7" style="text-align: right" title="Weighted Average Fair Value, Granted">3.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Expired</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20211231_zI0GvYE0Lli" style="text-align: right" title="Number of Warrants Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1153">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zJ3m9g150fRb" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1155">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue_c20210101__20211231_zRryHhVq4t1i" style="text-align: right" title="Weighted Average Fair Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1157">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Forfeited/Cancelled</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231_zxdYOGQuov42" style="text-align: right" title="Number of Warrants Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1159">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zZeNGQ4VFTl6" style="text-align: right" title="Weighted Average Exercise Price, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1161">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue_c20210101__20211231_zLFQmA0k6r43" style="text-align: right" title="Weighted Average Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify">Exercised</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231_zB6Hy9h4MgPj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1165">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zeKmnrt1D1Ac" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1167">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231_zNJvTxhkQiEl" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1169">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2021</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231_zP0tRVtnrDHj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending">526,281</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zbzTbWnfSag3" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Ending">8.15</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue_iE_c20210101__20211231_zbnXEdStRhzj" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value, Ending">4.01</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_z9wk49yHjIt7" title="Weighted-average Remaining Contractual Life (Years) Outstanding, Ending">4.7</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zOA32fHdf4ul" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The intrinsic value of warrants exercised during the years ended December 31, 2021 and 2020 was $<span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriodTotalIntrinsicValue_pp0p0_c20210101__20211231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_ziiwU69AAvs5" title="Intrinsic value of warrants exercised">0</span> and approximately $<span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriodTotalIntrinsicValue_pn5n6_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionsMember_zYr3dLcsF7o" title="Intrinsic value of warrants exercised">9.7</span> million, respectively. The aggregate intrinsic value of outstanding warrants at December 31, 2021 was approximately $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_pp0p0_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z17zlr2H7eVl" title="Intrinsic value of options outstanding">497,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_ecustom--ClassOfWarrantExercisable_iI_c20211231_zCR4tHSVU0g4" title="Warrants exercisable">70,000</span> warrants are exercisable at December 31, 2021. As discussed in Note 3 and Note 4, approximately <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231_zIbB2J8b7as2" title="Warrants purchase">456,000</span> warrants to purchase shares of the Company’s common stock were issued in connection with the acquisition of ACI and IdMo. The ability to exercise the warrants is contingent upon the achievement of certain development and revenue milestones on or before January 1, 2027. There was no unrecognized stock-based compensation expense related to warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 4 for additional information regarding the fair value calculation of the warrants issued during the year ended December 31, 2021. The fair values for the warrants issued during the year ended December 31, 2020 were estimated at the date of grant using the Black Scholes model with the following weighted average assumptions:</span></p> <p id="xdx_89B_ecustom--ScheduleOfFairValuesWarrantsAssumptionsTableTextBlock_zqSOWiYk8mai" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B3_zwJgYjTNt9Pe" style="display: none">Schedule of Fair Value of Warrants Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zTa8wc1yHAq1" title="Warrants outstanding, measurement input">0.34</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z5upFdIICx5f" title="Warrants, expected life">5.0</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zADCevmXEtLj" title="Warrants outstanding, measurement input">61.42</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dn_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zgdrggoMTiy" title="Warrants outstanding, measurement input">None</span></span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AF_z5u27N2jcE3j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Issued for Services</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has issued restricted stock to third parties for services provided. The grant date fair value of the restricted stock granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the stock awards. The Company issued <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20211231__srt--TitleOfIndividualAxis__custom--ThirdPartiesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrorJRhIKQ07" title="Number of shares issued for services">5,548</span> and <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20201231__srt--TitleOfIndividualAxis__custom--ThirdPartiesMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z7aVaQlQib6f" title="Number of shares issued for services">83,935</span> shares of restricted stock for services during the years ended December 31, 2021 and 2020, respectively, and there was no unrecognized stock-based compensation expense related to restricted stock issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based Compensation Expense</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zYppEJUwsZDl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized stock-based compensation expense related to the types of awards discussed above as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_z4J5iA0u0fxf" style="display: none">Schedule of Recognized Stock-based Compensation Expense </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20210101__20211231_zT4Hf0hlHu41" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20200101__20201231_zxacGCeS2hB5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMscvFbk3PUc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">292,754</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">901,345</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvvTXrYkiacd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,164,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,861</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9i08GP7cQDd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1211"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">303,802</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zHVTkU2ozsn1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,900</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,032,033</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zeM83qAn8CVi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,509,404</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,738,041</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zDMo5YgxXMig" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 6000000 2095266 <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zMfb86rXn0r7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes option activity during the years ended December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_z03x74Z7fs93" style="display: none">Schedule of Option Activity </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify">    </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2019</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20200101__20201231_ztdVRq5N7rE8" style="width: 12%; text-align: right" title="Number of Options Outstanding, Beginning">2,021,817</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20200101__20201231_zZWf6QXaooHk" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning">1.69</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20200101__20201231_zf1NGllhgP23" style="width: 12%; text-align: right" title="Weighted Average Fair Value Outstanding, Beginning">0.83</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20200101__20201231_z59B0Xpb03oc" style="text-align: right" title="Number of Options Outstanding, Granted">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_znF4tsjzrcUh" style="text-align: right" title="Weighted Average Exercise Price Granted">8.14</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231_zWjTCvmZ7Mwk" style="text-align: right" title="Weighted Average Fair Value Granted">4.74</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">     </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Expired</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20200101__20201231_zT3WstzYKuwf" style="text-align: right" title="Number of Options Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zmP4Yj006WC3" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl0975">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20200101__20201231_z0JCWPwmbCAj" style="text-align: right" title="Weighted Average Fair Value Expired"><span style="-sec-ix-hidden: xdx2ixbrl0977">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Forfeited/Cancelled</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20200101__20201231_zsFbtyYEgiH2" style="text-align: right" title="Number of Options Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0979">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231_zLYxE78b8gDf" style="text-align: right" title="Weighted Average Exercise Price Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0981">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20200101__20201231_zRwwh1Ig0Wc5" style="text-align: right" title="Weighted Average Fair Value Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl0983">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify">Exercised</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_iN_di_c20200101__20201231_zHmP1kvljX9b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding, Exercised">(871,229</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20200101__20201231_zWfbptXIaKW2" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price Exercised">1.68</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised_iE_pid_c20200101__20201231_z4PGQSkTTkNc" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value Exercised">0.89</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2020</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20211231_zWqhIAv9C4pk" style="text-align: right" title="Number of Options Outstanding, Beginning">1,300,588</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20211231_zJAhXB8AAiQ3" style="text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning">2.44</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20210101__20211231_zlFwd1sRp1V2" style="text-align: right" title="Weighted Average Fair Value Outstanding, Beginning">1.24</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20210101__20211231_zDDDwxugm0vd" style="text-align: right" title="Number of Options Outstanding, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0997">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zjOw7uQYPt3h" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="-sec-ix-hidden: xdx2ixbrl0999">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231_z5RLnB4mfnCi" style="text-align: right" title="Weighted Average Fair Value Granted"><span style="-sec-ix-hidden: xdx2ixbrl1001">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Expired</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20210101__20211231_zwUUtk5ntwy9" style="text-align: right" title="Number of Options Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1003">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zOJoZ0jOMXB7" style="text-align: right" title="Weighted Average Exercise Price Expired"><span style="-sec-ix-hidden: xdx2ixbrl1005">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20210101__20211231_z53mqZjkAmVg" style="text-align: right" title="Weighted Average Fair Value Expired"><span style="-sec-ix-hidden: xdx2ixbrl1007">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Forfeited/Cancelled</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20210101__20211231_zegbUITxxHAi" style="text-align: right" title="Number of Options Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1009">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_za8NHKjNXDy" style="text-align: right" title="Weighted Average Exercise Price Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1011">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_c20210101__20211231_zpW4uc6RxFL1" style="text-align: right" title="Weighted Average Fair Value Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1013">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify">Exercised</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_ecustom--StockIssuedDuringPeriodSharesStockOptionsExercised1_iN_di_c20210101__20211231_z13yGKE6Lmmh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options Outstanding, Exercised">(189,225</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20211231_zXTl5utKRtvc" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price Exercised">2.38</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised_iE_pid_c20210101__20211231_zWUmpRzg3FPl" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value Exercised">1.12</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2021</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20211231_zF3A17QbjeMb" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Outstanding, Ending">1,111,363</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zseBZ53bLYsc" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending">2.12</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20210101__20211231_zbhLRzuALPce" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value Outstanding, Ending">1.31</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20210101__20211231_zugm00qLGxK1" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average Remaining Contractual Life (years) Outstanding, Ending">6.62</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercisable at December 31, 2021</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20210101__20211231_z3URBBN68syl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Options Exercisable Ending">1,094,697</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20211231_zmeQJBC1ofd4" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Exercisable Ending">2.01</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable_iE_pid_c20210101__20211231_zaXDswJXKuHl" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value, Exercisable Ending">1.18</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20211231_zhvOZgXRUVD3" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-average Remaining Contractual Life (years), Exercisable Ending">6.59</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2021817 1.69 0.83 150000 8.14 4.74 871229 1.68 0.89 1300588 2.44 1.24 189225 2.38 1.12 1111363 2.12 1.31 P6Y7M13D 1094697 2.01 1.18 P6Y7M2D 1300000 11800000 7600000 7100000 16666 78115 P0Y6M <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zuQMSoTypzkk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B5_zGZYUBOR4y57" style="display: none">Schedule of Fair Value of Options Weighted Average Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20210101__20211231_zXvOiKUIXLSg" title="Risk-free interest rate"><span style="-sec-ix-hidden: xdx2ixbrl1049">-</span></span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231_zqFi97nu0QEk" title="Risk-free interest rate">1.05</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c20210101__20211231_z4MN2Gzt3Mq7" title="Expected life (years)"><span style="-sec-ix-hidden: xdx2ixbrl1053">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231_z9SGo41sCH01" title="Expected life (years)">7.3</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">       <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20210101__20211231_z3M9emPm5qn4" title="Expected volatility"><span style="-sec-ix-hidden: xdx2ixbrl1057">-</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231_z7SXVIPxgUl1" title="Expected volatility">62.82</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dpxL_uPure_c20210101__20211231_z9xxifgwo94f" style="text-align: right" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1061">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dpn_uPure_c20200101__20201231_zhbbCav9JuG2" style="text-align: right" title="Expected dividend yield"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</span></td><td style="text-align: left"> </td></tr> </table> 0.0105 P7Y3M18D 0.6282 0 <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zdxbdHWLfY52" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The grant date fair value of RSUs granted is determined using the closing market price of the Company’s common stock on the grant date with the associated compensation expense amortized over the vesting period of the awards. The following table sets forth the outstanding RSUs and related activity for the years ended December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zSPdVrsBLCA9" style="display: none">Schedule of Outstanding Restricted Stock Units and Related Activity </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of RSUs</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested at December 31, 2019</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zKj7oMdvTZS" style="text-align: right" title="Number of Restricted Stock Units, Outstanding Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1067">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2KO0l2hhhge" style="text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1069">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: justify">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztHOH8AexPU" style="width: 16%; text-align: right" title="Number of Restricted Stock Units, Granted">549,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRD8wDeHFPVg" style="width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value, Granted">10.49</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0d2hrhaDSQ6" style="text-align: right" title="Number of Restricted Stock Units, Vested">(27,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zHwkNVsfq80e" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">10.49</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXhA4vanc5Sb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Restricted Stock Units, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1079">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20200101__20201231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zdpgeWJJSZtc" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1081">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested at December 31, 2020</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpIxJz52LHOa" style="text-align: right" title="Number of Restricted Stock Units, Outstanding Beginning">522,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0k7esXOm9I9" style="text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Beginning">10.49</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zOcWgmeoo1q7" style="text-align: right" title="Number of Restricted Stock Units, Granted">1,217,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0lhzF20z274" style="text-align: right" title="Weighted Average Grant Date Fair Value, Granted">9.76</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Vested</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zU59ccI4xKZ7" style="text-align: right" title="Number of Restricted Stock Units, Vested">(438,502</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zj4OBMLUd9i6" style="text-align: right" title="Weighted Average Grant Date Fair Value, Vested">10.10</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify">Forfeited/Cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_di_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z8wTTKHzZV6d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Restricted Stock Units, Forfeited/Cancelled">(34,083</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfunQIOUTEY9" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited/Cancelled">9.91</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unvested at December 31, 2021</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znJYHW8cebcg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Restricted Stock Units, Outstanding Ending">1,267,415</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqEk7mxbcjJ3" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding Ending">9.94</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 549500 10.49 27000 10.49 522500 10.49 1217500 9.76 438502 10.10 34083 9.91 1267415 9.94 11600000 P2Y3M18D <p id="xdx_89D_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zoc3OClcrw9c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes warrant activity during the years ended December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zDPlnfi3RWNk" style="display: none">Schedule of Warrant Activity </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 35%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2019</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20201231_zgSmBBhNcfH7" style="width: 12%; text-align: right" title="Number of Warrants Outstanding, Beginning">983,535</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20200101__20201231_zTTpPpAxtjFg" style="width: 12%; text-align: right" title="Weighted Average Exercise Price, Beginning">1.44</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue_iS_c20200101__20201231_zhaJPvQ9a8q1" style="width: 12%; text-align: right" title="Weighted Average Fair Value, Beginning">1.03</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"> </td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231_zz8Ugk0nrQRl" style="text-align: right" title="Number of Warrants Outstanding, Granted">20,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20201231_zSBS8JTaKKuj" style="text-align: right" title="Weighted Average Exercise Price, Granted">1.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231_zYedL0cnZYEk" style="text-align: right" title="Weighted Average Fair Value, Granted">15.19</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Expired</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20200101__20201231_zHSZza5Q46Gg" style="text-align: right" title="Number of Warrants Outstanding, Expired">(9,090</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="text-align: right" title="Weighted Average Exercise Price, Expired">6.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue_c20200101__20201231_pdd" style="text-align: right" title="Weighted Average Fair Value, Expired">0.17</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Forfeited/Cancelled</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20201231_pdd" style="text-align: right" title="Number of Warrants Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1127">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="text-align: right" title="Weighted Average Exercise Price, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1129">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue_c20200101__20201231_pdd" style="text-align: right" title="Weighted Average Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1131">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify">Exercised</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20200101__20201231_zcPYfJXd5BX1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Exercised">(924,445</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20200101__20201231_pdd" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Exercised">1.42</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_c20200101__20201231_z9m0ZiGZGdE6" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value, Exercised">1.43</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2020</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231_z8A0MfXBQMs3" style="text-align: right" title="Number of Warrants Outstanding, Beginning">70,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20211231_zlJurqfxwpL1" style="text-align: right" title="Weighted Average Exercise Price, Beginning">1.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue_iS_c20210101__20211231_zFA1Kkjk4hve" style="text-align: right" title="Weighted Average Fair Value, Beginning">5.21</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20200101__20201231_zPqMwsByDKX1" title="Weighted-average Remaining Contractual Life (Years) Outstanding, Beginning">3.3</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Granted</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231_zpEOrU0KXted" style="text-align: right" title="Number of Warrants Outstanding, Granted">456,281</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20211231_z93lk9ynJ1Ra" style="text-align: right" title="Weighted Average Exercise Price, Granted">9.13</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231_zbwuFdjcDFX7" style="text-align: right" title="Weighted Average Fair Value, Granted">3.83</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">Expired</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20211231_zI0GvYE0Lli" style="text-align: right" title="Number of Warrants Outstanding, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1153">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20211231_zJ3m9g150fRb" style="text-align: right" title="Weighted Average Exercise Price, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1155">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue_c20210101__20211231_zRryHhVq4t1i" style="text-align: right" title="Weighted Average Fair Value, Expired"><span style="-sec-ix-hidden: xdx2ixbrl1157">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Forfeited/Cancelled</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20211231_zxdYOGQuov42" style="text-align: right" title="Number of Warrants Outstanding, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1159">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20211231_zZeNGQ4VFTl6" style="text-align: right" title="Weighted Average Exercise Price, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1161">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue_c20210101__20211231_zLFQmA0k6r43" style="text-align: right" title="Weighted Average Fair Value, Forfeited/Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1163">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify">Exercised</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231_zB6Hy9h4MgPj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants Outstanding, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1165">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_c20210101__20211231_zeKmnrt1D1Ac" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1167">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_c20210101__20211231_zNJvTxhkQiEl" style="padding-bottom: 1.5pt; text-align: right" title="Weighted Average Fair Value, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1169">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December 31, 2021</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231_zP0tRVtnrDHj" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding, Ending">526,281</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice_iE_c20210101__20211231_zbzTbWnfSag3" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, Ending">8.15</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue_iE_c20210101__20211231_zbnXEdStRhzj" style="padding-bottom: 2.5pt; text-align: right" title="Weighted Average Fair Value, Ending">4.01</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_z9wk49yHjIt7" title="Weighted-average Remaining Contractual Life (Years) Outstanding, Ending">4.7</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 983535 1.44 1.03 20000 1.40 15.19 9090 6.00 0.17 924445 1.42 1.43 70000 1.83 5.21 P3Y3M18D 456281 9.13 3.83 526281 8.15 4.01 P4Y8M12D 0 9700000 497000 70000 456000 <p id="xdx_89B_ecustom--ScheduleOfFairValuesWarrantsAssumptionsTableTextBlock_zqSOWiYk8mai" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B3_zwJgYjTNt9Pe" style="display: none">Schedule of Fair Value of Warrants Assumptions</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zTa8wc1yHAq1" title="Warrants outstanding, measurement input">0.34</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_z5upFdIICx5f" title="Warrants, expected life">5.0</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zADCevmXEtLj" title="Warrants outstanding, measurement input">61.42</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dn_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zgdrggoMTiy" title="Warrants outstanding, measurement input">None</span></span></td><td style="text-align: left"> </td></tr> </table> 0.34 P5Y 61.42 0 5548 83935 <p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationActivityTableTextBlock_zYppEJUwsZDl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized stock-based compensation expense related to the types of awards discussed above as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_z4J5iA0u0fxf" style="display: none">Schedule of Recognized Stock-based Compensation Expense </span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20210101__20211231_zT4Hf0hlHu41" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20200101__20201231_zxacGCeS2hB5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMscvFbk3PUc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">292,754</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">901,345</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvvTXrYkiacd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,164,750</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,861</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9i08GP7cQDd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1211"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">303,802</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--AwardTypeAxis__us-gaap--StockCompensationPlanMember_zHVTkU2ozsn1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,900</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,032,033</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--AllocatedShareBasedCompensationExpense_zeM83qAn8CVi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,509,404</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,738,041</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 292754 901345 5164750 500861 303802 51900 1032033 5509404 2738041 <p id="xdx_805_eus-gaap--IncomeTaxDisclosureTextBlock_zaJ9u6yheya5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12 – <span id="xdx_829_zk712nVAcEcg">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zTKXUnErz1fa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of the provision for income taxes consists of the following for the years ended December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_z7Cp1oOGdV0i" style="display: none">Schedule of Components Income Tax Provision</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20210101__20211231_zShenNxzG1c8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20200101__20201231_z2PbwxMbRZt1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zzWXkxpJ1Uog" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCFSALzO40_zM0KfOCi5CIf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%">Federal</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,092,730</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1228">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCFSALzO40_zVqlAThyPHG1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">886,173</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">637,760</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_i01T_mtCFSALzO40_maITEBzvit_zOBsNLOVyZB4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total current</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,978,903</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">637,760</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zykaTr8BkKGh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDFSALzrPD_zYzLaIbsrmd6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,394,686</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(452,544</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDFSALzrPD_zztA6NM79arb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">603,642</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(94,680</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_i01T_mtDFSALzrPD_maITEBzvit_z0q8kKyykqu9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total deferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,998,328</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(547,224</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzvit_zP1MFqpfiuT" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total income tax expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,977,231</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">90,536</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_z1mePTVWcASi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zvzNopN7hBW8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zaoIomXFB0K2" style="display: none">Schedule of Benefit from Income Taxes and Effective Tax Rates</span><span/></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210101__20211231_z6980I8hDI6g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20200101__20201231_zHgGNEOhd5ol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_zXpdCr0b1Na6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Federal income tax expense at statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_z43tTiqrxf6a" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income tax expense, net of federal tax benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.3</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentAbstract_iB_zd3FK1leP3Ig" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Permanent differences:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationForeignderivedIntangibleIncomeDeduction_i01_dp_uPure_z072WVQLRVM3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">- Foreign derived intangible income deduction</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3.5)</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1.7)</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_i01_dp_uPure_zoaAMt4usOA6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">- Stock based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8.8)</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_i01_dp_uPure_zNUDpmBZLhVd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">- Other permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.4)</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_iN_dpi_uPure_zOXzPfkrL0Ga" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2.6)</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2.0)</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance_dp_uPure_ztGJKUAy8S02" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in uncertain tax positions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.1</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_zGOC15NIMPec" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12.1)</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_uPure_zjv7Wy0H8TB2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1.0)</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.2)</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_dp_uPure_z91TLon6B3Rk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">19.7</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.2</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> <p id="xdx_8A0_z9mcYJ1gy8Qk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zo7zM9wTTR57" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax assets consist of the following components as of December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BE_zR77eQ2jgJHh" style="display: none">Schedule of Deferred Tax Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20211231_zRuUXuwIUBOe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20201231_zXG8j3w83SFe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zVed8GQr78j2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_i01I_maDTAGzwm0_zUL3t1hIswf8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Accrued liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1291">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">37,898</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_i01I_maDTAGzwm0_zCvfju4P0uDb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Reserves and allowances</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">166,050</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,049</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_i01I_maDTAGzwm0_zNaj9KdaNZ34" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Deferred compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">393,871</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">241,652</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_maDTAGzwm0_z5clgJ7hJoP1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Research and development credits</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1300"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">423,001</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGzwm0_msDITLzwoD_z5ZVNCX4T4kk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total deferred tax assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">559,921</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">902,600</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zBYs5mvz33Zf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i01NI_di_maDITLzcCv_z8VYSyUfNLuj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(477,542</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(233,951</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_i01NI_di_maDITLzcCv_zBRpgH0PzwD1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Intangibles, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,743,972</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1313"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_i01NI_di_maDITLzcCv_zdpp1B28ptK2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Prepaids</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(560,093</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(66,456</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_di_maDITLzcCv_zogUOEOWEOA5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,758</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(54,969</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_di_mtDITLzcCv_mtDITLzwoD_zBMEIkuZDu4e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,788,365</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(355,376</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net deferred tax assets (liabilities)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--DeferredTaxAssetsOther_iI_c20211231_z7QLOaeDwNB9" style="text-align: right" title="Net deferred tax assets (liabilities)">(7,228,444</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsOther_iI_c20201231_zIu00fQcG41j" style="text-align: right" title="Net deferred tax assets (liabilities)">547,224</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_zDUT23wXA6k7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1328"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1329"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets (liabilities)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsNet_iNI_di_c20211231_zj9KDJmsXWrb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred tax assets (liabilities)">(7,228,444</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DeferredTaxAssetsNet_iI_c20201231_zV3CypcZDxS9" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred tax assets (liabilities)">547,224</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zcK4IhvjT9K5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At December 31, 2021, the Company had <span id="xdx_900_eus-gaap--OperatingLossCarryforwards_iI_do_c20211231_zUEXTNAo39Ji" title="Net operating loss carry-forwards">no</span> federal or state net operating loss carryforwards and <span id="xdx_904_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_dxL_c20211231_zdNQYfU1vWod" title="Research and development credit carry forwards::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1337">no</span></span> federal or state research and development credit carryforwards. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of December 31, 2020, in part because in that year the Company achieved three years of cumulative pre-tax income, management determined that there was sufficient positive evidence to conclude that it was more likely than not that its deferred taxes were realizable. The Company therefore fully reduced its valuation allowance accordingly by $<span id="xdx_907_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_c20200101__20201231_zDm9TNvDXbU4" title="Deferred tax valuation allowance">5,161,500</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">ASC Topic 740-10-05 requires that the impact of a tax position be recognized in the financial statements if that position is more likely than not of being sustained on audit, based on the technical merits of the position. Our unrecognized tax benefit balances included $<span id="xdx_902_eus-gaap--UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_iI_c20211231_zSG1ucZ4iKjc" title="Unrecognized tax benefits that would impact effective tax rate">1,067,853</span> at December 31, 2021 and $<span id="xdx_905_eus-gaap--UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_iI_c20201231_zvagCgJ0Lhv3" title="Unrecognized tax benefits that would impact effective tax rate">447,831</span> at December 31, 2020 of tax positions that, if recognized, would impact our effective tax rate. The Company expects no material changes to the liability for unrecognized tax benefits in the next 12 months. Interest and penalties associated with uncertain tax positions are recorded as a component of income tax expense. A reconciliation of the beginning and ending amount of unrecognized benefits is as follows:</span></p> <p id="xdx_89E_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_z22VrorrMuhf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_za9mSYEJIH0g" style="display: none">Schedule of Unrecognized Tax Benefits</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Unrecognized tax benefits at the beginning of the year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--UnrecognizedTaxBenefits_iS_c20210101__20211231_z2rLK0m68jT5" style="width: 16%; text-align: right" title="Unrecognized tax benefits at the beginning of the year">447,831</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--UnrecognizedTaxBenefits_iS_c20200101__20201231_zFX9j6gPsrge" style="width: 16%; text-align: right" title="Unrecognized tax benefits at the beginning of the year"><span style="-sec-ix-hidden: xdx2ixbrl1349">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Gross increases - current year tax positions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c20210101__20211231_zErnTsgUcFtf" style="text-align: right" title="Gross increases- current year tax positions">770,069</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c20200101__20201231_z1SoVnocukT" style="text-align: right" title="Gross increases - current year tax positions">232,145</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross increases - prior year tax positions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_c20210101__20211231_z3OcJzGmbz85" style="text-align: right" title="Gross increases- prior year tax positions"><span style="-sec-ix-hidden: xdx2ixbrl1355">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_c20200101__20201231_ztt2M6GbsmF7" style="text-align: right" title="Gross increases - prior year tax positions">215,686</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Gross decreases - prior year tax positions</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_iN_di_c20210101__20211231_zzOs3EuHtwoa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross decreases - prior year tax positions">(150,047</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_iN_di_c20200101__20201231_zqeqCjL4JRo9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross decreases- prior year tax positions"><span style="-sec-ix-hidden: xdx2ixbrl1361">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Unrecognized tax benefits at end of year</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--UnrecognizedTaxBenefits_iE_c20210101__20211231_zREENLBpF47e" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized tax benefits at end of year">1,067,853</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--UnrecognizedTaxBenefits_iE_c20200101__20201231_zSJpCk3fmkkh" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized tax benefits at end of year">447,831</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Interest and penalties in year-end balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_iE_c20210101__20211231_z5sQtFWK2gV1" style="border-bottom: Black 2.5pt double; text-align: right" title="Interest and penalties in year-end balance"><span style="-sec-ix-hidden: xdx2ixbrl1367">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_iE_c20200101__20201231_zZ4KIHyneUth" style="border-bottom: Black 2.5pt double; text-align: right" title="Interest and penalities in year- end balance"><span style="-sec-ix-hidden: xdx2ixbrl1369">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_z7WNCykoi0q8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to taxation in the United States and other state jurisdictions. The tax years from December 31, 2017 through December 31, 2021 remain open to examination for federal income tax purposes and by the other major taxing jurisdictions to which the Company is subject. The Company is not currently under examination by any taxing authority.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zTKXUnErz1fa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of the provision for income taxes consists of the following for the years ended December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_z7Cp1oOGdV0i" style="display: none">Schedule of Components Income Tax Provision</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20210101__20211231_zShenNxzG1c8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20200101__20201231_z2PbwxMbRZt1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40C_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zzWXkxpJ1Uog" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Current:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maCFSALzO40_zM0KfOCi5CIf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%">Federal</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">6,092,730</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1228">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maCFSALzO40_zVqlAThyPHG1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">886,173</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">637,760</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefit_i01T_mtCFSALzO40_maITEBzvit_zOBsNLOVyZB4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total current</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,978,903</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">637,760</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zykaTr8BkKGh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Deferred:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maDFSALzrPD_zYzLaIbsrmd6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,394,686</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(452,544</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maDFSALzrPD_zztA6NM79arb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">State</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">603,642</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(94,680</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_i01T_mtDFSALzrPD_maITEBzvit_z0q8kKyykqu9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total deferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,998,328</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(547,224</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzvit_zP1MFqpfiuT" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total income tax expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,977,231</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">90,536</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 6092730 886173 637760 6978903 637760 1394686 -452544 603642 -94680 1998328 -547224 8977231 90536 <p id="xdx_899_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zvzNopN7hBW8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_zaoIomXFB0K2" style="display: none">Schedule of Benefit from Income Taxes and Effective Tax Rates</span><span/></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20210101__20211231_z6980I8hDI6g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20200101__20201231_zHgGNEOhd5ol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_uPure_zXpdCr0b1Na6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Federal income tax expense at statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_uPure_z43tTiqrxf6a" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income tax expense, net of federal tax benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.3</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentAbstract_iB_zd3FK1leP3Ig" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Permanent differences:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationForeignderivedIntangibleIncomeDeduction_i01_dp_uPure_z072WVQLRVM3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">- Foreign derived intangible income deduction</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3.5)</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1.7)</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_i01_dp_uPure_zoaAMt4usOA6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">- Stock based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.2</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8.8)</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_i01_dp_uPure_zNUDpmBZLhVd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">- Other permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.4)</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_iN_dpi_uPure_zOXzPfkrL0Ga" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development credits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2.6)</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2.0)</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance_dp_uPure_ztGJKUAy8S02" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Change in uncertain tax positions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.1</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_uPure_zGOC15NIMPec" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in valuation allowance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12.1)</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_dp_uPure_zjv7Wy0H8TB2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1.0)</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.2)</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_dp_uPure_z91TLon6B3Rk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">19.7</td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.2</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> 0.210 0.210 0.039 0.033 -0.035 -0.017 0.002 -0.088 0.003 -0.004 0.026 0.020 0.014 0.011 0.000 -0.121 -0.010 -0.002 0.197 0.002 <p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zo7zM9wTTR57" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net deferred tax assets consist of the following components as of December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BE_zR77eQ2jgJHh" style="display: none">Schedule of Deferred Tax Assets</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20211231_zRuUXuwIUBOe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20201231_zXG8j3w83SFe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zVed8GQr78j2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_i01I_maDTAGzwm0_zUL3t1hIswf8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Accrued liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1291">-</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">37,898</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_i01I_maDTAGzwm0_zCvfju4P0uDb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Reserves and allowances</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">166,050</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,049</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_i01I_maDTAGzwm0_zNaj9KdaNZ34" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Deferred compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">393,871</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">241,652</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_maDTAGzwm0_z5clgJ7hJoP1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Research and development credits</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1300"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">423,001</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGzwm0_msDITLzwoD_z5ZVNCX4T4kk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total deferred tax assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">559,921</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">902,600</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxLiabilitiesAbstract_iB_zBYs5mvz33Zf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i01NI_di_maDITLzcCv_z8VYSyUfNLuj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(477,542</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(233,951</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_i01NI_di_maDITLzcCv_zBRpgH0PzwD1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Intangibles, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(6,743,972</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1313"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_i01NI_di_maDITLzcCv_zdpp1B28ptK2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Prepaids</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(560,093</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(66,456</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesOther_i01NI_di_maDITLzcCv_zogUOEOWEOA5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,758</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(54,969</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DeferredIncomeTaxLiabilities_i01NTI_di_mtDITLzcCv_mtDITLzwoD_zBMEIkuZDu4e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total deferred tax liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,788,365</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(355,376</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net deferred tax assets (liabilities)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--DeferredTaxAssetsOther_iI_c20211231_z7QLOaeDwNB9" style="text-align: right" title="Net deferred tax assets (liabilities)">(7,228,444</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--DeferredTaxAssetsOther_iI_c20201231_zIu00fQcG41j" style="text-align: right" title="Net deferred tax assets (liabilities)">547,224</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_zDUT23wXA6k7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1328"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1329"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets (liabilities)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DeferredTaxAssetsNet_iNI_di_c20211231_zj9KDJmsXWrb" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred tax assets (liabilities)">(7,228,444</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--DeferredTaxAssetsNet_iI_c20201231_zV3CypcZDxS9" style="border-bottom: Black 2.5pt double; text-align: right" title="Net deferred tax assets (liabilities)">547,224</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 37898 166050 200049 393871 241652 423001 559921 902600 477542 233951 6743972 560093 66456 6758 54969 7788365 355376 -7228444 547224 7228444 547224 0 5161500 1067853 447831 <p id="xdx_89E_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_z22VrorrMuhf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_za9mSYEJIH0g" style="display: none">Schedule of Unrecognized Tax Benefits</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Unrecognized tax benefits at the beginning of the year</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--UnrecognizedTaxBenefits_iS_c20210101__20211231_z2rLK0m68jT5" style="width: 16%; text-align: right" title="Unrecognized tax benefits at the beginning of the year">447,831</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--UnrecognizedTaxBenefits_iS_c20200101__20201231_zFX9j6gPsrge" style="width: 16%; text-align: right" title="Unrecognized tax benefits at the beginning of the year"><span style="-sec-ix-hidden: xdx2ixbrl1349">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Gross increases - current year tax positions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c20210101__20211231_zErnTsgUcFtf" style="text-align: right" title="Gross increases- current year tax positions">770,069</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c20200101__20201231_z1SoVnocukT" style="text-align: right" title="Gross increases - current year tax positions">232,145</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross increases - prior year tax positions</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_c20210101__20211231_z3OcJzGmbz85" style="text-align: right" title="Gross increases- prior year tax positions"><span style="-sec-ix-hidden: xdx2ixbrl1355">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_c20200101__20201231_ztt2M6GbsmF7" style="text-align: right" title="Gross increases - prior year tax positions">215,686</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Gross decreases - prior year tax positions</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_iN_di_c20210101__20211231_zzOs3EuHtwoa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross decreases - prior year tax positions">(150,047</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_iN_di_c20200101__20201231_zqeqCjL4JRo9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Gross decreases- prior year tax positions"><span style="-sec-ix-hidden: xdx2ixbrl1361">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Unrecognized tax benefits at end of year</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--UnrecognizedTaxBenefits_iE_c20210101__20211231_zREENLBpF47e" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized tax benefits at end of year">1,067,853</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--UnrecognizedTaxBenefits_iE_c20200101__20201231_zSJpCk3fmkkh" style="border-bottom: Black 2.5pt double; text-align: right" title="Unrecognized tax benefits at end of year">447,831</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"> </td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Interest and penalties in year-end balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_iE_c20210101__20211231_z5sQtFWK2gV1" style="border-bottom: Black 2.5pt double; text-align: right" title="Interest and penalties in year-end balance"><span style="-sec-ix-hidden: xdx2ixbrl1367">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_iE_c20200101__20201231_zZ4KIHyneUth" style="border-bottom: Black 2.5pt double; text-align: right" title="Interest and penalities in year- end balance"><span style="-sec-ix-hidden: xdx2ixbrl1369">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 447831 770069 232145 215686 150047 1067853 447831 <p id="xdx_806_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zcaJ6fsseAFa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 13 – <span id="xdx_827_zl7CfGXc9Xhg">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company acquired the exclusive rights to the CoPrimer technology pursuant to an exclusive license agreement, dated April 2014 (the “Exclusive License Agreement”), between the Company and DNA Logix, Inc., which was assigned to Dr. Brent Satterfield, an executive officer, prior to the Company’s acquisition of DNA Logix, Inc. On March 1, 2017, the Company entered into an amendment to its Exclusive License Agreement for its Cooperative Primers (“License”) technology with Dr. Satterfield. The amendment provided in part that all accrued royalties under the License ceased as of January 1, 2017, and the Company agreed to pay to Dr. Satterfield $<span id="xdx_901_eus-gaap--AccruedRoyaltiesCurrent_iI_c20170101__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--DrBrentSatterfieldMember_zNjZTymIIkl2" title="Accrued royalties">700,000</span> of accrued royalties at the rate of $<span id="xdx_902_eus-gaap--PaymentsForRoyalties_c20170101__20170130__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--DrBrentSatterfieldMember_zeTE9fSKO6Re" title="Payment for royalties per month">10,000</span> per month starting in January 2017. At December 31, 2021, the aggregate balance of this related party liability was $<span id="xdx_908_eus-gaap--DueToRelatedPartiesCurrentAndNoncurrent_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--ExclusiveLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--DrBrentSatterfieldMember_zI7dC55ozIji" title="Due to related party">0</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 700000 10000 0 <p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zyWzXGnIz1X5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 14 – <span id="xdx_82B_zdGMdmEjK4D4">Commitments and Contingencies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Lease Obligations</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s offices are located at 2401 S. Foothill Dr., Suite D, Salt Lake City, Utah 84109-1479. In February 2020, the Company entered into a <span id="xdx_900_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20200229_zMmnWzJ0bGQe" title="Operating lease, term">4</span>-year lease agreement for its office space and in March 2020, the Company entered into an addendum with our landlord for additional space. The aggregate space consists of approximately <span id="xdx_902_eus-gaap--AreaOfLand_iI_uSqft_c20211231_zxmCxfnxSgl7" title="Area of land">13,687</span> square feet at a monthly rate of $<span id="xdx_90C_eus-gaap--PaymentsForRent_c20210101__20211231_zVg4Yn7l6DCb" title="Payments for rent">28,825</span> and expires in <span id="xdx_904_eus-gaap--LeaseExpirationDate1_dxL_c20210101__20211231_zIwM2LtuO1wc" title="Lease expiration date::XDX::2024-02-29"><span style="-sec-ix-hidden: xdx2ixbrl1387">February 2024</span></span>. As a result of business acquisitions during the year ended December 31, 2021, the Company also leases additional laboratory and office space under two month-to-month leases. For the years ended December 31, 2021 and 2020, the Company expensed $<span id="xdx_90C_eus-gaap--LeaseAndRentalExpense_c20210101__20211231_zdYqWXwLRjd8" title="Rent expenses">346,350</span> and $<span id="xdx_905_eus-gaap--LeaseAndRentalExpense_c20200101__20201231_zAn8BdbhBI09" title="Rent expenses">311,963</span>, respectively, for rent. The Company’s future minimum lease payments were as follows as of December 31, 2021:</span></p> <p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zJa74hmiEoC1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zUcB0xAq46F9" style="display: none">Schedule of Future Minimum Lease Payments</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="4" style="border-bottom: Black 1.5pt solid; text-align: justify; font-weight: bold">Year Ending December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzrRH_ziBMHOHeBkXa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 80%; text-align: justify">2022</td><td style="width: 2%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">293,595</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzrRH_zP52gnggo36f" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">2023</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">303,059</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzrRH_zDIGLmTsKza6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify">2024</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,774</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzrRH_zrkX3FUZqnFg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total lease payments </span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">647,428</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A0_zRuJYDZ1hGDg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Litigation</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities for loss contingencies arising from claims, assessments, litigation, fines, and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Five different securities class action complaints were filed in July, September and December by certain stockholders of the Company against the Company claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company. The plaintiffs demand compensatory damages sustained as a result of the Company’s alleged wrongdoing in an amount to be proven at trial. The Company believes these lawsuits are without merit and intends to defend the cases vigorously. The Company is unable to estimate a range of loss, if any, that could result were there to be an adverse final decision in these cases. As of the date of this report, the Company does not believe it is probable that these cases will result in an unfavorable outcome; however, if an unfavorable outcome were to occur in these cases, it is possible that the impact could be material to the Company’s results of operations in the period(s) in which any such outcome becomes probable and estimable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> P4Y 13687 28825 346350 311963 <p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zJa74hmiEoC1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zUcB0xAq46F9" style="display: none">Schedule of Future Minimum Lease Payments</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="4" style="border-bottom: Black 1.5pt solid; text-align: justify; font-weight: bold">Year Ending December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzrRH_ziBMHOHeBkXa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 80%; text-align: justify">2022</td><td style="width: 2%; text-align: left"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">293,595</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzrRH_zP52gnggo36f" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify">2023</td><td style="text-align: left"> </td> <td style="text-align: left"> </td><td style="text-align: right">303,059</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzrRH_zDIGLmTsKza6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: justify">2024</td><td style="padding-bottom: 1.5pt; text-align: left"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">50,774</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzrRH_zrkX3FUZqnFg" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total lease payments </span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">647,428</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zHRGrULDy1Ag" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.35pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 15 – <span id="xdx_82A_zcMuOF8q4j85">Subsequent Events</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2022, the Company’s Board of Directors authorized a share repurchase program that would allow the Company to repurchase up to $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_pn5n6_c20220301__20220331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zqJAGcwb79vk" title="Employee stock purchase plan">30</span> million of CODX common stock. The repurchase program does not obligate the Company to acquire any particular amount of common shares, and the repurchase program may be suspended or discontinued at any time at the Company’s discretion. The timing and amount of any share repurchases under the share repurchase program will be determined by Co-Diagnostics’ management at its discretion based on ongoing assessments of the capital needs of the business, the market price of the Company’s common stock, corporate and regulatory requirements, and general market conditions. Share repurchases under the program may be made through a variety of methods, which may include open market purchases, in block trades, accelerated share repurchase transactions, exchange transactions, the use of trading plans intended to qualify under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or any combination of such methods.</span></p> 30000000 EXCEL 84 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

%2,$E X304 -(I / " 3\\ M 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " "Y@'A4)V75I0P" "$)0 M&@ @ &Y00$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0 M2P$"% ,4 " "Y@'A4[M7M&.8! #U) $P @ ']0P$ I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 1P!' &@3 41@$ ! end XML 85 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 86 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 87 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 133 362 1 false 59 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://codiagnostics.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://codiagnostics.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://codiagnostics.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://codiagnostics.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity Sheet http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity Consolidated Statement of Changes in Stockholders' Equity Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statement of Changes in Stockholders' Equity (Parenthetical) Sheet http://codiagnostics.com/role/StatementOfChangesInStockholdersEquityParenthetical Consolidated Statement of Changes in Stockholders' Equity (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statements of cash Flows Sheet http://codiagnostics.com/role/StatementsOfCashFlows Consolidated Statements of cash Flows Statements 7 false false R8.htm 00000008 - Disclosure - Overview and Basis of Presentation Sheet http://codiagnostics.com/role/OverviewAndBasisOfPresentation Overview and Basis of Presentation Notes 8 false false R9.htm 00000009 - Disclosure - Summary of Significant Accounting Policies Sheet http://codiagnostics.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Business Combinations Sheet http://codiagnostics.com/role/BusinessCombinations Business Combinations Notes 10 false false R11.htm 00000011 - Disclosure - Fair Value Measurements Sheet http://codiagnostics.com/role/FairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 00000012 - Disclosure - Property and Equipment Sheet http://codiagnostics.com/role/PropertyAndEquipment Property and Equipment Notes 12 false false R13.htm 00000013 - Disclosure - Goodwill and Intangible Assets Sheet http://codiagnostics.com/role/GoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 13 false false R14.htm 00000014 - Disclosure - Accrued Expenses Sheet http://codiagnostics.com/role/AccruedExpenses Accrued Expenses Notes 14 false false R15.htm 00000015 - Disclosure - Revenue Sheet http://codiagnostics.com/role/Revenue Revenue Notes 15 false false R16.htm 00000016 - Disclosure - Stockholders??? Equity Sheet http://codiagnostics.com/role/StockholdersEquity Stockholders??? Equity Notes 16 false false R17.htm 00000017 - Disclosure - Earnings per Share Sheet http://codiagnostics.com/role/EarningsPerShare Earnings per Share Notes 17 false false R18.htm 00000018 - Disclosure - Stock-Based Compensation Sheet http://codiagnostics.com/role/Stock-basedCompensation Stock-Based Compensation Notes 18 false false R19.htm 00000019 - Disclosure - Income Taxes Sheet http://codiagnostics.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 00000020 - Disclosure - Related Party Transactions Sheet http://codiagnostics.com/role/RelatedPartyTransactions Related Party Transactions Notes 20 false false R21.htm 00000021 - Disclosure - Commitments and Contingencies Sheet http://codiagnostics.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 21 false false R22.htm 00000022 - Disclosure - Subsequent Events Sheet http://codiagnostics.com/role/SubsequentEvents Subsequent Events Notes 22 false false R23.htm 00000023 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://codiagnostics.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 00000024 - Disclosure - Business Combinations (Tables) Sheet http://codiagnostics.com/role/BusinessCombinationsTables Business Combinations (Tables) Tables http://codiagnostics.com/role/BusinessCombinations 24 false false R25.htm 00000025 - Disclosure - Fair Value Measurements (Tables) Sheet http://codiagnostics.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://codiagnostics.com/role/FairValueMeasurements 25 false false R26.htm 00000026 - Disclosure - Property and Equipment (Tables) Sheet http://codiagnostics.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://codiagnostics.com/role/PropertyAndEquipment 26 false false R27.htm 00000027 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://codiagnostics.com/role/GoodwillAndIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://codiagnostics.com/role/GoodwillAndIntangibleAssets 27 false false R28.htm 00000028 - Disclosure - Accrued Expenses (Tables) Sheet http://codiagnostics.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://codiagnostics.com/role/AccruedExpenses 28 false false R29.htm 00000029 - Disclosure - Revenue (Tables) Sheet http://codiagnostics.com/role/RevenueTables Revenue (Tables) Tables http://codiagnostics.com/role/Revenue 29 false false R30.htm 00000030 - Disclosure - Earnings per Share (Tables) Sheet http://codiagnostics.com/role/EarningsPerShareTables Earnings per Share (Tables) Tables http://codiagnostics.com/role/EarningsPerShare 30 false false R31.htm 00000031 - Disclosure - Stock-Based Compensation (Tables) Sheet http://codiagnostics.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://codiagnostics.com/role/Stock-basedCompensation 31 false false R32.htm 00000032 - Disclosure - Income Taxes (Tables) Sheet http://codiagnostics.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://codiagnostics.com/role/IncomeTaxes 32 false false R33.htm 00000033 - Disclosure - Commitments and Contingencies (Tables) Sheet http://codiagnostics.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://codiagnostics.com/role/CommitmentsAndContingencies 33 false false R34.htm 00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies 34 false false R35.htm 00000035 - Disclosure - Schedule of Assets and Liabilities assumed (Details) Sheet http://codiagnostics.com/role/ScheduleOfAssetsAndLiabilitiesAssumedDetails Schedule of Assets and Liabilities assumed (Details) Details 35 false false R36.htm 00000036 - Disclosure - Business Combinations (Details Narrative) Sheet http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative Business Combinations (Details Narrative) Details http://codiagnostics.com/role/BusinessCombinationsTables 36 false false R37.htm 00000037 - Disclosure - Schedule of Fair Value Assets and Liabilities (Details) Sheet http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails Schedule of Fair Value Assets and Liabilities (Details) Details 37 false false R38.htm 00000038 - Disclosure - Schedule of Changes in Fair Value Measurement (Details) Sheet http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails Schedule of Changes in Fair Value Measurement (Details) Details 38 false false R39.htm 00000039 - Disclosure - Schedule of Contingent Consideration Common Stock and Warrants (Details) Sheet http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails Schedule of Contingent Consideration Common Stock and Warrants (Details) Details 39 false false R40.htm 00000040 - Disclosure - Schedule of Property and Equipment (Details) Sheet http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails Schedule of Property and Equipment (Details) Details 40 false false R41.htm 00000041 - Disclosure - Schedule of Intangible Assets (Details) Sheet http://codiagnostics.com/role/ScheduleOfIntangibleAssetsDetails Schedule of Intangible Assets (Details) Details 41 false false R42.htm 00000042 - Disclosure - Schedule of Future Amortization Expense (Details) Sheet http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails Schedule of Future Amortization Expense (Details) Details 42 false false R43.htm 00000043 - Disclosure - Schedule of Accrued Expenses (Details) Sheet http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails Schedule of Accrued Expenses (Details) Details 43 false false R44.htm 00000044 - Disclosure - Summary of Revenue by Geographic Area (Details) Sheet http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails Summary of Revenue by Geographic Area (Details) Details 44 false false R45.htm 00000045 - Disclosure - Schedule of Deferred Revenue (Details) Sheet http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails Schedule of Deferred Revenue (Details) Details 45 false false R46.htm 00000046 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://codiagnostics.com/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://codiagnostics.com/role/StockholdersEquity 46 false false R47.htm 00000047 - Disclosure - Schedule of Basic and Diluted Earnings Per Share (Details) Sheet http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails Schedule of Basic and Diluted Earnings Per Share (Details) Details 47 false false R48.htm 00000048 - Disclosure - Earnings per Share (Details Narrative) Sheet http://codiagnostics.com/role/EarningsPerShareDetailsNarrative Earnings per Share (Details Narrative) Details http://codiagnostics.com/role/EarningsPerShareTables 48 false false R49.htm 00000049 - Disclosure - Schedule of Option Activity (Details) Sheet http://codiagnostics.com/role/ScheduleOfOptionActivityDetails Schedule of Option Activity (Details) Details 49 false false R50.htm 00000050 - Disclosure - Schedule of Fair Value of Options Weighted Average Assumptions (Details) Sheet http://codiagnostics.com/role/ScheduleOfFairValueOfOptionsWeightedAverageAssumptionsDetails Schedule of Fair Value of Options Weighted Average Assumptions (Details) Details 50 false false R51.htm 00000051 - Disclosure - Schedule of Outstanding Restricted Stock Units and Related Activity (Details) Sheet http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails Schedule of Outstanding Restricted Stock Units and Related Activity (Details) Details 51 false false R52.htm 00000052 - Disclosure - Schedule of Warrant Activity (Details) Sheet http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails Schedule of Warrant Activity (Details) Details 52 false false R53.htm 00000053 - Disclosure - Schedule of Fair Value of Warrants Assumptions (Details) Sheet http://codiagnostics.com/role/ScheduleOfFairValueOfWarrantsAssumptionsDetails Schedule of Fair Value of Warrants Assumptions (Details) Details 53 false false R54.htm 00000054 - Disclosure - Schedule of Recognized Stock-based Compensation Expense (Details) Sheet http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails Schedule of Recognized Stock-based Compensation Expense (Details) Details 54 false false R55.htm 00000055 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://codiagnostics.com/role/Stock-basedCompensationTables 55 false false R56.htm 00000056 - Disclosure - Schedule of Components Income Tax Provision (Details) Sheet http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails Schedule of Components Income Tax Provision (Details) Details 56 false false R57.htm 00000057 - Disclosure - Schedule of Benefit from Income Taxes and Effective Tax Rates (Details) Sheet http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails Schedule of Benefit from Income Taxes and Effective Tax Rates (Details) Details 57 false false R58.htm 00000058 - Disclosure - Schedule of Deferred Tax Assets (Details) Sheet http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails Schedule of Deferred Tax Assets (Details) Details 58 false false R59.htm 00000059 - Disclosure - Schedule of Unrecognized Tax Benefits (Details) Sheet http://codiagnostics.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails Schedule of Unrecognized Tax Benefits (Details) Details 59 false false R60.htm 00000060 - Disclosure - Income Taxes (Details Narrative) Sheet http://codiagnostics.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://codiagnostics.com/role/IncomeTaxesTables 60 false false R61.htm 00000061 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://codiagnostics.com/role/RelatedPartyTransactions 61 false false R62.htm 00000063 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://codiagnostics.com/role/CommitmentsAndContingenciesTables 62 false false R63.htm 00000064 - Disclosure - Subsequent Events (Details Narrative) Sheet http://codiagnostics.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://codiagnostics.com/role/SubsequentEvents 63 false false All Reports Book All Reports form10-k.htm codx-20211231.xsd codx-20211231_cal.xml codx-20211231_def.xml codx-20211231_lab.xml codx-20211231_pre.xml ex10-6.htm ex10-7.htm ex10-9.htm ex10-9_1.htm ex10-9_2.htm ex21-1.htm ex23-1.htm ex3-1_3.htm ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm ex4-1.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 90 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-k.htm": { "axisCustom": 1, "axisStandard": 21, "contextCount": 133, "dts": { "calculationLink": { "local": [ "codx-20211231_cal.xml" ] }, "definitionLink": { "local": [ "codx-20211231_def.xml" ] }, "inline": { "local": [ "form10-k.htm" ] }, "labelLink": { "local": [ "codx-20211231_lab.xml" ] }, "presentationLink": { "local": [ "codx-20211231_pre.xml" ] }, "schema": { "local": [ "codx-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 557, "entityCount": 1, "hidden": { "http://codiagnostics.com/20211231": 13, "http://fasb.org/us-gaap/2021-01-31": 108, "http://xbrl.sec.gov/dei/2021q4": 3, "total": 124 }, "keyCustom": 42, "keyStandard": 320, "memberCustom": 19, "memberStandard": 36, "nsprefix": "CODX", "nsuri": "http://codiagnostics.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://codiagnostics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Business Combinations", "role": "http://codiagnostics.com/role/BusinessCombinations", "shortName": "Business Combinations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Fair Value Measurements", "role": "http://codiagnostics.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Property and Equipment", "role": "http://codiagnostics.com/role/PropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Goodwill and Intangible Assets", "role": "http://codiagnostics.com/role/GoodwillAndIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Accrued Expenses", "role": "http://codiagnostics.com/role/AccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Revenue", "role": "http://codiagnostics.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Stockholders\u2019 Equity", "role": "http://codiagnostics.com/role/StockholdersEquity", "shortName": "Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Earnings per Share", "role": "http://codiagnostics.com/role/EarningsPerShare", "shortName": "Earnings per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Stock-Based Compensation", "role": "http://codiagnostics.com/role/Stock-basedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Income Taxes", "role": "http://codiagnostics.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "role": "http://codiagnostics.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Related Party Transactions", "role": "http://codiagnostics.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Commitments and Contingencies", "role": "http://codiagnostics.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Subsequent Events", "role": "http://codiagnostics.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Business Combinations (Tables)", "role": "http://codiagnostics.com/role/BusinessCombinationsTables", "shortName": "Business Combinations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Fair Value Measurements (Tables)", "role": "http://codiagnostics.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Property and Equipment (Tables)", "role": "http://codiagnostics.com/role/PropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Goodwill and Intangible Assets (Tables)", "role": "http://codiagnostics.com/role/GoodwillAndIntangibleAssetsTables", "shortName": "Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Accrued Expenses (Tables)", "role": "http://codiagnostics.com/role/AccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - Revenue (Tables)", "role": "http://codiagnostics.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://codiagnostics.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - Earnings per Share (Tables)", "role": "http://codiagnostics.com/role/EarningsPerShareTables", "shortName": "Earnings per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://codiagnostics.com/role/Stock-basedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - Income Taxes (Tables)", "role": "http://codiagnostics.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://codiagnostics.com/role/CommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "role": "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueAcquisitions", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - Schedule of Assets and Liabilities assumed (Details)", "role": "http://codiagnostics.com/role/ScheduleOfAssetsAndLiabilitiesAssumedDetails", "shortName": "Schedule of Assets and Liabilities assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - Business Combinations (Details Narrative)", "role": "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative", "shortName": "Business Combinations (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_srt_MinimumMember", "decimals": null, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LiabilitiesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - Schedule of Fair Value Assets and Liabilities (Details)", "role": "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails", "shortName": "Schedule of Fair Value Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LiabilitiesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "CODX:ContingentConsideredIssuedForBusinessAcquisitions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - Schedule of Changes in Fair Value Measurement (Details)", "role": "http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails", "shortName": "Schedule of Changes in Fair Value Measurement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "CODX:ContingentConsideredIssuedForBusinessAcquisitions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - Schedule of Contingent Consideration Common Stock and Warrants (Details)", "role": "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails", "shortName": "Schedule of Contingent Consideration Common Stock and Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_us-gaap_MeasurementInputSharePriceMember", "decimals": "INF", "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations", "role": "http://codiagnostics.com/role/StatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - Schedule of Property and Equipment (Details)", "role": "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails", "shortName": "Schedule of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - Schedule of Intangible Assets (Details)", "role": "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsDetails", "shortName": "Schedule of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_InProcessResearchAndDevelopmentMember", "decimals": null, "lang": "en-US", "name": "CODX:IndefiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - Schedule of Future Amortization Expense (Details)", "role": "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails", "shortName": "Schedule of Future Amortization Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedPayrollTaxesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - Schedule of Accrued Expenses (Details)", "role": "http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails", "shortName": "Schedule of Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedPayrollTaxesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - Summary of Revenue by Geographic Area (Details)", "role": "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "shortName": "Summary of Revenue by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - Schedule of Deferred Revenue (Details)", "role": "http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails", "shortName": "Schedule of Deferred Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31", "decimals": "0", "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "role": "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "lang": null, "name": "CODX:StockIssuedDuringPeriodSharesIssuedForVestAndRestrictedStockUnits", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - Schedule of Basic and Diluted Earnings Per Share (Details)", "role": "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails", "shortName": "Schedule of Basic and Diluted Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "lang": null, "name": "CODX:WeightedAverageNumberOfBasicSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - Earnings per Share (Details Narrative)", "role": "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "shortName": "Earnings per Share (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_CommonStockMember", "decimals": "-5", "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - Schedule of Option Activity (Details)", "role": "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails", "shortName": "Schedule of Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31_us-gaap_ConvertiblePreferredStockMember_us-gaap_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statement of Changes in Stockholders' Equity", "role": "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity", "shortName": "Consolidated Statement of Changes in Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31_us-gaap_ConvertiblePreferredStockMember_us-gaap_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - Schedule of Fair Value of Options Weighted Average Assumptions (Details)", "role": "http://codiagnostics.com/role/ScheduleOfFairValueOfOptionsWeightedAverageAssumptionsDetails", "shortName": "Schedule of Fair Value of Options Weighted Average Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - Schedule of Outstanding Restricted Stock Units and Related Activity (Details)", "role": "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "shortName": "Schedule of Outstanding Restricted Stock Units and Related Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - Schedule of Warrant Activity (Details)", "role": "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails", "shortName": "Schedule of Warrant Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - Schedule of Fair Value of Warrants Assumptions (Details)", "role": "http://codiagnostics.com/role/ScheduleOfFairValueOfWarrantsAssumptionsDetails", "shortName": "Schedule of Fair Value of Warrants Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "CODX:ScheduleOfFairValuesWarrantsAssumptionsTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_MeasurementInputOptionVolatilityMember", "decimals": "INF", "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - Schedule of Recognized Stock-based Compensation Expense (Details)", "role": "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "shortName": "Schedule of Recognized Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "CODX:ClassOfWarrantExercisable", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - Stock-Based Compensation (Details Narrative)", "role": "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative", "shortName": "Stock-Based Compensation (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "CODX:ClassOfWarrantExercisable", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - Schedule of Components Income Tax Provision (Details)", "role": "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails", "shortName": "Schedule of Components Income Tax Provision (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - Schedule of Benefit from Income Taxes and Effective Tax Rates (Details)", "role": "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails", "shortName": "Schedule of Benefit from Income Taxes and Effective Tax Rates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - Schedule of Deferred Tax Assets (Details)", "role": "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails", "shortName": "Schedule of Deferred Tax Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000059 - Disclosure - Schedule of Unrecognized Tax Benefits (Details)", "role": "http://codiagnostics.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails", "shortName": "Schedule of Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statement of Changes in Stockholders' Equity (Parenthetical)", "role": "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquityParenthetical", "shortName": "Consolidated Statement of Changes in Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31_us-gaap_IPOMember", "decimals": "0", "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000060 - Disclosure - Income Taxes (Details Narrative)", "role": "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative", "shortName": "Income Taxes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2017-01-01_custom_ExclusiveLicenseAgreementMember_custom_DrBrentSatterfieldMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedRoyaltiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000061 - Disclosure - Related Party Transactions (Details Narrative)", "role": "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2017-01-01_custom_ExclusiveLicenseAgreementMember_custom_DrBrentSatterfieldMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedRoyaltiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-02-29", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000063 - Disclosure - Commitments and Contingencies (Details Narrative)", "role": "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "Commitments and Contingencies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-02-29", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-03-012022-03-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_srt_MaximumMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000064 - Disclosure - Subsequent Events (Details Narrative)", "role": "http://codiagnostics.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-03-012022-03-31_us-gaap_SubsequentEventMember_us-gaap_CommonStockMember_srt_MaximumMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - Consolidated Statements of cash Flows", "role": "http://codiagnostics.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Overview and Basis of Presentation", "role": "http://codiagnostics.com/role/OverviewAndBasisOfPresentation", "shortName": "Overview and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Summary of Significant Accounting Policies", "role": "http://codiagnostics.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 59, "tag": { "CODX_AdvancedConceptionsIncAndIdahoMolecularIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advanced Conceptions, Inc. and Idaho Molecular, Inc. [Member]", "label": "Advanced Conceptions, Inc. and Idaho Molecular, Inc. [Member]" } } }, "localname": "AdvancedConceptionsIncAndIdahoMolecularIncMember", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative", "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_AdvancedConceptionsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Advanced Conceptions Inc [Member]", "label": "Advanced Conceptions Inc [Member]" } } }, "localname": "AdvancedConceptionsIncMember", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_BusinessCombinationContingentConsiderationLiabilityMeasurementInputExpectedTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Value of input, expected term used to measure contingent consideration liability from business combination.", "label": "Business combination,contingent consideration, term" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInputExpectedTerm", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "durationItemType" }, "CODX_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesNonCompetitionAgreements": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business combination recognized identifiable assets acquired and liabilities non competition agreements.", "label": "Non competition agreements" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesNonCompetitionAgreements", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "CODX_ClassOfWarrantExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant exercisable.", "label": "Warrants exercisable" } } }, "localname": "ClassOfWarrantExercisable", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "CODX_CommonStockOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock One [Member]", "label": "Common Stock One [Member]" } } }, "localname": "CommonStockOneMember", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_CommonStockThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Three [Member]", "label": "Common Stock Three [Member]" } } }, "localname": "CommonStockThreeMember", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_CommonStockTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Two [Member]", "label": "Common Stock Two [Member]" } } }, "localname": "CommonStockTwoMember", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_ContingentConsideredIssuedForBusinessAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contingent considered issued for business acquisitions.", "label": "Contingent considered issued for business acquisitions" } } }, "localname": "ContingentConsideredIssuedForBusinessAcquisitions", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "CODX_DecreaseDueToRefundsToCustomersAndApplicationToOpenBalances": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Decrease due to refunds to customers and application to open balances.", "label": "DecreaseDueToRefundsToCustomersAndApplicationToOpenBalances", "negatedLabel": "Decrease due to refunds to customers and application to open balances" } } }, "localname": "DecreaseDueToRefundsToCustomersAndApplicationToOpenBalances", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "CODX_DrBrentSatterfieldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dr. Brent Satterfield [Member]", "label": "Dr. Brent Satterfield [Member]" } } }, "localname": "DrBrentSatterfieldMember", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_EarningsBasicPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnings basic per share.", "label": "Basic earnings per share" } } }, "localname": "EarningsBasicPerShare", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "CODX_EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation change in valuation allowance.", "label": "Change in uncertain tax positions" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "xbrltype": "percentItemType" }, "CODX_EffectiveIncomeTaxRateReconciliationForeignderivedIntangibleIncomeDeduction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconcilation foreign derived intangible income deduction.", "label": "- Foreign derived intangible income deduction" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignderivedIntangibleIncomeDeduction", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "xbrltype": "percentItemType" }, "CODX_ExclusiveLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exclusive License Agreement [Member]", "label": "Exclusive License Agreement [Member]" } } }, "localname": "ExclusiveLicenseAgreementMember", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_FairValueByFairValueHierarchyLevelAxAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value by fair value hierachy level axis.", "label": "Fair Value By Fair Value Hierarchy Level Ax [Axis]", "verboseLabel": "FairValueByFairValueHierarchyLevelAxAxis [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxAxis", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "CODX_FairValueByFairValueHierarchyLevelAxDomain": { "auth_ref": [], "localname": "FairValueByFairValueHierarchyLevelAxDomain", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "CODX_FairValueOfContingentCommonStockAndWarrantsIssuedAsConsiderationForBusinessAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of contingent common stock and warrants issued as consideration for business acquisitions.", "label": "Fair value of contingent common stock and warrants issued as consideration for business acquisitions" } } }, "localname": "FairValueOfContingentCommonStockAndWarrantsIssuedAsConsiderationForBusinessAcquisitions", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CODX_FairValueOfContingentConsiderationToCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of contingent consideration to common stock.", "label": "Contingent consideration common stock" } } }, "localname": "FairValueOfContingentConsiderationToCommonStock", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "CODX_FairValueOfContingentConsiderationToWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of contigent consideration to warrants.", "label": "Contingent consideration warrants" } } }, "localname": "FairValueOfContingentConsiderationToWarrants", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "CODX_IncreaseDueToNoteReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase due to note receivable.", "label": "Increase due to note receivable" } } }, "localname": "IncreaseDueToNoteReceivable", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "CODX_IncreaseDueToPrepaymentsFromCustomers": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase due to prepayments from customers.", "label": "Increase due to prepayments from customers" } } }, "localname": "IncreaseDueToPrepaymentsFromCustomers", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "CODX_IndefiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indefinite lived intangible asset useful life.", "label": "Estimated useful lives in years, term" } } }, "localname": "IndefiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "CODX_InvestmentRelationsServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investment Relations Services [Member]", "label": "Investment Relations Services [Member]" } } }, "localname": "InvestmentRelationsServicesMember", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_MeasurementInputAssetVolatilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input Asset Volatility [Member]", "label": "Measurement Input Asset Volatility [Member]" } } }, "localname": "MeasurementInputAssetVolatilityMember", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "CODX_MeasurementInputCostOfCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input Cost of Capital [Member]", "label": "Measurement Input Cost of Capital [Member]" } } }, "localname": "MeasurementInputCostOfCapitalMember", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "CODX_MeasurementInputEquityVolatilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input Equity Volatility [Member]", "label": "Measurement Input Equity Volatility [Member]" } } }, "localname": "MeasurementInputEquityVolatilityMember", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "CODX_MeasurementInputRevenueVolatilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input Revenue Volatility [Member]", "label": "Measurement Input Revenue Volatility [Member]" } } }, "localname": "MeasurementInputRevenueVolatilityMember", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "CODX_MeasurementInputStrikePriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input Strike Price [Member]", "label": "Measurement Input Strike Price [Member]" } } }, "localname": "MeasurementInputStrikePriceMember", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "CODX_NetProceedsFromIssuanceOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net proceeds from issuance of common stock.", "label": "Net proceeds from issuance of common stock" } } }, "localname": "NetProceedsFromIssuanceOfCommonStock", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "CODX_NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non cash or part non cash inventory moved to property plant and equipment.", "label": "Inventory moved to property, plant and equipment" } } }, "localname": "NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CODX_OptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options [Member]", "label": "Options [Member]" } } }, "localname": "OptionsMember", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_PaymentsToAcquireInterestInJointVentures": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to acquire interest in joint ventures.", "label": "PaymentsToAcquireInterestInJointVentures", "negatedLabel": "Investment in joint venture" } } }, "localname": "PaymentsToAcquireInterestInJointVentures", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CODX_PaymentsToShareHoldersValueAcquisitions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments to share holders value acquisitions.", "label": "Payable to shareholders" } } }, "localname": "PaymentsToShareHoldersValueAcquisitions", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative", "http://codiagnostics.com/role/ScheduleOfAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "CODX_ProceedsFromExerciseOfOptionsAndWarrants": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from exercise of options and warrants.", "label": "Proceeds from exercise of options and warrants" } } }, "localname": "ProceedsFromExerciseOfOptionsAndWarrants", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "CODX_RestOfWorldMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rest of World [Member]", "label": "Rest of World [Member]" } } }, "localname": "RestOfWorldMember", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "CODX_ScheduleOfFairValuesWarrantsAssumptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Fair Values Warrants Assumptions [Table text block]", "label": "Schedule of Fair Value of Warrants Assumptions" } } }, "localname": "ScheduleOfFairValuesWarrantsAssumptionsTableTextBlock", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Fair Value, Exercised.", "label": "Weighted Average Fair Value, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, non-option, granted in period, weighted average exercise price.", "label": "Weighted Average Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price, beginning.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Weighted Average Exercise Price, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the non-option plan.", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Weighted Average Exercise Price, Ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of warrants exercised.", "label": "Intrinsic value of warrants exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "CODX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price, Forfeited/Cancelled.", "label": "Weighted Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to non-options of the plan that expired.", "label": "Weighted Average Exercise Price, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price, Forfeited/Cancelled.", "label": "Weighted Average Exercise Price, Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Exercise Price, Granted.", "label": "Weighted Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted-average Remaining Contractual Life (Years) Outstanding, Beginning.", "label": "Weighted-average Remaining Contractual Life (Years) Outstanding, Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted-average Remaining Contractual Life (Years) Outstanding, Ending.", "label": "Weighted-average Remaining Contractual Life (Years) Outstanding, Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "durationItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Fair Value, Beginning.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue", "periodEndLabel": "Weighted Average Fair Value, Ending", "periodStartLabel": "Weighted Average Fair Value, Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercised.", "label": "Weighted Average Fair Value, Expired" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted Average Fair Value, Forfeited/Cancelled.", "label": "Weighted Average Fair Value, Forfeited/Cancelled" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercisable.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable", "periodEndLabel": "Weighted Average Fair Value, Exercisable Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award options non vested weighted average grant date fair value exercised.", "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised", "periodEndLabel": "Weighted Average Fair Value Exercised" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "CODX_StockIssuedDuringPeriodSharesContingentConsideration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares contingent consideration.", "label": "Number of shares on contingent consideration" } } }, "localname": "StockIssuedDuringPeriodSharesContingentConsideration", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "CODX_StockIssuedDuringPeriodSharesForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares forfeited during period.", "label": "[custom:StockIssuedDuringPeriodSharesForfeited]" } } }, "localname": "StockIssuedDuringPeriodSharesForfeited", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "CODX_StockIssuedDuringPeriodSharesIssuedForVestAndRestrictedStockUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares issued for vest and restricted stock units.", "label": "Vest and restricted stock units" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForVestAndRestrictedStockUnits", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "CODX_StockIssuedDuringPeriodSharesStockOptionsExercised1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "StockIssuedDuringPeriodSharesStockOptionsExercised1", "negatedLabel": "Number of Options Outstanding, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised1", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "CODX_StockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options [Member]", "label": "Stock Options [Member]" } } }, "localname": "StockOptionsMember", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_TaxesPayableNoncurrent": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Taxes payable non current.", "label": "TaxesPayableNoncurrent", "verboseLabel": "Income taxes payable" } } }, "localname": "TaxesPayableNoncurrent", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "CODX_ThirdPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Parties [Member]", "label": "Third Parties [Member]" } } }, "localname": "ThirdPartiesMember", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative", "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_TwoCustomersTogetherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Customers Together [Member]", "label": "Two Customers Together [Member]" } } }, "localname": "TwoCustomersTogetherMember", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_TwoThousandFifteenLongTermIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2015 Long Term Incentive Plan [Member]", "label": "2015 Long Term Incentive Plan [Member]" } } }, "localname": "TwoThousandFifteenLongTermIncentivePlanMember", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "CODX_WeightedAverageNumberOfBasicSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average number of basic shares outstanding.", "label": "Weighted average shares, basic" } } }, "localname": "WeightedAverageNumberOfBasicSharesOutstanding", "nsuri": "http://codiagnostics.com/20211231", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r514", "r516", "r517" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r514", "r516", "r517" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r514", "r516", "r517" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r514", "r516", "r517" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r514", "r516", "r517" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r516" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r508" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r512" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://codiagnostics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_AmericasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Americas [Member]" } } }, "localname": "AmericasMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r163", "r263", "r269", "r477" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r220", "r227", "r285", "r287", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r474", "r478", "r500", "r501" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative", "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsDetails", "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://codiagnostics.com/role/SubsequentEventsDetailsNarrative", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r220", "r227", "r285", "r287", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r474", "r478", "r500", "r501" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative", "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsDetails", "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r163", "r263", "r269", "r477" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r160", "r263", "r267", "r440", "r473", "r475" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r160", "r263", "r267", "r440", "r473", "r475" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r220", "r227", "r275", "r285", "r287", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r474", "r478", "r500", "r501" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative", "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsDetails", "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://codiagnostics.com/role/SubsequentEventsDetailsNarrative", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r220", "r227", "r275", "r285", "r287", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r474", "r478", "r500", "r501" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative", "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsDetails", "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://codiagnostics.com/role/SubsequentEventsDetailsNarrative", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r161", "r162", "r263", "r268", "r476", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r161", "r162", "r263", "r268", "r476", "r485", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r164", "r418" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative", "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative", "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r43", "r423" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r165", "r166" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r6", "r31", "r165", "r166" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetNoncurrent": { "auth_ref": [ "r31", "r165", "r449", "r461" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent.", "label": "Accounts Receivable, after Allowance for Credit Loss, Noncurrent", "verboseLabel": "Note receivable" } } }, "localname": "AccountsReceivableNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses, current", "verboseLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrent": { "auth_ref": [ "r14", "r48" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Payroll liabilities" } } }, "localname": "AccruedPayrollTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r13", "r14", "r48" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalesCommissionCurrent": { "auth_ref": [ "r13", "r14", "r48" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Distributor commissions" } } }, "localname": "AccruedSalesCommissionCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r42", "r199" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r63", "r64", "r406", "r407", "r408", "r409", "r410", "r411" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r32", "r324", "r423" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r106", "r107", "r108", "r321", "r322", "r323", "r389" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r289", "r318", "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r37", "r171", "r180" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Potentially dilutive shares", "verboseLabel": "Securities excluded from computation of diluted earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area of land" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r382" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current.", "label": "Contingent consideration liabilities, current" } } }, "localname": "AssetAcquisitionContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r382" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent.", "label": "Contingent consideration liabilities" } } }, "localname": "AssetAcquisitionContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r100", "r149", "r152", "r158", "r178", "r207", "r208", "r209", "r211", "r212", "r213", "r214", "r215", "r216", "r218", "r219", "r385", "r387", "r404", "r421", "r423", "r445", "r462" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r10", "r12", "r59", "r100", "r178", "r207", "r208", "r209", "r211", "r212", "r213", "r214", "r215", "r216", "r218", "r219", "r385", "r387", "r404", "r421", "r423" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r392" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total assets measured at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r290", "r320" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r284", "r286" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative", "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r284", "r286", "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative", "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r378", "r379", "r381" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business combination, consideration transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business combination,contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r377", "r380" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "periodEndLabel": "Asset acquisition contingent consideration liability noncurrent", "periodStartLabel": "Asset acquisition contingent consideration liability noncurrent" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfChangesInFairValueMeasurementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combinations" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BusinessCombinations" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "auth_ref": [ "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Accounts receivables" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": { "auth_ref": [ "r375" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities", "negatedLabel": "Accounts payable and accrued other expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r375" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedLabel": "Deferred tax liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r374", "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Total indentifiable net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r374", "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Property and equipments" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities": { "auth_ref": [ "r374", "r375" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This item represents liabilities associated with restructuring or exit activities of the acquiree, existing at the acquisition date (present liabilities of the acquiree).", "label": "Research and development in process" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestructuringLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Total" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "verboseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r3", "r105", "r144" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Overview and Basis of Presentation" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/OverviewAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r38", "r90" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r20", "r91" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r83", "r90", "r93" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r83", "r405" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r98", "r100", "r121", "r122", "r123", "r125", "r127", "r136", "r137", "r138", "r178", "r207", "r212", "r213", "r214", "r218", "r219", "r225", "r226", "r229", "r233", "r404", "r519" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Warrants to purchase shares of common stock", "verboseLabel": "Warrants purchase" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r51", "r205", "r451", "r466" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 14)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r202", "r203", "r204", "r206", "r487" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Aggregate number of common shares reserved" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r106", "r107", "r389" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity", "http://codiagnostics.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical", "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r29", "r239" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r29", "r423" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value; 100,000,000 shares authorized; 33,819,862 and 28,558,033 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r142", "r143", "r163", "r402", "r403", "r486" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r142", "r143", "r163", "r402", "r403", "r484", "r486" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r142", "r143", "r163", "r402", "r403", "r484", "r486" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r139", "r459" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentrations Risk and Significant Customers" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r142", "r143", "r163", "r402", "r403" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration risk percentage", "verboseLabel": "Percentage of revenue" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r142", "r143", "r163", "r402", "r403", "r486" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure": { "auth_ref": [ "r392" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of contingent consideration in a business combination that is classified in shareholders' equity.", "label": "Fair value of contingent shares" } } }, "localname": "ContingentConsiderationClassifiedAsEquityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Schedule of Deferred Revenue" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r244", "r245", "r264" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Deferred revenue, Ending balance", "periodStartLabel": "Deferred revenue, beginning balance" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r244", "r245", "r264" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r265" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "negatedLabel": "Revenue recognized included in deferred revenue balance at the beginning of the period" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r225", "r226", "r229" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity", "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r74", "r100", "r178", "r207", "r208", "r209", "r212", "r213", "r214", "r215", "r216", "r218", "r219", "r404" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal, State and Local, Tax Expense (Benefit)", "totalLabel": "Total current" } } }, "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current:" } } }, "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r101", "r354", "r362" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r101", "r354", "r362" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r140", "r163" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r101", "r355", "r362" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "verboseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal, State and Local, Tax Expense (Benefit)", "totalLabel": "Total deferred" } } }, "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred:" } } }, "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r332", "r333" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred tax asset" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r88", "r101", "r355", "r362", "r363", "r364" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r25", "r26", "r345", "r446", "r460" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r332", "r333" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r101", "r355", "r362" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "verboseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r346" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "auth_ref": [ "r352", "r353" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.", "label": "Research and development credits", "verboseLabel": "Research and development credit carry forwards" } } }, "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative", "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r348" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "negatedLabel": "Net deferred tax assets (liabilities)", "verboseLabel": "Net deferred tax assets (liabilities)" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r352", "r353" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Net deferred tax assets (liabilities)" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "auth_ref": [ "r352", "r353" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.", "label": "Deferred compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r352", "r353" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Accrued liabilities" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "auth_ref": [ "r352", "r353" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.", "label": "Reserves and allowances" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r347" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Less valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r352", "r353" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "negatedLabel": "Intangibles, net" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r352", "r353" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "negatedLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.", "label": "Deferred Tax Liabilities, Prepaid Expenses", "negatedLabel": "Prepaids" } } }, "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r352", "r353" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "negatedLabel": "Property and equipment, net" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfDeferredTaxAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r88", "r147" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://codiagnostics.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r263", "r267", "r268", "r269", "r270", "r271", "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r290", "r320" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Stock-Based Compensation" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r43", "r104", "r210", "r212", "r213", "r217", "r218", "r219", "r417" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses (related party), current" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r104", "r210", "r212", "r213", "r217", "r218", "r219", "r417", "r450", "r468" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to related party" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesNoncurrent": { "auth_ref": [ "r50", "r104", "r210", "r212", "r213", "r217", "r218", "r219", "r417" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.", "label": "Accrued expenses (related party), noncurrent" } } }, "localname": "DueToRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r68", "r111", "r112", "r113", "r114", "r115", "r119", "r121", "r125", "r126", "r127", "r131", "r132", "r390", "r391", "r455", "r470" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings per common share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r68", "r111", "r112", "r113", "r114", "r115", "r121", "r125", "r126", "r127", "r131", "r132", "r390", "r391", "r455", "r470" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted", "verboseLabel": "Diluted earnings per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails", "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r128", "r129" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Income per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r128", "r129", "r130", "r133" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r102", "r335", "r365" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Federal income tax expense at statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r335", "r365" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r335", "r365" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "- Other permanent differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": { "auth_ref": [ "r335", "r365" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent", "negatedLabel": "Research and development credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r335", "r365" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Permanent differences:" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "auth_ref": [ "r327", "r335" ], "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "- Stock based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r335", "r365" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "State income tax expense, net of federal tax benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBenefitFromIncomeTaxesAndEffectiveTaxRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r319" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Unrecognized stock-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Unrecognized stock-based compensation recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r63", "r64", "r65", "r106", "r107", "r108", "r110", "r116", "r118", "r135", "r179", "r239", "r241", "r321", "r322", "r323", "r358", "r359", "r389", "r406", "r407", "r408", "r409", "r410", "r411", "r479", "r480", "r481", "r524" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative", "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative", "http://codiagnostics.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity method investment ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": { "auth_ref": [ "r70", "r71", "r88" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.", "label": "Gain (loss) on equity method investment in joint venture" } } }, "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r39", "r82", "r177", "r404" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity-Method Investments" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r392", "r393", "r394", "r400" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r392", "r393", "r394", "r399", "r400" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Schedule of Changes in Fair Value Measurement" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails", "http://codiagnostics.com/role/ScheduleOfFairValueOfWarrantsAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails", "http://codiagnostics.com/role/ScheduleOfFairValueOfWarrantsAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Schedule of Contingent Consideration Common Stock and Warrants" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r392", "r393" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value Assets and Liabilities" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r221", "r223", "r224", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r393", "r427", "r428", "r429" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r392", "r393", "r396", "r397", "r401" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r221", "r276", "r277", "r282", "r283", "r393", "r427" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r221", "r223", "r224", "r276", "r277", "r282", "r283", "r393", "r428" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r221", "r223", "r224", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r393", "r429" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency." } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r221", "r223", "r224", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r427", "r428", "r429" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r398", "r401" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Estimated useful lives in years" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r194" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Less accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r195" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r195" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r195" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r190", "r191", "r194", "r196", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r194", "r442" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible assets, gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r190", "r193" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r194", "r441" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite lived intangible assets remaining amortization period" } } }, "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r88" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://codiagnostics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Loss on disposition of assets", "negatedLabel": "Loss on disposition of assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfInvestments": { "auth_ref": [ "r88" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.", "label": "Gain (Loss) on Sale of Investments", "negatedLabel": "Loss (gain) from equity method investment" } } }, "localname": "GainLossOnSaleOfInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative", "verboseLabel": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative", "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r141", "r486" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r187", "r188", "r423", "r444" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/ScheduleOfAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/GoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r73", "r100", "r149", "r151", "r154", "r157", "r159", "r178", "r207", "r208", "r209", "r212", "r213", "r214", "r215", "r216", "r218", "r219", "r404" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r66", "r149", "r151", "r154", "r157", "r159", "r443", "r453", "r456", "r471" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r102", "r336", "r343", "r350", "r360", "r366", "r368", "r369", "r370" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r103", "r117", "r118", "r148", "r334", "r361", "r367", "r472" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://codiagnostics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax provision", "totalLabel": "Total income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfComponentsIncomeTaxProvisionDetails", "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r62", "r330", "r331", "r343", "r344", "r349", "r356" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income taxes paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r87" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r87" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r87" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "verboseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r87", "r437" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "verboseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r87" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r87" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r189", "r192" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r81", "r84", "r92" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r55" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r57", "r423" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r16", "r58", "r95", "r134", "r182", "r183", "r184", "r438" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r56" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Rent expenses" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).", "label": "Leaseholds and Leasehold Improvements [Member]" } } }, "localname": "LeaseholdsAndLeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Schedule of Future Minimum Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r414" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r414" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "verboseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r414" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r414" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "verboseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating lease, term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r46", "r100", "r153", "r178", "r207", "r208", "r209", "r212", "r213", "r214", "r215", "r216", "r218", "r219", "r386", "r387", "r388", "r404", "r421", "r422" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r36", "r100", "r178", "r404", "r423", "r447", "r464" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r49", "r100", "r178", "r207", "r208", "r209", "r212", "r213", "r214", "r215", "r216", "r218", "r219", "r386", "r387", "r388", "r404", "r421", "r422", "r423" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r392" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Total liabilities measured at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r17", "r18", "r19", "r23", "r24", "r100", "r178", "r207", "r208", "r209", "r212", "r213", "r214", "r215", "r216", "r218", "r219", "r386", "r387", "r388", "r404", "r421", "r422" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r452" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable securities (certificates of deposit)" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r8", "r47" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable investment securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Investment Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueOfWarrantsAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails", "http://codiagnostics.com/role/ScheduleOfFairValueOfWarrantsAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputOptionVolatilityMember": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns.", "label": "Measurement Input, Option Volatility [Member]" } } }, "localname": "MeasurementInputOptionVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueOfWarrantsAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails", "http://codiagnostics.com/role/ScheduleOfFairValueOfWarrantsAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails", "http://codiagnostics.com/role/ScheduleOfFairValueOfWarrantsAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails", "http://codiagnostics.com/role/ScheduleOfFairValueOfWarrantsAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r83" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r83" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r83", "r86", "r89" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r60", "r61", "r65", "r67", "r89", "r100", "r109", "r111", "r112", "r113", "r114", "r117", "r118", "r124", "r149", "r151", "r154", "r157", "r159", "r178", "r207", "r208", "r209", "r212", "r213", "r214", "r215", "r216", "r218", "r219", "r391", "r404", "r454", "r469" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://codiagnostics.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income, as reported" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails", "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity", "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recently Issued Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash investing and financing transactions" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r76" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "auth_ref": [ "r6", "r7", "r30", "r165", "r166", "r448" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.", "label": "Note receivable" } } }, "localname": "NotesAndLoansReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r149", "r151", "r154", "r157", "r159" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r351" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Net operating loss carry-forwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r13", "r14", "r15", "r48" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Payments for rent" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRoyalties": { "auth_ref": [ "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for royalties during the current period.", "label": "Payment for royalties per month" } } }, "localname": "PaymentsForRoyalties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r80" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Public offering costs", "negatedLabel": "Payment of offering costs", "verboseLabel": "Offering costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquityParenthetical", "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r77" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Business combinations, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r175" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable investment securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r78" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r290", "r320" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r28", "r225" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Convertible preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Convertible preferred stock , shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r28", "r225" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Convertible preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Convertible preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r28", "r423" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2021 and December 31, 2020" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r9", "r11", "r185", "r186" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r79" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from sale of common stock", "verboseLabel": "Issuance of common stock gross proceeds" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows", "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from maturities of marketable investment securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r42", "r200" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r201", "r488", "r489", "r490" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r41", "r198" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r21", "r22", "r200", "r423", "r458", "r465" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r40", "r200", "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r21", "r200" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r21", "r198" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Estimated useful life of property", "verboseLabel": "Property and equipment estimated useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r69", "r181" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Bad debt expense" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentsJointVentures": { "auth_ref": [ "r467" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The book value of investments in real estate joint ventures including direct and indirect investments.", "label": "Investment in joint venture" } } }, "localname": "RealEstateInvestmentsJointVentures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r415", "r416", "r417", "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r328", "r439", "r502" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development", "verboseLabel": "Research and development costs" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r33", "r241", "r324", "r423", "r463", "r482", "r483" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r106", "r107", "r108", "r110", "r116", "r118", "r179", "r321", "r322", "r323", "r358", "r359", "r389", "r479", "r481" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r145", "r146", "r150", "r155", "r156", "r160", "r161", "r163", "r262", "r263", "r440" ], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r145", "r146", "r150", "r155", "r156", "r160", "r161", "r163", "r262", "r263", "r440" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r96", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r274" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Deferred Revenue" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r266", "r274" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r96", "r97" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of common stock purchase price per shares" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesAndExciseTaxPayableCurrent": { "auth_ref": [ "r14", "r43" ], "calculation": { "http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Sales tax payable" } } }, "localname": "SalesAndExciseTaxPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r142", "r163" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfRevenueByGeographicAreaDetails", "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r372", "r373" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Assets and Liabilities assumed" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components Income Tax Provision" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Basic and Diluted Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Benefit from Income Taxes and Effective Tax Rates" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r190", "r193", "r441" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r190", "r193" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r42", "r200" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r72", "r161" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Summary of Revenue by Geographic Area" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r302", "r307", "r310" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Schedule of Recognized Stock-based Compensation Expense" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r290", "r320" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Outstanding Restricted Stock Units and Related Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r293", "r307", "r310" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Fair Value of Options Weighted Average Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r242", "r288" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Warrant Activity" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r342", "r357" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Future Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://codiagnostics.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r87" ], "calculation": { "http://codiagnostics.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Number of Restricted Stock Units, Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Weighted Average Grant Date Fair Value, Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Number of Restricted Stock Units, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Weighted Average Grant Date Fair Value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of Restricted Stock Units, Outstanding Ending", "periodStartLabel": "Number of Restricted Stock Units, Outstanding Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant Date Fair Value, Outstanding Ending", "periodStartLabel": "Weighted Average Grant Date Fair Value, Outstanding Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of Restricted Stock Units, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Weighted Average Grant Date Fair Value, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueOfOptionsWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueOfOptionsWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueOfOptionsWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised", "negatedLabel": "Number of Warrants Outstanding, Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations", "negatedLabel": "Number of Warrants Outstanding, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.", "label": "Number of Warrants Outstanding, Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Number of Warrants Outstanding, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r294", "r296" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Number of Warrants Outstanding, Ending", "periodStartLabel": "Number of Warrants Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Number of common shares availalble for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Number of Options Exercisable Ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price, Exercisable Ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r309" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Number of Options Outstanding, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Number of Options Outstanding, Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Number of Options Outstanding, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Weighted Average Fair Value Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r320" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Intrinsic value of options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r295", "r320" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Options Outstanding, Ending", "periodStartLabel": "Number of Options Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Outstanding, Ending", "periodStartLabel": "Weighted Average Exercise Price Outstanding, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r288", "r291" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOutstandingRestrictedStockUnitsAndRelatedActivityDetails", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted Average Exercise Price Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Weighted Average Exercise Price Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Weighted Average Exercise Price Forfeited/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted Average Exercise Price Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r290", "r292" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Stock-based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r313", "r325" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfFairValueOfOptionsWeightedAverageAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted-average Remaining Contractual Life (years), Exercisable Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Unvested options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options forfeited.", "label": "Weighted Average Fair Value Forfeited/Cancelled" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Fair Value Outstanding, Ending", "periodStartLabel": "Weighted Average Fair Value Outstanding, Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted-average Remaining Contractual Life (years) Outstanding, Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Weighted Average Fair Value Expired" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r94", "r105" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r27", "r28", "r29", "r98", "r100", "r121", "r122", "r123", "r125", "r127", "r136", "r137", "r138", "r178", "r207", "r212", "r213", "r214", "r218", "r219", "r225", "r226", "r229", "r233", "r239", "r404", "r519" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r54", "r63", "r64", "r65", "r106", "r107", "r108", "r110", "r116", "r118", "r135", "r179", "r239", "r241", "r321", "r322", "r323", "r358", "r359", "r389", "r406", "r407", "r408", "r409", "r410", "r411", "r479", "r480", "r481", "r524" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative", "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative", "http://codiagnostics.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r106", "r107", "r108", "r135", "r440" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-based Payment Arrangement [Member]" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r28", "r29", "r241" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Common stock issued for acquisitions, shares", "verboseLabel": "Stock Issued During Period, Shares, Acquisitions" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity", "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r53", "r222", "r239", "r240", "r241" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Conversion of preferred stock to common, shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Number of shares issued for services" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative", "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r28", "r29", "r239", "r241" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Public offering, net of offering costs, shares", "terseLabel": "Number of common stock issued", "verboseLabel": "Number of shares exchanged" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BusinessCombinationsDetailsNarrative", "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity", "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Common stock issued for warrant exercises, shares" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock-based compensation expense, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r28", "r29", "r239", "r241", "r299" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Common stock issued for option exercises, shares", "verboseLabel": "Number of shares issued for exercise of options" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity", "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r54", "r239", "r241" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Common stock issued for acquisitions", "terseLabel": "Stock issued during period, value acquisitions", "verboseLabel": "Fair value of common stock issued as consideration for business acquisitions" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfAssetsAndLiabilitiesAssumedDetails", "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity", "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r54", "r239", "r241" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Conversion of preferred stock to common" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r28", "r29", "r239", "r241" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r28", "r29", "r239", "r241" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Public offering, net of offering costs of $1,457,922" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Common stock issued for warrant exercises" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock-based compensation expense" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r54", "r239", "r241" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Common stock issued for option exercises", "verboseLabel": "Number of shares issued for exercise of options, value" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity", "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r29", "r34", "r35", "r100", "r173", "r178", "r404", "r423" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets", "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r99", "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r241", "r243" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r412", "r425" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r412", "r425" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r412", "r425" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r412", "r425" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r424", "r426" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r45" ], "calculation": { "http://codiagnostics.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Income taxes payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r167", "r168", "r169", "r170", "r172", "r174" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r329", "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized tax benefits at end of year", "periodStartLabel": "Unrecognized tax benefits at the beginning of the year" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r339" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedLabel": "Gross decreases- prior year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued": { "auth_ref": [ "r337" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties Accrued", "periodEndLabel": "Interest and penalities in year- end balance" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r340" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Gross increases - current year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r339" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Gross increases - prior year tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized tax benefits that would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r348" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Deferred tax valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/EarningsPerShareDetailsNarrative", "http://codiagnostics.com/role/ScheduleOfRecognizedStock-basedCompensationExpenseDetails", "http://codiagnostics.com/role/Stock-basedCompensationDetailsNarrative", "http://codiagnostics.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants measurement input", "verboseLabel": "Warrants outstanding, measurement input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails", "http://codiagnostics.com/role/ScheduleOfFairValueOfWarrantsAssumptionsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants measurement, term", "verboseLabel": "Warrants, expected life" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfContingentConsiderationCommonStockAndWarrantsDetails", "http://codiagnostics.com/role/ScheduleOfFairValueOfWarrantsAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": { "auth_ref": [ "r392" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of warrants not settleable in cash classified as equity.", "label": "Fair value of contingent warrants" } } }, "localname": "WarrantsNotSettleableInCashFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfAssetsAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Dilutive effect of stock options, warrants and RSUs" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r120", "r127" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Shares used to compute diluted earnings per share", "verboseLabel": "Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/ScheduleOfBasicAndDilutedEarningsPerShareDetails", "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r119", "r127" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://codiagnostics.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r197": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r201": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r206": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r243": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r274": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r383": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r426": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(7))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(9))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r503": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r504": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r505": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r506": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r507": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r508": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r509": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r511": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r512": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r513": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r514": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r515": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r516": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r517": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r518": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r519": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r521": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r522": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r523": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 91 0001493152-22-007662-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-007662-xbrl.zip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ǹ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�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ȉ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end